Compositions and methods for diagnosing and treating mental disorders

Abstract
The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.
Description
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

Not applicable.


BACKGROUND OF THE INVENTION

Schizophrenia and other mental disorders are a major public health problem, affecting a significant portion of the adult population of the United States each year. While it has been hypothesized that mental disorders, including psychotic disorders such as schizophrenia as well as mood disorders such as major depression and bipolar disorder have genetic roots, little progress has been made in identifying gene sequences and gene products that play a role in causing these disorders, as is true for many diseases with a complex genetic origin (see, e.g., Burmeister, Biol. Psychiatry 45:522-532 (1999)). Relying on the discovery that certain genes expressed in particular brain pathways and regions are likely involved in the development of mental disorders, the present invention provides methods for diagnosis and treatment of mental disorders such as schizophrenia, as well as methods for identifying compounds effective in treating mental disorders.


BRIEF SUMMARY OF THE INVENTION

In order to further understand the neurobiology of psychotic disorders such as schizophrenia, the inventors of the present application have used DNA microarrays to study expression profiles of human post-mortem brains from patients diagnosed with schizophrenia. The work has focused on ten brain regions that are pathways or circuits involved in schizophrenia: anterior cingulate cortex (AnCg), dorsolateral prefrontal cortex (DLPFC), amygdala (AMY), cerebellar cortex (CB), entorhinal cortex (ERC), superior temporal gyrtus (STG), parietal cortex (PC), nucleus accumbens (nAcc), ventral thalamus (VThal), medial thalamus (MThal) and/or the hippocampus (HC).


The present invention demonstrates, for the first time, differential expression of genes in selected regions of brains of patients suffering from psychotic disorders, such as schizophrenia, in comparison with normal control subjects. These genes include the 1021 nucleic acids listed in Table 1; the genes listed in Table 22 which are differentially expressed in the DLPFC, AnCg and amygdala using Affymetrix chips and using brains with no agonal factors (904 genes); the genes listed in Table 23 which are differentially expressed in the DLPFC, AnCg and amygdala using Affymetrix chips and using brains with agonal factors (“affymetrix based on AFS postive”) (231 genes); and the genes listed in Table 24 wich are from the DLFC are are significantly different using the Codelink platform (89 genes).


In addition, the present invention identifies genes involved in psychotic disorders, where the proteins encoded by the nucleic acids listed in Tables 2-21 are components of biochemical pathways that play a role in mental disorders, e.g., psychotic disorders such as schizophrenia. Finally, Table 25 lists biochemical pathways involved in psychotic disorders, e.g., schizophrenia.


Genes that are differentially expressed in schizophrenia and by gender are useful in diagnosing psychotic disorders, e.g., providing SNPs, biomarkers, diagnostic probe sets for PCR and chip assays, and antigens and antibodies for immunoassays such as ELISA and immunohistochemical assays. Differential expression by brain region similarly is a useful diagnostic and therapeutic tool, as psychotic disorders such as schizophrenia primarily affect certain brain regions that are part of circuits or pathways involved in schizophrenia. The identification of genes, proteins, and biochemical assays involved in psychotic disorders also provides the means for drug discovery for anti-psychotic therapeutics.


This invention thus provides methods for determining whether a subject has or is predisposed for a mental disorder such as schizophrenia. The invention also provides methods of providing a prognosis and for monitoring disease progression and treatment. Furthermore, the present invention provides nucleic acid and protein targets for assays for drugs for the treatment of mental disorders such as schizophrenia.


In one aspect, the methods comprise the steps of: (i) obtaining a biological sample from a subject; (ii) contacting the sample with a reagent that selectively associates with a polynucleotide or polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleotide sequence listed in Tables 1 and 22-24; and (iii) detecting the level of reagent that selectively associates with the sample, thereby determining whether the subject has or is predisposed for a mental disorder.


In some embodiments, the reagent is an antibody. In some embodiments, the reagent is a nucleic acid. In some embodiments, the reagent associates with a polynucleotide. In some embodiments, the reagent associates with a polypeptide. In some embodiments, the polynucleotide comprises a nucleotide sequence listed in Tables 1 and 22-24. In some embodiment, the polypeptide comprises an amino acid sequence of a gene listed in Tables 1 and 22-24. In some embodiments, the level of reagent that associates with the sample is different (i.e., higher or lower) from a level associated with humans without a mental disorder. In some embodiments, the biological sample is obtained from amniotic fluid, spinal fluid, or saliva. In some embodiments, the mental disorder is a mood disorder. In some embodiments, the mental disorder is a psychotic disorder such as schizophrenia.


The invention also provides methods of identifying a compound for treatment of a mental disorder. In some embodiments, the methods comprises the steps of: (i) contacting the compound with a polypeptide, which is encoded by a polynucleotide that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence of Tables 1 and 22-24; and (ii) determining the functional effect of the compound upon the polypeptide, thereby identifying a compound for treatment of a mental disorder.


In some embodiments, the contacting step is performed in vitro. In some embodiment, the polypeptide comprises an amino acid sequence of a gene listed in Tables 1 and 22-24. In some embodiments, the polypeptide is expressed in a cell or biological sample, and the cell or biological sample is contacted with the compound. In some embodiments, the mental disorder is a mood disorder or psychotic disorder. In some embodiments, the mood disorder is selected from the group consisting of bipolar disorder I and II and major depression. In some embodiments, the psychotic disorder is schizophrenia. In some embodiments, the methods further comprise administering the compound to an animal and determining the effect on the animal, e.g., an invertebrate, a vertebrate, or a mammal. In some embodiments, the determining step comprises testing the animal's mental function.


In some embodiments, the methods comprise the steps of (i) contacting the compound to a cell, the cell comprising a polynucleotide that hybridizes under stringent conditions to a nucleotide sequence of Tables 1 and 22-24; and (ii) selecting a compound that modulates expression of the polynucleotide, thereby identifying a compound for treatment of a mental disorder. In some embodiments, the polynucleotide comprises a nucleotide sequence listed in Tables 1 and 22-24. In some embodiment, the expression of the polynucleotide is enhanced. In some embodiments, the expression of the polynucleotide is decreased. In some embodiments, the methods further comprise administering the compound to an animal and determining the effect on the animal. In some embodiments, the determining step comprises testing the animal's mental function. In some embodiments, the mental disorder is a mood disorder or a psychotic disorder. In some embodiments, the mood disorder is selected from the group consisting of bipolar disorder I and II and major depression. In some embodiments, the psychotic disorder is schizophrenia.


The invention also provides methods of treating a mental disorder in a subject. In some embodiments, the methods comprise the step of administering to the subject a therapeutically effective amount of a compound identified using the methods described above. In some embodiments, the mental disorder is a mood disorder or a psychotic disorder. In some embodiments, the mood disorder is selected from the group consisting of bipolar disorder I and II and major depression. In some embodiments, the psychotic disorder is schizophrenia. In some embodiments, the compound is a small organic molecule, an antibody, an antisense molecule, an aptamer, an siRNA molecule, or a peptide.


The invention also provides methods of treating mental disorder in a subject, comprising the step of administering to the subject a therapeutically effective amount of a polypeptide, which is encoded by a polynucleotide that hybridizes under stringent conditions to a nucleic acid of Tables 1 and 22-24. In some embodiments, the polypeptide comprises an amino acid sequence encoded by a gene listed in Tables 1 and 22-24. In some embodiments, the mental disorder is a mood disorder or a psychotic disorder. In some embodiments, the psychotic disorder is schizophrenia. In some embodiments, the mood disorder is a bipolar disorder I or II or major depression.


The invention also provides methods of treating mental disorder in a subject, comprising the step of administering to the subject a therapeutically effective amount of a polynucleotide, which hybridizes under stringent conditions to a nucleic acid of Tables 1 and 22-24. In some embodiments, the mental disorder is a mood disorder or a psychotic disorder. In some embodiments, the psychotic disorder is schizophrenia. In some embodiments, the mood disorder is a bipolar disorder or major depression.




BRIEF DESCRIPTION OF THE DRAWINGS

Table 1: Table 1 lists genes differentially expressed in mental disorder subjects suffering from schizophrenia. The table gives the ratio of expression as compared to normal controls. Thus, a gene that is over-expressed in subjects suffering from schizophrenia will have a value greater than one, while those that are underexpressed will have a value less than one.


Table 2: Table 2 lists neurofilament genes differentially expressed in all brain regions assayed.


Table 3: Table 3 lists developmental genes differentially expressed in all brain regions assayed.


Table 4: Table 4 lists extracellular genes differentially expressed in all brain regions assayed.


Table 5: Table 5 lists cell to cell signaling genes differentially expressed in all brain regions assayed.


Table 6: Table 6 lists synaptic transmission genes differentially expressed in all brain regions assayed.


Table 7: Table 7 lists organogenesis genes differentially expressed in all brain regions assayed.


Table 8: Table 8 lists cytoplasmic genes differentially expressed in VThal.


Table 9: Table 9 lists synaptic transmission genes differentially expressed in VThal.


Table 10: Table 10 lists 26S proteasome genes differentially expressed in VThal.


Table 11: Table 11 lists macromolecule biosynthesis genes differentially expressed in VThal.


Table 12: Table 12 lists neurofilament genes differentially expressed in MThal.


Table 13: Table 13 lists extracellular genes differentially expressed in HC.


Table 14: Table 14 lists proteasome complex genes differentially expressed in AnCg.


Table 15: Table 15 lists sterol biosynthesis genes differentially expressed in PC.


Table 16 Table 16 lists 26S proteasome genes differentially expressed in nAcc.


Table 17: Table 17 lists cytoplasmic genes differentially expressed in nAcc.


Table 18: Table 18 lists biotic stimulation genes differentially expressed in HC.


Table 19: Table 19 lists ribosomal genes differentially expressed in DLPFC.


Table 20: Table 20 lists protein targeting genes differentially expressed in AnCg.


Table 21: Table 21 lists endoplasmic reticulum (ER) genes differentially expressed in AnCg.


Table 22: Table 22 lists selected genes (i.e., synaptic transmission, ribosomal genes, cation homeostasis genes, and heat shock protein genes) differentially expressed by at least 1.2 fold in any brain region.


Table 22: Table 22 provides a list of genes differentially expressed in the DLPFC, AnCg and amygdala using Affymetrix chips and using brains with no agonal factors (904 genes).


Table 23: Table 23 provides a list of genes differentially expressed in the DLPFC, AnCg and amygdala using Affymetrix chips and using brains with agonal factors (“affymetrix based on AFS postive”) (231 genes).


Table 24: Table 24 provides a list of genes from the DLFC that were significantly different using the Codelink platform (89 genes).


Table 25: Table 25 lists biochemical pathways involved in psychotic disorders.


Definitions

A “mental disorder” or “mental illness” or “mental disease” or “psychiatric or neuropsychiatric disease or illness or disorder” refers to mood disorders (e.g., major depression, mania, and bipolar disorders), psychotic disorders (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, and shared psychotic disorder), personality disorders, anxiety disorders (e.g., obsessive-compulsive disorder) as well as other mental disorders such as substance-related disorders, childhood disorders, dementia, autistic disorder, adjustment disorder, delirium, multi-infarct dementia, and Tourette's disorder as described in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM IV). Typically, such disorders have a complex genetic and/or a biochemical component.


“A psychotic disorder” refers to a condition that affects the mind, resulting in at least some loss of contact with reality. Symptoms of a psychotic disorder include, e.g., hallucinations, changed behavior that is not based on reality, delusions and the like. See, e.g., DSM IV. Schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, substance-induced psychotic disorder, and shared psychotic disorder are examples of psychotic disorders.


“Schizophrenia” refers to a psychotic disorder involving a withdrawal from reality by an individual. Symptoms comprise for at least a part of a month two or more of the following symptoms: delusions (only one symptom is required if a delusion is bizarre, such as being abducted in a space ship from the sun); hallucinations (only one symptom is required if hallucinations are of at least two voices talking to one another or of a voice that keeps up a running commentary on the patient's thoughts or actions); disorganized speech (e.g., frequent derailment or incoherence); grossly disorganized or catatonic behavior; or negative symptoms, i.e., affective flattening, alogia, or avolition. Schizophrenia encompasses disorders such as, e.g., schizoaffective disorders. Diagnosis of schizophrenia is described in, e.g., DSM IV. Types of schizophrenia include, e.g., paranoid, disorganized, catatonic, undifferentiated, and residual.


A “mood disorder” refers to disruption of feeling tone or emotional state experienced by an individual for an extensive period of time. Mood disorders include major depression disorder (i.e., unipolar disorder), mania, dysphoria, bipolar disorder, dysthymia, cyclothymia and many others. See, e.g., Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM IV).


“Major depression disorder,” “major depressive disorder,” or “unipolar disorder” refers to a mood disorder involving any of the following symptoms: persistent sad, anxious, or “empty” mood; feelings of hopelessness or pessimism; feelings of guilt, worthlessness, or helplessness; loss of interest or pleasure in hobbies and activities that were once enjoyed, including sex; decreased energy, fatigue, being “slowed down”; difficulty concentrating, remembering, or making decisions; insonmia, early-morning awakening, or oversleeping; appetite and/or weight loss or overeating and weight gain; thoughts of death or suicide or suicide attempts; restlessness or irritability; or persistent physical symptoms that do not respond to treatment, such as headaches, digestive disorders, and chronic pain. Various subtypes of depression are described in, e.g., DSM IV.


“Bipolar disorder” is a mood disorder characterized by alternating periods of extreme moods. A person with bipolar disorder experiences cycling of moods that usually swing from being overly elated or irritable (mania) to sad and hopeless (depression) and then back again, with periods of normal mood in between. Diagnosis of bipolar disorder is described in, e.g., DSM IV. Bipolar disorders include bipolar disorder I (mania with or without major depression) and bipolar disorder II (hypomania with major depression), see, e.g., DSM IV.


An “agonist” refers to an agent that binds to a polypeptide or polynucleotide of the invention, stimulates, increases, activates, facilitates, enhances activation, sensitizes or up regulates the activity or expression of a polypeptide or polynucleotide of the invention.


An “antagonist” refers to an agent that inhibits expression of a polypeptide or polynucleotide of the invention or binds to, partially or totally blocks stimulation, decreases, prevents, delays activation, inactivates, desensitizes, or down regulates the activity of a polypeptide or polynucleotide of the invention.


“Inhibitors,” “activators,” and “modulators” of expression or of activity are used to refer to inhibitory, activating, or modulating molecules, respectively, identified using in vitro and in vivo assays for expression or activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term “modulator” includes inhibitors and activators. Inhibitors are agents that, e.g., inhibit expression of a polypeptide or polynucleotide of the invention or bind to, partially or totally block stimulation or enzymatic activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity of a polypeptide or polynucleotide of the invention, e.g., antagonists. Activators are agents that, e.g., induce or activate the expression of a polypeptide or polynucleotide of the invention or bind to, stimulate, increase, open, activate, facilitate, enhance activation or enzymatic activity, sensitize or up regulate the activity of a polypeptide or polynucleotide of the invention, e.g., agonists. Modulators include naturally occurring and synthetic ligands, antagonists, agonists, small chemical molecules and the like. Assays to identify inhibitors and activators include, e.g., applying putative modulator compounds to cells, in the presence or absence of a polypeptide or polynucleotide of the invention and then determining the functional effects on a polypeptide or polynucleotide of the invention activity. Samples or assays comprising a polypeptide or polynucleotide of the invention that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of effect. Control samples (untreated with modulators) are assigned a relative activity value of 100%. Inhibition is achieved when the activity value of a polypeptide or polynucleotide of the invention relative to the control is about 80%, optionally 50% or 25-1%. Activation is achieved when the activity value of a polypeptide or polynucleotide of the invention relative to the control is 110%, optionally 150%, optionally 200-500%, or 1000-3000% higher.


The term “test compound” or “drug candidate” or “modulator” or grammatical equivalents as used herein describes any molecule, either naturally occurring or synthetic, e.g., protein, oligopeptide (e.g., from about 5 to about 25 amino acids in length, preferably from about 10 to 20 or 12 to 18 amino acids in length, preferably 12, 15, or 18 amino acids in length), small organic molecule, polysaccharide, lipid, fatty acid, polynucleotide, RNAi, oligonucleotide, etc. The test compound can be in the form of a library of test compounds, such as a combinatorial or randomized library that provides a sufficient range of diversity. Test compounds are optionally linked to a fusion partner, e.g., targeting compounds, rescue compounds, dimerization compounds, stabilizing compounds, addressable compounds, and other functional moieties. Conventionally, new chemical entities with useful properties are generated by identifying a test compound (called a “lead compound”) with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.


A “small organic molecule” refers to an organic molecule, either naturally occurring or synthetic, that has a molecular weight of more than about 50 Daltons and less than about 2500 Daltons, preferably less than about 2000 Daltons, preferably between about 100 to about 1000 Daltons, more preferably between about 200 to about 500 Daltons. An “siRNA” or “RNAi” refers to a nucleic acid that forms a double stranded RNA, which double stranded RNA has the ability to reduce or inhibit expression of a gene or target gene when the siRNA expressed in the same cell as the gene or target gene. “siRNA” or “RNAi” thus refers to the double stranded RNA formed by the complementary strands. The complementary portions of the siRNA that hybridize to form the double stranded molecule typically have substantial or complete identity. In one embodiment, an siRNA refers to a nucleic acid that has substantial or complete identity to a target gene and forms a double stranded siRNA. Typically, the siRNA is at least about 15-50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, preferable about preferably about 20-30 base nucleotides, preferably about 20-25 or about 24-29 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length.


“Determining the functional effect” refers to assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a polynucleotide or polypeptide of the invention (such as a polynucleotide of Tables 1 and 22-24 or a polypeptide encoded by a gene of Tables 1 and 22-24), e.g., measuring physical and chemical or phenotypic effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein; measuring inducible markers or transcriptional activation of the protein; measuring binding activity or binding assays, e.g. binding to antibodies; measuring changes in ligand binding affinity; measurement of calcium influx; measurement of the accumulation of an enzymatic product of a polypeptide of the invention or depletion of an substrate; measurement of changes in protein levels of a polypeptide of the invention;

    • measurement of RNA stability; G-protein binding; GPCR phosphorylation or dephosphorylation; signal transduction, e.g., receptor-ligand interactions, second messenger concentrations (e.g., cAMP, EP3, or intracellular Ca2+); identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, calorimetric reactions, antibody binding, inducible markers, and ligand binding assays.


Samples or assays comprising a nucleic acid or protein disclosed herein that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.


“Biological sample” includes sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. Such samples include blood, spinal fluid, sputum, tissue, lysed cells, brain biopsy, cultured cells, e.g., primary cultures, explants, and transformed cells, stool, urine, etc. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate, e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.


“Antibody” refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.


An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.


Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)′2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)′2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)′2 dimer into an Fab′ monomer. The Fab′ monomer is essentially an Fab with part of the hinge region (see, Paul (Ed.) Fundamental Immunology, Third Edition, Raven Press, NY (1993)). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv).


The terms “peptidomimetic” and “mimetic” refer to a synthetic chemical compound that has substantially the same structural and functional characteristics of the polynucleotides, polypeptides, antagonists or agonists of the invention. Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed “peptide mimetics” or “peptidomimetics” (Fauchere, Adv. Drug Res. 15:29 (1986); Veber and Freidinger TINS p. 392 (1985); and Evans et al., J. Med. Chem. 30:1229 (1987), which are incorporated herein by reference). Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent or enhanced therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biological or pharmacological activity), such as a CCX CKR, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of, e.g., —CH2NH—, —CH2S—, —CH2—CH2—, —CH═CH— (cis and trans), —COCH2—, —CH(OH)CH2—, and —CH2SO—. The mimetic can be either entirely composedof synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or activity. For example, a mimetic composition is within the scope of the invention if it is capable of carrying out the binding or enzymatic activities of a polypeptide or polynucleotide of the invention or inhibiting or increasing the enzymatic activity or expression of a polypeptide or polynucleotide of the invention.


The term “gene” means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).


The term “isolated,” when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. In particular, an isolated gene is separated from open reading frames that flank the gene and encode a protein other than the gene of interest. The term “purified” denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.


The term “nucleic acid” or “polynucleotide” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, haplotypes, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Cassol et al. (1992); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.


The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full-length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds.


The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. “Amino acid mimetics” refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.


Amino acids may be referred to herein by either the commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.


“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, “conservatively modified variants” refers to those nucleic acids that encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein that encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence.


As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.


The following eight groups each contain amino acids that are conservative substitutions for one another:

  • 1) Alanine (A), Glycine (G);
  • 2) Aspartic acid (D), Glutamic acid (E);
  • 3) Asparagine (N), Glutamine (Q);
  • 4) Arginine (R), Lysine (K);
  • 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
  • 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
  • 7) Serine (S), Threonine (T); and
  • 8) Cysteine (C), Methionine (M)
  • (see, e.g., Creighton, Proteins (1984)).


“Percentage of sequence identity” is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.


The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be “substantially identical.” This definition also refers to the complement of a test sequence. Optionally, the identity exists over a region that is at least about 50 nucleotides in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides in length.


For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.


A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).


An example of an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nuc. Acids Res. 25:3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.


The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.


An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.


The phrase “selectively (or specifically) hybridizes to” refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).


The phrase “stringent hybridization conditions” refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, optionally 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42° C., or 5×SSC, 1% SDS, incubating at 65° C., with wash in 0.2×SSC, and 0.1% SDS at 65° C. Such washes can be performed for 5, 15, 30, 60, 120, or more minutes. Nucleic acids that hybridize to the genes listed in Tables 1-22 are encompassed by the invention.


Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides that they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 1×SSC at 45° C. Such washes can be performed for 5, 15, 30, 60, 120, or more minutes. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.


For PCR, a temperature of about 36° C. is typical for low stringency amplification, although annealing temperatures may vary between about 32° C. and 48° C. depending on primer length. For high stringency PCR amplification, a temperature of about 62° C. is typical, although high stringency annealing temperatures can range from about 50° C. to about 65° C., depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90° C.-95° C. for 30 sec-2 min., an annealing phase lasting 30 sec.-2 min., and an extension phase of about 72° C. for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).


The phrase “a nucleic acid sequence encoding” refers to a nucleic acid that contains sequence information for a structural RNA such as rRNA, a tRNA, or the primary amino acid sequence of a specific protein or peptide, or a binding site for a trans-acting regulatory agent. This phrase specifically encompasses degenerate codons (i.e., different codons which encode a single amino acid) of the native sequence or sequences which may be introduced to conform with codon preference in a specific host cell.


The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (nonrecombinant) form of the cell or express native genes that are otherwise abnormally expressed, under-expressed or not expressed at all.


The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).


An “expression vector” is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.


The phrase “specifically (or selectively) binds to an antibody” or “specifically (or selectively) immunoreactive with”, when referring to a protein or peptide, refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised against a protein having an amino acid sequence encoded by any of the polynucleotides of the invention can be selected to obtain antibodies specifically immunoreactive with that protein and not with other proteins, except for polymorphic variants. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays, Western blots, or immunohistochemistry are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See, Harlow and Lane Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, NY (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Typically, a specific or selective reaction will be at least twice the background signal or noise and more typically more than 10 to 100 times background.


One who is “predisposed for a mental disorder” as used herein means a person who has an inclination or a higher likelihood of developing a mental disorder when compared to an average person in the general population.




DETAILED DESCRIPTION OF THE INVENTION

I. Introduction


To understand the complex genetic basis of mental disorders, the present invention provides studies that have been conducted to investigate the expression patterns of genes that are differentially expressed specifically in central nervous system of subjects with psychotic disorders. The large spectrum of symptoms associated with mental disorders is a reflection of the complex genetic basis and complex gene expression patterns in patients with mental disorders. Different combinations of the genes disclosed herein can be responsible for one or more mental disorders. Furthermore, brain pathways or circuits as well as subcellular pathways are important for understanding the development and diagnosis of mental disorders. The selected brain regions described herein (anterior cingulate cortex (AnCg), dorsolateral prefrontal cortex (DLPFC), cerebellar cortex (CB), entorhinal cortex (ERC), superior temporal gyrus (STG), parietal cortex (PC), nucleus accumbens (nAcc), ventral thalamus (VThal), medial thalamus (MThal) and/or the hippocampus (HC)) are implicated in the clinical symptoms of mental disorders such as psychotic disorders, e.g., schizophrenia. Brain imaging studies focusing on particular brain regions, cytoarchitectural changes in brain regions, expression of key neurotransmittors or related molecules in brain regions, and subcellular pathways in brain regions all contribute to the development of mental disorders, and thus are an important consideration in the diagnosis and therapeutic uses described herein.


The present invention demonstrates the altered expression (either higher or lower) of the genes of Tables 1-25 at the mRNA level in the brains of patients with mental disorders (e.g., schizophrenia) in comparison with normal individuals. This invention thus provides methods for diagnosis of mental disorders such as mood disorders (e.g., bipolar disorder, major depression, and the like), psychotic disorders (e.g., schizophrenia, and the like), and other mental disorders by detecting the level of a transcript or translation product of the genes listed in Tables 1-25 as well as their corresponding biochemical pathways. The chromosomal location of such genes can be used to discover other genes in the region that are linked to development of a particular disorder.


The invention further provides methods of identifying a compound useful for the treatment of such disorders by selecting compounds that modulates the functional effect of the translation products or the expression of the transcripts described herein. The invention also provides for methods of treating patients with such mental disorders, e.g., by administering the compounds of the invention or by gene therapy.


The genes and the polypeptides that they encode, which are associated with psychotic disorders such as schizophrenia, are useful for facilitating the design and development of various molecular diagnostic tools such as GeneChips™ containing probe sets specific for all or selected mental disorders, including but not limited to psychotic disorders, and as an ante- and/or post-natal diagnostic tool for screening newborns in concert with genetic counseling. Other diagnostic applications include evaluation of disease susceptibility, prognosis, and monitoring of disease or treatment process, as well as providing individualized medicine via predictive drug profiling systems, e.g., by correlating specific genomic motifs with the clinical response of a patient to individual drugs. In addition, the present invention is useful for multiplex SNP or haplotype profiling, including but not limited to the identification of pharmacogenetic targets at the gene, mRNA, protein, and pathway level. Profiling of splice variants is also useful for diagnostic and therapeutic applications.


The genes and the polypeptides that they encode, described herein, as also useful as drug targets for the development of therapeutic drugs for the treatment or prevention of mental disorders, including but not limited to psychotic disorders such as schizophrenia. Mental disorders have a high co-morbidity with other neurological disorders, such as Parkinson's disease or Alzheimeres. Therefore, the present invention can be used for diagnosis and treatment of patients with multiple disease states that include a mental disorder such as a psychotic disorder.


Antipsychotic medicines are in general equally effect for the treatment of schizophrenia, but act by different mechanisms. The similar effectiveness of the drugs for treatment of schizophrenia suggests that they act through a yet as unidentified common pathway. As demonstrated by the results shown herein, these drugs regulate a common gene, and/or a common group of genes as well as a unique set of genes.


II. General Recombinant Nucleic Acid Methods for use with the Invention


In numerous embodiments of the present invention, polynucleotides of the invention will be isolated and cloned using recombinant methods. Such polynucleotides include, e.g., those listed in Tables 1-22, which can be used for, e.g., protein expression or during the generation of variants, derivatives, expression cassettes, to monitor gene expression, for the isolation or detection of sequences of the invention in different species, for diagnostic purposes in a patient, e.g., to detect mutations or to detect expression levels of nucleic acids or polypeptides of the invention. In some embodiments, the sequences of the invention are operably linked to a heterologous promoter. In one embodiment, the nucleic acids of the invention are from any mammal, including, in particular, e.g., a human, a mouse, a rat, a primate, etc.


A. General Recombinant Nucleic Acids Methods


This invention relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd ed. 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994)).


For nucleic acids, sizes are given in either kilobases (kb) or base pairs (bp). These are estimates derived from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences. For proteins, sizes are given in kilodaltons (kDa) or amino acid residue numbers. Proteins sizes are estimated from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from published protein sequences.


Oligonucleotides that are not commercially available can be chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, Tetrahedron Letts. 22:1859-1862 (1981), using an automated synthesizer, as described in Van Devanter et. al., Nucleic Acids Res. 12:6159-6168 (1984). Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson & Reanier, J. Chrom. 255:137-149 (1983).


The sequence of the cloned genes and synthetic oligonucleotides can be verified after cloning using, e.g., the chain termination method for sequencing double-stranded templates of Wallace et al., Gene 16:21-26 (1981).


B. Cloning Methods for the Isolation of Nucleotide Sequences Encoding Desired Proteins


In general, the nucleic acids encoding the subject proteins are cloned from DNA sequence libraries that are made to encode cDNA or genomic DNA. The particular sequences can be located by hybridizing with an oligonucleotide probe, the sequence of which can be derived from the sequences of the genes listed in Tables 1-22, which provide a reference for PCR primers and defines suitable regions for isolating specific probes. Alternatively, where the sequence is cloned into an expression library, the expressed recombinant protein can be detected immunologically with antisera or purified antibodies made against a polypeptide comprising an amino acid sequence encoded by a gene listed in Tables 1-25.


Methods for making and screening genomic and cDNA libraries are well known to those of skill in the art (see, e.g., Gubler and Hoffman Gene 25:263-269 (1983); Benton and Davis Science, 196:180-182 (1977); and Sambrook, supra). Brain cells are an example of suitable cells to isolate RNA and cDNA sequences of the invention.


Briefly, to make the cDNA library, one should choose a source that is rich in mRNA. The mRNA can then be made into cDNA, ligated into a recombinant vector, and transfected into a recombinant host for propagation, screening and cloning. For a genomic library, the DNA is extracted from a suitable tissue and either mechanically sheared or enzymatically digested to yield fragments of preferably about 5-100 kb. The fragments are then separated by gradient centrifugation from undesired sizes and are constructed in bacteriophage lambda vectors. These vectors and phage are packaged in vitro, and the recombinant phages are analyzed by plaque hybridization. Colony hybridization is carried out as generally described in Grunstein et al., Proc. Natl. Acad. Sci. USA., 72:3961-3965 (1975).


An alternative method combines the use of synthetic oligonucleotide primers with polymerase extension on an mRNA or DNA template. Suitable primers can be designed from specific sequences of the invention. This polymerase chain reaction (PCR) method amplifies the nucleic acids encoding the protein of interest directly from mRNA, cDNA, genomic libraries or cDNA libraries. Restriction endonuclease sites can be incorporated into the primers. Polymerase chain reaction or other in vitro amplification methods may also be useful, for example, to clone nucleic acids encoding specific proteins and express said proteins, to synthesize nucleic acids that will be used as probes for detecting the presence of mRNA encoding a polypeptide of the invention in physiological samples, for nucleic acid sequencing, or for other purposes (see, U.S. Pat. Nos. 4,683,195 and 4,683,202). Genes amplified by a PCR reaction can be purified from agarose gels and cloned into an appropriate vector.


Appropriate primers and probes for identifying polynucleotides of the invention from mammalian tissues can be derived from the sequences provided herein. For a general overview of PCR, see, Innis et al. PCR Protocols: A Guide to Methods and Applications, Academic Press, San Diego (1990).


Synthetic oligonucleotides can be used to construct genes. This is done using a series of overlapping oligonucleotides, usually 40-120 bp in length, representing both the sense and anti-sense strands of the gene. These DNA fragments are then annealed, ligated and cloned.


A gene encoding a polypeptide of the invention can be cloned using intermediate vectors before transformation into mammalian cells for expression. These intermediate vectors are typically prokaryote vectors or shuttle vectors. The proteins can be expressed in either prokaryotes, using standard methods well known to those of skill in the art, or eukaryotes as described infra.


III. Purification of Proteins of the Invention


Either naturally occurring or recombinant polypeptides of the invention can be purified for use in functional assays. Naturally occurring polypeptides, e.g., polypeptides encoded by genes listed in Tables 1-22, can be purified, for example, from mouse or human tissue such as brain or any other source of an ortholog. Recombinant polypeptides can be purified from any suitable expression system.


The polypeptides of the invention may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (see, e.g., Scopes, Protein Purification: Principles and Practice (1982); U.S. Pat. No. 4,673,641; Ausubel et al., supra; and Sambrook et al., supra).


A number of procedures can be employed when recombinant polypeptides are purified. For example, proteins having established molecular adhesion properties can be reversible fused to polypeptides of the invention. With the appropriate ligand, the polypeptides can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fuised protein is then removed by enzymatic activity. Finally the polypeptide can be purified using immunoaffinity columns.


A. Purification of Proteins from Recombinant Bacteria


When recombinant proteins are expressed by the transformed bacteria in large amounts, typically after promoter induction, although expression can be constitutive, the proteins may form insoluble aggregates. There are several protocols that are suitable for purification of protein inclusion bodies. For example, purification of aggregate proteins (hereinafter referred to as inclusion bodies) typically involves the extraction, separation and/or purification of inclusion bodies by disruption of bacterial cells typically, but not limited to, by incubation in a buffer of about 100-150 μg/ml lysozyme and 0.1% Nonidet P40, a non-ionic detergent. The cell suspension can be ground using a Polytron grinder (Brinkman Instruments, Westbury, N.Y.). Alternatively, the cells can be sonicated on ice. Alternate methods of lysing bacteria are described in Ausubel et al. and Sambrook et al., both supra, and will be apparent to those of skill in the art.


The cell suspension is generally centrifuged and the pellet containing the inclusion bodies resuspended in buffer which does not dissolve but washes the inclusion bodies, e.g., 20 mM Tris-HCl (pH 7.2), 1 mM EDTA, 150 mM NaCl and 2% Triton-X 100, a non-ionic detergent. It may be necessary to repeat the wash step to remove as much cellular debris as possible. The remaining pellet of inclusion bodies may be resuspended in an appropriate buffer (e.g., 20 mM sodium phosphate, pH 6.8, 150 mM NaCl). Other appropriate buffers will be apparent to those of skill in the art.


Following the washing step, the inclusion bodies are solubilized by the addition of a solvent that is both a strong hydrogen acceptor and a strong hydrogen donor (or a combination of solvents each having one of these properties). The proteins that formed the inclusion bodies may then be renatured by dilution or dialysis with a compatible buffer. Suitable solvents include, but are not limited to, urea (from about 4 M to about 8 M), formamide (at least about 80%, volume/volume basis), and guanidine hydrochloride (from about 4 M to about 8 M). Some solvents that are capable of solubilizing aggregate-forming proteins, such as SDS (sodium dodecyl sulfate) and 70% formic acid, are inappropriate for use in this procedure due to the possibility of irreversible denaturation of the proteins, accompanied by a lack of immunogenicity and/or activity. Although guanidine hydrochloride and similar agents are denaturants, this denaturation is not irreversible and renaturation may occur upon removal (by dialysis, for example) or dilution of the denaturant, allowing re-formation of the immunologically and/or biologically active protein of interest. After solubilization, the protein can be separated from other bacterial proteins by standard separation techniques.


Alternatively, it is possible to purify proteins from bacteria periplasm. Where the protein is exported into the periplasm of the bacteria, the periplasmic fraction of the bacteria can be isolated by cold osmotic shock in addition to other methods known to those of skill in the art (see, Ausubel et al., supra). To isolate recombinant proteins from the periplasm, the bacterial cells are centrifuged to form a pellet. The pellet is resuspended in a buffer containing 20% sucrose. To lyse the cells, the bacteria are centrifuged and the pellet is resuspended in ice-cold 5 mM MgSO4 and kept in an ice bath for approximately 10 minutes. The cell suspension is centrifuged and the supernatant decanted and saved. The recombinant proteins present in the supernatant can be separated from the host proteins by standard separation techniques well known to those of skill in the art.


B. Standard Protein Separation Techniques For Purifying Proteins


1. Solubility Fractionation


Often as an initial step, and if the protein mixture is complex, an initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. The preferred salt is ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol is to add saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This will precipitate the most hydrophobic proteins. The precipitate is discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, through either dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.


2. Size Differential Filtration


Based on a calculated molecular weight, a protein of greater and lesser size can be isolated using ultrafiltration through membranes of different pore sizes (for example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed as described below.


3. Column Chromatography


The proteins of interest can also be separated from other proteins on the basis of their size, net surface charge, hydrophobicity and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art.


It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).


IV. Detection of Gene Expression


Those of skill in the art will recognize that detection of expression of polynucleotides of the invention has many uses. For example, as discussed herein, detection of the level of polypeptides or polynucleotides of the invention in a patient is useful for diagnosing mood disorders or psychotic disorder or a predisposition for a mood disorder or psychotic disorder. Moreover, detection of gene expression is useful to identify modulators of expression of the polypeptides or polynucleotides of the invention.


A variety of methods of specific DNA and RNA measurement using nucleic acid hybridization techniques are known to those of skill in the art (see, Sambrook, supra). Some methods involve an electrophoretic separation (e.g., Southern blot for detecting DNA, and Northern blot for detecting RNA), but measurement of DNA and RNA can also be carried out in the absence of electrophoretic separation (e.g., by dot blot). Southern blot of genomic DNA (e.g., from a human) can be used for screening for restriction fragment length polymorphism (RFLP) to detect the presence of a genetic disorder affecting a polypeptide of the invention.


The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in Hames and Higgins Nucleic Acid Hybridization, A Practical Approach, IRL Press (1985); Gall and Pardue, Proc. Natl. Acad. Sci. U.S.A., 63:378-383 (1969); and John et al. Nature, 223:582-587 (1969).


Detection of a hybridization complex may require the binding of a signal-generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal. The binding of the signal generation complex is also readily amenable to accelerations by exposure to ultrasonic energy.


The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzyme molecules to the antibodies or in some cases, by attachment to a radioactive label (see, e.g., Tijssen, “Practice and Theory of Enzyme Immunoassays,” Laboratory Techniques in Biochemistry and Molecular Biology, Burdon and van Knippenberg Eds., Elsevier (1985), pp. 9-20).


The probes are typically labeled either directly, as with isotopes, chromophores, lumiphores, chromogens, or indirectly, such as with biotin, to which a streptavidin complex may later bind. Thus, the detectable labels used in the assays of the present invention can be primary labels (where the label comprises an element that is detected directly or that produces a directly detectable element) or secondary labels (where the detected label binds to a primary label, e.g., as is common in immunological labeling). Typically, labeled signal nucleic acids are used to detect hybridization. Complementary nucleic acids or signal nucleic acids may be labeled by any one of several methods typically used to detect the presence of hybridized polynucleotides. The most common method of detection is the use of autoradiography with 3H, 125I, 35S, 14C, or 32P-labeled probes or the like.


Other labels include, e.g., ligands that bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand. An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden Introduction to Immunocytochemistry, 2nd ed., Springer Verlag, NY (1997); and in Haugland Handbook of Fluorescent Probes and Research Chemicals, a combined handbook and catalogue Published by Molecular Probes, Inc. (1996).


In general, a detector which monitors a particular probe or probe combination is used to detect the detection reagent label. Typical detectors include spectrophotometers, phototubes and photodiodes, microscopes, scintillation counters, cameras, film and the like, as well as combinations thereof. Examples of suitable detectors are widely available from a variety of commercial sources known to persons of skill in the art. Commonly, an optical image of a substrate comprising bound labeling moieties is digitized for subsequent computer analysis.


Most typically, the amount of RNA is measured by quantifying the amount of label fixed to the solid support by binding of the detection reagent. Typically, the presence of a modulator during incubation will increase or decrease the amount of label fixed to the solid support relative to a control incubation which does not comprise the modulator, or as compared to a baseline established for a particular reaction type. Means of detecting and quantifying labels are well known to those of skill in the art.


In preferred embodiments, the target nucleic acid or the probe is immobilized on a solid support. Solid supports suitable for use in the assays of the invention are known to those of skill in the art. As used herein, a solid support is a matrix of material in a substantially fixed arrangement.


A variety of automated solid-phase assay techniques are also appropriate. For instance, very large scale immobilized polymer arrays (VLSIPS™), available from Affymetrix, Inc. (Santa Clara, Calif.) can be used to detect changes in expression levels of a plurality of genes involved in the same regulatory pathways simultaneously. See, Tijssen, supra., Fodor et al. (1991) Science, 251: 767-777; Sheldon et al. (1993) Clinical Chemistry 39(4): 718-719, and Kozal et al. (1996) Nature Medicine 2(7): 753-759.


Detection can be accomplished, for example, by using a labeled detection moiety that binds specifically to duplex nucleic acids (e.g., an antibody that is specific for RNA-DNA duplexes). One preferred example uses an antibody that recognizes DNA-RNA heteroduplexes in which the antibody is linked to an enzyme (typically by recombinant or covalent chemical bonding). The antibody is detected when the enzyme reacts with its substrate, producing a detectable product. Coutlee et al. (1989) Analytical Biochemistry 181:153-162; Bogulavski (1986) et al. J. Immunol. Methods 89:123-130; Prooijen-Knegt (1982) Exp. Cell Res. 141:397-407; Rudkin (1976) Nature 265:472-473, Stollar (1970) Proc. Nat'l Acad. Sci. USA 65:993-1000; Ballard (1982) Mol. Immunol. 19:793-799; Pisetsky and Caster (1982) Mol. Immunol. 19:645-650; Viscidi et al. (1988) J. Clin. Microbial. 41:199-209; and Kiney et al. (1989) J. Clin. Microbiol. 27:6-12 describe antibodies to RNA duplexes, including homo and heteroduplexes. Kits comprising antibodies specific for DNA:RNA hybrids are available, e.g., from Digene Diagnostics, Inc. (Beltsville, Md.).


In addition to available antibodies, one of skill in the art can easily make antibodies specific for nucleic acid duplexes using existing techniques, or modify those antibodies that are commercially or publicly available. In addition to the art referenced above, general methods for producing polyclonal and monoclonal antibodies are known to those of skill in the art (see, e.g., Paul (3rd ed.) Fundamental Immunology Raven Press, Ltd., NY (1993); Coligan Current Protocols in Immunology Wiley/Greene, NY (1991); Harlow and Lane Antibodies: A Laboratory Manual Cold Spring Harbor Press, NY (1988); Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, Calif., and references cited therein; Goding Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, N.Y., (1986); and Kohler and Milstein Nature 256: 495-497 (1975)). Other suitable techniques for antibody preparation include selection of libraries of recombinant antibodies in phage or similar vectors (see, Huse et al. Science 246:1275-1281 (1989); and Ward et al. Nature 341:544-546 (1989)). Specific monoclonal and polyclonal antibodies and antisera will usually bind with a KD of at least about 0.1 μM, preferably at least about 0.01 μM or better, and most typically and preferably, 0.001 μM or better.


The nucleic acids used in this invention can be either positive or negative probes. Positive probes bind to their targets and the presence of duplex formation is evidence of the presence of the target. Negative probes fail to bind to the suspect target and the absence of duplex formation is evidence of the presence of the target. For example, the use of a wild type specific nucleic acid probe or PCR primers may serve as a negative probe in an assay sample where only the nucleotide sequence of interest is present.


The sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system that multiplies the target nucleic acid being detected. Examples of such systems include the polymerase chain reaction (PCR) system, in particular RT-PCR or real time PCR, and the ligase chain reaction (LCR) system. Other methods recently described in the art are the nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario) and Q Beta Replicase systems. These systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or ligated only when a selected sequence is present. Alternatively, the selected sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.


An alternative means for determining the level of expression of the nucleic acids of the present invention is in situ hybridization. In situ hybridization assays are well known and are generally described in Angerer et al., Methods Enzymol. 152:649-660 (1987). In an in situ hybridization assay, cells or tissue, preferentially human cells or tissue from a selected brain region, are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled. The probes are preferably labeled with radioisotopes or fluorescent reporters.


V. Immunological Detection of the Polypeptides of the Invention


In addition to the detection of polynucleotide expression using nucleic acid hybridization technology, one can also use immunoassays to detect polypeptides of the invention. Immunoassays can be used to qualitatively or quantitatively analyze polypeptides. A general overview of the applicable technology can be found in Harlow & Lane, Antibodies: A Laboratory Manual (1988).


A. Antibodies to Target Polypeptides or other Immunogens


Methods for producing polyclonal and monoclonal antibodies that react specifically with a protein of interest or other immunogen are known to those of skill in the art (see, e.g., Coligan, supra; and Harlow and Lane, supra; Stites et al., supra and references cited therein; Goding, supra; and Kohler and Milstein Nature, 256:495-497 (1975)). Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors (see, Huse et al., supra; and Ward et al., supra). For example, in order to produce antisera for use in an immunoassay, the protein of interest or an antigenic fragment thereof, is isolated as described herein. For example, a recombinant protein is produced in a transformed cell line. An inbred strain of mice or rabbits is immunized with the protein using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen.


Polyclonal sera are collected and titered against the immunogen in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 104 or greater are selected and tested for their cross-reactivity against unrelated proteins or even other homologous proteins from other organisms, using a competitive binding immunoassay. Specific monoclonal and polyclonal antibodies and antisera will usually bind with a KD of at least about 0.1 mM, more usually at least about 1 μM, preferably at least about 0.1 μM or better, and most preferably, 0.01 μM or better.


A number of proteins of the invention comprising immunogens may be used to produce antibodies specifically or selectively reactive with the proteins of interest. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Naturally occurring protein, such as one comprising an amino acid sequence encoded by a gene listed in Table 1-25 may also be used either in pure or impure form. Synthetic peptides made using the protein sequences described herein may also be used as an immunogen for the production of antibodies to the protein. Recombinant protein can be expressed in eukaryotic or prokaryotic cells and purified as generally described supra. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated for subsequent use in immunoassays to measure the protein.


Methods of production of polyclonal antibodies are known to those of skill in the art. In brief, an immunogen, preferably a purified protein, is mixed with an adjuvant and animals are immunized. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the polypeptide of interest. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (see, Harlow and Lane, supra).


Monoclonal antibodies may be obtained using various techniques familiar to those of skill in the art. Typically, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see, Kohler and Milstein, Eur. J. Immunol. 6:511-519 (1976)). Alternative methods of immortalization include, e.g., transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse et al., supra.


Once target protein specific antibodies are available, the protein can be measured by a variety of immunoassay methods with qualitative and quantitative results available to the clinician. For a review of immunological and immunoassay procedures in general see, Stites, supra. Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in Maggio Enzyme Immunoassay, CRC Press, Boca Raton, Fla. (1980); Tijssen, supra; and Harlow and Lane, supra.


Immunoassays to measure target proteins in a human sample may use a polyclonal antiserum that was raised to the protein (e.g., one has an amino acid sequence encoded by a gene listed in Table 1-25) or a fragment thereof. This antiserum is selected to have low cross-reactivity against different proteins and any such cross-reactivity is removed by immunoabsorption prior to use in the immunoassay.


B. Immunological Binding Assays


In a preferred embodiment, a protein of interest is detected and/or quantified using any of a number of well-known immunological binding assays (see, e.g., U.S. Pat. Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also Asai Methods in Cell Biology Volume 37: Antibodies in Cell Biology, Academic Press, Inc. NY (1993); Stites, supra. Immunological binding assays (or immunoassays) typically utilize a “capture agent” to specifically bind to and often immobilize the analyte (in this case a polypeptide of the present invention or antigenic subsequences thereof). The capture agent is a moiety that specifically binds to the analyte. In a preferred embodiment, the capture agent is an antibody that specifically binds, for example, a polypeptide of the invention. The antibody may be produced by any of a number of means well known to those of skill in the art and as described above.


Immunoassays also often utilize a labeling agent to specifically bind to and label the binding complex formed by the capture agent and the analyte. The labeling agent may itself be one of the moieties comprising the antibody/analyte complex. Alternatively, the labeling agent may be a third moiety, such as another antibody, that specifically binds to the antibody/protein complex.


In a preferred embodiment, the labeling agent is a second antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second antibody can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.


Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G, can also be used as the label agents. These proteins are normal constituents of the cell walls of streptococcal bacteria. They exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, generally, Kronval, et al. J. Immunol., 111:1401-1406 (1973); and Akerstrom, et al. J. Immunol., 135:2589-2542 (1985)).


Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. The incubation time will depend upon the assay format, analyte, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10° C. to 40° C.


1. Non-Competitive Assay Formats


Immunoassays for detecting proteins of interest from tissue samples may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of captured analyte (in this case the protein) is directly measured. In one preferred “sandwich” assay, for example, the capture agent (e.g., antibodies specific for a polypeptide encoded by a gene listed in Table 1-25) can be bound directly to a solid substrate where it is immobilized. These immobilized antibodies then capture the polypeptide present in the test sample. The polypeptide thus immobilized is then bound by a labeling agent, such as a second antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.


2. Competitive Assay Formats


In competitive assays, the amount of analyte (such as a polypeptide encoded by a gene listed in Table 1-25) present in the sample is measured indirectly by measuring the amount of an added (exogenous) analyte displaced (or competed away) from a capture agent (e.g., an antibody specific for the analyte) by the analyte present in the sample. In one competitive assay, a known amount of, in this case, the protein of interest is added to the sample and the sample is then contacted with a capture agent, in this case an antibody that specifically binds to a polypeptide of the invention. The amount of immunogen bound to the antibody is inversely proportional to the concentration of immunogen present in the sample. In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. For example, the amount of the polypeptide bound to the antibody may be determined either by measuring the amount of subject protein present in a protein/antibody complex or, alternatively, by measuring the amount of remaining uncomplexed protein. The amount of protein may be detected by providing a labeled protein molecule.


Immunoassays in the competitive binding format can be used for cross-reactivity determinations. For example, a protein of interest can be immobilized on a solid support. Proteins are added to the assay which compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to that of the protein of interest. The percent cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the considered proteins, e.g., distantly related homologs.


The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps a protein of the present invention, to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than 10 times the amount of the protein partially encoded by a sequence herein that is required, then the second protein is said to specifically bind to an antibody generated to an immunogen consisting of the target protein.


3. Other Assay Formats


In a particularly preferred embodiment, western blot (immunoblot) analysis is used to detect and quantify the presence of a polypeptide of the invention in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support (such as, e.g., a nitrocellulose filter, a nylon filter, or a derivatized nylon filter) and incubating the sample with the antibodies that specifically bind the protein of interest. For example, the antibodies specifically bind to a polypeptide of interest on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the antibodies against the protein of interest.


Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (e.g., antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (see, Monroe et al. (1986) Amer. Clin. Prod. Rev. 5:34-41).


4. Labels


The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well developed in the field of immunoassays and, in general, most labels useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (e.g., Dynabeads™), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., 3H, 125I, 35S, 14C, or 32P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.


The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on the sensitivity required, the ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.


Non-radioactive labels are often attached by indirect means. The molecules can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorescent compound. A variety of enzymes and fluorescent compounds can be used with the methods of the present invention and are well-known to those of skill in the art (for a review of various labeling or signal producing systems which may be used, see, e.g., U.S. Pat. No. 4,391,904).


Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, by means of photographic film, by the use of electronic detectors such as charge-coupled devices (CCDS) or photomultipliers and the like. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally simple colorimetric labels may be detected directly by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.


Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need to be labeled and the presence of the target antibody is detected by simple visual inspection.


VI. Screening for Modulators of Polypeptides and Polynucleotides of the Invention


Modulators of polypeptides or polynucleotides of the invention, i.e. agonists or antagonists of their activity or modulators of polypeptide or polynucleotide expression, are useful for treating a number of human diseases, including mood disorders or psychotic disorders. Administration of agonists, antagonists or other agents that modulate expression of the polynucleotides or polypeptides of the invention can be used to treat patients with mood disorders or psychotic disorders.


A. Screening Methods


A number of different screening protocols can be utilized to identify agents that modulate the level of expression or activity of polypeptides and polynucleotides of the invention in cells, particularly mammalian cells, and especially human cells. In general terms, the screening methods involve screening a plurality of agents to identify an agent that modulates the polypeptide activity by binding to a polypeptide of the invention, modulating inhibitor binding to the polypeptide or activating expression of the polypeptide or polynucleotide, for example.


1. Binding Assays


Preliminary screens can be conducted by screening for agents capable of binding to a polypeptide of the invention, as at least some of the agents so identified are likely modulators of polypeptide activity. The binding assays usually involve contacting a polypeptide of the invention with one or more test agents and allowing sufficient time for the protein and test agents to form a binding complex. Any binding complexes formed can be detected using any of a number of established analytical techniques. Protein binding assays include, but are not limited to, methods that measure co-precipitation, co-migration on non-denaturing SDS-polyacrylamide gels, and co-migration on Western blots (see, e.g., Bennet and Yamamura, (1985) “Neurotransmitter, Hormone or Drug Receptor Binding Methods,” in Neurotransmitter Receptor Binding (Yamamura, H. I., et al., eds.), pp. 61-89. The protein utilized in such assays can be naturally expressed, cloned or synthesized.


Binding assays are also useful, e.g., for identifying endogenous proteins that interact with a polypeptide of the invention. For example, antibodies, receptors or other molecules that bind a polypeptide of the invention can be identified in binding assays.


2. Expression Assays


Certain screening methods involve screening for a compound that up or down-regulates the expression of a polypeptide or polynucleotide of the invention. Such methods generally involve conducting cell-based assays in which test compounds are contacted with one or more cells expressing a polypeptide or polynucleotide of the invention and then detecting an increase or decrease in expression (either transcript, translation product, or catalytic product). Some assays are performed with peripheral cells, or other cells, that express an endogenous polypeptide or polynucleotide of the invention.


Polypeptide or polynucleotide expression can be detected in a number of different ways. As described infra, the expression level of a polynucleotide of the invention in a cell can be determined by probing the mRNA expressed in a cell with a probe that specifically hybridizes with a transcript (or complementary nucleic acid derived therefrom) of a polynucleotide of the invention. Probing can be conducted by lysing the cells and conducting Northern blots or without lysing the cells using in situ-hybridization techniques. Alternatively, a polypeptide of the invention can be detected using immunological methods in which a cell lysate is probed with antibodies that specifically bind to a polypeptide of the invention.


Other cell-based assays are reporter assays conducted with cells that do not express a polypeptide or polynucleotide of the invention. Certain of these assays are conducted with a heterologous nucleic acid construct that includes a promoter of a polynucleotide of the invention that is operably linked to a reporter gene that encodes a detectable product. A number of different reporter genes can be utilized. Some reporters are inherently detectable. An example of such a reporter is green fluorescent protein that emits fluorescence that can be detected with a fluorescence detector. Other reporters generate a detectable product. Often such reporters are enzymes. Exemplary enzyme reporters include, but are not limited to, β-glucuronidase, chloramphenicol acetyl transferase (CAT); Alton and Vapnek (1979) Nature 282:864-869), luciferase, β-galactosidase, green fluorescent protein (GFP) and alkaline phosphatase (Toh, et al. (1980) Eur. J. Biochem. 182:231-238; and Hall et al. (1983) J. Mol. Appl. Gen. 2:101).


In these assays, cells harboring the reporter construct are contacted with a test compound. A test compound that either activates the promoter by binding to it or triggers a cascade that produces a molecule that activates the promoter causes expression of the detectable reporter. Certain other reporter assays are conducted with cells that harbor a heterologous construct that includes a transcriptional control element that activates expression of a polynucleotide of the invention and a reporter operably linked thereto. Here, too, an agent that binds to the transcriptional control element to activate expression of the reporter or that triggers the formation of an agent that binds to the transcriptional control element to activate reporter expression, can be identified by the generation of signal associated with reporter expression.


The level of expression or activity can be compared to a baseline value. As indicated above, the baseline value can be a value for a control sample or a statistical value that is representative of expression levels for a control population (e.g., healthy individuals not having or at risk for mood disorders or psychotic disorders). Expression levels can also be determined for cells that do not express a polynucleotide of the invention as a negative control. Such cells generally are otherwise substantially genetically the same as the test cells.


A variety of different types of cells can be utilized in the reporter assays. Cells that express an endogenous polypeptide or polynucleotide of the invention include, e.g., brain cells, including cells from the cerebellum, anterior cingulate cortex, or dorsolateral prefrontal cortex. Cells that do not endogenously express polynucleotides of the invention can be prokaryotic, but are preferably eukaryotic. The eukaryotic cells can be any of the cells typically utilized in generating cells that harbor recombinant nucleic acid constructs. Exemplary eukaryotic cells include, but are not limited to, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cell lines and stem cells, e.g., neural stem cells.


Various controls can be conducted to ensure that an observed activity is authentic including running parallel reactions with cells that lack the reporter construct or by not contacting a cell harboring the reporter construct with test compound. Compounds can also be further validated as described below.


3. Catalytic Activity


Catalytic activity of polypeptides of the invention can be determined by measuring the production of enzymatic products or by measuring the consumption of substrates. Activity refers to either the rate of catalysis or the ability to the polypeptide to bind (Km) the substrate or release the catalytic product (Kd).


Analysis of the activity of polypeptides of the invention are performed according to general biochemical analyses. Such assays include cell-based assays as well as in vitro assays involving purified or partially purified polypeptides or crude cell lysates. The assays generally involve providing a known quantity of substrate and quantifying product as a function of time.


4. Validation


Agents that are initially identified by any of the foregoing screening methods can be further tested to validate the apparent activity. Preferably such studies are conducted with suitable animal models. The basic format of such methods involves administering a lead compound identified during an initial screen to an animal that serves as a model for humans and then determining if expression or activity of a polynucleotide or polypeptide of the invention is in fact upregulated. The animal models utilized in validation studies generally are mammals of any kind. Specific examples of suitable animals include, but are not limited to, primates, mice, and rats.


5. Animal models


Animal models of mental disorders also find use in screening for modulators. In one embodiment, rat models of schizophrenia or other mental disorder, such as depression, are used for screening. In one embodiment, invertebrate models such as Drosophila models can be used, screening for modulators of Drosophila orthologs of the human genes disclosed herein. In another embodiment, transgenic animal technology including gene knockout technology, for example as a result of homologous recombination with an appropriate gene targeting vector, or gene overexpression, will result in the absence, decreased or increased expression of a polynucleotide or polypeptide of the invention. The same technology can also be applied to make knockout cells. When desired, tissue-specific expression or knockout of a polynucleotide or polypeptide of the invention may be necessary. Transgenic animals generated by such methods find use as animal models of mental disorder and are useful in screening for modulators of mental disorder.


Knockout cells and transgenic mice can be made by insertion of a marker gene or other heterologous gene into an endogenous gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting an endogenous polynucleotide of the invention with a mutated version of the polynucleotide, or by mutating an endogenous polynucleotide, e.g., by exposure to carcinogens.


For development of appropriate stem cells, a DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).


B. Modulators of Polypeptides or Polynucleotides of the Invention


The agents tested as modulators of the polypeptides or polynucleotides of the invention can be any small chemical compound, or a biological entity, such as a protein, sugar, nucleic acid or lipid. Alternatively, modulators can be genetically altered versions of a polypeptide or polynucleotide of the invention. Typically, test compounds will be small chemical molecules and peptides. Essentially any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds that can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, Mo.), Aldrich (St. Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland) and the like. Modulators also include agents designed to reduce the level of mRNA of the invention (e.g. antisense molecules, ribozymes, DNAzymes and the like) or the level of translation from an mRNA.


In one preferred embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.


A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.


Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., PCT Publication No. WO 91/19735), encoded peptides (e.g., PCT Publication WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)), nucleic acid libraries (see Ausubel, Berger and Sambrook, all supra), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science, 274:1520-1522 (1996) and U.S. Pat. No. 5,593,853), small organic molecule libraries (see, e.g., benzodiazepines, Baum C&EN, January 18, page 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514, and the like).


Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville Ky.; Symphony, Rainin, Woburn, Mass.; 433A Applied Biosystems, Foster City, Calif.; 9050 Plus, Millipore, Bedford, Mass.). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J.; Tripos, Inc., St. Louis, Mo.; 3D Pharmaceuticals, Exton, Pa.; Martek Biosciences, Columbia, Md., etc.).


C. Solid State and Soluble High Throughput Assays


In the high throughput assays of the invention, it is possible to screen up to several thousand different modulators or ligands in a single day. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100 to about 1500 different compounds. It is possible to assay several different plates per day; assay screens for up to about 6,000-20,000 different compounds are possible using the integrated systems of the invention. More recently, microfluidic approaches to reagent manipulation have been developed.


The molecule of interest can be bound to the solid state component, directly or indirectly, via covalent or non-covalent linkage, e.g., via a tag. The tag can be any of a variety of components. In general, a molecule that binds the tag (a tag binder) is fixed to a solid support, and the tagged molecule of interest is attached to the solid support by interaction of the tag and the tag binder.


A number of tags and tag binders can be used, based upon known molecular interactions well described in the literature. For example, where a tag has a natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an immunoglobulin, etc.). Antibodies to molecules with natural binders such as biotin are also widely available and appropriate tag binders (see, SIGMA Immunochemicals 1998 catalogue SIGMA, St. Louis Mo.).


Similarly, any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair. Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature. For example, in one common configuration, the tag is a first antibody and the tag binder is a second antibody which recognizes the first antibody. In addition to antibody-antigen interactions, receptor-ligand interactions are also appropriate as tag and tag-binder pairs, such as agonists and antagonists of cell membrane receptors (e.g., cell receptor-ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors, immunoglobulin receptors and antibodies, the cadherin family, the integrin family, the selectin family, and the like; see, e.g., Pigott & Power, The Adhesion Molecule Facts Book I (1993)). Similarly, toxins and venoms, viral epitopes, hormones (e.g., opiates, steroids, etc.), intracellular receptors (e.g., which mediate the effects of various small ligands, including steroids, thyroid hormone, retinoids and vitamin D; peptides), drugs, lectins, sugars, nucleic acids (both linear and cyclic polymer configurations), oligosaccharides, proteins, phospholipids and antibodies can all interact with various cell receptors.


Synthetic polymers, such as polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneimines, polyarylene sulfides, polysiloxanes, polyimides, and polyacetates can also form an appropriate tag or tag binder. Many other tag/tag binder pairs are also useful in assay systems described herein, as would be apparent to one of skill upon review of this disclosure.


Common linkers such as peptides, polyethers, and the like can also serve as tags, and include polypeptide sequences, such as poly-Gly sequences of between about 5 and 200 amino acids. Such flexible linkers are known to those of skill in the art. For example, poly(ethelyne glycol) linkers are available from Shearwater Polymers, Inc., Huntsville, Ala. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.


Tag binders are fixed to solid substrates using any of a variety of methods currently available. Solid substrates are commonly derivatized or functionalized by exposing all or a portion of the substrate to a chemical reagent which fixes a chemical group to the surface which is reactive with a portion of the tag binder. For example, groups which are suitable for attachment to a longer chain portion would include amines, hydroxyl, thiol, and carboxyl groups. Aminoalkylsilanes and hydroxyalkylsilanes can be used to functionalize a variety of surfaces, such as glass surfaces. The construction of such solid phase biopolymer arrays is well described in the literature (see, e.g., Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1963) (describing solid phase synthesis of, e.g., peptides); Geysen et al., J. Immun. Meth. 102:259-274 (1987) (describing synthesis of solid phase components on pins); Frank and Doring, Tetrahedron 44:60316040 (1988) (describing synthesis of various peptide sequences on cellulose disks); Fodor et al., Science, 251:767-777 (1991); Sheldon et al., Clinical Chemistry 39(4):718-719 (1993); and Kozal et al., Nature Medicine 2(7):753759 (1996) (all describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.


The invention provides in vitro assays for identifying, in a high throughput format, compounds that can modulate the expression or activity of the polynucleotides or polypeptides of the invention. In a preferred embodiment, the methods of the invention include such a control reaction. For each of the assay formats described, “no modulator” control reactions that do not include a modulator provide a background level of binding activity.


In some assays it will be desirable to have positive controls to ensure that the components of the assays are working properly. At least two types of positive controls are appropriate. First, a known activator of a polynucleotide or polypeptide of the invention can be incubated with one sample of the assay, and the resulting increase in signal resulting from an increased expression level or activity of polynucleotide or polypeptide determined according to the methods herein. Second, a known inhibitor of a polynucleotide or polypeptide of the invention can be added, and the resulting decrease in signal for the expression or activity can be similarly detected.


D. Computer-Based Assays


Yet another assay for compounds that modulate the activity of a polypeptide or polynucleotide of the invention involves computer assisted drug design, in which a computer system is used to generate a three-dimensional structure of the polypeptide or polynucleotide based on the structural information encoded by its amino acid or nucleotide sequence. The input sequence interacts directly and actively with a pre-established algorithm in a computer program to yield secondary, tertiary, and quaternary structural models of the molecule. Similar analyses can be performed on potential receptors or binding partners of the polypeptides or polynucleotides of the invention. The models of the protein or nucleotide structure are then examined to identify regions of the structure that have the ability to bind, e.g., a polypeptide or polynucleotide of the invention. These regions are then used to identify polypeptides that bind to a polypeptide or polynucleotide of the invention.


The three-dimensional structural model of a protein is generated by entering protein amino acid sequences of at least 10 amino acid residues or corresponding nucleic acid sequences encoding a potential receptor into the computer system. The amino acid sequences encoded by the nucleic acid sequences provided herein represent the primary sequences or subsequences of the proteins, which encode the structural information of the proteins. At least 10 residues of an amino acid sequence (or a nucleotide sequence encoding 10 amino acids) are entered into the computer system from computer keyboards, computer readable substrates that include, but are not limited to, electronic storage media (e.g., magnetic diskettes, tapes, cartridges, and chips), optical media (e.g., CD ROM), information distributed by internet sites, and by RAM. The three-dimensional structural model of the protein is then generated by the interaction of the amino acid sequence and the computer system, using software known to those of skill in the art.


The amino acid sequence represents a primary structure that encodes the information necessary to form the secondary, tertiary, and quaternary structure of the protein of interest. The software looks at certain parameters encoded by the primary sequence to generate the structural model. These parameters are referred to as “energy terms,” and primarily include electrostatic potentials, hydrophobic potentials, solvent accessible surfaces, and hydrogen bonding. Secondary energy terms include van der Waals potentials. Biological molecules form the structures that minimize the energy terms in a cumulative fashion. The computer program is therefore using these terms encoded by the primary structure or amino acid sequence to create the secondary structural model.


The tertiary structure of the protein encoded by the secondary structure is then formed on the basis of the energy terms of the secondary structure. The user at this point can enter additional variables such as whether the protein is membrane bound or soluble, its location in the body, and its cellular location, e.g., cytoplasmic, surface, or nuclear. These variables along with the energy terms of the secondary structure are used to form the model of the tertiary structure. In modeling the tertiary structure, the computer program matches hydrophobic faces of secondary structure with like, and hydrophilic faces of secondary structure with like.


Once the structure has been generated, potential ligand binding regions are identified by the computer system. Three-dimensional structures for potential ligands are generated by entering amino acid or nucleotide sequences or chemical formulas of compounds, as described above. The three-dimensional structure of the potential ligand is then compared to that of a polypeptide or polynucleotide of the invention to identify binding sites of the polypeptide or polynucleotide of the invention. Binding affinity between the protein and ligands is determined using energy terms to determine which ligands have an enhanced probability of binding to the protein.


Computer systems are also used to screen for mutations, polymorphic variants, alleles and interspecies homologs of genes encoding a polypeptide or polynucleotide of the invention. Such mutations can be associated with disease states or genetic traits and can be used for diagnosis. As described above, GeneChip™ and related technology can also be used to screen for mutations, polymorphic variants, alleles and interspecies homologs. Once the variants are identified, diagnostic assays can be used to identify patients having such mutated genes. Identification of the mutated a polypeptide or polynucleotide of the invention involves receiving input of a first amino acid sequence of a polypeptide of the invention (or of a first nucleic acid sequence encoding a polypeptide of the invention), e.g., any amino acid sequence having at least 60%, optionally at least 70% or 85%, identity with the amino acid sequence of interest, or conservatively modified versions thereof. The sequence is entered into the computer system as described above. The first nucleic acid or amino acid sequence is then compared to a second nucleic acid or amino acid sequence that has substantial identity to the first sequence. The second sequence is entered into the computer system in the manner described above. Once the first and second sequences are compared, nucleotide or amino acid differences between the sequences are identified. Such sequences can represent allelic differences in various polynucleotides, including SNPs and/or haplotypes, of the invention, and mutations associated with disease states and genetic traits.


VII. Compositions, Kits and Integrated Systems


The invention provides compositions, kits and integrated systems for practicing the assays described herein using polypeptides or polynucleotides of the invention, antibodies specific for polypeptides or polynucleotides of the invention, etc.


The invention provides assay compositions for use in solid phase assays; such compositions can include, for example, one or more polynucleotides or polypeptides of the invention immobilized on a solid support, and a labeling reagent. In each case, the assay compositions can also include additional reagents that are desirable for hybridization. Modulators of expression or activity of polynucleotides or polypeptides of the invention can also be included in the assay compositions.


The invention also provides kits for carrying out the therapeutic and diagnostic assays of the invention. The kits typically include a probe that comprises an antibody that specifically binds to polypeptides or polynucleotides of the invention, and a label for detecting the presence of the probe. The kits may include several polynucleotide sequences encoding polypeptides of the invention. Kits can include any of the compositions noted above, and optionally further include additional components such as instructions to practice a high-throughput method of assaying for an effect on expression of the genes encoding the polypeptides of the invention, or on activity of the polypeptides of the invention, one or more containers or compartments (e.g., to hold the probe, labels, or the like), a control modulator of the expression or activity of polypeptides of the invention, a robotic armature for mixing kit components or the like.


The invention also provides integrated systems for high-throughput screening of potential modulators for an effect on the expression or activity of the polypeptides of the invention. The systems typically include a robotic armature which transfers fluid from a source to a destination, a controller which controls the robotic armature, a label detector, a data storage unit which records label detection, and an assay component such as a microtiter dish comprising a well having a reaction mixture or a substrate comprising a fixed nucleic acid or immobilization moiety.


A number of robotic fluid transfer systems are available, or can easily be made from existing components. For example, a Zymate XP (Zymark Corporation; Hopkinton, Mass.) automated robot using a Microlab 2200 (Hamilton; Reno, Nev.) pipetting station can be used to transfer parallel samples to 96 well microtiter plates to set up several parallel simultaneous STAT binding assays.


Optical images viewed (and, optionally, recorded) by a camera or other recording device (e.g., a photodiode and data storage device) are optionally further processed in any of the embodiments herein, e.g., by digitizing the image and storing and analyzing the image on a computer. A variety of commercially available peripheral equipment and software is available for digitizing, storing and analyzing a digitized video or digitized optical image, e.g., using PC, MACINTOSH®, or UNIX® based (e.g., SUN® work station) computers.


One conventional system carries light from the specimen field to a cooled charge-coupled device (CCD) camera, in common use in the art. A CCD camera includes an array of picture elements (pixels). The light from the specimen is imaged on the CCD. Particular pixels corresponding to regions of the specimen (e.g., individual hybridization sites on an array of biological polymers) are sampled to obtain light intensity readings for each position. Multiple pixels are processed in parallel to increase speed. The apparatus and methods of the invention are easily used for viewing any sample, e.g., by fluorescent or dark field microscopic techniques. Lasar based systems can also be used.


VIII. Administration and Pharmaceutical compositions


Modulators of the polynucleotides or polypeptides of the invention (e.g., antagonists or agonists) can be administered directly to a mammalian subject for modulation of activity of those molecules in vivo. Administration is by any of the routes normally used for introducing a modulator compound into ultimate contact with the tissue to be treated and is well known to those of skill in the art. Although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.


Diseases that can be treated include the following, which include the corresponding reference number from Morrison, DSM-IV Made Easy, 1995: Schizophrenia, Catatonic, Subchronic, (295.21); Schizophrenia, Catatonic, Chronic (295.22); Schizophrenia, Catatonic, Subchronic with Acute Exacerbation (295.23); Schizophrenia, Catatonic, Chronic with Acute Exacerbation (295.24); Schizophrenia, Catatonic, in Remission (295.55); Schizophrenia, Catatonic, Unspecified (295.20); Schizophrenia, Disorganized, Subchronic (295.11); Schizophrenia, Disorganized, Chronic (295.12); Schizophrenia, Disorganized, Subchronic with Acute Exacerbation (295.13); Schizophrenia, Disorganized, Chronic with Acute Exacerbation (295.14); Schizophrenia, Disorganized, in Remission (295.15); Schizophrenia, Disorganized, Unspecified (295.10); Schizophrenia, Paranoid, Subchronic (295.31); Schizophrenia, Paranoid, Chronic (295.32); Schizophrenia, Paranoid, Subchronic with Acute Exacerbation (295.33); Schizophrenia, Paranoid, Chronic with Acute Exacerbation (295.34); Schizophrenia, Paranoid, in Remission (295.35); Schizophrenia, Paranoid, Unspecified (295.30); Schizophrenia, Undifferentiated, Subchronic (295.91); Schizophrenia, Undifferentiated, Chronic (295.92); Schizophrenia, Undifferentiated, Subchronic with Acute Exacerbation (295.93); Schizophrenia, Undifferentiated, Chronic with Acute Exacerbation (295.94); Schizophrenia, Undifferentiated, in Remission (295.95); Schizophrenia, Undifferentiated, Unspecified (295.90); Schizophrenia, Residual, Subchronic (295.61); Schizophrenia, Residual, Chronic (295.62); Schizophrenia, Residual, Subchronic with Acute Exacerbation (295.63); Schizophrenia, Residual, Chronic with Acute Exacerbation (295.94); Schizophrenia, Residual, in Remission (295.65); Schizophrenia, Residual, Unspecified (295.60); Delusional (Paranoid) Disorder (297.10); Brief Reactive Psychosis (298.80); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70); Induced Psychotic Disorder (297.30); Psychotic Disorder NOS (Atypical Psychosis) (298.90); Personality Disorders, Paranoid (301.00); Personality Disorders, Schizoid (301.20); Personality Disorders, Schizotypal (301.22); Personality Disorders, Antisocial (301.70); Personality Disorders, Borderline (301.83) and bipolar disorders, maniac, hypomaniac, dysthymic or cyclothymic disorders, substance-induced major depression, psychotic disorder, including schizophrenia (paranoid, catatonic, delusional) having schizoaffective disorder, and substance-induced psychotic disorder.


In some embodiments, modulators of polynucleotides or polypeptides of the invention can be combined with other drugs useful for treating mental disorders including psychotic disorders, e.g., schizophrenia; and mood disorders, e.g., bipolar disorders, or major depression. In some preferred embodiments, pharmaceutical compositions of the invention comprise a modulator of a polypeptide of polynucleotide of the invention combined with at least one of the compounds useful for treating schizophrenia, bipolar disorder, or major depression, e.g., such as those described in U.S. Pat. Nos. 6,297,262; 6,284,760; 6,284,771; 6,232,326; 6,187,752; 6,117,890; 6,239,162 or 6,166,008.


The pharmaceutical compositions of the invention may comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, e.g., Remington's Pharmaceutical Sciences, 17th ed. 1985)).


The modulators (e.g., agonists or antagonists) of the expression or activity of the a polypeptide or polynucleotide of the invention, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be “nebulized”) to be administered via inhalation or in compositions useful for injection. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.


Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, orally, nasally, topically, intravenously, intraperitoneally, or intrathecally. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The modulators can also be administered as part of a prepared food or drug.


The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial response in the subject over time. The optimal dose level for any patient will depend on a variety of factors including the efficacy of the specific modulator employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the mental disorder. The size of the dose also will be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a particular compound or vector in a particular subject.


In determining the effective amount of the modulator to be administered a physician may evaluate circulating plasma levels of the modulator, modulator toxicity, and the production of anti-modulator antibodies. In general, the dose equivalent of a modulator is from about 1 ng/kg to 10 mg/kg for a typical subject.


For administration, modulators of the present invention can be administered at a rate determined by the LD-50 of the modulator, and the side effects of the modulator at various concentrations, as applied to the mass and overall health of the subject. Administration can be accomplished via single or divided doses.


IX. Gene Therapy Applications


A variety of human diseases can be treated by therapeutic approaches that involve stably introducing a gene into a human cell such that the gene is transcribed and the gene product is produced in the cell. Diseases amenable to treatment by this approach include inherited diseases, including those in which the defect is in a single or multiple genes. Gene therapy is also useful for treatment of acquired diseases and other conditions. For discussions on the application of gene therapy towards the treatment of genetic as well as acquired diseases, see, Miller, Nature 357:455-460 (1992); and Mulligan, Science 260:926-932 (1993).


In the context of the present invention, gene therapy can be used for treating a variety of disorders and/or diseases in which the polynucleotides and polypeptides of the invention has been implicated. For example, compounds, including polynucleotides, can be identified by the methods of the present invention as effective in treating a mental disorder. Introduction by gene therapy of these polynucleotides can then be used to treat, e.g., mental disorders including mood disorders or psychotic disorders (e.g., schizophrenia).


A. Vectors for Gene Delivery


For delivery to a cell or organism, the polynucleotides of the invention can be incorporated into a vector. Examples of vectors used for such purposes include expression plasmids capable of directing the expression of the nucleic acids in the target cell. In other instances, the vector is a viral vector system wherein the nucleic acids are incorporated into a viral genome that is capable of transfecting the target cell. In a preferred embodiment, the polynucleotides can be operably linked to expression and control sequences that can direct expression of the gene in the desired target host cells. Thus, one can achieve expression of the nucleic acid under appropriate conditions in the target cell.


B. Gene Delivery Systems


Viral vector systems useful in the expression of the nucleic acids include, for example, naturally occurring or recombinant viral vector systems. Depending upon the particular application, suitable viral vectors include replication competent, replication deficient, and conditionally replicating viral vectors. For example, viral vectors can be derived from the genome of human or bovine adenoviruses, vaccinia virus, herpes virus, adeno-associated virus, minute virus of mice (MVM), HIV, sindbis virus, and retroviruses (including but not limited to Rous sarcoma virus), and MoMLV. Typically, the genes of interest are inserted into such vectors to allow packaging of the gene construct, typically with accompanying viral DNA, followed by infection of a sensitive host cell and expression of the gene of interest.


As used herein, “gene delivery system” refers to any means for the delivery of a nucleic acid of the invention to a target cell. In some embodiments of the invention, nucleic acids are conjugated to a cell receptor ligand for facilitated uptake (e.g., invagination of coated pits and internalization of the endosome) through an appropriate linking moiety, such as a DNA linking moiety (Wu et al., J. Biol. Chem. 263:14621-14624 (1988); WO 92/06180). For example, nucleic acids can be linked through a polylysine moiety to asialo-oromucocid, which is a ligand for the asialoglycoprotein receptor of hepatocytes.


Similarly, viral envelopes used for packaging gene constructs that include the nucleic acids of the invention can be modified by the addition of receptor ligands or antibodies specific for a receptor to permit receptor-mediated endocytosis into specific cells (see, e.g., WO 93/20221, WO 93/14188, and WO 94/06923). In some embodiments of the invention, the DNA constructs of the invention are linked to viral proteins, such as adenovirus particles, to facilitate endocytosis (Curiel et al., Proc. Natl. Acad. Sci. U.S.A. 88:8850-8854 (1991)). In other embodiments, molecular conjugates of the instant invention can include microtubule inhibitors (WO/9406922), synthetic peptides mimicking influenza virus hemagglutinin (Plank et al., J. Biol. Chem. 269:12918-12924 (1994)), and nuclear localization signals such as SV40 T antigen (WO93/19768).


Retroviral vectors are also useful for introducing the nucleic acids of the invention into target cells or organisms. Retroviral vectors are produced by genetically manipulating retroviruses. The viral genome of retroviruses is RNA. Upon infection, this genomic RNA is reverse transcribed into a DNA copy which is integrated into the chromosomal DNA of transduced cells with a high degree of stability and efficiency. The integrated DNA copy is referred to as a provirus and is inherited by daughter cells as is any other gene. The wild type retroviral genome and the proviral DNA have three genes: the gag, the pol and the env genes, which are flanked by two long terminal repeat (LTR) sequences. The gag gene encodes the internal structural (nucleocapsid) proteins; the pol gene encodes the RNA directed DNA polymerase (reverse transcriptase); and the env gene encodes viral envelope glycoproteins. The 5′ and 3′ LTRs serve to promote transcription and polyadenylation of virion RNAs. Adjacent to the 5′ LTR are sequences necessary for reverse transcription of the genome (the tRNA primer binding site) and for efficient encapsulation of viral RNA into particles (the Psi site) (see, Mulligan, In: Experimental Manipulation of Gene Expression, Inouye (ed), 155-173 (1983); Mann et al., Cell 33:153-159 (1983); Cone and Mulligan, Proceedings of the National Academy of Sciences, U.S.A., 81:6349-6353 (1984)).


The design of retroviral vectors is well known to those of ordinary skill in the art. In brief, if the sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virions) are missing from the viral genome, the result is a cis-acting defect which prevents encapsidation of genomic RNA. However, the resulting mutant is still capable of directing the synthesis of all virion proteins. Retroviral genomes from which these sequences have been deleted, as well as cell lines containing the mutant genome stably integrated into the chromosome are well known in the art and are used to construct retroviral vectors. Preparation of retroviral vectors and their uses are described in many publications including, e.g., European Patent Application EPA 0 178 220; U.S. Pat. No. 4,405,712, Gilboa Biotechniques 4:504-512 (1986); Mann et al., Cell 33:153-159 (1983); Cone and Mulligan Proc. Natl. Acad. Sci. USA 81:6349-6353 (1984); Eglitis et al. Biotechniques 6:608-614 (1988); Miller et al. Biotechniques 7:981-990 (1989); Miller (1992) supra; Mulligan (1993), supra; and WO 92/07943.


The retroviral vector particles are prepared by recombinantly inserting the desired nucleotide sequence into a retrovirus vector and packaging the vector with retroviral capsid proteins by use of a packaging cell line. The resultant retroviral vector particle is incapable of replication in the host cell but is capable of integrating into the host cell genome as a proviral sequence containing the desired nucleotide sequence. As a result, the patient is capable of producing, for example, a polypeptide or polynucleotide of the invention and thus restore the cells to a normal phenotype.


Packaging cell lines that are used to prepare the retroviral vector particles are typically recombinant mammalian tissue culture cell lines that produce the necessary viral structural proteins required for packaging, but which are incapable of producing infectious virions. The defective retroviral vectors that are used, on the other hand, lack these structural genes but encode the remaining proteins necessary for packaging. To prepare a packaging cell line, one can construct an infectious clone of a desired retrovirus in which the packaging site has been deleted. Cells comprising this construct will express all structural viral proteins, but the introduced DNA will be incapable of being packaged. Alternatively, packaging cell lines can be produced by transforming a cell line with one or more expression plasmids encoding the appropriate core and envelope proteins. In these cells, the gag, pol, and env genes can be derived from the same or different retroviruses.


A number of packaging cell lines suitable for the present invention are also available in the prior art. Examples of these cell lines include Crip, GPE86, PA317 and PG13 (see Miller et al., J. Virol. 65:2220-2224 (1991)). Examples of other packaging cell lines are described in Cone and Mulligan Proceedings of the National Academy of Sciences, USA, 81:6349-6353 (1984); Danos and Mulligan Proceedings of the National Academy of Sciences, USA, 85:6460-6464 (1988); Eglitis et al. (1988), supra; and Miller (1990), supra.


Packaging cell lines capable of producing retroviral vector particles with chimeric envelope proteins may be used. Alternatively, amphotropic or xenotropic envelope proteins, such as those produced by PA317 and GPX packaging cell lines may be used to package the retroviral vectors.


In some embodiments of the invention, an antisense polynucleotide is administered which hybridizes to a gene encoding a polypeptide of the invention. The antisense polypeptide can be provided as an antisense oligonucleotide (see, e.g., Murayama et al., Antisense Nucleic Acid Drug Dev. 7:109-114 (1997)). Genes encoding an antisense nucleic acid can also be provided; such genes can be introduced into cells by methods known to those of skill in the art. For example, one can introduce an antisense nucleotide sequence in a viral vector, such as, for example, in hepatitis B virus (see, e.g., Ji et al., J. Viral Hepat. 4:167-173 (1997)), in adeno-associated virus (see, e.g., Xiao et al., Brain Res. 756:76-83 (1997)), or in other systems including, but not limited, to an HVJ (Sendai virus)-liposome gene delivery system (see, e.g., Kaneda et al., Ann. NY Acad. Sci. 811:299-308 (1997)), a “peptide vector” (see, e.g., Vidal et al., CR Acad. Sci III 32:279-287 (1997)), as a gene in an episomal or plasmid vector (see, e.g., Cooper et al., Proc. Natl. Acad. Sci. U.S.A. 94:6450-6455 (1997), Yew et al. Hum Gene Ther. 8:575-584 (1997)), as a gene in a peptide-DNA aggregate (see, e.g., Niidome et al., J. Biol. Chem. 272:15307-15312 (1997)), as “naked DNA” (see, e.g., U.S. Pat. Nos. 5,580,859 and 5,589,466), in lipidic vector systems (see, e.g., Lee et al., Crit Rev Ther Drug Carrier Syst. 14:173-206 (1997)), polymer coated liposomes (U.S. Pat. Nos. 5,213,804 and 5,013,556), cationic liposomes (Epand et al., U.S. Pat. Nos. 5,283,185; 5,578,475; 5,279,833; and 5,334,761), gas filled microspheres (U.S. Pat. No. 5,542,935), ligand-targeted encapsulated macromolecules (U.S. Pat. Nos. 5,108,921; 5,521,291; 5,554,386; and 5,166,320).


In another embodiment, conditional expression systems, such as those typified by the tet-regulated systems and the RU-486 system, can be used (see, e.g., Gossen & Bujard, PNAS 89:5547 (1992); Oligino et al., Gene Ther. 5:491-496 (1998); Wang et al., Gene Ther. 4:432-441 (1997); Neering et al., Blood 88:1147-1155 (1996); and Rendahl et al., Nat. Biotechnol. 16:757-761 (1998)). These systems impart small molecule control on the expression of the target gene(s) of interest.


C. Pharmaceutical Formulations


When used for pharmaceutical purposes, the vectors used for gene therapy are formulated in a suitable buffer, which can be any pharmaceutically acceptable buffer, such as phosphate buffered saline or sodium phosphate/sodium sulfate, Tris buffer, glycine buffer, sterile water, and other buffers known to the ordinarily skilled artisan such as those described by Good et al. Biochemistry 5:467 (1966).


The compositions can additionally include a stabilizer, enhancer, or other pharmaceutically acceptable carriers or vehicles. A pharmaceutically acceptable carrier can contain a physiologically acceptable compound that acts, for example, to stabilize the nucleic acids of the invention and any associated vector. A physiologically acceptable compound can include, for example, carbohydrates, such as glucose, sucrose or dextrans; antioxidants, such as ascorbic acid or glutathione; chelating agents; low molecular weight proteins or other stabilizers or excipients. Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents, or preservatives, which are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid. Examples of carriers, stabilizers, or adjuvants can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985).


D. Administration of Formulations


The formulations of the invention can be delivered to any tissue or organ using any delivery method known to the ordinarily skilled artisan. In some embodiments of the invention, the nucleic acids of the invention are formulated in mucosal, topical, and/or buccal formulations, particularly mucoadhesive gel and topical gel formulations. Exemplary permeation enhancing compositions, polymer matrices, and mucoadhesive gel preparations for transdermal delivery are disclosed in U.S. Pat. No. 5,346,701.


E. Methods of Treatment


The gene therapy formulations of the invention are typically administered to a cell. The cell can be provided as part of a tissue, such as an epithelial membrane, or as an isolated cell, such as in tissue culture. The cell can be provided in vivo, ex vivo, or in vitro.


The formulations can be introduced into the tissue of interest in vivo or ex vivo by a variety of methods. In some embodiments of the invention, the nucleic acids of the invention are introduced into cells by such methods as microinjection, calcium phosphate precipitation, liposome fusion, or biolistics. In further embodiments, the nucleic acids are taken up directly by the tissue of interest.


In some embodiments of the invention, the nucleic acids of the invention are administered ex vivo to cells or tissues explanted from a patient, then returned to the patient. Examples of ex vivo administration of therapeutic gene constructs include Nolta et al., Proc Natl. Acad. Sci. USA 93(6):2414-9 (1996); Koc et al., Seminars in Oncology 23 (1):46-65 (1996); Raper et al., Annals of Surgery 223(2):116-26 (1996); Dalesandro et al., J. Thorac. Cardi. Surg., 11(2):416-22 (1996); and Makarov et al., Proc. Natl. Acad. Sci. USA 93(1):402-6 (1996).


X. Diagnosis of Mood Disorders and Psychotic Disorders


The present invention also provides methods of diagnosing mood disorders (such as major depression or bipolar disorder), psychotic disorders (such as schizophrenia). In one preferred embodiment, the disease state encompasses psychotic disorders. Diagnosis involves determining the level of a polypeptide or polynucleotide of the invention in a patient and then comparing the level to a baseline or range. Typically, the baseline value is representative of a polypeptide or polynucleotide of the invention in a healthy person not suffering from a mood disorder or psychotic disorder or under the effects of medication or other drugs. Variation of levels of a polypeptide or polynucleotide of the invention from the baseline range (either up or down) indicates that the patient has a mood disorder or psychotic disorder or at risk of developing at least some aspects of a mood disorder or psychotic disorder. In some embodiments, the level of a polypeptide or polynucleotide of the invention are measured by taking a blood, urine or tissue sample from a patient and measuring the amount of a polypeptide or polynucleotide of the invention in the sample using any number of detection methods, such as those discussed herein, e.g., SNPs or haplotypes associated with this genes. The genes provided herein also can be used to develop probe sets for PCR and chip assays.


Single nucleotide polymorphism (SNP) analysis is also useful for detecting differences between alleles of the polynucleotides (e.g., genes) of the invention. SNPs linked to genes encoding polypeptides of the invention are useful, for instance, for diagnosis of diseases (e.g., mood disorders such as bipolar disease, major depression, and schizophrenia disorders) whose occurrence is linked to the gene sequences of the invention. For example, if an individual carries at least one SNP linked to a disease-associated allele of the gene sequences of the invention, the individual is likely predisposed for one or more of those diseases. If the individual is homozygous for a disease-linked SNP, the individual is particularly predisposed for occurrence of that disease. In some embodiments, the SNP associated with the gene sequences of the invention is located within 300,000; 200,000; 100,000; 75,000; 50,000; or 10,000 base pairs from the gene sequence.


Various real-time PCR methods can be used to detect SNPs, including, e.g., Taqman or molecular beacon-based assays (e.g., U.S. Pat. Nos. 5,210,015; 5,487,972; Tyagi et al., Nature Biotechnology 14:303 (1996); and PCT WO 95/13399 are useful to monitor for the presence of absence of a SNP. Additional SNP detection methods include, e.g., DNA sequencing, sequencing by hybridization, dot blotting, oligonucleotide array (DNA Chip) hybridization analysis, or are described in, e.g., U.S. Pat. No. 6,177,249; Landegren et al., Genome Research, 8:769-776 (1998); Botstein et al., Am J Human Genetics 32:314-331 (1980); Meyers et al., Methods in Enzymology 155:501-527 (1987); Keen et al., Trends in Genetics 7:5 (1991); Myers et al., Science 230:1242-1246 (1985); and Kwok et al., Genomics 23:138-144 (1994).


In some embodiments, the level of the enzymatic product of a polypeptide or polynucleotide of the invention is measured and compared to a baseline value of a healthy person or persons. Modulated levels of the product compared to the baseline indicates that the patient has a mood disorder or psychotic disorder or is at risk of developing at least some aspects of a mood disorder or psychotic disorder. Patient samples, for example, can be blood, PBS, lymphocytes, saliva, CSF, urine or tissue samples.


Immunoassays using antigens and antibodies for genes differentially expressed in psychotic disorders are also useful for immunoassays such as ELISA and immunohistochemical assays. The genes described herein are also useful for making differential diagnoses for psychiatric disorders.


It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.


EXAMPLES
Example 1
Identification of Genes Dysregulated in Psychotic Disorders

Post mortem mental disorder brains (i.e. from schizophrenia patients) and control brains were used in this study. Each brain pair (case and control) was matched on the basis of gender, age, and postmortem interval. Ten brain regions, anterior cingulate cortex (AnCg), dorsolateral prefrontal cortex (DLPFC), cerebellar cortex (CB), entorhinal cortex (ERC), superior temporal gyrus (STG), parietal cortex (PC), nucleus accumbens (nAcc), ventral thalamus (VThal), medial thalamus (MThal) and/or the hippocampus (HC) were extracted for RNA and subjected to microarray analysis using Affymetrix oligonucleotide GeneChips™. Each RNA sample was subjected to two independent analyses. The results were analyzed using multiple statistical tools and algorithms with various stringencies. The patient's particular conditions in their terminal phase (agonal factors, e.g., seizure, coma, hypoxia, dehydration, and pyrexia) and the conditions of the brain tissue after death (postmortem factors, e.g., postmortem interval, and freezer interval) are two major influences on RNA preservation in postmortem brain tissue. Brain pH has been evaluated as an indicator for agonal status, and as an indicator of RNA preservation. Subjects with agonal factors and low pH samples, in which RNA quality was found to be compromised were eliminated from the study. The genes identified using this study are listed in Table 1.


Genes differentially expressed in mental disorders and their gene ontologies are listed in Tables 2-22. Each gene ontology (GO) term is listed with accompanying gene list of differentially expressed genes that belong to the given GO term. A separate table is given for each term either within specific brain regions or across a union of regions as indicated. An annotated table showing the enrichment of synaptic transmission, neurogenesis, ribosomal, cation homeostasis, and heat shock protein is included for genes 1.2 fold in any brain region. The current invention establishes a strong association between schizophrenia and genes in chromosomes 2, 5, 6 and 12.


Within genes differentially expressed in both Bipolar disorders (BP) and Schizophrenia (SZ) in either the AnCg or DLPFC, the direction of change in the disease state compared to controls is typically the same. Conversely, genes commonly differentially expressed in both SZ and Mayor depression (MD) are often disregulated in opposing directions. For example, genes disregulated in both SZ and MD are typically increased in SZ and decreased in MD. This is true for both the AnCg and DLPFC but is most striking in the DLPFC.


Example 1
Identification of Genes Dysregulated in Psychotic Disorders

The genes listed in Tables 22-25 are from the analysis of 3 brain regions, Dorsolateral Prefrontal Cortex (DLFC), Anterior Cingulate (AnCg) and Amigdala (AMY). The analysis was based on a new cohort of 10 schizophrenics and 7 controls. The criteria for selecting the brains were agonal factor (AFS=0), pH (>6.4), and ratio 28S/18S. Data was analyzed by GCRMA. Duplicated experimental data was averaged. Student t test was applied for statistical significance. The criteria of p<0.05, and fold change>1.2 or <0.83333 were used for significant criteria.


Example 3
Variation in GRM3 Affects Cognition, Prefrontal Glutamate, and Risk for Schizophrenia

As described in Egan et al., Proc. Nat'l Acad. Sci. USA 101:12604-12609 (2004) (herein incorporated by reference in its entirety), the metabotropic glutamate receptor GRM3 is involved in schizophrenia. A common GRM3 haplotype is strongly associated with schizophrenia. Within this hapltotype, the A allele of a single-nucleotdite polymorphism (SNP) 4 (hCV11245618) in intron 2 is overtransmitted.


The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, databases, Genbank sequences, GO terms, patents, and patent applications cited herein are hereby incorporated by reference.

TABLE 1GenBankAccessionNos.Gene NameChromosomeAnCgCBDLPFCERCHCnAccPCSTGMthalVthalU487051.391.27NM_000991.1ribosomal protein L28|19|19q|19q13|1.231.241.25NM_003753.1eukaryotic translation initiation factor|22|22q|22q13|1.253, subunit 7 zeta, 66/67 kDaNM_003753.1eukaryotic translation initiation factor|22|22q|22q13|1.253, subunit 7 zeta, 66/67 kDaNM_004500.1heterogeneous nuclear|14|14q|14q11|1.311.23ribonucleoprotein C (C1/C2)NM_004404.1neural precursor cell expressed,|2|2q|1.251.201.471.21developmentally down-regulated 5NM_003754.1eukaryotic translation initiation factor|11|1.201.223, subunit 5 epsilon, 47 kDaNM_007104.2ribosomal protein L10a|6|6p|6p21|1.211.23NM_001344.1defender against cell death 1|14|14q|14q11|1.231.291.321.251.27L05095.1hypothetical protein FLJ22875|15|15q|15q22|1.23U16738.1ribosomal protein L14|3|3p|3p22|1.22BE869922H3 histone, family 3A|1|1q|1.261.34AK024976.1coated vesicle membrane protein|12|12q|12q24|1.241.25BG168896farnesyltransferase, CAAX box, alpha|8|8p|8p22|1.361.251.39N32864histidine triad nucleotide binding|5|5q|5q31|1.201.23protein 1AI862255ATPase, H+ transporting, lysosomal|5|5q|5q35|1.241.421.231.271.221.219 kDa, V0 subunit eNM_002444.1moesin|X|Xq|Xq11|1.211.381.39NM_006265.1RAD21 homolog (S. pombe)|8|8q|1.22NM_004068.1adaptor-related protein complex 2,|3|3q|1.251.26mu 1 subunitNM_004872.1chromosome 1 open reading frame 8|1|1p|1p36|1.221.35NM_004184.2adaptor-related protein complex 1,|19|19p|19p13|1.241.221.351.231.42mu 1 subunitNM_005022.1profilin 1|17|17p|17p13|1.211.31BC003623.1tyrosine 3-|8|8q|8q23|0.800.74monooxygenase/tryptophan 5-monooxygenase activation protein,zeta polpeptideU28964.1tyrosine 3-|8|8q|8q23|0.790.730.69monooxygenase/tryptophan 5-monooxygenase activation protein,zeta polypeptideNM_000454.1superoxide dismutase 1, soluble|21|21q|21q22|1.23(amyotrophic lateral sclerosis 1(adult))NM_023009.1macrophage myristoylated alanine-|1|1p|1p34|1.27rich C kinase substrateNM_005566.1lactate dehydrogenase A|11|11p|11p15|1.311.251.291.29J02783.1procollagen-proline, 2-oxoglutarate 4-|17|17q|1.21dioxygenase (proline 4-hydroxylase),beta polypeptide (protein disulfideisomerase; thyroid hormone bindingprotein p55)NM_014765.1translocase of outer mitochondrial|1|1q|1.231.201.22membrane 20 (yeast) homologNM_003118.1secreted protein, acidic, cysteine-rich|5|5q|5q31|1.731.47(osteonectin)NM_006145.1DnaJ (Hsp40) homolog, subfmaily B,|19|19p|19p13|1.31member 1NM_004339.2pituitary tumor-transforming 1|21|21q|21q22|1.391.291.521.401.201.241.261.25interacting proteinNM_006708.1glyoxalase I|6|6p|6p21|1.20BC000478.1heat shock 70 kDa protein 9B|5|5q|5q31|1.23(mortalin-2)NM_006826.1tyrosine 3-|2|1.301.26monooxygenase/tryptophan 5-monooxygenase activation protein,theta polypeptideNM_000177.1gelsolin (amyloidosis, Finnish type)|9|9q|1.251.43NM_003746.1dynein, cytoplasmic, light polypeptide 1|12|12q|12q24|AB034747.1LPS-induced TNF-alpha factor|16|16p|16p13|1.511.301.201.531.351.63NM_006013.1ribosomal protein L10|X|Xq|1.22AA699583ARP2 actin-related protein 2 homolog|2|2p|1.271.201.25(yeast)NM_000291.1phosphoglycerate kinase 1|X|Xq|1.34NM_000291.1phosphoglycerate kinase 1|X|Xq|1.211.21BG231932ceroid-lipofuscinosis, neuronal 2, late|11|11P|1.361.221.27127infantile (Jansky-Bielschowskydisease)BF112006RAN, member RAS oncogene family|6|6p|1.24AF054183.1RAN, member RAS oncogene family|6|6p|1.261.23N92494vitamin A responsive; cytoskeleton|3|3p|1.261.271.341.24relatedNM_001003.1ribosomal protein, large, P1|15|15q|1.22NM_001903.1catenin (cadherin-associated protein),|5|5q|1.241.381.391.301.39alpha 1 (102 kDaBF686442prothymosin, alpha (gene sequence|2|2q|2q35|1.351.3528)NM_001019.1ribosomal protein S15a|16|16p|1.25NM_002539.1ornithine decarboxylase 1|2|2p|1.281.281.201.25NM_005345.3heat shock 70 kDa protein 1A|6|6p|6p21|1.331.521.22NM_005345.3heat shock 70 kDa protein 1A|6|6p|6p21|1.371.551.221.30NM_006513.1seryl-tRNA synthetase|1|1p|1p13|1.201.24NM_003217.1testis enhanced gene transcript (BAX|12|12q|12q12|1.261.241.20inhibitor 1)BE256479heat shock 60 kDa protein 1|12|12q|1.331.47(chaperonin)NM_002156.1heat shock 60 kDa protein 1|12|12q|1.25(chaperonin)NM_006429.1chaperonin containing TCP1, subunit|2|2p|1.237 (eta)NM_002812.1proteasome (prosome, macropain)|19|19q|19q13|1.2026S subunit, non-ATPase, 8NM_013995.1lysosomal-associated membrane|X|Xq|1.201.771.481.361.74protein 2NM_000992.1ribosomal protein L29|3|3p|p21|1.201.201.211.24NM_002808.1proteasome (prosome, macropain)|3|3q|3q27|1.2226S subunit, non-ATPase, 2AB032261.1stearoyl-CoA desaturase (delta-9-|10|10q|10q23|0.59desaturase)NM_005745.3accessory protein BAP31|X|Xq|1.26NM_005548.1lysyl-tRNA synthetase|16|16q|16q23|1.361.201.261.291.27BE869583anti-oxidant protein 2 (non-selenium|1|1q|1q23|1.211.261.20glutathione peroxidase, acidiccalcium-independent phospholipaseA2)NM_004905.1anti-oxidant protein 2 (non-selenium|1|1q|1q23|1.30glutathione peroxidase, acidiccalcium-independent phospholipaseA2)NM_016127.1hypothetical protein MGC8721|8|8p|1.24AA479488S-adenosylhomocysteine hydrolase-|1|1p|1.641.281.451.531.261.281.35like 1AA479488S-adenosylhomocysteine hydrolase-|1|1p|1.321.221.431.281.24like 1NM_006621.1S-adenosylhomocysteine hydrolase-|1|1p|1.451.201.431.351.221.251.20like 1NM_002106.1H2A histone family, member Z|4|4q|1.281.271.261.24NM_001012.1ribosomal protein S8|1|1p|1p34|1.26NM_014762.124-dehydrocholesterol reductase|1|1p|1p33|1.271.20NM_000980.1ribosomal protein L18a|19|19p|1.301.301.411.24NM_002778.1prosaposin (variant Gaucher disease|10|10q|10q21|1.211.221.20and variant metachromaticleukodystrophy)NM_006585.1chaperonin containing TCP1, subunit|21|21q|21q22|1.311.231.271328 (theta)NM_002793.1proteasome (prosome, macropain)|6|6q|1.27subunit, beta type, 1NM_006430.1chaperonin containing TCP1, subunit|2|2p|1.201.241.321.294 (delta)AL534104DnaJ (Hsp40) homolog, subfamily A,|9|9p|9p13|1.27member 1NM_001539.1DnaJ (Hsp40) homolog, subfamily A,|9|9p|9p13|1.26member 1NM_003366.1ubiquinol-cytochrome c reductase|16|16p|1.361.241.29core protein IINM_016081.1palladin|4|4q|4q32|1.291.321.221.31NM_012215.1meningioma expressed antigen 5|10|10q|10q24|1.23(hyaluronidase)NM_001004.1ribosomal protein, large P2|11|11p|11p15|1.22NM_005998.1chaperonin containing TCP1, subunit|1|1q|1.201.241.201.233 (gamma)NM_000973.1ribosomal protein L8|8|8q|8q24|1.23NM_005625.1syndecan binding protein (syntenin)|8|8q|1.23AI348010Homo sapiens cDNA FLJ36224 fis,1.211.291.231.251.331.23clone THYMU2000990NM_000942.1peptidylprolyl isomerase B|15|15q|15q21|1.26(cyclophilin B)BG107676stress-associated endoplasmic|3|3q|3q25|1.331.21reticulum protein 1; ribosomeassociated membrane protein 4AL136807.1stress-associated endoplasmic|3|3q|3q25|1.20reticulum protein 1; ribosomeassociated membrane protein 4AF090891.1Tax1 (human T-cell leukemia virus|7|7p|1.25type I) binding protein 1NM_000611.1CD59 antigen p18-20 (antigen|11|11p|1.361.411.301.231.211.421.46identified by monoclonal antibodies16.3A5, EJ16, EJ30, EL32 and G344)NM_001769.1CD9 antigen (p24)|12|12p|12p13|1.501.311.47NM_005642.1TAF7 RNA polymerase II, TATA box|5|5q|1.251.26binding protein (TBP)-associatedfactor, 55 kDaNM_002414.1antigen identified by monoclonal|X|Xp|Xp22|1.521.311.671.431.311.261.44antibodies 12E7, F21 and O13BE545756adducin 3 (gamma)|10|10q|10q24|1.331.44NM_004417.2dual specificity phosphatase 1|5|5q|0.660.72NM_022551.1ribosomal protein S18|6|6p|6p21|1.241.251.22BE966599heterogeneous nuclear|5|5q|1.23ribonucleoprotein A0NM_006097.1myosin, light polypeptide 9,|20|20q|20q11|0.710.770.80regulatoryNM_002901.1reticulocalbin 1, EF-hand calcium|11|11p|1.26binding domainNM_004082.2dynactin 1 (p150, glued homolog,|2|2p|1.22Drosophila)NM_002266.1karyopherin alpha 2 (RAG cohort 1,|17|17q|17q23|1.28importin alpha 1)BE299495hypothetical protein FLJ20719|1|1p|1.20NM_002305.2lectin, galactoside-binding, soluble, 1|22|22q|22q13|1.29(galectin 1)AF053641.1CSE1 chromosome segregation 1-|20|20q|1.431.261.431.311.311.331.321.34like (yeast)NM_001873.1carboxypeptidase E|4|4q|4q32|NM_001970.1eukaryotic translation initiation factor|17|17p|17p13|1.611.691.461.672.385ANM_019597.1heterogeneous nuclear|X|Xq|1.22ribonucleoprotein H2 (H′)NM_006164.1nuclear factor (erythroid-derived 2)-|2|2q|1.361.231.25like 2NM_021079.1N-myristoyltransferase 1|17|17q|17q21|1.261.22AL556190cold shock domain protein A|12|12p|12p13|1.50NM_001553.1insulin-like growth factor binding|4|4q|1.201.241.26protein 7NM_001553.1insulin-like growth factor binding|4|4q|1.331.381.351.31protein 7NM_003945.1ATPase, H+ transporting, lysosomal|5|5q|5q35|1.271.201.351.201.269 kDa, V0 subunit eNM_002775.1protease, serine, 11 (IGF binding)|10|10q|10q26|1.221.491.23AB018009.1solute carrier family 7 (cationic amino|16|16q|16q24|1.51acid transporter, y+ system), member 5AI860431proteasome (prosome, macropain)|2|2q|2q36|1.271.211.2426S subunit, non-ATPase, 1NM_002592.1proliferating cell nuclear antigen|20|20p|20pter|1.32NM_001428.1enolase 1, (alpha)|1|1p|1p36|1.27NM_002817.1proteasome (prosome, macropain)|11|11p|11p15|1.251.221.211.2926S subunit, non-ATPase, 13NM_017670.1hypothetical protein FLJ20113|11|11q|11q13|NM_001020.1ribosomal protein S16|19|19q|19q13|1.231.241.21AI768845synaptophysin-like protein|7|7q|7q11|1.38NM_006754.1synaptophysin-like protein|7|7q|7q11|1.31NM_001175.1Rho GDP dissociation inhibitor (GDI)|12|12p|12p12|1.251.29betaNM_015626.1SOCS box-containing WD protein|17|17q|17q11|SWiP-1NM_000311.1prion protein (p27-30) (Creutzfeld-|20|20p|20pter|1.24Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familialinsomnia)NM_001975.1enolase 2, (gamma, neuronal)|12|12p|1.211.31NM_006435.1interferon induced transmembrane|11|11p|11p15|1.411.331.421.441.421.441.341.591.491.53protein 2 (1-8D)NM_002787.1proteasome (prosome, macropain)|7|7p|7p15|1.2112.2subunit, alpha type, 2NM_001423.1epithelial membrane protein 1|12|12p|12p12|1.51BC003570.1vesicle-associated membrane protein|1|1p|1p36|1.401.281.333 (cellubrevin)NM_003633.1ectodermal-neural cortex (with BTB-|5|5q|5q12|0.830.80like domain)NM_024551.1hypothetical protein FLJ21432|12|12p|12p13|1.351.261.33NM_002084.2glutathione peroxidase 3 (plasma)|5|5q|0.641.541.45AI356398zinc finger protein 36, C3H type-like 2|2|2p|2p22|1.39NM_006623.1phosphoglycerate dehydrogenase|1|1p|1.381.201.26BC000687.1translocating chain-associating|8|8q|8q13|1.361.351.33membrane proteinNM_002795.1proteasome (prosome, macropain)|17|17q|1.211.20subunit, beta type, 3NM_003107.1SRY (sex determining region Y)-box 4|6|6p|6p22|0.680.660.63NM_005410.1selenoprotein P, plasma, 1|5|5q|1.241.471.381.42NM_001387.1dihydropyrimidinase-like 3|5|5q|1.38NM_001752.1catalase|11|11p|1.391.311.231.221.23AF248966.1ATPase, H+ transporting, lysosomal|X|Xq|1.401.271.32interacting protein 2NM_005765.1ATPase, H+ transporting, lysosomal|X|Xq|1.22interacting protein 2NM_001839.1calponin 3, acidic|1|1p|1p22|1.851.511.741.811.481.691.531.97NM_006310.1aminopeptidase puromycin sensitive|17|17q|1.21NM_006310.1aminopeptidase puromycin sensitive|17|17q|1.26NM_006755.1transaldolase 1|11|11p|11p15|1.261.261.211.48NM_004832.1glutathione-S-transferase like;|10|10q|10q25|1.211.251.25glutathione transferase omegaBC005020.1peptidylprolyl isomerase F|10|10q|10q22|1.251.35(cyclophilin F)AI889739myosin, heavy polypeptide 11,|16|16p|16p13|0.73smooth muscleNM_022844.1myosin, heavy polypeptide 11,|16|16p|16p13|0.76smooth muscleAI078167nuclear factor of kappa light|14|14q|1.221.251.351.30polypeptide gene enhancer in B-cellsinhibitor, alphaBG500067Ras-GTPase-activating protein SH3-|5|5q|5q33|1.351.211.261.331.211.331.24domain-binding proteinBG398414replication protein A1, 70 kDa|17|17p|17p13|1.311.291.431.341.411.271.33NM_002945.1replication protein A1, 70 kDa|17|17p|17p13|1.241.291.201.24NM_002788.1proteasome (prosome, macropain)|14|14p|1.231.201.261.22subunit, alpha type, 3NM_004238.1thyroid hormone receptor interactor|2|2q|2q36|1.221.201.2512J03263.1lysosomal-associated membrane|13|13q|1.291.31protein 1NM_005561.2lysosomal-associated membrane|13|13q|1.321.331.341.67protein 1NM_013943.1chloride intracellular channel 4|1|1p|1p36|1.361.611.271.26NM_004039.1annexin A2|15|15q|15q21|1.291.601.30NM_007184.1nischarin|3|3p|3p21|1.28NM_003641.1interferon induced transmembrane|11|1.431.391.371.461.401.211.471.391.51protein 1 (9-27)NM_000696.1aldehyde dehydrogenase 9 family,|1|1q|1q22|1.21member A1NM_001349.1aspartyl-tRNA synthetase|2|2q|2q14|NM_005506.1scavenger receptor class B, member 2|4|4q|14q21|1.321.41NM_006837.1COP9 constitutive photomorphogenic|8|8q|8q12|1.21homolog subunit 5 (Arabidopsis)NM_005776.1cornichon-like|14|14q|14q22|1.351.301.21NM_000210.1integrin, alpha 6|2|2q|2q31|1.331.261.251.201.34AL525798fatty-acid-Coenzyme A ligase, long-|2|2q|2q34|1.221.25chain 3NM_004457.2fatty-acid-Coenzyme A ligase, long-|2|2q|2q34|1.281.28chain 3NM_000165.2gap junction protein, alpha 1, 43 kDa|6|6q|6q21|1.521.93(connexin 43)NM_002356.4myristoylated alanine-rich protein|6|6q|6q22|1.26kinase C subtrateNM_001964.1early growth response 1|5|5q|5q31|0.770.770.660.730.710.68NM_002806.1proteasome (prosome, macropain)|14|14q|14q22|1.291.241.281.331.2926S subunit, ATPase, 6D42063.1RAN binding protein 2|2|2q|2q12|1.321.441.221.41AI589086Lysosomal-associated multispanning|1|1p|1.26membrane protein-5NM_005627.1serum/glucocorticoid regulated|6|6q|1.721.641.301.341.291.58kinaseNM_002822.1protein tyrosine kinase 9|12|12p|12p11|1.30AI763123adducin 3 (gamma)|10|10q|10q24|1.331.23NM_019903.1adducin 3 (gamma)|10|10q|10q24|1.39NM_004552.1NADH dehydrogenase (ubiquinone)|1|1p|1p34|1.22Fe—S protein 5, 15 kDa (NADH-coenzyme Q reductase)NM_006636.2methylene tetrahydrofolate|2|2p|1.381.36dehydrogenase (NAD+ dependent),methenyltetrahydrofolatecyclohydrolaseNM_007282.1ring finger protein 13|3|3q|3q25|1.431.56NM_002933.1ribonuclease, RNase A family, 1|14|14q|14q11|1.261.50(pancreatic)AW1509537-dehydrocholesterol reductase|11|11q|11q13|1.261.211.22NM_001360.17-dehydrocholesterol reductase|11|11q|11q13|1361.291.35NM_001540.2heat shock 27 kDa protein 1|7|7p|7p12|1.551.351.591.621.221.651.32AI826799EGF-containing fibulin-like|2|2p|0.630.620.740.67extracellular matrix protein 1NM_004105.2EGF-containing fibulin-like|2|2p|0.680.570.71extracellular matrix protein 1AB029551.1RING1 and YY1 binding protein|3|3p|1.351.261.24NM_00235.1lipase A, lysosomal acid, cholesterol|10|10q|10q23|1.371.531.211.311.341.261.58esterase (Wolman disease)NM_000305.1paraoxonase 2|7|7q|7q21|1.281.570.81NM_004048.1beta-2-microglobulin|15|15q|15q21|1.341.341.20NM_003365.1ubiquinol-cytochrome c reductase|3|3p|3p21|1.22core protein INM_006431.1chaperonin containing TCP1, subunit|12|12q|12q13|1.212 (beta)NM_005720.1actin related protein 2/3 complex,|7|7q|7q11|1.251.29subunit 1B, 41 kDaNM_021122.2fatty-acid-Coenzyme A ligase, long-|4|4q|4q34|1.641.731.381.721.561.76chain 2NM_001690.1ATPase, H+ transporting, lysosomal|3|3q|3q13|1.3070 kDa, V1 subunit A, isoform 1NM_012334.1myosin X|5|5p|5p15|1.320.830.73AW157070epidermal growth factor receptor|7|7p|1.200.770.76(erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)AI743792sialyltransferase 1 (beta-galactoside|3|3q|3q27|1.281.221.27alpha-2,6-sialytransferase)NM_006519.1t-complex-associated-testis-|6|6q|6q25|1.361.211.401.331.281.241.28expressed 1-like 1NM_003257.1tight junction protein 1 (zona|15|15q|1.26occludens 1)AF083441.1putative translation initiation factor|17|1.23BC000603.1ribosomal protein L38|17|17q|17q23|1.23NM_003012.2secreted frizzled-related protein 1|8|8p|8p12|0.65NM_004788.1ubiquitination factor E4A (UFD2|11|11q|11q23|1.211.341.24homolog, yeast)NM_000527.2low density lipoprotein receptor|19|19p|19p13|1.351.341.231.341.27(familial hypercholesterolemia)NM_005003.1NADH dehydrogenase (ubiquinone)|16|16p|16p11|1.221, alpha/beta subcomplex, 1, 8 kDaNM_003003.1SEC14-like 1 (S. cerevisiae)17|17q|17q25|1.25NM_004817.1tight junction protein 2 (zona|9|9q|9q13|1.561.391.661.421.46occludens 2)AI635449LIV-1 protein, estrogen regulated|18|18q|18q12|1.22AF043453.1sorting nexin 2|5|5q|1.271.291.24AA541758copine III|8|8q|8q21|1.381.261.34AW006290sudD suppressor of bimD6 homolog|18|18q|18q11|1.211.311.26(A. nidulans)AA081084transcriptional co-activator with PDZ-|3|3q|3q23|1.21binding motif (TAZ)AA747426interferon-related developmental|7|7q|7q22|regulator 1NM_007146.1zinc finger protein 161|17|17q|17q23|NM_017458.1major vault protein|16|16p|16p13|1.211.23AL117354CGI-100 protein|1|1p|1pter|1.351.241.331.21NM_005629.1solute carrier family 6|X|Xq|1.291.251.26(neurotransmitter transporter,creatine), member 8NM_006387.2calcium homeostasis endoplasmic|19|19p|19p13|reticulum proteinNM_002796.1proteasome (prosome, macropain)|1|1q|1.211.221.271.28subunit, beta type, 4BE561596metastasis associated 1|14|14q|14q32|NM_003165.1syntaxin binding protein 1|9|9q|9q34|1.211.21NM_005180.1hypothetical protein MGC12685|10|10p|10p11|1.25NM_004894.1chromosome 14 open reading frame 2|14|14q|14q32|1.21NM_002615.1serine (or cysteine) proteinase|17|17p|17p13|0.561.231.20inhibitor, clade F (alpha-2antiplasmin, pigment epitheliumderived factor) member 1NM_007033.1similar to S. cerevisiae RER1|1|1p|1pter|1.21NM_000786.1cytochrome P450, 51 (lanosterol 14-|7|7q|7q21|130alpha-demethylase)NM_002135.1nuclear receptor subfamily 4, group|12|12q|0.780.790.820.790.740.75A, member 1NM_001444.1fatty acid binding protein 5 (psoriasis-|8|8q|8q21|1.431.341.501.231.511.41associated)AI093579integrin, alpha V (vitronectin receptor,|2|2q|2q31|1.351.291.24alpha polypeptide, antigen CD51)AF231124.1sparc/osteonectin, cwcv and kazal-|5|5q|1.24like domains proteoglycan (testican)NM_001085.2serine (or cysteine) proteinase|14|14q|14q32|1.971.501.611.521.411.551.721.961.65inhibitor, clade A (alpha-1antiproteinase, antitrypsin), member 3AW026535leptin receptor gene-related protein|1|1.361.23NM_017526.1leptin receptor gene-related protein|1|1.23NM_006178.1N-ethylmaleimide-sensitive factor|17|17q|1.281.41NM_005532.1interferon, alpha-inducible protein 27|14|14q|1.311.201.391.231.261.361.55NM_000104.2cytochrome P450, subfamily I (dioxin-|2|2p|1.311.221.461.32inducible), polypeptide 1 (glaucoma3, primary infantile)NM_000104.2cytochrome P450, subfamily I (dioxin-|2|2p|1.661.681.401.681.51inducible), polypeptide 1 (glaucoma3, primary infantile)BF346014Homo sapiens mRNA; cDNA0.70DKFZp434G012 (from cloneDKFZp434G012)NM_004236.1thyroid receptor interacting protein 15|15|15q|15q21|1.281.251.211.301.30BC002637.1GS3955 protein|2|2p|2p25|0.800.770.790.79NM_003640.1inhibitor of kappa light polypeptide|9|9q|1.261.201.301.241.21gene enhancer in B-cells, kinasecomplex-associated proteinNM_006931.1solute carrier family 2 (facilitated|12|12p|12p13|1.351.23glucose transporter), member 3NM_006736.1DnaJ (Hsp40) homolog, subfamily B,|2|2q|2q32|1.261.241.241.201.291.25member 2NM_001313.1collapsin response mediator protein 1|4|4p|4p16|0.830.83AL5186273-hydroxy-3-methylglutaryl-|5|5q|5q13|1.411.34Coenzyme A reductaseNM_004757.1small inducible cytokine subfamily E,|4|4q|1.201.23member 1 (endothelial monocyte-activating)NM_016441.1cysteine-rich motor neuron 1|2|2p|1.261.22NM_005965.1myosin, light polypeptide kinase|3|3q|1.341.35AL718418stress 70 protein chaperone,|21|21q|1.36microsome-associated, 60 kDaNM_015607.1DKFZP547E1010 protein|1|1q|1q21|1.241.251.24NM_014902.1KIAA0964 protein|20|20q|20q11|0.81NM_005346.2heat shock 70 kDa protein 1B|6|6p|6p21|1.541.451.480.71BC000436.1endosulfine alpha|1|1q|1q21|0.830.800.81NM_003489.1nuclear receptor interacting protein 1|21|21q|21q11|1.23NM_004447.1epidermal growth factor receptor|12|12q|12q23|1.20.1.25pathway substrate 8NM_000935.1procollagen-lysine, 2-oxoglutarate 5-|3|3q|3q23|1.351.251.26dioxygenase (lysine hydroxylase) 2AI005043Homo sapiens mRNA; cDNA1.671.441.291.591.74DKFZp667A0918 (from cloneDKFZp667A0918)NM_003859.1dolichyl-phosphate|20|20q|20q13|1.281.201.31mannosyltransferase polypeptide 1,catalytic subunitNM_000271.1Niemann-Pick disease, type C1|18|18q|18q11|1.491.271.58AA675892transducer of ERBB2, 1|17|17q|1.321.260.83NM_002015.2forkhead box O1A|13|13q|13q14|1.22(rhabdomyosarcoma)NM_014814.1KIAA0107 gene product|3|3p|3p14|1.211.20NM_007373.1soc-2 suppressor of clear homolog|10|10q|1.22(C. elegans)NM_000436.13-oxoacid CoA transferase|5|5p|1.22NM_014016.1SAC1 suppressor of actin mutations|3|3p|3p21|1.211-like (yeast)NM_006323.1SEC24 related gene family, member|4|4q|1.291.331.33B (S. cerevisiae)NM_004172.1solute carrier family 1 (glial high|5|5p|1.451.351.761.31affinity glutamate transporter),member 3NM_001151.1solute carrier family 25 (mitochondrial|4|4q|1.21carrier; adenine nucleotidetranslocator), member 4NM_000295.1serine (or cysteine) proteinase|14|14q|14q32|1.23inhibitor, clade A (alpha-1antiproteinase, antitrypsin), member 1NM_000029.1angiotensinogen (serine (or cysteine)|1|1q|1q42|1.211.741.231.22proteinase inhibitor, clade A (alpha-1antiproteinase, antitrypsin), member8)AL080081.1DnaJ (Hsp40) homolog, subfamily B,|7|7q|1.281.23member 9NM_002858.2ATP-binding cassette, sub-family D|1|1p|1p22|1.22(ALD), member 3NM_000194.1hypoxanthine|X|Xq|Xq26|1.22phosphoribosyltransferase 1 (Lesch-Nyhan syndrome)NM_004762.1pleckstrin homology, Sec7 and|17|17q|1.25coiled/coil domains 1(cytohesin 1)NM_019058.1HIF-1 responsive RTP801|10|10p|10pter|1.371.411.631.511.311.431.50T62571microtubule-associated protein 7|6|6q|6q23|1.471.361.38BC002642.1cathepsin S|1|1q|1.21NM_006005.2Wolfram syndrome 1 (wolframin)|4|4p|1.201.201.24BF726212Homo sapiens, clone1.28IMAGE: 4246029, mRNANM_003850.1succinate-CoA ligase, ADP-forming,|13|13q|13q12|1.281.22beta subunitNM_005433.1v-yes-1 Yamaguchi sarcoma viral|18|18p|18p11|1.211.29oncogene homolog 1NM_005433.1v-yes-1 Yamaguchi sarcoma viral|18|18p|18p11|1.26oncogene homolog 1AI382146SRY (sex determining region Y)-box|17|17q|17q24|1.261.301.601.249 (campomelic dysplasia, autosomalsex-reversal)NM_000346.1SRY (sex determining region, Y)-box|17|17q|17q24|1.431.361.561.329 (campomelic dysplasia, autosomalsex-reversal)NM_000877.1interleukin 1 receptor, type I|2|2q|1.251.24NM_000491.2complement component 1, q|1|1p|1p36|1.581.391.491.321.361.37subcomponent, beta polypeptideNM_004889.1ATP synthase, H+ transporting,|7|7q|7q11|1.21mitochondrial F0 complex, subunit f,isoform 2N21138Rho-related BTB domain containing 3|5|5q|5q21|1.301.201.641.411.361.22NM_014899.1Rho-related BTB domain containing 3|5|5q|5q21|1.321.271.611.271.431.33NM_007029.1stathmin-like 2|8|8q|8q13|1.401.22NM_005539.1inositol polyphosphate-5-|10|10q|10q26|0.791.22phosphatase, 40 kDaNM_005581.1Lutheran blood group (Auberger b|19|19q|19q13|0.80antigen included)NM_000990.1ribosomal protein L27a|11|11p|1.261.23NM_002844.1protein tyrosine phosphatase,|6|6q|6q22|1.281.34receptor type, KJ04183.1lysosomal-associated membrane|X|Xq|1.591.651.321.471.431.86protein 2NM_002294.1lysosomal-associated membrane|X|Xq|1.511.431.311.65protein 2NM_014849.1synaptic vesicle glycoprotein 2|1|1q|1q21|0.80NM_004636.1sema domain, immunoglobulin|3|3p|3p21|1.341.25domain (Ig), short basic domain,secreted, (semaphorin) 3BNM_013450.1bromodomain adjacent to zinc finger|2|2q|2q23|1.29domain, 2BNM_005211.1colony stimulating factor 1 receptor,|5|5q|5q33|1.24formerly McDonough feline sarcomaviral (v-fms) oncogene homologNM_005426.1tumor protein p53 binding protein, 2|1|1q|1q42|1.271.471.291.231.23NM_006206.1platelet-derived growth factor|4|4q|4q11|0.740.740.550.770.75receptor, alpha polypeptideNM_003642.1histone acetyltransferase 1|2|2q|2q31|1.381.301.231.23NM_001706.1B-cell CLL/lymphoma 6 (zinc finger|3|3q|1.301.281.43protein 51)AB020645.1glutaminase|2|2q|2q32|0.82AF097493.1glutaminase|2|2q|2q32|0.72NM_001482.1glycine amidinotransferase (L-|15|15q|1.26arginine: glycine amidinotransferase)NM_014737.1Ras association (RalGDS/AF-6)|20|20p|20pter|1.25domain family 2NM_006876.1UDP-GIcNAc: betaGal beta-1,3-N-|11|11q|11q12|1.301.251.35acetylglucosaminyltransferase 6NM_004999.1myosin VI|6|6q|1.42AW235612spinocerebellar ataxia 1|6|6p|0.780.750.590.720.64(olivopontocerebellar ataxia 1,autosomal dominant, ataxin 1)NM_006457.1LIM protein (similar to rat protein|4|4q|1.28kinase C-binding enigma)AA810268mitogen-activated protein kinase|17|17p|17p11|0.80kinase 4AW440492ATPase, Na+/K+ transporting, alpha|1|1q|1q21|1.241.321.292 (+) polypeptideNM_000702.1ATPase, Na+/K+ transporting, alpha|1|1q|1q21|1.291.411.431.282 (+) polypeptideNM_004973.2jumonji homolog (mouse)|6|6p|6p24|1.28NM_007269.1syntaxin binding protein 3|1|1p|1p13|1.291.21NM_014970.1kinesin-associated protein 3|1|1q|1.261.30NM_004454.1ets variant gene 5 (ets-related|3|3q|0.800.800.73molecule)AW117368ADP-ribosylation factor guanine|8|8p|8pter|1.221.34nucleotide factor 6NM_015310.1ADP-ribosylation factor guanine|8|8p|8pter|1.31nucleotide factor 6N33009apolipoprotein E|19|19q|19q13|1.411.241.661.33NM_000041.1apolipoprotein E|19|19q|19q13|1.241.570.81BE973687hairy homolog (Drosophila)|3|3q|3q28|0.83NM_002789.1proteasome (prosome, macropain)|15|15q|15q24|1.211.231.28subunit, alpha type, 4NM_001063.1transferrin|3|3q|1.441.201.98NM_002765.1phosphoribosyl pyrophosphate|X|Xp|Xp22|1.28synthetase 2NM_000560.1CD53 antigen|1|1p|1.26NM_014034.1DKFZP547E2110 protein|6|6q|6q22|1.251.261.23NM_004045.1ATX1 antioxidant protein 1 homolog|5|5q|1.22(yeast)NM_002970.1spermidine/spermine N1-|X|Xp|Xp22|1.20acetyltransferaseNM_014302.1Sec61 gamma|7|7p|7p14|1.221.231.25NM_005822.1Down syndrome critical region gene|6|6p|6p12|1.241-like 1NM_006378.1sema domain, immunoglobulin|9|9q|9q22|1.261.28domain (Ig), transmembrane domain(TM) and short cytoplasmic domain,(semaphorin) 4DNM_002055.1glial fibrillary acidic protein|17|17q|1.59NM_001206.1basic transcription element binding|9|9q|1.401.261.401.521.27protein 1BF672975lipoprotein lipase|8|8p|0.811.28NM_000237.1lipoprotein lipase|8|8p|0.77AW298170mitogen-activated protein kinase|14|14q|14q11|kinase kinase kinase 5NM_006575.1mitogen-activated protein kinase|14|14q|14q11|1.51kinase kinase kinase 5NM_005103.2fasciculation and elongation protein|11|11q|11q24|1.28zeta 1 (zygin I)NM_014795.1zinc finger homeobox 1b|2|2q|1.210.76NM_003136.1signal recognition particle 54 kDa|14|14q|1.351.281.26NM_004553.1NADH dehydrogenase (ubiquinone)|5|5p|5p15|1.201.25Fe—S protein 6, 13 kDa (NADH-coenzyme Q reductase)NM_016235.1G protein-coupled receptor, family C,|16|16p|1.591.361.231.44group 5, member BNM_022969.1fibroblast growth factor receptor 2|10|10q|1.341.350.831.25(bacteria-expressed kinase,keratinocyte growth factor receptor,craniofacial dysostosis 1, Crouzonsyndrome, Pfeiffer syndrome,Jackson-Weiss syndrome)U91903.1frizzled-related protein|2|2q|0.800710.520.790.660.730.77NM_001463.1frizzled-related protein|2|2q|0.660.830.780.81NM_013989.1deiodinase, iodothyronine, type II|14|14q|14q24|0.570.83NM_003748.1aldehyde dehydrogenase 4 family,|1|1p|1.25member A1NM_002221.1inositol 1,4,5-trisphosphate 3-kinase B|1|1q|1q41|1.321.631.311.291.23NM_012198.1grancalcin, EF-hand calcium binding|2|2q|2q24|1.281.201.211.351.391.35proteinNM_006379.1sema domain, immunoglobulin|7|7q|7q21|1.220.72domain (Ig), short basic domain,secreted, (semaphorin) 3CNM_006107.1acid-inducible phosphoprotein|17|BG252490DnaJ (Hsp40) homolog, subfamily B,|1|1p|1p31|1.22member 4AV727449p300/CBP-associated factor|3|3p|1.421.501.321.211.22NM_015833.1adenosine deaminase, RNA-specific,|21|21q|21q22|0.81B1 (RED1 homolog rat)NM_022832.1hypothetical protein FLJ12552|4|4p|1.24NM_022832.1hypothetical protein FLJ12552|4|4P|1.21NM_005694.1COX17 homolog, cytochrome c|3|3q|3q13|1.25oxidase assembly protein (yeast)NM_014999.1RAB21, member RAS oncogene|12|12q|12q13|1.241.301.211.361.271.36familyNM_014799.1hephaestin|X|Xq|Xq11|1.421.291.231.30NM_006359.1solute carrier family 9|X|Xq|Xq26|1.25(sodium/hydrogen exchanger),isoform 6NM_000784.1cytochrome P450, subfamily XXVIIA|2|2q|2q33|1.22(steroid 27-hydroxylase,cerebrotendinous xanthomatosis),polypeptide 1NM_004480.1fucosyltransferase 8 (alpha (1,6)|14|14q|14q24|fucosyltransferase)NM_005639.1synaptotagmin I|12|0.830.761.310.52NM_000570.1Fc fragment of IgG, low affinity IIIb,|1|1q|1.311.23receptor for (CD16)NM_014575.1schwannomin interacting protein 1|3|3q|3q25|1.281.241.321.45NM_013279.1chromosome 11 open reading frame 9|11|11q|11q12|1.241.64NM_003595.1tyrosylprotein sulfotransferase 2|22|22q|22q12|1.231.221.24NM_006176.1neurogranin (protein kinase C|11|11q|0.780.82substrate, RC3)NM_003332.1TYRO protein tyrosine kinase binding|19|19q|19q13|1.231.381.281.28proteinNM_016013.1CGI-65 protein|15|15q|15q11|1.24NM_003272.1transmembrane 7 superfamily|1|1q|1q42|1.291.21member 1 (upregulated in kidney)NM_003596.1tyrosylprotein sulfotransferase 1|7|7q|7q11|1.351.371.291.31AA044154KIAA0999 protein|11|11q|11q23|AW194947ectonucleotide|6|6p|6p12|1.491.291.521.231.211.431.361.61pyrophosphatase/phosphodiesterase4 (putative function)NM_000097.1coproporphyrinogen oxidase|3|3q|1.32(coproporphyria, harderoporphyria)NM_001860.1solute carrier family 31 (copper|9|9q|9q31|1.301.53transporters), member 2NM_005619.1reticulon 2|19|19q|19q13|NM_020309.1Homo sapiens cDNA FLJ33742 fis,0.810.770.74clone BRAWH2019053, highly similarto Homo sapiens BNPI mRNA forbrain-specific Na-dependentinorganic phosphate cotransporterNM_004106.1Fc fragment of IgE, high affinity I,|1|1q|1.20receptor for; gamma polypeptideNM_005386.1neuronatin|20|20q|20q11|0.790.610.650.810.69NM_000115.1endothelin receptor type B|13|13q|1.431.70BF002254golgi phosphoprotein 4|3|3q|0.80NM_002450.1metallothionein 1L|16|16q|1.431.501.471.391.381.35NM_021107.1mitochondrial ribosomal protein S12|19|19q|19q13|1.281.23NM_005613.2regulator of G-protein signalling 4|1q|1q23|0.680.79NM_003930.1src family associated phosphoprotein 2|7|7p|7p21|1.361.221.231.36NM_001993.2coagulation factor III (thromboplastin,|1|1p|1p22|1.481.601.371.391.35tissue factor)NM_014810.1centrosome-associated protein 350|1|1p|1p36|1.341.361.26NM_003657.1breast carcinoma amplified sequence 1|20|20q|20q13|0.65NM_000142.2fibroblast growth factor receptor 3|4|4p|4p16|1.280.73(achondroplasia, thanatophoricdwarfism)NM_005864.1signal transduction protein (SH3|14|14q|14q11|1.301.360.771.33containing)BC005248.1eukaryotic translation initiation factor|Y|Yq|Yq11|1.441.281.441.341.251.311.321.301A, Y chromosomeNM_021076.1neurofilament, heavy polypeptide|22|22q|22q12|0.760.64200 kDaNM_000153.1galactosylceramidase (Krabbe|14|14q|1.291.281.241.231.22disease)M27968.1fibroblast growth factor 2 (basic)|4|4q|4q26|1.26NM_002006.1fibroblast growth factor 2 (basic)|4|4q|4q26|1.601.441.24NM_016725.1folate receptor 1 (adult)|11|11q|11q13|0.590.820.83NM_000698.1arachidonate 5-lipoxygenase|10|10q|10q11|1.341.29BG260394synuclein, alpha (non A4 component|4|4q|1.261.32of amyloid precursor)NM_002851.1protein tyrosine phosphatase,|7|7q|7q31|1.210.720.82receptor-type, Z polypeptide 1NM_005261.1GTP binding protein overexpressed|8|8q|8q13|0.83in skeletal muscleNM_024112.1chromosome 9 open reading frame|9|9q|9q34|0.820.790.8116NM_015993.1transmembrane 4 superfamily|16|16q|1.201.53member 11 (plasmolipin)NM_001958.1eukaryotic translation elongation|20|20q|20q13|1.27factor 1 alpha 2NM_006822.1RAB40B, member RAS oncogene|17|17q|17q25|1.211.221.251.58familyNM_004508.1isopentenyl-diphosphate delta|10|10p|10p15|1.201.201.29isomeraseNM_006002.1ubiquitin carboxyl-terminal esterase|13|13q|13q21|1.32L3 (ubiquitin thiolesterase)NM_004385.1chondroitin sulfate proteoglycan 2|5|5q|5q14|1.241.27(versican)NM_006186.1nuclear receptor subfamily 4, group|2|2q|2q22|0.820.810.780.71A, member 2AF074393.1ribosomal protein S6 kinase, 90 kDa,|14|14q|14q31|1.201.531.221.37polypeptide 5NM_012294.1guanine nucleotide exchange factor|7|7p|7p21|1.381.481.86for Rap1; M-Ras-regulated GEFNM_007191.1WNT inhibitory factor 1|12|12q|12q13|1.570.780.43NM_000130.2coagulation factor V (proaccelerin,|1|1q|0.800.63labile factor)NM_004445.1EphB6|7|7q|7q33|0.82NM_007168.1ATP-binding cassette, sub-family A|17|17q|1.861.581.481.271.391.311.99(ABC1), member 8NM_014747.1KIAA0237 gene product|1|1p|1pter|0.83NM_002774.1kallikrein 6 (neurosin, zyme)|19|19q|19q13|1.301.241.60NM_005950.1metallothionein 1G|16|16q|1.201.23BE670563guanine nucleotide binding protein (G|16|16q|1.21protein), alpha activating activitypolypeptide ONM_014210.1ecotropic viral integration site 2A|17|17q|17q11|1.671.241.591.302.03NM_002371.2mal, T-cell differentiation protein|2|1.231.811.431.211.521.341.64NM_004434.1echinoderm microtubule associated|14|4q|1.23protein like 1NM_000096.1ceruloplasmin (ferroxidase)|3|3q|3q23|1.34AF040254.1doublecortex; lissencephaly, X-linked|X|Xq|Xq22|0.830.77(doublecortin)NM_002594.1proprotein convertase subtilisin/kexin|20|20p|20p11|0.790.75type 2NM_003358.1UDP-glucose ceramide|9|9q|1.301.231.32glucosyltransferaseNM_000166.1gap junction protein, beta 1, 32 kDa|X|Xq|Xq13|1.27(connexin 32, Charcot-Marie-Toothneuropathy, X-linked)AA988241RAB3A, member RAS oncogene|19|19p|19p13|0.78familyNM_004660.2DEAD/H (Asp-Glu-Ala-Asp/His) box|Y|Yq|1.421.311.571.43polypeptide, Y chromosomeNM_001446.1fatty acid binding protein 7, brain|6|6q|6q22|0.80NM_003832.1phosphoserine phosphatase-like|7|7q|7q11|1.52NM_000222.1v-kit Hardy-Zuckerman 4 feline|4|4q|4q11|0.59sarcoma viral oncogene homologNM_002643.1phosphatidylinositol glycan, class F|2|2p|2p21|1.201.201.201.22NM_002643.1phosphatidylinositol glycan, class F|2|2p|2p21|1.261.221.241.231.231.22NM_006365.1Homo sapiens cDNA FLJ37174 fis,1.230.68clone BRACE2028406NM_002372.1mannosidase, alpha, class 2A,|5|5q|5q21|1.35member 1NM_000384.1apolipoprotein B (including Ag(x)|2|2p|2p24|0.780.82antigen)NM_005382.1neurofilament 3 (150 kDa medium)|8|8p|0.821.271.580.59NM_002983.1chemokine (C—C motif) ligand 3|17|17q|17q11|0.830.820.79NM_002029.1formyl peptide receptor 1|19|19q|19q13|1.25U29586.1sarcoglycan, beta (43 kDa dystrophin-|4|4q|1.25associated glycoprotein)BF439316transmembrane protein with EGF-like|9|9q|and two follistatin-like domains 1NM_002157.1heat shock 10 kDa protein 1|2|2q|2q33|1.211.241.301.27(chaperonin 10)AV724192KIAA0644 gene product|7|7p|7p21|1.370.780.76AI003579solute carrier family 6|3|3p|3p25|0.750.800.73(neurotransmitter transporter, GABA),member 1NM_006946.1spectrin, beta, non-erythrocytic 2|11|11q|0.740.79NM_000168.2GLI-Kruppel family member GL13|7|7p|0.830.82(Greig cephalopolysyndactylysyndrome)NM_005389.1protein-L-isoaspartate (D-aspartate)|6|6q|6q24|1.30O-methyltransferaseNM_000216.1Kallmann syndrome 1 sequence|X|Xp|Xp22|1.411.321.46NM_022817.1period homolog 2 (Drosophila)|2|2q|2q37|0.760.770.80NM_001635.1amphiphysin (Stiff-Man syndrome|7|7p|7p14|1.34with breast cancer 128 kDaautoantigen)NM_000901.1nuclear receptor subfamily 3, group|4|4q|4q31|1.261.34C, member 2NM_000817.1glutamate decarboxylase 1 (brain,|2|2q|0.820.830.780.6667 kDa)NM_000824.1glycine receptor, beta|4|4q|4q31|0.77AB017120.1BAI1-associated protein 2|17|17q|1.24NM_005856.1receptor (calcitonin) activity modifying|7|7p|7p13|1.231.221.34protein 3NM_006984.1claudin 10|13|13q|13q31|1.211.270.740.74NM_002854.1parvalbumin|22|22q|22q13|0.690.710.750.64NM_004411.1dynein, cytoplasmic, intermediate|7|7q|7q21|1.221.221.32polypeptide 1NM_005025.1serine (or cysteine) proteinase|3|3q|3q26|1.201.201.271.28inhibitor, clade I (neuroserpin),member 1NM_003986.1butyrobetaine (gamma), 2-|11|11p|1.321.34oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1NM_001918.1dihydrolipoamide branched chain|1|1p|transacylase (E2 component ofbranched chain keto aciddehydrogenase complex; maplesyrup urine disease)NM_015831.1acetylcholinesterase (YT blood|7|7q|1.34group)NM_015642.1zinc finger protein 288|3|3q|3q13|1.30NM_004166.1chemokine (C—C motif) ligand 14|17|17q|17q11|0.81NM_004734.1doublecortin and CaM kinase-like 1|13|13q|13q13|1.45NM_005525.1hydroxysteroid (11-beta)|1|1q|1q32|1.371.321.241.51dehydrogenase 1NM_001740.2calbindin 2, 29 kDa (calretinin)|16|16q|16q22|0.801.38NM_000055.1butyrylcholinesterase|3|3q|3q26|0.75NM_021647.1KIAA0626 gene product|4|4q|4q32|1.321.211.31BC001777.1hippocalcin|1|1p|1p35|0.810.810.800.830.820.75NM_007281.1scrapie responsive protein 1|4|4q|4q31|1.301.361.441.441.391.36NM_001888.1crystallin, mu|16|16p|16p13|0.81NM_001037.1sodium channel, voltage-gated, type|19|19q|19q13|0.810.75I, beta polypeptideNM_003186.2transgelin|11|11q|11q23|0.651.291.271.501.491.38NM_006198.1Purkinje cell protein 4|21|21q|21q22|0.740.790.720.65NM_005739.2RAS guanyl releasing protein 1|15|15q|0.661.36calcium and DAG-regulated)NM_014897.1KIAA0924 protein|17|17q|1.221.28NM_000950.1proline-rich Gla (G-carboxyglutamic|X|Xp|Xp21|1.311.281.46acid) polypeptide 1AW014927calbindin 1, 28 kDa|8|8q|8q21|0.61NM_004929.2calbindin 1, 28 kDa|8|8q|8q21|0.70BC002599.1corticotropin releasing hormone|8|8q|0.830.82NM_000756.1corticotropin releasing hormone|8|8q|0.720.700.690.63NM_003558.1phosphatidylinositol-4-phosphate 5-|9|9q|0.66kinase, type I, betaNM_007023.1cAMP-regulated guanine nucleotide|2|2q|2q31|0.740.610.69exchange facter IINM_006998.1secretagogin, EF-hand calcium|6|6p|6p22|1.29binding proteinAL022718odz, odd Oz/ten-m homolog|X|Xq|0.781(Drosophila)NM_004102.2fatty acid binding protein 3, muscle|1|1p|1p33|0.73and heart (mammary-derived growthinhibitor)NM_001392.1dystrobrevin, alpha|18|18q|1.891.411.731.751.751.561.861.571.521.53NM_004352.1cerebellin 1 precursor|16|16q|16q12|0.81NM_003026.1SH3-domain GRB2-like 2|9|9p|1.211.36NM_000840.1glutamate receptor, metabotropic 3|7|7q|7q21|1.241.35NM_000729.2cholecystokinin|3|3p|3p22|1.69NM_004271.1MD-1, RP105-associated|6|6p|6p24|1.20NM_004476.1folate hydrolase (prostate-specific|11|11p|11p11|1.79membrane antigen) 1AI818488adducin 3 (gamma)|10|10q|10q24|1.23NM_003914.1cyclin A1|13|13q|13q12|0.83NM_002612.1pyruvate dehydrogenase kinase,|7|7q|7q21|1.241.601.27isoenzyme 4NM_005954.1metallothionein 3 (growth inhibitory|16|16q|1.241.431.341.271.28factor (neurotrophic))NM_004795.1klotho|13|13q|0.551.20NM_002433.1myelin oligodendrocyte glycoprotein|6|6p|6p22|1.691.391.541.271.93NM_000905.1neuropeptide Y|7|7p|7p15|0.590.71NM_000266.1Norrie disease (pseudoglioma)|X|Xp|Xp11|1.331.231.261.33NM_006681.1neuromedin U|4|4q|1.57NM_000049.1aspartoacylase (aminoacylase 2,|17|17p|17pter|1.551.451.531.211.271.77Canavan disease)NM_004794.1RAB33A, member RAS oncogene|X|Xq|Xq26|1.301.321.37familyNM_003430.1zinc finger protein 91 (HPF7, HTF10)|19|19p|19p13|0.770.770.790.720.680.75NM_006157.1NEL-like 1 (chicken)|11|11p|11p15|0.69NM_014682.1zinc finger protein 387|8|8q|8q11|1.71NM_003180.1synaptotagmin V|19|19q|0.830.80NM_005584.1mab-21-like 1 (C. elegans)|13|13q|0.780.68NM_003551.1non-metastatic cells 5, protein|5|5q|0.82expressed in (nucleoside-diphosphate kinase)NM_002500.1neurogenic differentiation 1|2|2q|0.77NM_001036.1ryanodine receptor 3|15|15q|15q14|1.411.411.341.241.35NM_004291.1cocaine- and amphetamine-regulated|5|5q|5q13|1.422.00transcriptNM_006123.1iduronate 2-sulfatase (Hunter|X|Xq|syndrome)NM_005097.1leucine-rich, glioma inactivated 1|10|10q|1.24NM_003412.1Zic family member 1 (odd-paired|3|3q|1.341.30homolog, Drosophila)NM_018057.1homolog of rat orphan transporter v7-3|12|12q|12q21|1.571.201.361.351.26NM_020987.1ankyrin 3, node of Ranvier (ankyrin|10|10q|1.20G)NM_014717.1KIAA0390 gene product|19|19q|19q13|1.471.321.63NM_005951.1metallothionein 1H|16|16q|1.22NM_004746.1discs, large (Drosophila) homolog-|18|18p|18p11|0.800.81associated protein 1NM_006240.1protien phosphatase, EF hand|X|Xp|Xp22|0.65calcium-binding domain 1NM_003182.1tachykinin, precursor 1 (substance K,|7|7q|7q21|0.660.530.490.55substabce P, neurokinin 1, neurokinin2, neuromedin L, neurokinin alpha,neuropeptide K, neuropeptidegamma)NM_015364.1MD-2 protein|8|8q|8q13|1.231.32NM_004654.2ubiquitin specific protease 9, Y|Y|Yq|Yq11|1.301.34chromosome (fat facets-likeDrosophila)NM_000079.1cholinergic receptor, nicotinic, alpha|2|2q|2q24|0.79polypeptide 1 (muscle)NM_005413.1sine oculis homeobox homolog 3|2|2p|2p16|0.78(Drosophila)NM_000407.3glycoprotein lb (platelet), beta|22|22q|22q11|0.800.750.64polypeptideNM_013445.1glutamate decarboxylase 1 (brain,|2|2q|0.760.770.790.6867 kDa)NM_000806.2gamma-aminobutyric acid (GABA) A|5|5q|5q34|0.810.730.71receptor, alpha 1NM_001163.1amyloid beta (A4) precursor protein-|9|9q|9q13|0.79binding, family A, member 1 (X11)NM_003991.1endothelin receptor type B|13|13q|1.250.78NM_014927.1connector enhancer of KSR2|X|Xp|Xp22|1.351.30NM_014926.1KIAA0848 protein|3|3q|3q26|0.81AF153820.1potassium inwardly-rectifying|17|17q|17q23|1.351.47channel, subfamily J, member 2NM_002347.1lymphocyte antigen 6 complex, locus H|8|8q|8q24|0.76NM_000496.1crystallin, beta B2|22|22q|22q11|0.800.760.79NM_000818.1glutamate decarboxylase 2|10|10p|10p11|0.810.800.750.66(pancreatic islets and brian, 65 kDa)NM_024411.1prodynorphin|20|20p|20pter|0.73NM_002677.1peripheral myelin protein 2|8|8q|8q21|1.440.64NM_000816.1gamma-aminobutyric acid (GABA) A|5|5q|5q31|0.74receptor, gamma 2AL138761Ste20-related serine/threonine kinase|10|10q|10q25|1.211.221.341.26NM_005071.1solute carrier family 1 (high affinity|19|19p|19p13|0.74aspartate/glutamate transporter),member 6U82532.1Rho GDP dissociation inhibitor (GDI)|16|16p|16p13|0.790.790.81gammaNM_012344.1neurotensin receptor 2|2|2p|2p25|1.31NM_002509.1NK2 transcription factor homolog B|20|20p|20pter|1.211.251.35(Drosophila)NM_002590.2protocadherin 8|13|13q|13q14|0.64NM_006644.1heat shock 105 kD|13|13q|13q12|1.241.360.831.221.43NM_002930.1Ras-like without CAAX 2|18|18q|18q12|1.24NM_000812.2gamma-aminobutyric acid (GABA) A|4|4p|1.251.28receptor, beta 1NM_000807.1gamma-aminobutyric acid (GABA) A|4|4p|1.40receptor, alpha 2NM_001321.1cysteine and glycine-rich protein 2|12|12q|12q21|1.541.251.541.431.271.341.29NM_002650.1phosphatidylinositol 4-kinase,|22|22q|22q11|0.82catalytic, alpha polypeptideNM_002562.1purinergic receptor P2X, ligand-gated|12|12q|1.331.351.641.271.251.33ion channel, 7NM_000621.15-hydroxytryptamine (serotonin)|13|13q|13q|14|0.79receptor 2ANM_006352.1zinc finger protein 238|1|1q|1q44|0.710.77NM_001954.2discoidin domain receptor family,|6|6p|6p21|1.471.281.31member 1NM_004466.2glypican 5|13|13q|1.300.80NM_000811.1gamma-aminobutyric acid (GABA) A|5|5q|0.83receptor, alpha 6NM_004459.2fetal Alzheimer antigen|17|17q|NM_014461.1contactin 6|3|3p|3p26|0.80NM_004065.1cerebellar degeneration-related|X|Xq|Xq27|1.54protein 1, 34 kDaNM_000838.2glutamate receptor, metabotropic 1|6|6q|1.25NM_000868.15-hydroxytryptamine (serotonin)|X|Xq|0.330.76receptor 2CNM_012090.1microtubule-actin crosslinking factor 1|1|1p|1p32|NM_000864.15-hydroxytryptamine (serotonin)|1|1p|1p36|0.83receptor 1DNM_002570.1paired basic amino acid cleaving|15|15q|1.58system 4AF220532.1nuclear receptor subfamily 2, group|6|6q|0.83E, member 1NM_020149.1Meis1, myeloid ecotropic viral|15|15q|15q13|1.221.210.65integration site 1 homolog 2 (mouse)NM_000385.2aquaporin 1 (channel-forming integral|7|7p|1.871.561.731.321.611.96protein, 28 kDa)NM_007177.1TU3A protein|3|3p|3p21|1.271.421.251.241.32NM_001939.1dystrophin related protein 2|X|Xq|0.81NM_006501.1myelin-associated oligodendrocyte|3|3p|3p21|1.210.68basic proteinNM_013436.1NCK-associated protein 1|2|2q|1.27NM_0.14033.1DKFZP586A0522 protein|12|12q|1.441.401.741.301.30NM_001965.1early growth response 4|2|2p|0.790.620.570.700.630.69NM_015874.1H-2K binding factor-2|9|1.371.331.361.201.27NM_004161.1RAB1A, member RAS oncogene|2|2p|1.30familyNM_000313.1protein S (alpha)|3|3p|3p11|0.591.33NM_015530.1golgi reassembly stacking protein 2,|2|2p|2p24|1.291.261.241.2655 kDaL36675.1synuclein, alpha (non A4 component|4|4q|1.371.23of amyloid precursor)NM_003085.2synuclein, beta|5|5q|NM_004902.1RNA-binding region (RNP1, RRM)|20|20q|20q11|1.301.211.291.23containing 2NM_006930.1S-phase kinase-associated protein|5|5q|5q22|1A (p19A)NM_007274.1brain acyl-CoA hydrolase|1|1p|1p36|1.26NM_018407.11.241.391.24NM_021575.1adaptor-related protein complex 2,|19|19q|19q13|1.21sigma 1 subunitNM_002848.21.311.27NM_003471.1potassium voltage-gated channel,|3|3q|3q26|0.830.821.47shaker-related subfamily, betamember 1M87771.1fibroblast growth factor receptor 2|10|10q|1.401.460.811.36(bacteria-expressed kinase,keratinocyte growth factor receptor,craniofacial dysostosis 1, Crouzonsyndrome, Pfeiffer syndrome,Jackson-Weiss syndrome)NM_17618.1hypothetical protein FLJ20006|16|16q|16q23|NM_000175.1glucose phosphate isomerase|19|19q|19q13|1.211.23NM_003360.1UDP glycosyltransferase 8 (UDP-|4|4q|1.74galactose ceramidegalactosyltransferase)NM_004171.1solute carrier family 1 (glial high|11|11p|11p13|0.610.76affinity glutamate transporter),member 2NM_006016.1CD164 antigen, sialomucin|6|6q|NM_000457.1hepatocyte nuclear factor 4, alpha|20|20q|20q12|0.79NM_000592.2complement component 4B|6|6p|6p21|1.451.431.371.371.481.771.38NM_000815.1gamma-aminobutyric acid (GABA) A|1|1p|1p36|0.750.78receptor, deltaNM_006161.1neurogenin 1|5|5q|5q23|0.83NM_005952.1metallothionein 1X|16|16q|1.381.431.351.27J05021.1villin 2 (ezrin)|6|6q|6q25|1.280.790.64BC003576.1actinin, alpha 1|14|14q|1.271.28AA872727farnesyl-diphosphate|8|8p|8p23|1.281.301.271.241.321.381.33farnesyltransferase 1BG327863CD24 antigen (small cell lung|6|6q|0.730.82carcinoma cluster 4 antigen)BC004443.1ATPase, H+ transporting, lysosomal|22|22q|22q11|1.221.261.2431 kDa, V1 subunit E isoform 1L19184.1peroxiredoxin 1|1|1p|1p34|1.221.22M23254.1calpain 2, (m/II) large subunit|1|1q|1q41|1.201.29BC001188.1transferrin receptor (p90, CD71)|3|3q|3q26|1.251.41U14990.1ribosomal protein S3|11|11q|11q13|1.271.241.30D30658.1glycyl-tRNA synthetase|7|7p|1.25BC001019.1ribosomal protein L39|X|Xq|Xq22|1.25AL080102.1eukaryotic translation initiation factor 5|14|14q|14q32|1.241.201.211.261.31AF092131.1NADH dehydrogenase (ubiquinone)|11|11q|1.261.25flavoprotein 1, 51 kDaU59321.1DEAD/H (Asp-Glu-Ala-Asp/His) box|22|22q|22q13|0.580.70polypeptide 17, 72 kDaBC000905.1RAB1A, member RAS oncogene|2|2p|1.23familyBC000461.1eukaryotic translation initiation factor|20|20p|20pter|1.281.211.261.241.422, subunit 2 beta, 38 kDaD83043.1major histocompatibility complex,|6|6p|6p21|1.381.281.271.331.321.441.39class I, BNM_002865.1RAB2, member RAS oncogene family|8|8q|8q11|0.79NM_002865.1RAB2, member RAS oncogene family|8|8q|8q11|1.21AF070655.1ATP synthase, H+ transporting,|3|3q|1.241.24mitochondrial F0 complex, subunit gM18767.1complement component 1, s|12|12p|1.221.27subcomponentAA580004ADP-ribosylation factor 1|1|1q|1.221.311.30D89976.15-aminoimidazole-4-carboxamide|2|2q|1.211.251.241.231.231.28ribonucleotide formyltransferase/IMPcyclohydrolaseD13119.1ATP synthase, H+ transporting,|12|12q|1.241.22mitochondrial F0 complex, subunit c(subunit 9), isoform 2D89729.1exportin 1 (CRM1 homolog, yeast)|2|2p|1.301.371.20L20817.1discoidin domain receptor family,|6|6p|6p21|1.401.201.36member 1AF154847.1VAMP (vesicle-associated membrane|18|18|18p11|1.21protein)-associated protein A, 33 kDaAL136969.1homolog of yeast long chain|6|6p|6p21|1.701.421.261.521.261.34polyunsaturated fatty acid elongationenzyme 2M25915.1clusterin (complement lysis inhibitor,|8|8p|8p21|1.411.321.361.221.221.20SP-40,40, sulfated glycoprotein 2,testosterone-repressed prostatemessage 2, apolipoprotein J)M25915.1clusterin (complement lysis inhibitor,|8|8p|8p21|1.501.231.441.381.201.211.251.21SP-40,40, sulfated glycoprotein 2,testosterone-repressed prostatemessage 2, apolipoprotein J)NM_006947.1signal recognition particle 72 kDa|4|4q|1.23NM_006947.1signal recognition particle 72 kDa|4|4q|1.25BC002979.1proteasome (prosome, macropain)|14|14q|1.241.201.22subunit, alpha type, 6BC000903.1high-mobility group box 2|4|4q|1.611.421.481.341.431.39BC004489.1major histocompatibility complex,|6|6p|6p21|1.411.321.401.321.301.391.401.341.51class I, CBC000419.1catechol-O-methyltransferase|22|22q|22q11|0.79AL037339PTK2 protein tyrosine kinase 2|8|8q|8q24|1.21AB014560.1Ras-GTPase activating protein SH3|4|4q|4q21|1.301.231.28domain-binding protein 2BC005247.1isopentenyl-diphosphate delta|10|10p|10p15|1.201.251.35isomeraseBC003143.1dual specificity phosphatase 6|12|12q|12q22|0.771.24BC001362.12′,3′-cyclic nucleotide 3′|17|17q|1.251.241.46phosphodiesteraseAV752215sorcin|7|7q|7q21|1.251.211.26L12387.1sorcin|7|7q|7q21|1.231.251.221.20AF161522.1chromosome 3 open reading fram 4|3|3p|3p11|1.541.401.321.54BC004954.1ribosomal protein L13|16|16q|16q24|1.21BC002515.1aldehyde dehydrogenase 7 family,|5|5q|1.431.591.231.25member A1U62891.1dUTP pyrophosphatase|15|15q|15q15|1.231.22BE540552fatty acid desaturase 1|11|11q|11q12|1.31BE540552fatty acid desaturase 1|11|11q|11q12|1.29AL512760.1fatty acid desaturase 1|11|11q|11q12|1.381.26BC002719.1eukaryotic translation initiation factor|15|15q|1.201.223, subunit 1 alpha, 35 kDaAL559478transcription factor 12 (HTF4, helix-|15|15q|1.33loop-helix transcription factors 4)BC001329.1KIAA0202 protein|5|5q|1.271.31AK026678.1stromal antigen 2|X|Xq|1.35AF141349.1hypothetical protein DKFZp434N0650|21|21q|21q22|1.221.22BF673013spectrin SH3 domain binding protein 1|10|10p|10p11|1.331.20AF006516.1spectrin SH3 domain binding protein 1|10|10p|10p11|1.26D86550.1dual-specificity tyrosine-(Y)-|21|21q|21q22|1.22phosphorylation regulated kinase 1AU17496.1proteasome (prosome, macropain)|6|6p|6p21|1.21subunit, beta type, 8 (largemultifunctional protease 7)AL518391aquaporin 1 (channel-forming integral|7|7p|1.971.941.981.341.381.662.49protein, 28 kDa)AL050264.1TU3A protein|3|3p|3p21|1.261.441.301.201.35AL049597SH3-domain GRB2-like endophilin B1|1|1p|1.241.25AF061730.1CGI-150 protein|17|17p|17p13|1.341.26AF141347.1tubulin, alpha 3|12|12q|12q12|1.25AF289489.1aspartate beta-hydroxylase|8|8q|8q12|1.531.491.311.22AV704962sterol-C4-methyl oxidase-like|4|4q|4q32|1.251.471.221.381.411.28AF234997.1Tax interaction protein 1|17|17p|1.481.341.681.371.391.311.731.361.321.40AF016004.1glycoprotein M6B|X|Xp|Xp22|1.400.831.21AF016004.1Homo sapiens cDNA FLJ38338 fis,1.211.241.211.23clone FCBBF3027104, highly similarto Mus musculus proteolipid M6Bisoform alpha-beta-TMD-omega(M6B) mRNAAF016004.1glycoprotein M6B|X|Xp|Xp22|1.431.20AW516932down-regulator of transcription 1,|1|1p|1p22|1.251.21TBP-binding (negative cofactor 2)BC004490.1v-fos FBJ murine osteosarcoma viral|14|14q|14q24|0.710.740.610.65oncogene homologBC004291.1hypothetical protein MGC17226|1|1q|1q21|1.32N22468MADS box transcription enhancer|5|5q|1.301.29factor 2, polypeptide C (myocyteenhancer factor 2C)AW469573mitogen inducible 2|14|14q|14q22|1.311.37Z24725.1mitogen inducible 2|14|14q|14q22|1.471.351.641.311.23BC002511.1carbonyl reductase 1|21|21q|21q22|1.411.381.201.251.40AF098865.1squalene epoxidase|8|8q|8q24|1.291.26U72069.1karyopherin (importin) beta 2|5|5q|5q13|1.23AF070560.1O-linked N-acetylglucosamine|X|Xq|1.221.311.25(GlcNAc) transferase (UDP-N-acetylglucosamine: polypeptide-N-acetylglucosaminyl transferase)BC000961.2degenerative spermatocyte homolog,|1|1q|1.24lipid desaturase (Drosophila)AF020043.1chondroitin sulfate proteoglycan 6|10|10q|1.281.221.20(bamacan)BC002675.1hypothetical protein MGC4276 similar|9|9q|9q22|1.26to CG8198AF007162.1crystallin, alpha B|11|11q|11q22|1.311.801.571.311.281.351.311.75NM_001546.1inhibitor of DNA binding 4, dominant|6|6p|6p22|1.461.48negative helix-loop-helix proteinNM_001546.1inhibitor of DNA binding 4, dominant|6|6p|6p22|1.370.75negative helix-loop-helix proteinM36532.1carbonic anhydrase II|8|8q|1.360.691.541.59U65585.1major histocompatibility complex,|6|6p|6p21|1.271.23class II, DR beta IBC003525.1MAX protein|14|14q|1.25AF063020.1PC4 and SFRS1 interacting protein 2|9|9p|9p22|1.251.211.201.31BC002449.1hypothetical protein FLJ13612|2|2q|2q36|1.521.311.211.231.29AB000889.1phosphatidic acid phosphatase type|1|1p|1pter|1.311.701.300.742BL35594.1ectonucleotide|8|8q|8q24|0.631.251.391.271.68pyrophosphatase/phosphodiesterase2 (autotaxin)M80927.1chitinase 3-like 1 (cartilage|1|1q|1q31|1.871.601.531.741.521.321.451.43glycoprotein-39)M80927.1chitinase 3-like 1 (cartilage|1|1q|1q31|1.491.491.56glycoprotein-39)AL109965chromosome 20 open reading frame|20|20q|20q11|1.21104U48437.1amyloid beta (A4) precursor-like|19|19q|19q13|1.271.45protein 1AL565812pleiotrophin (heparin binding growth|7|7q|7q33|0.760.64factor 8, neurite growth-promotingfactor 1)M57399.1pleiotrophin (heparin binding growth|7|7q|7q33|0.690.790.79factor 8, neurite growth-promotingfactor 1)D49958.1glycoprotein M6A|4|4q|0.75NM_000618.1insulin-like growth factor 1|12|12q|12q22|0.830.790.65(somatomedin C)BC001745.1DNA segment on chromosome 4|4|4p|4p16|0.821.23(unique) 234 expressed sequenceAL049933.1guanine nucleotide binding protein (G|7|7q|1.381.401.70protein), alpha inhibiting activitypolypeptide 1AF114784.1methyl-CpG binding domain protein 4|3|3q|3q21|1.23BC001387.1HRAS-like suppressor 3|11|11q|11q13|1.241.561.341.201.321.63AL530874EphB2|1|1p|1p36|0.82U51120.1p21/Cdc42/Rac1-activated kinase 1|11|11q|11q13|0.78(STE20 homolog, yeast)U87460.1G protein-coupled receptor 37|7|7q|1.671.371.301.80(endothelin receptor type B-like)AI803181brain cell membrane protein 1|X|Xp|Xp11|1.321.261.22AL136550.1brain cell membrane protein 1|X|Xp|Xp11|1.511.361.21M65217.1heat shock transcription factor 2|6|6q|6q22|1.26AF162690.1transthyretin (prealbumin,|18|18q|18q12|0.530.130.810.450.38amyloidosis type I)BC005383.1centrin, EF-hand protein, 3 (CDC31|5|5q|5q14|1.421.221.421.271.35homolog, yeast)AL136924.1Ras and Rab interactor 21.461.241.20M13975.1protein kinase C, beta 1|16|16p|16p11|0.83BC001766.1S100 calcium binding protein, beta|21|21q|21q22|1.351.501.261.241.35(neural)U19495.1chemokine (C—X—C motif) ligand 12|10|10q|10q11|0.801.21(stromal cell-derived factor 1)BC004492.1DKFZP586A0522 protein|12|12q|L20860.1glycoprotein lb (platelet), beta|22|22q|22q11|polypeptideAL049569peptidyl arginine deiminase, type II|1|1p|1p35|1.25AL567302glutamate receptor, ionotropic, AMPA 1|5|5q|5q31|1.340.751.24AF001294.1tumor suppressing subtransferable|11|11p|11p15|0.78candidate 3U43148.1patched homolog (Drosophila)|9|9q|9q22|1.22AB002384.1chromosome 6 open reading frame|6|6p|6p22|0.6632J04543.1annexin A7|10|10q|10q21|1.301.301.30M83248.1secreted phosphoprotein 1|4|4q|4q21|1.401.881.951.441.351.961.941.272.05(osteopontin, bone sialoprotein I,early T-lymphocyte activation 1)AF055585.1slit homolog 2 (Drosophila)|4|4p|4p15|1.200.81AL162079.1solute carrier family 16|1|1p|1.511.321.391.271.49(monocarboxylic acid transporters),member 1U90223.1dUTP pyrophosphatase|15|15q|15q15|1.211.23AF225981.1ATPase, Ca++ transporting, type 2C,|3|3q|3q21|1.30member 1D14826.1cAMP responsive element modulator|10|10p|10p12|1.261.20AF069755.1G protein-coupled receptor 51|9|9q|9q22|0.790.78AF079363.1sperm associated antigen 6|10|10p|10p12|0.650.73D63412.1aquaporin 4|18|18q|18q11|2.031.621.761.311.33D63412.1aquaporin 4|18|18q|18q11|1.821.621.691.25U63622.1aguaporin 4|18|18q|18q11|1.772.091.841.451.231.40U46745.1dystrobrevin, alpha|18|18q|1.581.371.391.521.371.38D49372.1chemokine (C—C motif) ligand 11|17|17q|17q21|AW070431myelin basic protein|18|18q|1.711.441.371.96AF074979.1regulator of G-protein signalling 20|8|8q|8q12|1.311.291.250.761.211.24L03203.1peripheral myelin protein 22|17|17p|17p12|1.271.581.391.551.68D25547.1protein-L-isoaspartate (D-aspartate)|6|6q|6q24|1.26O-methyltransferaseAB007880.1KIAA0420 gene product|16|16p|16p13|1.57AJ007557.1potassium inwardly-rectifying|2|2q|0.800.66channel, subfamily J, member 13AF169148.1calcium binding protein 1 (calbrain)|12|12q|12q24|0.781.261.37AB000263.1cortistatin|1|1p|1p36|0.81D28114.1myelin-associated oligodendrocyte|3|3p|3p21|0.65basic proteinBC002665.1proteolipid protein 1 (Pelizaeus-|X|Xq|Merzbacher disease, spasticparaplegia 2, uncomplicated)AF001383.1bridging integrator 1|2|2q|1.311.361.39U87558.1bridging integrator 1|2|2q|1.351.281.231.381.38AF028832.1heat shock 90 kDa protein 1, alpha|14|14q|14q32|1.23BC000513.1cholinergic receptor, nicotinic, alpha|15|15q|0.720.69polypeptide 3BC000314.1reticulon 1|14|14q|14q21|1.221.31AF120274.1artemin|1|1p|1p33|0.82AW139618synapsin II|3|3p|0.77AF112221.1KIAA0871 protein|4|4q|4q13|1.311.441.26U28936.1tyrosine 3-|17|17p|17p13|monooxygenase/tryptophan 5-monooxygenase activation protein,epsilon polypeptideAB034951.1heat shock 70 kDa protein 8|11|11q|11q23|1.23BC003092.1retinoblastoma binding protein 4|1|1p|1p34|1.261.26BC000740.1cholecystokinin B receptor|11|11p|11p15|0.790.81AB009288.1copine VI (neuronal)|14|14q|14q11|0.761.20AF164622.1golgin-67|15|15q|15q11|0.73BC001388.1annexin A2|15|15q|15q21|1.261.611.28AF225986.1sodium channel, voltage-gated, type|2|2q|0.810.66III, alpha polypeptideAB033605.1proteasome (prosome, macropain)|1|1q|1q21|1.271.2626S subunit, non-ATPase, 4M37712.1cell division cycle 2-like 2|1|1p|1p36|1.30D82346.1potassium voltage-gated channel,|20|20q|20q13|0.80KQT-like subfamily, member 2AF022375.1vascular endothelial growth factor|6|6p|0.700.810.690.630.680.70BC000906.1NAD(P)H dehydrogenase, quinone 1|16|16q|16q22|1.281.20U26744.1dystrobrevin, alpha|18|18q|1.721.701.541.671.441.331.301.34AF028825.1discs, large (Drosophila) homolog 4|17|17p|17p13|0.82AF011390.1solute carrier family 4, sodium|4|4q|0.80bicarbonate cotransporter, member 4L11315.1discoidin domain receptor family,|6|6p|6p21|1.371.28member 1AF053640.1CSE1 chromosome segregation 1-|20|20q|1.28like (yeast)L05666.1glutamate receptor, ionotropic, N-|9|9q|9q34|methyl D-aspartate 1M81590.15-hydroxytryptamine (serotonin)|6|6q|0.80receptor 1BAF001602.1paraoxonase 2|7|7q|7q21|1.411.561.360.81D45421.1ectonucleotide|8|8q|8q24|0.581.271.63pyrophosphatase/phosphodiesterase2 (autotaxin)D14705.1catenin (cadherin-associated protein),|5|5q|1.361.251.251.34alpha 1 (102 kDaAF135593.1vacuolar protein sorting 41 (yeast)|7|7p|7p14|U34846.1aquaporin 4|18|18q|18q11|1.631.891.551.39BC003169.1calpain 3, (p94)|15|15q|15q15|1.61Z24727.1tropomyosin 1 (alpha)|15|15q|15q22|1.23L12723.1heat shock 70 kDa protein 4|5|5q|5q31|1.20BC006259.1cytoplasmic linker 2|7|7q|7q11|1.311.21Z25521.11.561.301.331.34AF015730.1glutamate receptor, ionotropic, N-|9|9q|9q34|0.81methyl D-aspartate 1L38019.1inositol 1,4,5-triphosphate receptor,|3|3p|3p26|0.650.82type 1D50855.1calcium-sensing receptor|3|3q|3q21|0.82(hypocalciuric hypercalcemia 1,severe neonatalhyperparathyroidism)AB013889.1potassium inwardly-rectifying|2|2q|0.60channel, subfamily J, member 13M81778.15-hydroxytryptamine (serotonin)|X|Xq|0.651.30receptor 2CAF112206.1RAB14, member RAS oncogene|9|9q|9q32|1.271.28familyU56725.1heat shock 70 kDa protein 2|14|14q|14q24|1.781.671.561.351.261.75AF020340.1guanylate cyclase 1, soluble, beta 3|4|4q|4q31|0.77M97260.1ATPase, Ca++ transporting, plasma|3|3p|3p26|0.780.730.79membrane 2AB050468.1leucine-rich repeats and1.311.551.361.271.26immunoglobulin-like domains 1U20489.10.690.830.730.830.830.770780.750.730.71M92439.1leucine-rich PPR-motif containing|2|2p|2p22|1.201.221.231.33M61900.11.29AF250307.1dynein, cytoplasmic, intermediate|2|2q|1.23polypeptide 2AF349571.1hemoglobin, alpha 1|16|16p|16p13|1.51AF353990.1beta-amyloid binding protein|1|1p|1p32|1.26precursorBC005916.1pleiotrophin (heparin binding growth|7|7q|7q33|0.820.660.780.78factor 8, neurite growth-promotingfactor 1)BC005931.1hemoglobin, alpha 2|16|16p|16p13|1.51BC005932.1proteasome (prosome, macropain)|11|11p|11p15|1.231.211.22subunit, alpha type, 1BC005939.1prostaglandin D2 synthase 21 kDa|9|9q|9q34|1.35(brain)BC005954.1NADH dehydrogenase (ubiquinone)|19|19p|1.30Fe—S protein 7, 20 kDa (NADH-coenzyme Q reductase)BC005961.1parathyroid hormone-like hormone|12|12p|12p12|0.65AF043179.1T cell receptor beta locus|7|7q|0.62AF172268.1KIAA0551 protein|3|3q|3q26|0.83U18800.1myelin oligodendrocyte glycoprotein|6|6p|6p22|1.391.66AF073745.2phosphodiesterase 4A, cAMP-|19|19p|19p13|specific (phosphodiesterase E2dunce homolog, Drosophila)L07950.11.371.251.381.341.321.341.431.611.49AF348514.1prothymosin, alpha (gene sequence|2|2q|2q35|1.361.3628)AY028632.1catalase|11|11p|1.291.331.251.21AF216292.1heat shock 70 kDa protein 5 (glucose-|9|9q|9q33|1.22regulated protein, 78 kDa)BG500301ESTs, Highly similar toITB1_HUMAN Integrinbeta-1 precursor (Fibronectinreceptor beta subunit) (CD29)(Integrin VLA-4 beta subunit)[H. sapiens]NM_002271.1karyopherin (importin) beta 3|13|13q|13q32|1.261.271.281.23BF246436putative translation initiation factor|17|1.261.211.241.33L27560.1Human insulin-like growth factor1.431.35binding protein 5 (IGFBP5) mRNAAK000826.1RAB7, member RAS oncogene family|3|3q|3q22|1.20X79067.1zinc finger protein 36, C3H type-like 1|14|14q|14q22|1.451.301.471.271.38AL516350actin related protein 2/3 complex,|1|1q|1q24|1.221.31subunit 5, 16 kDaBG538627pro-oncosis receptor inducing|11|11q|11q22|1.34membrane injury geneBG287862Homo sapiens cDNA FLJ33834 fis,1.20clone CTONG2004264, moderatelysimilar to NEUROBLASTDIFFERENTIATION ASSOCIATEDPROTEIN AHNAKNM_001068.1topoisomerase (DNA) II beta 180 kDa|3|3p|1.20AL567820actin, gamma 1|17|17q|1.22AK025647.1hypothetical protein H41|3|3q|3q22|1.25AK025557.1Homo sapiens cDNA: FLJ21904 fis,1.38clone HEP03585BE903880CD44 antigen (homing function and|11|11p|2.091.801.571.361.371.432.472.02Indian blood group system)BE734356myosin, light polypeptide 6, alkali,|12|12q|1.21smooth muscle and non-muscleBE858180paternally expressed 10|7|7q|1.220.79AL096842.1AT2 receptor-interacting protein 1|8|8p|1.661.481.221.241.421.231.57AW517686ESTs1.30NM_005953.1metallothionein 2A|16|16q|1.261.331.26NM_000954.1prostaglandin D2 synthase 21 kDa|9|9q|9q34|1.37(brain)AL541302serine (or cysteine) proteinase|2|2q|2q33|1.201.31inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1), member 2AF052169.1hypothetical protein BC013764|13|13q|13q22|1.751.381.301.421.25AL049265.1Homo sapiens mRNA; cDNA1.321.381.311.25DKFZp564F053 (from cloneDKFZp564F053)BF338947interferon induced transmembrane|11|1.511.381.521.521.461.511.371.641.551.54protein 3 (1-8U)AF132733.1DKFZP564G2022 protein|15|15q|1.201.33AL576654phosphatidic acid phosphatase type|1|1p|1pter|1.550.810.722BAL576654phosphatidic acid phosphatase type|1|1p|1pter|1.281.341.620.802BZ19574keratin 17|17|17q|17q12|0.60AL565074tubulin, alpha 1 (testis specific)|2|2q|2q36|1.361.451.391.37AI972475Homo sapiens cDNA FLJ20738 fis,1.361.321.211.281.251.271.41clone HEP08257AF142419.1homolog of mouse quaking QKI (KH|6|6q|6q26|0.78domain RNA binding protein)AF142419.1homolog of mouse quaking QKI (KH|6|6q|6q26|domain RNA binding protein)AA195999mitogen-activated protein kinase 1|22|22q|22q11|1.24AB011126.1formin-binding protein 17|9|9q|1.371.30BE620457neuropilin 1|10|10p|1.22AW167793glucosamine (N-acetyl)-6-sulfatase|12|12q|0.821.29(Sanfilippo disease IIID)AA621962myosin ID|17|17q|17q11|1.36BE780075transmembrane trafficking protein|14|14q|14q24|1.291.241.311.331.30AW043713sulfatase FP|8|8q|8q13|1.271.53AL137751.1radixin|11|11q|1.531.231.37AL137751.1radixin|11|11q|AV715767Homo sapiens mRNA; cDNA1.28DKFZp564A072 (from cloneDKFZp564A072AL049949.1Homo sapiens, similar to1.271.25Y43E12A.2.p, clone MGC: 33537IMAGE: 4821347, mRNA, completecdsAL049949.1Homo sapiens, similar to1.281.271.20Y43E12A.2.p, clone MGC: 33537IMAGE: 4821347, mRNA, completecdsAA630314ribosomal protein S2|16|16p|16p13|1.241.22AB033105.1DKFZP586B0923 protein|10|10q|10q22|1.241.21D26069.1centaurin, beta 2|3|3q|1.27AL135735phosphatidylinositol binding clathrin|11|11q|1.531.401.401.261.351.321.54assembly proteinBE568219phosphodiesterase 8A|15|15q|15q25|1.31AL080111.1NIMA (never in mitosis gene a)-|1|1q|1q31|1.271.250.82related kinase 7AU144066Homo sapiens cDNA FLJ11904 fis,1.23clone HEMBB1000048AL576253zizimin1|13|13q|13q32|1.261.31BE617588hippocalcin-like 1|2|2p|2p25|0.79AL573201KIAA0830 protein|11|11q1.241.351.301.211.58BF026595ribosomal protein S17|15|15q|1.23AB040884.1oxysterol binding protein-like 8|12|12q|0.810.720.560.75AW298092KIAA0776 protein|6|6q|6q16|1.30AL031781homolog of mouse quaking QKI (KH|6|6q|6q26|1.261.451.21domain RNA binding protein)AL581768tubulin, alpha 3|12|12q|12q12|1.261.22D42043.1KIAA0084 protein|3|3p|3p24|1.441.20AL575922myosin IF|19|19p|19p13|1.781.63BF966021ESTs, Highly similar to T08670 cell1.461.38division control protein homologDKFZp564M1416.1 - human(fragment) [H. sapiens]AB011178.1SCN Circadian Oscillatory Protein|18|18q|18q21|1.311.22(SCOP)U79297.1Homo sapiens mRNA; cDNA1.221.20DKFZp667C0525 (from cloneDKFZp667C0525)AA923354monoamine oxidase A|X|Xp|Xp11|1.221.20AL050144.1zinc finger protein 363|4|4q|4q21|1.291.201.401.221.201.211.211.24BG165094translocase of outer mitochondrial|1|1q|1.491.27membrane 20 (yeast) homologAB020684.1KIAA0877 protein|7|7p|7P15|1.211.30AK001389.1hypothetical protein DKFZp564O043|7|7p|1.231.301.27BE742268sortilin 1|1|1p|1p21|1.311.38AI700633Homo sapiens cDNA: FLJ22642 fis,clone HSI06970AA149644junctional adhesion molecule 3|11|11q|1.52AK023253.1DnaJ (Hsp40) homolog, subfamily B,|9|9p|9p11|0.800.79member 5BE878277Homo sapiens cDNA FLJ13267 fis,1.231.511.271.251.201.231.55clone OVARC1000964AA584297low density lipoprotein receptor-|11|11p|11p11|1.351.221.221.23related protein 4AK024044.1Sjogren syndrome antigen A2|1|1q|1.34(60 kDa, ribonucleoproteinautoantigen SS-A/Ro)BG231551activated RNA polymerase II|5|5p|5p13|1.20transcription cofactor 4AI628605son of sevenless homolog 2|14|14q|(Drosophila)AI753659Sec23 homolog A (S. cerevisiae)|14|14q|14q13|1.371.23BG109746Homo sapiens cDNA FLJ33775 fis,1.26clone BRSSN2000498AI992251Homo sapiens cDNA FLJ14821 fis,1.301.391.201.321.231.51clone OVARC1000556, highly similarto RIBOSOMAL PROTEIN S6KINASE II ALPHA 2 (EC 2.7.1.—)BE251303calreticulin|19|19p|19p13|1.21AI769685cysteinyl-tRNA synthetase|11|11p|11p15|1.241.26BF791738KIAA0738 gene product|7|7q|BF115739Homo sapiens mRNA; cDNA1.27DKFZp434E033 (from cloneDKFZp434E033)AI377497mob protein|10|10q|1.20AB020717.1synaptojanin 1|21|21q|21q22|1.22AA114166ESTs, Weakly similar to S266891.351.201.24hypothetical protein hc1 - mouse(fragment) [M. musculus]BF347326myristoylated alanine-rich protein|6|6q|6q22|0.820.83kinase C substrateBF448315Homo sapiens clone 24630 mRNA1.331.22sequenceBF448315Homo sapiens clone 24630 mRNA1.431.521.22sequenceAU146655Homo sapiens cDNA FLJ11968 fis,1.25clone HEMBB1001133AL008583neuronal pentraxin receptor|22|22q|22q13|0.79AU145019KIAA1013 protein|3|3p|3p14|1.31AV682436ribosomal protein L35a|3|3q|3q29|1.251.220.750.73AW052179collagen, type IV, alpha 5 (Alport|X|Xq|1.30syndrome)BE908931ESTs, Highly similar to GCHUH1.260.78glycine cleavage system protein Hprecursor - human [H. sapiens]R38389olfactomedin 1|9|9q|9q34|0.79AL049423.1Homo sapiens, clone1.360.79IMAGE: 4182947, mRNAAL049423.1Homo sapiens, clone1.39IMAGE: 4182947, mRNAAU145005Sp3 transcription factor|2|2q|BG538564ferritin, light polypeptide|19|19q|19q13|1.381.431.321.291.22U93305synaptophysin|X|Xp|Xp11|AJ271832.1protein phosphatase 1B (formerly|2|2p|2p22|2C), magnesium-dependent, betaisoformBF590131Dicer1, Dcr-1 homolog (Drosophila)|14|14q|14q32|1.27AI922519rab6 GTPase activating protein (GAP|9|9q|9q34|1.231.251.21and centrosome-associated)AU150319TAP binding protein related|12|12p|12p13|1.281.201.211.701.52BF062629Ras-induced senescence 1|3|3p|3p21|0.820.801.56N33167cyclin-dependent kinase inhibitor 1C|11|11p|11p15|1.551.431.621.95(p57, Kip2)AI799007ribosomal protein S12|6|6q|6q23|1.21AW070229Homo sapiens unknown mRNA1.25AL022327megalencephalic|22|22q|22q13|1.31leukoencephalopathy with subcorticalcysts 1AI560720ribophorin II|20|20q|20q12|1.241.22BE259729ribosomal protein S19|19|19q|19q13|1.28U73304cannabinoid receptor 1(brain)|6|6q|6q14|0.800.66BF718769protein phosphatase 1, regulatory|2|2q|2q37|1.22subunit 7AL565749tubulin, beta, 4|16|16q|16q24|1.251.241.22U26662.1neuronal pentraxin II|7|7q|7q21|0.730.671.61BE908217annexin A2|15|15q|15q21|1.231.621.28M98528DNA segment on chromosome 4|4|4p|4p16|0.82(unique) 234 expressed sequenceBE962615sorting nexin 3|6|6q|6q22|1.22AB011131.1piccolo (presynaptic cytomatrix|7|7q|7q11|1.251.21protein)AI554300serine (or cysteine) proteinase|6|6p|1.251.231.24inhibitor, clade B (ovalbumin),member 1AB011152.1centaurin, delta 1|4|4p|4p15|1.241.461.21NM_007054.1kinesin family member 3A|5|5q|1.21AW235061solute carrier family 1|9|9p|1.24(neuronal/epithelial high affinityglutamate transporter, system Xag),member 1AA854017tyrosine 3-|2|1.241.221.31monooxygenase/tryptophan 5-monooxygenase activation protein,theta polypeptideBG260658CS box-containing WD protein1.20AI557312cytochrome c oxidase subunit Vb|2|1.21AW241752splicing factor, arginine/serine-rich 11|1|1p|AW950513achaete-scute complex-like 1|12|12q|12q22|0.83(Drosophila)BE550452Homer, neuronal immediate early|5|5q|5q14|0.710.81gene, 1BBE674466Homo sapiens clone 23688 mRNA0.811.291.53sequenceAI200589ribosomal protein S16|19|19q|19q13|1.21BF718636H2A histone family, member Z|4|4q|1.301.201.201.25NM_001048.1somatostatin|3|3q|0.670.581.270.720.65AL134612Homo sapiens clone 23798 and0.820.810.830.6223825 mRNA sequenceAI885290spondin 1, (f-spondin) extracellular|11|11p|11p14|1.371.28matrix proteinAA749101interferon induced transmembrane|11|1.271.311.471.231.311.211.40protein 1 (9-27)AL533838tubulin, beta polypeptide|6|6p|6p21|1.291.421.521.231.271.38BE857772ribosomal protein L37a|2|2q|1.22AA017721Homo sapiens mRNA; cDNA1.341.30DKFZp686F1844 (from cloneDKFZp686F1844)AI073407transferrin|3|3q|1.94BE043477ATPase, H+ transporting, lysosomal|5|5q|5q35|1.241.341.229 kDa, V0 subunit eAA555113ribosomal protein, large, P0|12|12q|12q24|1.23AA602532ceroid-lipofuscinosis, neuronal 2, late|11|11p|1.251.26infantile (Jansky-Bielschowskydisease)AA083483ferritin, heavy polypeptide 1|11|11q|1.341.391.221.351.271.23AL122077.1dynein, axonemal, heavy polypeptide|17|17q|1.3417W86293proteasome (prosome, macropain)|6|6q|1.211.25subunit, beta type, 1AI348935calreticulin|19|19p|19p13|1.321.32AI218219heat shock 90 kDa protein 1, beta|6|6p|1.24BF063121testis intracellular mediator protein|6|6p|6p21|NM_000703.1hypothetical protein MGC13276|19|19q|19q13|0.770.790.74AF127764.1calpain 3, (p94)|15|15q|15q15|1.54L03419.1Fc fragment of IgG, high affinity la,|1|1q|1q21|1.25receptor for (CD64)NM_006713.1activated RNA polymerase II|5|5p|5p13|1.321.33transcription cofactor 4AF065484.1sorting nexin 1|15|15q|15q22|1.31T16257Homo sapiens cDNA FLJ38058 fis,1.371.53clone CTONG2014898AL119322fibroblast growth factor 12|3|3q|0.73BG252666ATPase, Class I, type 8B, member 1|18|18q|18q21|BG034080bridging integrator 1|2|2q|1.25AL0503281.561.531.231.401.261.86AU134977multiple endocrine neoplasia I|11|11q|0.65BF674712neurotrophic tyrosine kinase,|9|9q|9q22|1.341.39receptor, type 2AI251890CDC-like kinase 1|2|2q|1.271.28AK024789.1KRAB zinc finger protein KR18|19|19q|19q13|AW516297ESTs, Weakly similar to hypothetical1.251.301.22protein FLJ20378 [Homo sapiens][H. sapiens]AK025457.1golgi apparatus protein 1|16|16q|16q22|1.241.27AL162013.1plexin A1|3|3q|3q21|0.820.72AB007958.1KIAA0489 proteinAW449813KIAA0918 protein|13|13q|13q31|0.80AA769818calcium channel, voltage-dependent,|19|19p|19p13|0.83P/Q type, alpha 1A subunitX06989.1amyloid beta (A4) precursor protein|21|21q|21q21|0.83(protease nexin-II, Alzheimerdisease)AL117593.1fasciculation and elongation protein|2|2p|1.231.231.261.32zeta 2 (zygin II)AL161952.1glutamate-ammonia ligase (glutamine|1|1q|1.341.33synthase)AB002438.1sema domain, transmembrane|5|5q|5q23|1.591.471.39domain (TM), and cytoplasmicdomain, (semaphorin) 6ABC004145.1trinucleotide repeat containing 4|1|1q|0.830.73AF035321.1dynamin 1|9|9q|0.801.21AA679705eukaryotic translation initiation factor|16|16p|16p11|1.431.221.251.341.381.281.401.351.423, subunit 8, 110 kDaAV721177phosphatidylinositol binding clathrin|11|11q|1.291.331.45assembly proteinAL109722.1Homo sapiens cDNA FLJ33753 fis,1.25clone BRCAN2000383AW168915Homo sapiens prostate-specific1.431.77membrane antigen PSM mRNA, exon6 alternative splice variant, partial cdsAK000270.1A kinase (PRKA) anchor protein|7|7q|7q21|1.28(yotiao) 9AK021882.1ras homolog gene family, member I|1|1p|1.76BF966183gamma-aminobutyric acid (GABA) A|15|15q|15q11|receptor, alpha 5AV693216plexin B1|3|3p|3p21|1.311.25AA131826Homo sapiens cDNA FLJ36627 fis,0.690.81clone TRACH2017965, highly similarto SPECTRIN BETA CHAIN, BRAINAK027146.1ribosomal protein L5|1|1p|1p22|1.261.26AB028977.1KIAA1054 protein|5|5q|5q13|0.43X63575.1ATPase, Ca++ transporting, plasma|3|3p|3p26|0.740.710.75membrane 2AW188940beta-2-microglobulin|15|15q|15q21|1.291.231.221.22s77154.1nuclear receptor subfamily 4, group|2|2q|2q22|0.730.65A, member 2AB018277.1BAI1-associated protein 3|16|16p|16p130.80083S69738.1chemokine (C—C motif) ligand 2|17|17q|17q11|1.21X98405.1myelin associated glycoprotein|19|19q|19q13|1.471.81X86401.1glycine amidinotransferase (L-|15|15q|1.28arginine: glycine amidinotransferase)AC0039991.20U23850.1inositol 1,4,5-triphosphate receptor,|3|3p|3p26|0.651.321.29type 1AF279774.1growth associated protein 43|3|3q|3q13|0.820.80AF095723.10.790.79AF217990.1homocysteine-inducible, endoplasmic|16|16q|16q12|1.431.24reticulum stress-inducible, ubiquitin-like domain member 1U88968.1enolase 1, (alpha)|1|1p|1p36|1.22M22094.1neural cell adhesion molecule 1|11|11q|11q23|1.461.301.43AL050361.1mitochondrial ribosomal protein S18B|6|6p|6p21|1.211.20NM_021103.1thymosin, beta 10|2|2p|2p11|1.251.221.271.42NM_000972.1ribosomal protein L7a1.20NM_001013.1ribosomal protein S9|19|19q|19q13|1.251.26NM_001029.1ribosomal protein S26|12|12q|1.331.351.371.231.271.251.391.31NM_018269.1SIPL protein|2|2p|2p25|1.411.311.521.291.601.321.30BE789881RAB31, member RAS oncogene|18|18p|18p11|1.301.341.221.321.29familyNM_006868.1RAB31, member RAS oncogene|18|18p|18p11|1.271.321.251.34familyAF183421.1RAB31, member RAS oncogene|18|18p|18p11|1.281.311.201.27familyNM_006555.1SNARE protein Ykt6|7|7p|7p15|0.81NM_004481.2UDP-N-acetyl-alpha-D-|1|1q|1q41|1.20galactosamine: polypeptide N-acetylgalactoasaminyltransfarase 2(GalNAc-T2)NM_016275.1selenoprotein T|3|3q|3q22|1.271.221.23NM_022748.1tumor endothelial marker 6|7|7p|7p15|0.750.58NM_002415.1macrophage migration inhibitory|22|22q|22q11|0.82factor (glycosylation-inhibiting factor)NM_016289.1MO25 protein|2|2q|2q36|1.281.251.271.361.28NM_003849.1succinate-CoA ligase, GDP-forming,|2|2p|2p11|1.221.24alpha subunitNM_014315.1host cell factor homolog|14|14q|14q21|1.241.321.28NM_014041.1signal peptidase 12 kDa|3|3p|3p21|1.20NM_015907.1leucine aminopeptidase 3|4|4p|4p15|1.341.301.251.311.34NM_018695.1erbb2 interacting protein|5|5q|5q12|1.441.581.331.23NM_016146.1PTD009 protein|11|11q|11q23|1.221.21NM_016146.1PTD009 protein|11|11q|11q23|1.211.221.28NM_019048.1hypothetical protein FLJ20752|2|2p|2p24|1.261.281.34NM_015920.1ribosomal protein S27-like|15|15q|15q21|1.241.261.23NM_014078.1mitochondrial ribosomal protein L13|8|8q|8q22|1.20NM_015961.1hypothetical protein HSPC177|9|9p|1.311.231.25NM_018478.1chromosome 20 open reading frame|20|20q|20q13|1.361.201.6335NM_004549.1NADH dehydrogenase (ubiquinone)|11|11q|11q13|1.211.201, subcomplex unknown, 2, 14.5 kDaNM_018047.1hypothetical protein FLJ10290|5|5q|5q33|1.22NM_018368.1hypothetical protein FLJ11240|6|6q|6q14|1.291.24NM_015523.1small fragment nuclease11|11q|11q23|1.221.24NM_014206.1chromosome 11 open reading frame|11|11q|11q12|1.271.211.211.3310NM_004547.2NADH dehydrogenase (ubiquinone) 1|3|3q|3q13|beta subcomplex, 4, 15 kDaNM_015991.1complement component 1, q|1|1p|1p36|1.251.24subcomponent, alpha polypeptideNM_016618.1hypothetical protein LOC51315|2|2p|2p11|NM_021730.1hypothetical protein PP1044|17|17p|17p13|1.54NM_022496.1hypothetical protein FLJ13433|12|12q|12q21|1.401.201.331.24NM_015987.1heme binding protein 1|12|12p|12p13|1.331.241.231.26NM_013372.1cysteine knot superfamily 1, BMP|15|15q|15q13|1.27antagonist 1NM_017945.1hypothetical protein FLJ20730|3|3q|3q13|1.391.341.47NM_019000.1hypothetical protein FLJ20152|5|5p|5p15|1.411.291.30NM_005461.1v-maf musculoaponeurotic|20|20q|20q11|1.291.561.551.311.62fibrosarcoma oncogene homolog B(avian)NM_015980.1HMP 19 protein|5|5q|5q35|0.72NM_018263.1KIAA1685 protein|2|2p|2p24|1.26NM_018103.1leucine-rich repeat-containing 5|1|1p|1p22|AW575493hypothetical protein FLJ21313|5|5q|5q23|1.391.571.471.30NM_016205.1platelet derived growth factor C|4|4q|1.21NM_014059.1RGC32 protein|13|13q|13q13|1.721.571.301.200.771.32NM_017610.1likely ortholog of mouse Arkadia|15|15q|1.24NM_020445.1actin-related protein 3-beta|7|7q|7q32|1.24NM_017899.1hypothetical protein FLJ20607|12|12q|12q24|0.78NM_016140.1brain specific protein|16|16q|16q23|1.401.221.60NM_020353.1phospholipid scramblase 4|3|3q|1.841.411.721.531.351.72NM_018374.1hypothetical protein FLJ11273|7|7p|7p22|1.29NM_014322.1opsin 3 (ecephalopsin, panopsin)|1|1q|0.06NM_007246.1kelch-like 2, Mayven (Drosophila)|4|4q|4q21|1.251.321.22NM_022367.1hypothetical protein FLJ12287 similar|1|1q|0.77to semaphorinsNM_016410.1hypothetical protein HSPC177|9|9p|1.211.20NM_024306.1fatty acid hydroxylase|16|16q|1.65NM_018644.1Homo sapiens mRNA; cDNA1.34DKFZp547E046 (from cloneDKFZp547E046NM_006054.1reticulon 3|11|11q|1.201.28NM_018658.1potassium inwardly-rectifying|17|17q|17q23|1.380.810.770.650.74channel, subfamily J, member 16NM_016533.1ninjurin 2|12|12p|1.50NM_005713.1collagen, type IV, alpha 3|5|5q|5q13|1.301.24(Goodpasture antigen) bindingproteinAL136591.1hippocalcin like 4|1|1p|1p34|0.75NM_006790.1titin immunoglobulin domain protein|5|5q|1.231.251.221.26(myotilin)NM_012259.1hairy/enhancer-of-split related with|6|6q|6q22|0.79YRPW motif 2NM_018342.1hypothetical protein FLJ11155|4|4q|4q32|0.590.670.460.770.62NM_015414.1ribosomal protein L36|19|19p|19p13|1.20NM_012082.2Friend of GATA2|8|8q|1.290.770.67NM_014018.1mitochondrial ribosomal protein S28|8|8q|8q21|1.201.251.261.21NM_012450.1solute carrier family 13|7|7q|0.800.480.52(sodium/sulfate symporters), member 4NM_015722.2calcyon; D1 dopamine receptor-|10|10q|10q26|1.311.29interacting proteinNM_013381.1thyrotropin-releasing hormone|12|12q|12q15|0.811.380.81degrading ectoenzymeNM_013251.1tachykinin 3 (neuromedin K,|12|12q|12q13|0.830.80neurokinin beta)NM_013257.1serum/glucocorticoid regulated|8|8q|8q12|1.461.311.261.41kinase-likeNM_012144.1dynein, axonemal, intermediate|9|9p|9p21|0.820.83poylpeptide 1NM_006658.1G-substrate|7|7p|0.83NM_018167.1function unknown protein 1|14|14q|14q32|0.83NM_006668.1cytochrome P450, subfamily 46|14|14q|14q32|0.82(cholesterol 24-hydroxylase)NM_018945.1phosphodiesterase 7B|6|6q|6q23|0.81NM_007071.1HERV-H LTR-associating 3|1|1p|1p31|1.201.251.23NM_017435.1solute carrier family 21 (organic anion|12|12p|12p13|1.491.330.75transporter), member 14NM_016348.1chromosome 5 open reading frame 4|5|5q|5q31|1.23NM_022469.1hypothetical protein FLJ21195 similar|1|1q|0.820.81to protein related to DAC andcerberusNM_015965.1cell death-regulatory protein GRIM19|19|19p|19p13|1.21NM_018513.10.80NM_020178.1Carbonic anhydrase-related protein|17|17q|0.7810NM_021154.1phosphoserine aminotransferase|9|9q|9q21|1.291.431.521.311.34NM_031279.1alanine-glyoxylate aminotransferase|4|4q|1.631.302.081.291.241.462-like 1NM_030817.1hypothetical protein DKFZp434F0318|12|12p|12p13|1.281.481.361.491.56NM_021615.1carbohydrate (N-acetylglucosamine|16|16q|1.221.311.246-O) sulfotransferase 6NM_017650.1protein phosphatase 1, regulatory|7|7q|7q11|1.27(inhibitor) subunit 9ANM_018723.1ataxin 2-binding protein 1|16|16p|16p13|1.231.23NM_004115.1fibroblast growth factor 14|13|13q|1.24NM_021191.1neurogenic differentiation 4|12|12q|0.81NM_005172.1atonal homolog 1 (Drosophila)|4|4q|0.80AW173623tumor differentially expressed 1|20|20q|20q13|1.24NM_004776.1UDP-Gal: betaGlcNAc beta 1,4-|20|20q|20q13|1.291.301.22galactosyltransferase, polypeptide 5AF034756.1karyopherin alpha 3 (importin alpha|13|13q|13q14|1.234)AW612574lecuine-rich acidic protein-like protein|1|1q|1q21|AB044088.1basic helix-loop-helix domain|12|12p|2p11|1.501.521.361.401.521.34containing, class B, 3AL442077.1chromosome 8 open reading frame 2|8|8p|8p11|1.341.26AU145941CDC14 cell division cycle 14 homolog|9|9q|19q22|1.27B (S. cerevisiae)AF130089.1aldehyde dehydrogenase 6 family,|14|14q|14q24|1.31member A1AF130089.1aldehyde dehydrogenase 6 family,|14|14q|14q24|1.401.351.611.341.281.27member A1AF246240.1uncharacterized hypothalamus|11|11q|11q14|protien HT007AF133207.1protien kinase H11|12|12q|12q24|1.341.281.451.251.491.39AB049652.1mitochondrial ribosomal protein L34|19|19p|19p13|1.211.241.271.201.221.31BF209507activated RNA polymerase II|5|5p|5p13|0.770.780.80transcription cofactor 4J02814.1chondroitin sulfate proteoglycan 2|5|5q|5q14|1.291.32(versican)BG287153mannosidase, alpha, class 1A,|6|6q|1.360.821.26member 1AF055030.1PHD zinc finger protein XAP135|6|6q|1.331.391.26AA707199neurotrophic tyrosine kinase,|9|9q|9q22|1.291.530.75receptor, type 2AA707199neurotrophic tyrosine kinase,|9|9q|9q22|1.471.67receptor, type 2AU157109KIAA1598 protein|10|10q|10q26|NM_006158.1neurofilament, light polypeptide|8|8p|0.821.371.350.5968 kDaAI307759karyopherin (importin) beta 2|5|5q|5q13|U70056seven in absentia homolog 1|16|16q|1.341.20(Drosophila)BF514079Kruppel-like factor 4 (gut)|9|9q|0.770.770.800.630.730.760.77N34407KIAA0608 protein|10|10q|10q24|1.261.50AF070641.1Homo sapiens clone 24421 mRNA0.810.56sequenceAI719730guanylate cycase 1, soluble alpha 3|4|4q|4q31|1.230.67AW303136ribosomal protein L38|17|17q|17q23|AW057781ribosomal protein L10|X|Xq|1.22AI984479Homo sapiens cDNA FLJ33067 fis,1.321.391.201.341.311.27clone TRACH2000148, weaklysimilar to POLY(A) POLYMERASE(EC 2.7.7.19)AI982754clusterin (complement lysis inhibitor,|8|8p|8p21|1.331.331.241.531.351.28SP-40,40, sulfated glycoprotein 2,testosterone-repressed prostatemessage 2, apolipoprotein J)AF015043.1SH3-domain binding protein 4|2|2q|2q37|1.331.231.25X15306neurofilament, heavy polypeptide|22|22q|22q12|0.730.771.261.260.551.65200 kDaU892813-hydroxysteroid epimerase|12|12q|1.21L19185peroxiredoxin 2|13|13q|1.21R61374hairy/enhancer-of-split related with|8|8q|1.24YRPW motif 1H93026elongation of very long chain fatty|1|1p|1p34|1.311.251.251.65acids (FEN1/Elo2, SUR4/Elo3,yeast)-like 1U84487chemokine (C—X3—C motif) ligand 1|16|16q|0.82









TABLE 2










ALL REGIONS - NEUROFILAMENT















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)





Hs.198760
4744
neurofilament, heavy
NEFH
NM_021076




polypeptide 200 kDa

(204412_s_at)


Hs.211584
4747
neurofilament, light
NEFL
AL537457




polypeptide 68 kDa

(221805_at)


Hs.71346
4741
neurofilament 3
NEF3
NM_005382




(150 kDa medium)

(205113_at)
















TABLE 3










ALL REGIONS - DEVELOPMENT











UniGene
LocusID
Description
Symbol
ACCESSION (Probe ID)














Hs.103724
5376
peripheral myelin protein 22
PMP22
L03203 (210139_s_at)


Hs.10526
1466
cysteine and glycine-rich protein 2
CSRP2
NM_001321






(207030_s_at)


Hs.111126
754
pituitary tumor-transforming 1
PTTG1IP
NM_004339 (200677_at)




interacting protein


Hs.111779
6678
secreted protein, acidic, cysteine-
SPARC
AL575922 (212667_at)




rich (osteonectin)


Hs.117546
4826
neuronatin
NNAT
NM_005386






(204239_s_at)


Hs.141308
4340
myelin oligodendrocyte glycoprotein
MOG
NM_002433 Table






2: (205989_s_at)


Hs.153684
2487
frizzled-related protein
FRZB
NM_001463






(203698_s_at)


Hs.154654
1545
cytochrome P450, family 1,
CYP1BI
NM_000104




subfamily B, polypeptide 1

(202437_s_at)


Hs.158213
9576
sperm associated antigen 6
SPAG6
AF079363 (210033_s_at)


Hs.158540
7368
UDP glycosyltransferase 8 (UDP-
UGT8
NM_003360




galactose ceramide

(208358_s_at)




galactosyltransferase)


Hs.169309
4336
myelin-associated oligodendrocyte
MOBP
D28114 (210193_at)




basic protein


Hs.169401
348
apolipoprotein E
APOE
N33009 (203381_s_at)


Hs.169487
9935
v-maf musculoaponeurotic
MAFB
NM_005461




fibrosarcoma oncogene homolog B

(218559_s_at)




(avian)


Hs.173594
5176
serine (or cysteine) proteinase
SERPINF1
NM_002615 (202283_at)




inhibitor, clade F (alpha-2




antiplasmin, pigment epithelium




derived factor), member 1


Hs.194695
9077
ras homolog gene family, member I
ARHI
AK021882 (215506_s_at)


Hs.198760
4744
neurofilament, heavy polypeptide
NEFH
NM_021076




200 kDa

(204412_s_at)


Hs.2316
6662
SRY (sex determining region Y)-
SOX9
AI382146 (202935_s_at)




box 9 (campomelic dysplasia,




autosomal sex-reversal)


Hs.2563
6863
tachykinin, precursor 1 (substance
TAC1
NM_003182




K, substance P, neurokinin 1,

(206552_s_at)




neurokinin 2, neuromedin L,




neurokinin alpha, neuropeptide K,




neuropeptide gamma)


Hs.25647
2353
v-fos FBJ murine osteosarcoma
FOS
BC004490 (209189_at)




viral oncogene homolog


Hs.284122
11197
WNT inhibitory factor 1
WIF1
NM_007191 (204712_at)


Hs.284244
2247
fibroblast growth factor 2 (basic)
FGF2
NM_002006






(204422_s_at)


Hs.288650
361
aquaporin 4
AQP4
D63412






(210066_s_at,210067_at)


Hs.293267
825
calpain 3, (p94)
CAPN3
AF127764 (214475_x_at)


Hs.295449
5816
parvalbumin
PVALB
NM_002854 (205336_at)


Hs.313
6696
secreted phosphoprotein 1
SPP1
M83248 (209875_s_at)




(osteopontin, bone sialoprotein I,




early T-lymphocyte activation 1)


Hs.33829
79365
basic helix-loop-helix domain
BHLHB3
BE857425 (221530_s_at)




containing, class B, 3


Hs.380674
302
annexin A2
ANXA2
BC001388 (210427_x_at)


Hs.408061
2171
fatty acid binding protein 5
FABP5
NM_001444




(psoriasis-associated)

(202345_s_at)


Hs.433399
6876
transgelin
TAGLN
NM_003186






(205547_s_at)


Hs.44
5764
pleiotrophin (heparin binding growth
PTN
AL565812 (209465_x_at)




factor 8, neurite growth-promoting




factor 1)


Hs.69547
4155
myelin basic protein
MBP
AW070431 (210136_at)


Hs.7306
6422
secreted frizzled-related protein1
SFRP1
NM_003012






(202037_s_at)


Hs.73793
7422
vascular endothelial growth factor
VEGF
AF022375 (210512_s_at)


Hs.74471
2697
gap junction protein, alpha 1,
GJA1
NM_000165 (201667_at)




43 kDa (connexin 43)


Hs.75106
1191
clusterin (complement lysis
CLU
AI982754 (222043_at)




inhibitor, SP-40,40, sulfated




glycoprotein 2, testosterone-




repressed prostate message 2,




apolipoprotein J)


Hs.79368
2012
epithelial membrane protein 1
EMP1
NM_001423 (201324_at)


Hs.80296
5121
Purkinje cell protein 4
PCP4
NM_006198 (205549_at)


Hs.80395
4118
mal, T-cell differentiation protein
MAL
NM_002371






(204777_s_at)


Hs.82002
1910
endothelin receptor type B
EDNRB
NM_000115 (204273_at)


Hs.83384
6285
S100 calcium binding protein, beta
S100B
BC001766 (209686_at)




(neural)


Hs.85112
3479
insulin-like growth factor 1
IGF1
AI972496 (209541_at)


Hs.89626
5744
parathyroid hormone-like hormone
PTHLH
BC005961 (211756_at)
















TABLE 4










ALL REGIONS - EXTRACELLULAR











UniGene
LocusID
Description
Symbol
ACCESSION (Probe ID)














Hs.111779
6678
secreted protein, acidic, cysteine-rich
SPARC
AL575922 (212667_at)




(osteonectin)


Hs.12409
6750
somatostatin
SST
NM_001048 (213921_at)


Hs.153684
2487
frizzled-related protein
FRZB
NM_001463






(203698_s_at)


Hs.154679
6857
synaptotagmin I
SYT1
AV723167 (203998_s_at)


Hs.169857
5445
paraoxonase 2
PON2
AF001602 (210830_s_at)


Hs.1707
9607
cocaine- and amphetamine-
CART
NM_004291 (206339_at)




regulated transcript


Hs.1832
4852
neuropeptide Y
NPY
NM_000905 (206001_at)


Hs.20021
6843
vesicle-associated membrane
VAMP1
AU150319 (213326_at)




protein 1 (synaptobrevin 1)


Hs.2563
6863
tachykinin, precursor 1 (substance K,
TAC1
NM_003182




substance P, neurokinin 1,

(206552_s_at)




neurokinin 2, neuromedin L,




neurokinin alpha, neuropeptide K,




neuropeptide gamma)


Hs.284244
2247
fibroblast growth factor 2 (basic)
FGF2
NM_002006






(204422_s_at)


Hs.313
6696
secreted phosphoprotein 1
SPP1
M83248 (209875_s_at)




(osteopontin, bone sialoprotein I,




early T-lymphocyte activation 1)


Hs.336678
1837
dystrobrevin, alpha
DTNA
NM_001392






(205741_s_at)


Hs.386793
2878
glutathione peroxidase 3 (plasma)
GPX3
NM_002084 (201348_at)


Hs.396489
7018
transferrin
TF
AI073407 (214063_s_at)


Hs.427202
7276
transthyretin (prealbumin,
TTR
AF162690 (209660_at)




amyloidosis type I)


Hs.433721
721
complement component 4B
C4B
NM_000592






(208451_s_at)


Hs.44
5764
pleiotrophin (heparin binding growth
PTN
AL565812 (209465_x_at)




factor 8, neurite growth-promoting




factor 1)


Hs.64016
5627
protein S (alpha)
PROS1
NM_000313






(207808_s_at)


Hs.7306
6422
secreted frizzled-related protein 1
SFRP1
NM_003012






(202037_s_at)


Hs.73793
7422
vascular endothelial growth factor
VEGF
AF022375 (210512_s_at)


Hs.75184
1116
chitinase 3-like 1 (cartilage
CHI3L1
M80927




glycoprotein-39)

(209395_at.209396_s_at)


Hs.75294
1392
corticotropin releasing hormone
CRH
NM_000756 (205630_at)


Hs.76224
2202
EGF-containing fibulin-like
EFEMP1
AI826799 (201842_s_at)




extracellular matrix protein 1


Hs.78224
6035
ribonuclease, RNase A family, 1
RNASE1
NM_002933 (201785_at)




(pancreatic)


Hs.80247
885
cholecystokinin
CCK
NM_000729 (205827_at)


Hs.8117
55914
erbb2 interacting protein
ERBB2IP
NM_018695






(217941_s_at)


Hs.83384
6285
S100 calcium binding protein, beta
S100B
BC001766 (209686_at)




(neural)


Hs.89626
5744
parathyroid hormone-like hormone
PTHLH
BC005961 (211756_at)


Hs.8986
713
complement component 1, q
C1QB
NM_000491 (202953_at)




subcomponent, beta polypeptide


Hs.94592
9365
klotho
KL
NM_004795 (205978_at)
















TABLE 5










ALL REGIONS - CELL TO CELL SIGNAL















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.103724
5376
peripheral myelin protein 22
PMP22
L03203






(210139_s_at)


Hs.12409
6750
somatostatin
SST
NM_001048






(213921_at)


Hs.141308
4340
myelin oligodendrocyte
MOG
NM_002433




glycoprotein

(205989_s_at)


Hs.154679
6857
synaptotagmin I
SYT1
AV723167






(203998_s_at)


Hs.170414
5046
paired basic amino acid cleaving
PACE4
NM_002570




system 4

(207414_s_at)


Hs.1707
9607
cocaine- and amphetamine-
CART
NM_004291




regulated transcript

(206339_at)


Hs.170808
2572
glutamate decarboxylase 2
GAD2
NM_000818




(pancreatic islets and brain,

(206780_at)




65 kDa)


Hs.1832
4852
neuropeptide Y
NPY
NM_000905






(206001_at)


Hs.19492
5100
protocadherin 8
PCDH8
NM_002590






(206935_at)


Hs.2563
6863
tachykinin, precursor 1 (substance
TAC1
NM_003182




K, substance P, neurokinin 1,

(206552_s_at)




neurokinin 2, neuromedin L,




neurokinin alpha, neuropeptide K,




neuropeptide gamma)


Hs.284122
11197
WNT inhibitory factor 1
WIF1
NM_007191






(204712_at)


Hs.284244
2247
fibroblast growth factor 2 (basic)
FGF2
NM_002006






(204422_s_at)


Hs.324784
2571
glutamate decarboxylase 1 (brain,
GAD1
NM_000817




67 kDa)

(205278_at)


Hs.3281
4885
neuronal pentraxin II
NPTX2
U26662






(213479_at)


Hs.336678
1837
dystrobrevin, alpha
DTNA
NM_001392






(205741_s_at)


Hs.3697
183
angiotensinogen (serine (or
AGT
NM_000029




cysteine) proteinase inhibitor,

(202834_at)




clade A (alpha-1 antiproteinase,




antitrypsin), member 8)


Hs.380
6506
solute carrier family 1 (glial high
SLC1A2
NM_004171




affinity glutamate transporter),

(208389_s_at)




member 2


Hs.46362
3358
5-hydroxytryptamine (serotonin)
HTR2C
M81778




receptor 2C

(211479_s_at)


Hs.69547
4155
myelin basic protein
MBP
AW070431






(210136_at)


Hs.74471
2697
gap junction protein, alpha 1,
GJA1
NM_000165




43 kDa (connexin 43)

(201667_at)


Hs.75294
1392
corticotropin releasing hormone
CRH
NM_000756






(205630_at)


Hs.75379
6507
solute carrier family 1 (glial high
SLC1A3
NM_004172




affinity glutamate transporter),

(202800_at)




member 3


Hs.89626
5744
parathyroid hormone-like hormone
PTHLH
BC005961






(211756_at)
















TABLE 6










ALL REGIONS - SYNAPTIC TRANS.















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.103724
5376
peripheral myelin protein 22
PMP22
L03203






(210139_s_at)


Hs.12409
6750
somatostatin
SST
NM_001048






(213921_at)


Hs.141308
4340
myelin oligodendrocyte glycoprotein
MOG
NM_002433






(205989_s_at)


Hs.154679
6857
synaptotagmin I
SYT1
AV723167






(203998_s_at)


Hs.1707
9607
cocaine- and amphetamine-regulated transcript
CART
NM_004291






(206339_at)


Hs.170808
2572
glutamate decarboxylase 2 (pancreatic islets and
GAD2
NM_000818




brain, 65 kDa)

(206780_at)


Hs.1832
4852
neuropeptide Y
NPY
NM_000905






(206001_at)


Hs.2563
6863
tachykinin, precursor 1 (substance K, substance
TAC1
NM_003182




P, neurokinin 1, neurokinin 2, neuromedin L,

(206552_s_at)




neurokinin alpha, neuropeptide K, neuropeptide




gamma)


Hs.324784
2571
glutamate decarboxylase 1 (brain, 67 kDa)
GAD1
NM_000817






(205278_at)


Hs.3281
4885
neuronal pentraxin II
NPTX2
U26662






(213479_at)


Hs.336678
1837
dystrobrevin, alpha
DTNA
NM_001392






(205741_s_at)


Hs.380
6506
solute carrier family 1 (glial high affinity glutamate
SLC1A2
NM_004171




transporter), member 2

(208389_s_at)


Hs.46362
3358
5-hydroxytryptamine (serotonin) receptor 2C
HTR2C
M81778






(211479_s_at)


Hs.69547
4155
myelin basic protein
MBP
AW070431






(210136_at)


Hs.75294
1392
corticotropin releasing hormone
CRH
NM_000756






(205630_at)


Hs.75379
6507
solute carrier family 1 (glial high affinity glutamate
SLC1A3
NM_004172




transporter), member 3

(202800_at)
















TABLE 7










ALL REGIONS - ORGANOGENESIS










UniGene
LocusID
Description
ACCESSION (Probe ID)













Hs.103724
5376
peripheral myelin protein 22
L03203 (210139_s_at)


Hs.10526
1466
cysteine and glycine-rich protein 2
NM_001321





(207030_s_at)


Hs.111779
6678
secreted protein, acidic, cysteine-rich
AL575922 (212667_at)




(osteonectin)


Hs.117546
4826
neuronatin
NM_005386





(204239_s_at)


Hs.141308
4340
myelin oligodendrocyte glycoprotein
NM_002433





(205989_s_at)


Hs.153684
2487
frizzled-related protein
NM_001463





(203698_s_at)


Hs.154654
1545
cytochrome P450, family 1, subfamily B,
NM_000104




polypeptide 1
(202437_s_at)


Hs.158540
7368
UDP glycosyltransferase 8 (UDP-galactose
NM_003360




ceramide galactosyltransferase)
(208358_s_at)


Hs.169309
4336
myelin-associated oligodendrocyte basic protein
D28114 (210193_at)


Hs.169487
9935
v-maf musculoaponeurotic fibrosarcoma
NM_005461




oncogene homolog B (avian)
(218559_s_at)


Hs.173594
5176
serine (or cysteine) proteinase inhibitor, clade F
NM_002615 (202283_at)




(alpha-2 antiplasmin, pigment epithelium




derived factor), member 1


Hs.198760
4744
neurofilament, heavy polypeptide 200 kDa
NM_021076





(204412_s_at)


Hs.2316
6662
SRY (sex determining region Y)-box 9
AI382146 (202935_s_at)




(campomelic dysplasia, autosomal sex-




reversal)


Hs.284244
2247
fibroblast growth factor 2 (basic)
NM_002006





(204422_s_at)


Hs.288650
361
aquaporin 4
D63412





(210066_s_at, 210067_at)


Hs.293267
825
calpain 3, (p94)
AF127764 (214475_x_at)


Hs.295449
5816
parvalbumin
NM_002854 (205336_at)


Hs.313
6696
secreted phosphoprotein 1 (osteopontin, bone
M83248 (209875_s_at)




sialoprotein I, early T-lymphocyte activation 1)


Hs.33829
79365
basic helix-loop-helix domain containing, class
BE857425 (221530_s_at)




B, 3


Hs.380674
302
annexin A2
BC001388 (210427_x_at)


Hs.408061
2171
fatty acid binding protein 5 (psoriasis-
NM_001444




associated)
(202345_s_at)


Hs.433399
6876
transgelin
NM_003186





(205547_s_at)


Hs.44
5764
pleiotrophin (heparin binding growth factor 8,
AL565812 (209465_x_at)




neurite growth-promoting factor 1)


Hs.69547
4155
myelin basic protein
AW070431 (210136_at)


Hs.73793
7422
vascular endothelial growth factor
AF022375 (210512_s_at)


Hs.74471
2697
gap junction protein, alpha 1, 43 kDa (connexin
NM_000165 (201667_at)




43)


Hs.79368
2012
epithelial membrane protein 1
NM_001423 (201324_at)


Hs.80296
5121
Purkinje cell protein 4
NM_006198 (205549_at)


Hs.80395
4118
mal, T-cell differentiation protein
NM_002371





(204777_s_at)


Hs.82002
1910
endothelin receptor type B
NM_000115 (204273_at)


Hs.83384
6285
S100 calcium binding protein, beta (neural)
BC001766 (209686_at)


Hs.85112
3479
insulin-like growth factor 1 (somatomedin C)
AI972496 (209541_at)


Hs.89626
5744
parathyroid hormone-like hormone
BC005961 (211756_at)
















TABLE 8










VThal - CYTOPLASM











UniGene
LocusID
Description
Symbol
ACCESSION (Probe ID)














Hs.104717
7461
cytoplasmic linker 2
CYLN2
BC006259 (211031_s_at)


Hs.1050
9267
pleckstrin homology,
PSCD1
NM_004762 (202880_s_at)




Sec7 and coiled-coil




domains 1(cytohesin 1)


Hs.106529
51103
CGI-65 protein
CIA30
NM_016013 (204125_at)


Hs.107164
6711
spectrin, beta, non-
SPTBN1
AA131826 (215918_s_at)




erythrocytic 1


Hs.111126
754
pituitary tumor-
PTTG1IP
NM_004339 (200677_at)




transforming 1 interacting




protein


Hs.112667
27019
dynein, axonemal,
DNAI1
NM_012144 (220125_at)




intermediate polypeptide 1


Hs.113503
3843
karyopherin (importin)
KPNB3
AU148466 (211953_s_at)




beta 3


Hs.11465
9446
glutathione-S-transferase
GSTTLp28
NM_004832 (201470_at)




like; glutathione




transferase omega


Hs.11806
1717
7-dehydrocholesterol
DHCR7
AW150953 (201790_s_at)




reductase


Hs.119251
7384
ubiquinol-cytochrome c
UQCRC1
NM_003365 (201903_at)




reductase core protein I


Hs.1197
3336
heat shock 10 kDa protein
HSPE1
NM_002157 (205133_s_at)




1 (chaperonin 10)


Hs.12163
8894
eukaryotic translation
EIF2S2
BC000461 (208726_s_at)




initiation factor 2, subunit




2 beta, 38 kDa


Hs.12956
30851
Tax interaction protein 1
TIP-1
AF234997 (209154_at)


Hs.1342
1329
cytochrome c oxidase
COX5B
AI557312 (213735_s_at)




subunit Vb


Hs.138617
9320
thyroid hormone receptor
TRIP12
NM_004238 (201546_at)




interactor 12


Hs.144063
6301
seryl-tRNA synthetase
SARS
NM_006513 (200802_at)


Hs.144672
8632
dynein, axonemal, heavy
DNAH17
AL122077 (214229_at)




polypeptide 17


Hs.146388
9053
microtubule-associated
MAP7
AW242297 (202890_at)




protein 7


Hs.146393
9709
homocysteine-inducible,
HERPUD1
AF217990 (217168_s_at)




endoplasmic reticulum




stress-inducible, ubiquitin-




like domain member 1


Hs.148495
5710
proteasome (prosome,
PSMD4
AB033605 (210460_s_at)




macropain) 26S subunit,




non-ATPase, 4


Hs.150101
3916
lysosomal-associated
LAMP1
J03263 (201551_s_at)




membrane protein 1


Hs.150580
10209
putative translation
SUI1
AF083441 (202021_x_at)




initiation factor


Hs.154654
1545
cytochrome P450, family
CYP1B1
AU144855 (202436_s_at)




1, subfamily B,




polypeptide 1


Hs.154672
10797
methylene
MTHFD2
NM_006636 (201761_at)




tetrahydrofolate




dehydrogenase (NAD+




dependent),




methenyltetrahydrofolate




cyclohydrolase


Hs.154679
6857
synaptotagmin I
SYT1
AV723167 (203998_s_at)


Hs.155097
760
carbonic anhydrase II
CA2
M36532 (209301_at)


Hs.157439
4166
carbohydrate (N-
CHST6
NM_021615 (221059_s_at)




acetylglucosamine 6-O)




sulfotransferase 6


Hs.159604
833
cysteinyl-tRNA
CARS
AI769685 (212971_at)




synthetase


Hs.16297
10063
COX17 homolog,
COX17
NM_005694 (203880_at)




cytochrome c oxidase




assembly protein (yeast)


Hs.1708
7203
chaperonin containing
CCT3
NM_005998 (200910_at)




TCP1, subunit 3 (gamma)


Hs.173125
10105
peptidylprolyl isomerase F
PPIF
BC005020 (201489_at)




(cyclophilin F)


Hs.173987
8669
eukaryotic translation
EIF3S1
BC002719 (208985_s_at)




initiation factor 3, subunit




1 alpha, 35 kDa


Hs.177556
1495
catenin (cadherin-
CTNNA1
D14705 (210844_x_at)




associated protein), alpha




1, 102 kDa


Hs.178551
6132
ribosomal protein L8
RPL8
NM_000973 (200936_at)


Hs.180062
5696
proteasome (prosome,
PSMB8
U17496 (209040_s_at)




macropain) subunit, beta




type, 8 (large




multifunctional protease




7)


Hs.180383
1848
dual specificity
DUSP6
BC003143 (208891_at)




phosphatase 6


Hs.180920
6203
ribosomal protein S9
RPS9
NM_001013 (217747_s_at)


Hs.180946
6125
ribosomal protein L5
RPL5
AK027146 (216044_x_at)


Hs.182579
51056
leucine aminopeptidase 3
LAP3
NM_015907 (217933_s_at)


Hs.183583
1992
serine (or cysteine)
SERPINB1
AI554300 (213572_s_at)




proteinase inhibitor, clade




B (ovalbumin), member 1


Hs.193163
274
bridging integrator 1
BIN1
AF001383 (210201_x_at)


Hs.20021
6843
vesicle-associated
VAMP1
AU150319 (213326_at)




membrane protein 1




(synaptobrevin 1)


Hs.20478
1200
ceroid-lipofuscinosis,
CLN2
BG231932 (200742_s_at)




neuronal 2, late infantile




(Jansky-Bielschowsky




disease)


Hs.211914
4727
NADH dehydrogenase
NDUFS7
BC005954 (211752_s_at)




(ubiquinone) Fe-S protein




7, 20 kDa (NADH-




coenzyme Q reductase)


Hs.220689
10146
Ras-GTPase-activating
G3BP
BG500067 (201503_at)




protein SH3-domain-




binding protein


Hs.23259
64431
actin-related protein 6
ACTR6
NM_022496 (218395_at)


Hs.23488
9861
KIAA0107 gene product
P44S10
NM_014814 (202753_at)


Hs.239926
6307
sterol-C4-methyl oxidase-
SC4MOL
AV704962 (209146_at)




like


Hs.24587
10278
embryonal Fyn-
EFS
NM_005864 (204400_at)




associated substrate


Hs.251531
5685
proteasome (prosome,
PSMA4
NM_002789 (203396_at)




macropain) subunit, alpha




type, 4


Hs.2554
6480
sialyltransferase 1 (beta-
SIAT1
AI743792 (201998_at)




galactoside alpha-2,6-




sialyltransferase)


Hs.25597
64834
elongation of very long
ELOVL1
H93026 (57163_at)




chain fatty acids




(FEN1/Elo2, SUR4/Elo3,




yeast)-like 1


Hs.25691
10268
receptor (calcitonin)
RAMP3
NM_005856 (205326_at)




activity modifying protein 3


Hs.26350
8459
tyrosylprotein
TPST2
NM_003595 (204079_at)




sulfotransferase 2


Hs.266940
6993
t-complex-associated-
TCTEL1
NM_006519 (201999_s_at)




testis-expressed 1-like 1


Hs.273
2581
galactosylceramidase
GALC
NM_000153 (204417_at)




(Krabbe disease)


Hs.274402
3304
heat shock 70 kDa protein
HSPA1B
NM_005346 (202581_at)




1B


Hs.279554
5719
proteasome (prosome,
PSMD13
NM_002817 (201232_s_at)




macropain) 26S subunit,




non-ATPase, 13


Hs.279574
51079
cell death-regulatory
GRIM19
NM_015965 (220864_s_at)




protein GRIM19


Hs.279901
51399
synbindin
CGI-104
NM_016146






(217958 at, 217959_s_at)


Hs.288654
3208
hippocalcin
HPCA
BC001777 (205454_at)


Hs.290070
2934
gelsolin (amyloidosis,
GSN
NM_000177 (200696_s_at)




Finnish type)


Hs.291904
10134
accessory protein BAP31
BCAP31
NM_005745 (200837_at)


Hs.293885
2617
glycyl-tRNA synthetase
GARS
D30658 (208693_s_at)


Hs.30212
9318
thyroid receptor
TRIP15
NM_004236 (202467_s_at)




interacting protein 15


Hs.3069
3313
heat shock 70 kDa protein
HSPA9B
BC000478 (200691_s_at)




9B (mortalin-2)


Hs.323567
950
scavenger receptor class
SCARB2
NM_005506 (201647_s_at)




B, member 2


Hs.333823
28998
mitochondrial ribosomal
MRPL13
NM_014078 (218049_s_at)




protein L13


Hs.334534
2799
glucosamine (N-acetyl)-6-
GNS
AW167793 (212335_at)




sulfatase (Sanfilippo




disease IIID)


Hs.334842
10376
tubulin, alpha, ubiquitous
K-ALPHA-1
AL581768 (212639_x_at)


Hs.336678
1837
dystrobrevin, alpha
DTNA
NM_001392 (205741_s_at)


Hs.337766
6142
ribosomal protein L18a
RPL18A
NM_000980 (200869_at)


Hs.346918
5684
proteasome (prosome,
PSMA3
NM_002788 (201532_at)




macropain) subunit, alpha




type, 3


Hs.351872
6272
sortilin 1
SORT1
BF447105 (212807_s_at)


Hs.355957
6231
ribosomal protein S26
RPS26
NM_001029 (217753_s_at)


Hs.356386
7879
RAB7, member RAS
RAB7
AK000826 (211961_s_at)




oncogene family


Hs.356463
2339
farnesyltransferase,
FNTA
BG168896 (200090_at)




CAAX box, alpha


Hs.377915
4124
mannosidase, alpha,
MAN2A1
NM_002372 (205105_at)




class 2A, member 1


Hs.380439
23208
synaptotagmin XI
SYT11
BC004291 (209198_s_at)


Hs.381255
8665
eukaryotic translation
EIF3S5
NM_003754 (200023_s_at)




initiation factor 3, subunit




5 epsilon, 47 kDa


Hs.394389
5479
peptidylprolyl isomerase
PPIB
NM_000942 (200968_s_at)




B (cyclophilin B)


Hs.395771
847
catalase
CAT
AY028632 (211922_s_at)


Hs.397609
6217
ribosomal protein S16
RPS16
NM_001020 (201258_at)


Hs.39871
4642
myosin ID
MYO1D
AA621962 (212338_at)


Hs.40500
11079
similar to S. cerevisiae
RER1
NM_007033 (202296_s_at)




RER1


Hs.406341
6187
ribosomal protein S2
RPS2
AA630314 (212433_x_at)


Hs.406532
6185
ribophorin II
RPN2
AI560720 (213399_x_at)


Hs.407981
5689
proteasome (prosome,
PSMB1
NM_002793 (200876_s_at)




macropain) subunit, beta




type, 1


Hs.408061
2171
fatty acid binding protein
FABP5
NM_001444 (202345_s_at)




5 (psoriasis-associated)


Hs.408767
1410
crystallin, alpha B
CRYAB
AF007162 (209283_at)


Hs.408943
5216
profilin 1
PFN1
NM_005022 (200634_at)


Hs.410276
5687
proteasome (prosome,
PSMA6
BC002979 (208805_at)




macropain) subunit, alpha




type, 6


Hs.410578
5034
procollagen-proline, 2-
P4HB
J02783 (200654_at)




oxoglutarate 4-




dioxygenase (proline 4-




hydroxylase), beta




polypeptide (protein




disulfide isomerase;




thyroid hormone binding




protein p55)


Hs.411773
5683
proteasome (prosome,
PSMA2
NM_002787 (201317_s_at)




macropain) subunit, alpha




type, 2


Hs.4147
23471
translocation associated
TRAM1
BC000687 (201398_s_at)




membrane protein 1


Hs.421194
8460
tyrosylprotein
TPST1
NM_003596 (204140_at)




sulfotransferase 1


Hs.424961
64981
mitochondrial ribosomal
MRPL34
AB049652 (221692_s_at)




protein L34


Hs.426142
5281
phosphatidylinositol
PIGF
NM_002643 (205077_s_at)




glycan, class F


Hs.426930
60
actin, beta
ACTB
X00351 (AFFX-






HSAC07/X00351_5_at, AFFX-






HSAC07/X00351_M_at)


Hs.429621
11091
WD repeat domain 5
WDR5
AF092131 (208714_at)


Hs.433394
7846
tubulin, alpha 3
TUBA3
AF141347 (209118_s_at)


Hs.433506
10095
actin related protein 2/3
ARPC1B
NM_005720 (201954_at)




complex, subunit 1B,




41 kDa


Hs.433702
1983
eukaryotic translation
EIF5
AL080102 (208708_x_at)




initiation factor 5


Hs.448357
4500
metallothionein 1L
MT1L
NM_002450 (204326_x_at)


Hs.4835
8663
eukaryotic translation
EIF3S8
AA679705 (215230_x_at)




initiation factor 3, subunit




8, 110 kDa


Hs.48876
2222
farnesyl-diphosphate
FDFT1
AA872727 (208647_at)




farnesyltransferase 1


Hs.49007
10914
poly(A) polymerase alpha
PAPOLA
AI984479 (222035_s_at)


Hs.49346
6729
signal recognition particle
SRP54
NM_003136 (203605_at)




54 kDa


Hs.49767
4726
NADH dehydrogenase
NDUFS6
NM_004553 (203606_at)




(ubiquinone) Fe-S protein




6, 13 kDa (NADH-




coenzyme, Q reductase)


Hs.55097
28957
mitochondrial ribosomal
MRPS28
NM_014018 (219819_s_at)




protein S28


Hs.55099
23637
rab6 GTPase activating
GAPCENA
AI922519 (213313_at)




protein (GAP and




centrosome-associated)


Hs.55682
8664
eukaryotic translation
EIF3S7
NM_003753 (200005_at)




initiation factor 3, subunit




7 zeta, 66/67 kDa


Hs.61490
29970
schwannomin interacting
SCHIP1
NM_014575 (204030_s_at)




protein 1


Hs.66708
9341
vesicle-associated
VAMP3
BC003570 (201336_at)




membrane protein 3




(cellubrevin)


Hs.66881
1781
dynein, cytoplasmic,
DNCI2
AF250307 (211684_s_at)




intermediate polypeptide 2


Hs.7043
8802
succinate-CoA ligase,
SUCLG1
NM_003849 (217874_at)




GDP-forming, alpha




subunit


Hs.70669
51617
HMP19 protein
HMP19
NM_015980 (218623_at)


Hs.74137
10972
transmembrane trafficking
TMP21
BE780075 (212352_s_at)




protein


Hs.74619
5708
proteasome (prosome,
PSMD2
NM_002808 (200830_at)




macropain) 26S subunit,




non-ATPase, 2


Hs.75232
6397
SEC14-like 1 (S. cerevisiae)
SEC14L1
AI017770 (202083_s_at)


Hs.7527
25996
small fragment nuclease
DKFZP566E144
NM_015523 (218194_at)


UniGene
LocusID
Description
Symbol
ACCESSION (Probe ID)


Hs.75283
6642
sorting nexin 1
SNX1
AF065484 (214531_s_at)


Hs.75318
7277
tubulin, alpha 1 (testis
TUBA1
AL565074 (212242_at)




specific)


Hs.75410
3309
heat shock 70 kDa protein
HSPA5
AF216292 (211936_at)




5 (glucose-regulated




protein, 78 kDa)


Hs.75428
6647
superoxide dismutase 1,
SOD1
NM_000454 (200642_at)




soluble (amyotrophic




lateral sclerosis 1 (adult))


Hs.75607
4082
myristoylated alanine-rich
MARCKS
AA770596 (213002_at)




protein kinase C substrate


Hs.75914
10959
coated vesicle membrane
RNP24
AK024976 (200087_s_at)




protein


Hs.76067
3315
heat shock 27 kDa protein 1
HSPB1
NM_001540 (201841_s_at)


Hs.76293
9168
thymosin, beta 10
TMSB10
NM_021103 (217733_s_at)


Hs.76640
28984
RGC32 protein
RGC32
NM_014059 (218723_s_at)


Hs.76918
4864
Niemann-Pick disease,
NPC1
NM_000271 (202679_at)




type C1


Hs.77290
6888
transaldolase 1
TALDO1
NM_006755 (201463_s_at)


Hs.77356
7037
transferrin receptor (p90,
TFRC
BC001188 (208691_at)




CD71)


Hs.77432
1956
epidermal growth factor
EGFR
AW 157070 (201983_s_at)




receptor (erythroblastic




leukemia viral (v-erb-b)




oncogene homolog,




avian)


Hs.77501
6443
sarcoglycan, beta (43 kDa
SGCB
U29586 (205120_s_at)




dystrophin-associated




glycoprotein)


Hs.77805
529
ATPase, H+ transporting,
ATP6V1E1
BC004443 (208678_at)




lysosomal 31 kDa, V1




subunit E isoform 1


Hs.77890
2983
guanylate cyclase 1,
GUCY1B3
AF020340 (211555_s_at)




soluble, beta 3


Hs.77899
7168
tropomyosin 1 (alpha)
TPM1
Z24727 (210986_s_at)


Hs.78305
5862
RAB2, member RAS
RAB2
AA535244 (208730_x_at)




oncogene family


Hs.78996
5111
proliferating cell nuclear
PCNA
NM_002592 (201202_at)




antigen


Hs.79150
10575
chaperonin containing
CCT4
NM_006430 (200877_at)




TCP1, subunit 4 (delta)


Hs.79226
9638
fasciculation and
FEZ1
NM_005103 (203562_at)




elongation protein zeta 1




(zygin I)


Hs.79357
5706
proteasome (prosome,
PSMC6
NM_002806 (201699_at)




macropain) 26S subunit,




ATPase, 6


Hs.79378
8900
cyclin A1
CCNA1
NM_003914 (205899_at)


Hs.79381
25801
grancalcin, EF-hand
GCA
NM_012198 (203765_at)




calcium binding protein


Hs.8021
23348
zizimin1
zizimin1
AL576253 (212538_at)


Hs.80395
4118
mal, T-cell differentiation
MAL
NM_002371 (204777_s_at)




protein


Hs.80680
9961
major vault protein
MVP
NM_017458 (202180_s_at)


Hs.80712
23176
likely ortholog of mouse
8-Sep
BC001329 (209000_s_at)




septin 8


Hs.80919
6856
synaptophysin-like protein
SYPL
AI768845 (201259_s_at)


Hs.82030
7453
tryptophanyl-tRNA
WARS
NM_004184 (200629_at)




synthetase


Hs.82222
7869
sema domain,
SEMA3B
NM_004636 (203071_at)




immunoglobulin domain




(Ig), short basic domain,




secreted, (semaphorin)




3B


Hs.82425
10092
actin related protein 2/3
ARPC5
AL516350 (211963_s_at)




complex, subunit 5,




16 kDa


Hs.82568
1593
cytochrome P450, family
CYP27A1
NM_000784 (203979_at)




27, subfamily A,




polypeptide 1


Hs.8262
3920
lysosomal-associated
LAMP2
J04183 (203041_s_at)




membrane protein 2


Hs.82890
1603
defender against cell
DAD1
NM_001344 (200046_at)




death 1


Hs.84665
9499
titin immunoglobulin
TTID
NM_006790 (219728_at)




domain protein (myotilin)


Hs.85226
3988
lipase A, lysosomal acid,
LIPA
NM_000235 (201847_at)




cholesterol esterase




(Wolman disease)


Hs.88778
873
carbonyl reductase 1
CBR1
BC002511 (209213_at)


Hs.89399
517
ATP synthase, H+
ATP5G2
D13119 (208764_s_at)




transporting,




mitochondrial F0




complex, subunit c




(subunit 9), isoform 2


Hs.89545
5692
proteasome (prosome,
PSMB4
NM_002796 (202243_s_at)




macropain) subunit, beta




type, 4


Hs.89866
1371
coproporphyrinogen
CPO
NM_000097 (204172_at)




oxidase (coproporphyria,




harderoporphyria)


Hs.9006
9218
VAMP (vesicle-associated
VAPA
AF154847 (208780_x_at)




membrane protein)-




associated protein A,




33 kDa


Hs.90073
1434
CSE1 chromosome
CSE1L
AF053640 (210766_s_at)




segregation 1-like (yeast)


Hs.90998
23157
septin 6
6-Sep
AV721177 (215236_s_at)


Hs.96427
23150
GRP1-binding protein
GRSP1
AU145019 (213056_at)




GRSP1


Hs.9964
6183
mitochondrial ribosomal
MRPS12
NM_021107 (204331_s_at)




protein S12


Hs.99858
6130
ribosomal protein L7a
RPL7A
NM_000972 (217740_x_at)
















TABLE 9










VThal - SYNAPTIC TRANSMISSION















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)





Hs.103724
5376
peripheral myelin
PMP22
L03203




protein 22


Hs.141308
4340
myelin
MOG
NM_002433




oligodendrocyte




glycoprotein


Hs.154679
6857
synaptotagmin I
SYT1
AV723167


Hs.170808
2572
glutamate
GAD2
NM_000818




decarboxylase 2




(pancreatic islets




and brain, 65 kDa)


Hs.324784
2571
glutamate
GAD1
NM_000817




decarboxylase 1




(brain, 67 kDa)


Hs.3281
4885
neuronal pentraxin II
NPTX2
U26662


Hs.336678
1837
dystrobrevin, alpha
DTNA
NM_001392


Hs.69547
4155
myelin basic protein
MBP
AW070431
















TABLE 10










VThal-26S PROTEOSOME















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.148495
5710
proteasome (prosome, macropain) 26S subunit,
PSMD4
AB033605




non-ATPase, 4

(210460_s_at)


Hs.180062
5696
proteasome (prosome, macropain) subunit, beta
PSMB8
U17496




type, 8 (large multifunctional protease 7)

(209040_s_at)


Hs.23488
9861
KIAA0107 gene product
P44S10
NM_014814






(202753_at)


Hs.251531
5685
proteasome (prosome, macropain) subunit, alpha
PSMA4
NM_002789




type, 4

(203396_at)


Hs.346918
5684
proteasome (prosome, macropain) subunit, alpha
PSMA3
NM_002788




type, 3

(201532_at)


Hs.407981
5689
proteasome (prosome, macropain) subunit, beta
PSMB1
NM_002793




type, 1

(200876_s_at)


Hs.411773
5683
proteasome (prosome, macropain) subunit, alpha
PSMA2
NM_002787




type, 2

(201317_s_at)


Hs.74619
5708
proteasome (prosome, macropain) 26S subunit,
PSMD2
NM_002808




non-ATPase, 2

(200830_at)


Hs.79357
5706
proteasome (prosome, macropain) 26S subunit,
PSMC6
NM_002806




ATPase, 6

(201699_at)


Hs.89545
5692
proteasome (prosome, macropain) subunit, beta
PSMB4
NM_002796




type, 4

(202243_s_at)
















TABLE 11










VThal - MACROMOLECULE BIOSYNTH











UniGene
LocusID
Description
Symbol
ACCESSION (Probe ID)














Hs.111039
4836
N-myristoyltransferase 1
NMT1
AF020500 (201157_s_at)


Hs.12163
8894
eukaryotic translation initiation
EIF2S2
BC000461 (208726_s_at)




factor 2, subunit 2 beta, 38 kDa


Hs.130181
2590
UDP-N-acetyl-alpha-D-
GALNT2
NM_004481




galactosamine:polypeptide N-

(217788_s_at)




acetylgalactosaminyltransferase 2




(GalNAc-T2)


Hs.144063
6301
seryl-tRNA synthetase
SARS
NM_006513 (200802_at)


Hs.150580
10209
putative translation initiation factor
SUI1
AF083441 (202021_x_at)


Hs.155103
9086
eukaryotic translation initiation factor
EIF1AY
BC005248 (204409_s_at)




factor 1A, Y chromosome


Hs.159604
833
cysteinyl-tRNA synthetase
CARS
AI769685 (212971_at)


Hs.170204
23043
KIAA0551 protein
KIAA0551
AF172268 (211828_s_at)


Hs.173987
8669
eukaryotic translation initiation
EIF3S1
BC002719 (208985_s_at)




factor 3, subunit 1 alpha, 35 kDa


Hs.178551
6132
ribosomal protein L8
RPL8
NM_000973 (200936_at)


Hs.180920
6203
ribosomal protein S9
RPS9
NM_001013






(217747_s_at)


Hs.180946
6125
ribosomal protein L5
RPL5
AK027146 (216044_x_at)


Hs.213289
3949
low density lipoprotein receptor
LDLR
NM_000527




(familial hypercholesterolemia)

(202068_s_at)


Hs.2554
6480
sialyltransferase 1 (beta-galactoside
SIAT1
AI743792 (201998_at)




alpha-2,6-sialyltransferase)


Hs.279901
51399
synbindin
CGI-104
NM_016146






(217958_at, 217959_s_at)


Hs.293885
2617
glycyl-tRNA synthetase
GARS
D30658 (208693_s_at)


Hs.333513
9255
small inducible cytokine subfamily
SCYE1
NM_004757




E, member 1 (endothelial monocyte-

(202542_s_at)




activating)


Hs.333823
28998
mitochondrial ribosomal protein L13
MRPL13
NM_014078






(218049_s_at)


Hs.337766
6142
ribosomal protein L18a
RPL18A
NM_000980 (200869_at)


Hs.355957
6231
ribosomal protein S26
RPS26
NM_001029






(217753_s_at)


Hs.377915
4124
mannosidase, alpha, class 2A,
MAN2A1
NM_002372 (205105_at)




member 1


Hs.381050
27087
beta-1,3-glucuronyltransferase 1
B3GAT1
NM_018644 (219521_at)




(glucuronosyltransferase P)


Hs.381255
8665
eukaryotic translation initiation
EIF3S5
NM_003754




factor 3, subunit 5 epsilon, 47 kDa

(200023_s_at)


Hs.397609
6217
ribosomal protein S16
RPS16
NM_001020 (201258_at)


Hs.406341
6187
ribosomal protein S2
RPS2
AA630314 (212433_x_at)


Hs.424961
64981
mitochondrial ribosomal protein L34
MRPL34
AB049652 (221692_s_at)


Hs.426142
5281
phosphatidylinositol glycan, class F
PIGF
NM_002643






(205077_s_at)


Hs.433702
1983
eukaryotic translation initiation
EIF5
AL080102 (208708_x_at)




factor 5


Hs.4835
8663
eukaryotic translation initiation
EIF3S8
AA679705 (215230_x_at)




factor 3, subunit 8, 110 kDa


Hs.55682
8664
eukaryotic translation initiation
EIF3S7
NM_003753 (200005_at)




factor 3, subunit 7 zeta, 66/67 kDa


Hs.76067
3315
heat shock 27 kDa protein 1
HSPB1
NM_001540






(201841_s_at)


Hs.8148
51714
selenoprotein T
SELT
NM_016275 (217811_at)


Hs.82030
7453
tryptophanyl-tRNA synthetase
WARS
NM_004184 (200629_at)


Hs.82890
1603
defender against cell death 1
DAD1
NM_001344 (200046_at)


Hs.85226
3988
lipase A, lysosomal acid, cholesterol
LIPA
NM_000235 (201847_at)




esterase (Wolman disease)


Hs.9964
6183
mitochondrial ribosomal protein S12
MRPS12
NM_021107






(204331_s_at)


Hs.99858
6130
ribosomal protein L7a
RPL7A
NM_000972






(217740_x_at)
















TABLE 12










Mthal - NEUROFILAMENT














Sym-
ACCESSION


UniGene
LocusID
Description
bol
(Probe ID)





Hs.198760
4744
neurofilament,
NEFH
NM_021076




heavy polypeptide

(204412_s_at)




200 kDa


Hs.211584
4747
neurofilament,
NEFL
AL537457




light polypeptide

(221805_at)




68 kDa


Hs.71346
4741
neurofilament 3
NEF3
NM_005382




(150 kDa medium)

(205113_at)
















TABLE 13










HC - EXTRACELLULAR















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)





Hs.12409
6750
somatostatin
SST
NM_001048






(213921_at)


Hs.2563
6863
tachykinin, precursor 1
TAC1
NM_003182




(substance K, substance P,

(206552_s_at)




neurokinin 1, neurokinin 2,




neuromedin L, neurokinin alpha,




neuropeptide K, neuropeptide gamma)


Hs.336678
1837
dystrobrevin, alpha
DTNA
NM_001392






(205741_s_at)


Hs.386793
2878
glutathione peroxidase 3
GPX3
NM_002084




(plasma)

(201348_at)


Hs.427202
7276
transthyretin (prealbumin,
TTR
AF162690




amyloidosis type 1)

(209660_at)


Hs.64016
5627
protein S (alpha)
PROS1
NM_000313






(207808_s_at)


Hs.7306
6422
secreted frizzled-related
SFRP1
NM_003012




protein 1

(202037_s_at)


Hs.75184
1116
chitinase 3-like 1
CHI3L1
M80927




(cartilage glycoprotein-39)

(209395_at,






209396_s_at)


Hs.76224
2202
EGF-containing fibulin-like
EFEMP1
AI826799




extracellular matrix protein 1

(201842_s_at)


Hs.94592
9365
klotho
KL
NM_004795






(205978_at)
















TABLE 14










AnCg - PROTEOSOME COMPLEX















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)





Hs.251531
5685
proteasome (prosome, macropain)
PSMA4
NM_002789




subunit, alpha type, 4

(203396_at)


Hs.346918
5684
proteasome (prosome, macropain)
PSMA3
NM_002788




subunit, alpha type, 3

(201532_at)


Hs.3887
5707
proteasome (prosome, macropain)
PSMD1
AI860431




26S subunit, non-ATPase, 1

(201198_s_at)


Hs.407981
5689
proteasome (prosome, macropain)
PSMB1
W86293




subunit, beta type, 1

(214288_s_at)


Hs.410276
5687
proteasome (prosome, macropain)
PSMA6
BC002979




subunit, alpha type, 6

(208805_at)


Hs.78466
5714
proteasome (prosome, macropain)
PSMD8
NM_002812




26S subunit, non-ATPase, 8

(200820_at)


Hs.82159
5682
proteasome (prosome, macropain)
PSMA1
BC005932




subunit, alpha type, 1

(211746_x_at)


Hs.89545
5692
proteasome (prosome, macropain)
PSMB4
NM_002796




subunit, beta type, 4

(202243_s_at)
















TABLE 15










PC - STEROL BIOSYNTHESIS















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)





Hs.11806
1717
7-dehydrocholesterol
DHCR7
NM_001360




reductase

(201791_s_at)


Hs.226213
1595
cytochrome P450, family 51,
CYP51A1
NM_000786




subfamily A, polypeptide 1

(202314_at)


Hs.239926
6307
sterol-C4-methyl
SC4MOL
AV704962




oxidase-like

(209146_at)


Hs.48876
2222
farnesyl-diphosphate
FDFT1
AA872727




farnesyltransferase 1

(208647_at)


Hs.71465
6713
squalene epoxidase
SQLE
AF098865






(209218_at)


Hs.75616
1718
24-dehydrocholesterol
DHCR24
NM_014762




reductase

(200862_at)


Hs.76038
3422
isopentenyl-diphosphate
IDI1
BC005247




delta isomerase

(208881_x_at)
















TABLE 16










nAcc-26S proteosome















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)





Hs.148495
5710
proteasome (prosome, macropain)
PSMD4
AB033605




26S subunit, non-ATPase, 4

(210460_s_at)


Hs.251531
5685
proteasome (prosome, macropain)
PSMA4
NM_002789




subunit, alpha type, 4

(203396_at)


Hs.346918
5684
proteasome (prosome, macropain)
PSMA3
NM_002788




subunit, alpha type, 3

(201532_at)


Hs.3887
5707
proteasome (prosome, macropain)
PSMD1
AI860431




26S subunit, non-ATPase, 1

(201198_s_at)


Hs.79357
5706
proteasome (prosome, macropain)
PSMC6
NM_002806




26S subunit, ATPase, 6

(201699_at)


Hs.82159
5682
proteasome (prosome, macropain)
PSMA1
BC005932




subunit, alpha type, 1

(211746_x_at)


Hs.82793
5691
proteasome (prosome, macropain)
PSMB3
NM_002795




subunit, beta type, 3

(201400_at)


Hs.89545
5692
proteasome (prosome, macropain)
PSMB4
NM_002796




subunit, beta type, 4

(202243_s_at)
















TABLE 17










nAcc - CYTOPLASM















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.100527
22866
connector enhancer
CNK2
NM_014927




of KSR2

(206731_at)


Hs.107476
10632
ATP synthase, H+ transporting,
ATP5L
AF070655




mitochondrial F0 complex, subunit g

(208746_x_at)


Hs.107526
9334
UDP-Gal: betaGlcNAc beta 1,4-
B4GALT5
BF691447




galactosyltransferase, polypeptide 5

(221484_at)


Hs.108802
4905
N-ethylmaleimide-sensitive factor
NSF
NM_006178






(202395_at)


Hs.108809
10574
chaperonin containing TCP1,
CCT7
NM_006429




subunit 7 (eta)

(200812_at)


Hs.112667
27019
dynein, axonemal, intermediate
DNAI1
NM_012144




polypeptide 1

(220125_at)


Hs.11465
9446
glutathione-S-transferase like;
GSTTLp28
NM_004832




glutathione transferase omega

(201470_at)


Hs.11899
3156
3-hydroxy-3-methylglutaryl-Coenzyme
HMGCR
AL518627




A reductase

(202539_s_at)


Hs.119000
87
actinin, alpha 1
ACTN1
BC003576






(208637_x_at)


Hs.12163
8894
eukaryotic translation initiation
EIF2S2
BC000461




factor 2, subunit 2 beta, 38 kDa

(208726_s_at)


Hs.122967
11275
kelch-like 2, Mayven (Drosophila)
KLHL2
NM_007246






(219157_at)


Hs.12376
27445
piccolo (presynaptic cytomatrix
PCLO
AB011131




protein)

(213558_at)


Hs.12451
2009
echinoderm microtubule associated
EML1
NM_004434




protein like 1

(204797_s_at)


Hs.12887
57180
actin-related protein 3-beta
ARP3BETA
NM_020445






(218868_at)


Hs.12956
30851
Tax interaction protein 1
TIP-1
AF234997






(209154_at)


Hs.14376
71
actin, gamma 1
ACTG1
AL567820






(211995_x_at)


Hs.146580
2026
enolase 2, (gamma, neuronal)
ENO2
NM_001975






(201313_at)


Hs.148495
5710
proteasome (prosome, macropain)
PSMD4
AB033605




26S subunit, non-ATPase, 4

(210460_s_at)


Hs.15071
10694
chaperonin containing TCP1, subunit
CCT8
NM_006585




8 (theta)

(200873_s_at)


Hs.152936
1173
adaptor-related protein complex 2,
AP2M1
NM_004068




mu 1 subunit

(200613_at)


Hs.154654
1545
cytochrome P450, family 1,
CYP1B1
AU144855




subfamily B, polypeptide 1

(202436_s_at)


Hs.154679
6857
synaptotagmin I
SYT1
AV723167






(203998_s_at)


Hs.159154
10381
tubulin, beta, 4
TUBB4
AL565749






(213476_x_at)


Hs.167791
5954
reticulocalbin 1, EF-hand calcium
RCN1
NM_002901




binding domain

(201063_at)


Hs.168075
3842
karyopherin (importin) beta 2
KPNB2
U72069






(209226_s_at)


Hs.169476
2597
glyceraldehyde-3-phosphate
GAPD
M33197 (AFFX-




dehydrogenase

HUMGAPDH/






M33197_5_at)


Hs.1708
7203
chaperonin containing
CCT3
NM_005998




TCP1, subunit 3 (gamma)

(200910_at)


Hs.172471
7881
potassium voltage-gated channel,
KCNAB1
NM_003471




shaker-related subfamily, beta member 1

(208213_s_at)


Hs.173554
7385
ubiquinol-cytochrome c reductase core
UQCRC2
NM_003366




protein II

(200883_at)


Hs.179661
203068
beta 5-tubulin
OK/SW-
AF141349





cl.56
(209026_x_at)


Hs.180920
6203
ribosomal protein S9
RPS9
NM_001013






(217747_s_at)


Hs.182217
8803
succinate-CoA ligase, ADP-forming,
SUCLA2
NM_003850




beta subunit

(202930_s_at)


Hs.193163
274
bridging integrator 1
BIN1
U87558






(210202_s_at)


Hs.2043
291
solute carrier family 25 (mitochondrial
SLC25A4
NM_001151




carrier; adenine nucleotide translocator),

(202825_at)




member 4


Hs.211584
4747
neurofilament, light polypeptide
NEFL
AL537457




68 kDa

(221805_at)


Hs.21276
10087
collagen, type IV, alpha 3 (Goodpasture
COL4A3BP
NM_005713




antigen) binding protein

(219625_s_at)


Hs.23259
64431
actin-related protein 6
ACTR6
NM_022496






(218395_at)


Hs.239356
6812
syntaxin binding protein 1
STXBP1
NM_003165






(202260_s_at)


Hs.239926
6307
sterol-C4-methyl oxidase-like
SC4MOL
AV704962






(209146_at)


Hs.251531
5685
proteasome (prosome, macropain)
PSMA4
NM_002789




subunit, alpha type, 4

(203396_at)


Hs.2554
6480
sialyltransferase 1 (beta-galactoside
SIAT1
AI743792




alpha-2,6-sialyltransferase)

(201998_at)


Hs.256697
3094
histidine triad nucleotide binding
HINT1
N32864




protein 1

(200093_s_at)


Hs.2642
1917
eukaryotic translation elongation
EEF1A2
NM_001958




factor 1 alpha 2

(204540_at)


Hs.272927
10484
Sec23 homolog A (S. cerevisiae)
SEC23A
AI753659






(212887_at)


Hs.2795
3939
lactate dehydrogenase A
LDHA
NM_005566






(200650_s_at)


Hs.279554
5719
proteasome (prosome, macropain)
PSMD13
NM_002817




26S subunit, non-ATPase, 13

(201232_s_at)


Hs.281866
523
ATPase, H+ transporting, lysosomal
ATP6V1A
NM_001690




70 kDa, V1 subunit A

(201971_s_at)


Hs.297939
1508
cathepsin B
CTSB
NM_001908






(200838_at,






200839_s_at)


Hs.30212
9318
thyroid receptor interacting
TRIP15
NM_004236




protein 15

(202467_s_at)


Hs.334842
10376
tubulin, alpha, ubiquitous
K-ALPHA-1
AL581768






(212639_x_at)


Hs.336678
1837
dystrobrevin, alpha
DTNA
NM_001392






(205741_s_at)


Hs.337766
6142
ribosomal protein L18a
RPL18A
NM_000980






(200869_at)


Hs.346918
5684
proteasome (prosome, macropain)
PSMA3
NM_002788




subunit, alpha type, 3

(201532_at)


Hs.347939
3040
hemoglobin, alpha 2
HBA2
BC005931






(211745_x_at)


Hs.353170
811
calreticulin
CALR
AA910371






(212952_at)


Hs.355957
6231
ribosomal protein S26
RPS26
NM_001029






(217753_s_at)


Hs.36587
5510
protein phosphatase 1, regulatory
PPP1R7
BF718769




subunit 7

(21 3465_s_at)


Hs.36927
10808
heat shock 105 kDa/110 kDa
HSPH1
NM_006644




protein 1

(206976_s_at)


Hs.386017
3831
kinesin 2 60/70 kDa
KNS2
AA284075






(212877_at,






212878_s_at)


Hs.3887
5707
proteasome (prosome, macropain)
PSMD1
AI860431




26S subunit, non-ATPase, 1

(201198_s_at)


Hs.408767
1410
crystallin, alpha B
CRYAB
AF007162






(209283_at)


Hs.409829
4725
NADH dehydrogenase (ubiquinone)
NDUFS5
NM_004552




Fe—S protein 5, 15 kDa

(201757_at)




(NADH-coenzyme Q reductase)


Hs.424220
3039
hemoglobin, alpha 1
HBA1
AF349571






(211699_x_at)


Hs.424961
64981
mitochondrial ribosomal protein L34
MRPL34
AB049652






(221692_s_at)


Hs.425293
4736
ribosomal protein L10a
RPL10A
NM_007104






(200036_s_at)


Hs.426142
5281
phosphatidylinositol glycan,
PIGF
NM_002643




class F

(205078_at)


Hs.426930
60
actin, beta
ACTS
X00351 (AFFX-






HSAC07/X00351_5_at)


Hs.429621
11091
WD repeat domain 5
WDR5
AF092131






208714_at)


Hs.430207
6159
ribosomal protein L29
RPL29
NM_000992






(200823_x_at)


Hs.432605
7357
UDP-glucose ceramide
UGCG
NM_003358




glucosyltransferase

(204881_s_at)


Hs.433496
9908
Ras-GTPase activating protein SH3
G3BP2
AB014560




domain-binding protein 2

(208841_s_at)


Hs.43670
11127
kinesin family member 3A
KIF3A
NM_007054






(213623_at)


Hs.4835
8663
eukaryotic translation initiation
EIF3S8
AA679705




factor 3, subunit 8, 110 kDa

(215230_x_at)


Hs.48876
2222
farnesyl-diphosphate
FDFT1
AA872727




farnesyltransferase 1

(208647_at)


Hs.49767
4726
NADH dehydrogenase (ubiquinone)
NDUFS6
NM_004553




Fe—S protein 6, 13 kDa

(203606_at)




(NADH-coenzyme Q reductase)


Hs.5556
4706
NADH dehydrogenase (ubiquinone) 1,
NDUFAB1
NM_005003




alpha/beta subcomplex, 1, 8 kDa

(202077_at)


Hs.57937
54715
ataxin 2-binding protein 1
A2BP1
NM_018723






(221217_s_at)


Hs.65248
1780
dynein, cytoplasmic, intermediate
DNCI1
NM_004411




polypeptide 1

(205348_s_at)


Hs.71346
4741
neurofilament 3 (150 kDa medium)
NEF3
NM_005382






(205113_at)


Hs.74571
375
ADP-ribosylation factor 1
ARF1
AA580004






(208750_s_at)


Hs.74617
1639
dynactin 1 (p150, glued homolog,
DCTN1
NM_004082





Drosophila)


(201082_s_at)


Hs.75149
6456
SH3-domain GRB2-like 2
SH3GL2
NM_003026






(205751_at)


Hs.75187
9804
translocase of outermitochondrial
TOMM20-
BG165094




membrane 20 (yeast) homolog
PENDING
(212773_s_at)


Hs.75318
7277
tubulin, alpha 1 (testis specific)
TUBA1
AL565074






(212242_at)


Hs.75616
1718
24-dehydrocholesterol reductase
DHCR24
NM_014762






(200862_at)


Hs.75893
288
ankyrin 3, node of Ranvier
ANK3
NM_020987




(ankyrin G)

(206385_s_at)


Hs.76067
3315
heat shock 27 kDa protein 1
HSPB1
NM_001540






(201841_s_at)


Hs.76293
9168
thymosin, beta 10
TMSB10
NM_021103






(217733_s_at)


Hs.76930
6622
synuclein, alpha (non A4 component
SNCA
BG260394




of amyloid precursor)

(204466_s_at)


Hs.77385
4637
myosin, light polypeptide 6, alkali,
MYL6
BE734356




smooth muscle and non-muscle

(212082_s_at)


Hs.77917
7347
ubiquitin carboxyl-terminal esterase
UCHL3
NM_006002




L3 (ubiquitin thiolesterase)

(204616_at)


Hs.78979
2734
golgi apparatus protein 1
GLG1
AK025457






(214730_s_at)


Hs.79356
7805
Lysosomal-associated multispanning
LAPTM5
AI589086




membrane protein-5

(201720_s_at)


Hs.79357
5706
proteasome (prosome, macropain)
PSMC6
NM_002806




26S subunit, ATPase, 6

(201699_at)


Hs.7936
10458
BAI1-associated protein 2
BAIAP2
AB017120






(205293_x_at)


Hs.79381
25801
grancalcin, EF-hand calcium binding
GCA
NM_012198




protein

(203765_at)


Hs.79404
27065
DNA segment on chromosome 4
D4S234E
BC001745




(unique) 234 expressed sequence

(209570_s_at)


Hs.80680
9961
major vault protein
MVP
NM_017458






(202180_s_at)


Hs.82030
7453
tryptophanyl-tRNA synthetase
WARS
NM_004184






(200629_at)


Hs.82159
5682
proteasome (prosome, macropain)
PSMA1
BC005932




subunit, alpha type, 1

(211746_x_at)


Hs.82314
3251
hypoxanthine phosphoribosyltransferase
HPRT1
NM_000194




1 (Lesch-Nyhan syndrome)

(202854_at)


Hs.8262
3920
lysosomal-associated membrane protein 2
LAMP2
J04183






(203041_s_at)


Hs.82793
5691
proteasome (prosome, macropain)
PSMB3
NM_002795




subunit, beta type, 3

(201400_at)


Hs.85226
3988
lipase A, lysosomal acid, cholesterol
LIPA
NM_000235




esterase (Wolman disease)

(201847_at)


Hs.8526
11041
UDP-GlcNAc: betaGal beta-1,3-N-
B3GNT6
NM_006876




acetylglucosaminyltransferase 6

(203188_at)


Hs.8679
11332
brain acyl-CoA hydrolase
BACH
NM_007274






(208002_s_at)


Hs.89399
517
ATP synthase, H+ transporting,
ATP5G2
D13119




mitochondrial FO complex, subunit c

(208764_s_at)




(subunit 9), isoform 2


Hs.89545
5692
proteasome (prosome, macropain)
PSMB4
NM_002796




subunit, beta type, 4

(202243_s_at)


Hs.90005
11075
stathmin-like 2
STMN2
NM_007029






(203001_s_at)


Hs.90073
1434
CSE1 chromosome segregation 1-like
CSE1L
AF053641




(yeast)

(201111_at)


Hs.9950
23480
Sec61 gamma
SEC61G
NM_014302






(203484_at)


Hs.99947
6252
reticulon 1
RTN1
BC000314






(210222_s_at)
















TABLE 18










HC - RESPONSE TO BIOTIC STIM















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.155024
604
B-cell CLL/lymphoma 6 (zinc finger
BCL6
NM_001706




protein 51)

(203140_at)


Hs.159590
4062
lymphocyte antigen 6 complex,
LY6H
NM_002347




locus H

(206773_at)


Hs.174142
1436
colony stimulating factor 1 receptor,
CSF1R
NM_005211




formerly McDonough feline sarcoma

(203104_at)




viral (v-fms) oncogene homolog


Hs.174195
10581
interferon induced transmembrane
IFITM2
NM_006435




protein 2 (1-8D)

(201315_x_at)


Hs.181301
1520
cathepsin S
CTSS
BC002642






(202901_x_at)


Hs.184018
9450
lymphocyte antigen 86
LY86
NM_004271






(205859_at)


Hs.234726
12
serine (or cysteine) proteinase
SERPINA3
NM_001085




inhibitor, clade A (alpha-1

(202376_at)




antiproteinase, antitrypsin), member 3


Hs.25647
2353
v-fos FBJ murine osteosarcoma viral
FOS
BC004490




oncogene homolog

(209189_at)


Hs.277477
3107
major histocompatibility complex,
HLA-C
BC004489




class I, C

(208812_x_at)


Hs.278613
3429
interferon, alpha-inducible
IFI27
NM_005532




protein 27

(202411_at)


Hs.297681
5265
serine (or cysteine) proteinase
SERPINA1
NM_000295




inhibitor, clade A (alpha-1

(202833_s_at)




antiproteinase, antitrypsin), member 1


Hs.303649
6347
chemokine (C—C motif) ligand 2
CCL2
S69738






(216598_s_at)


Hs.372679
2215
Fc fragment of IgG, low affinity
FCGR3B
NM_000570




IIIb, receptor for (CD16)

(204006_s_at)


Hs.375108
934
CD24 antigen (small cell lung
CD24
BG327863




carcinoma cluster 4 antigen)

(208650_s_at)


Hs.386793
2878
glutathione peroxidase 3 (plasma)
GPX3
NM_002084






(201348_at)


Hs.407995
4282
macrophage migration inhibitory
MIF
NM_002415




factor (glycosylation-inhibiting factor)

(217871_s_at)


Hs.433300
2207
Fc fragment of IgE, high affinity I,
FCER1G
NM_004106




receptor for; gamma polypeptide

(204232_at)


Hs.433414
10410
interferon induced transmembrane
IFITM3
BF338947




protein 3 (1-8U)

(212203_x_at)


Hs.458286
8519
interferon induced transmembrane
IFITM1
AA749101




protein 1 (9-27)

(214022_s_at)


Hs.62192
2152
coagulation factor III
F3
NM_001993




(thromboplastin, tissue factor)

(204363_at)


Hs.6510
29953
thyrotropin-releasing hormone
TRHDE
NM_013381




degrading ectoenzyme

(219937_at)


Hs.69328
23643
lymphocyte antigen 96
LY96
NM_015364






(206584_at)


Hs.69547
4155
myelin basic protein
MBP
AW070431






(210136_at)


Hs.72050
8382
non-metastatic cells 5, protein
NME5
NM_003551




expressed in (nucleoside-diphosphate

(206197_at)




kinase)


Hs.73817
6348
chemokine (C—C motif) ligand 3
CCL3
NM_002983






(205114_s_at)


Hs.75106
1191
clusterin (complement lysis inhibitor,
CLU
AI982754




SP-40, 40, sulfated glycoprotein 2,

(222043_at)




testosterone-repressed prostate




message 2, apolipoprotein J)


Hs.753
2357
formyl peptide receptor 1
FPR1
NM_002029






(205119_s_at)


Hs.77424
2209
Fc fragment of IgG, high affinity Ia,
FCGR1A
L03419




receptor for (CD64)

(214511_x_at)


Hs.77961
3106
major histocompatibility complex,
HLA-B
D83043




class I, B

(208729_x_at)


Hs.79022
2669
GTP binding protein overexpressed in
GEM
NM_005261




skeletal muscle

(204472_at)


Hs.80420
6376
chemokine (C-X3-C motif) ligand 1
CX3CL1
U84487 (823_at)


Hs.82112
3554
interleukin 1 receptor, type I
IL1R1
NM_000877






(202948_at)


Hs.82212
963
CD53 antigen
CD53
NM_000560






(203416_at)


Hs.83384
6285
S100 calcium binding protein,
S100B
BC001766




beta (neural)

(209686_at)


Hs.83656
397
Rho GDP dissociation inhibitor
ARHGDIB
NM_001175




(GDI) beta

(201288_at)


Hs.89499
240
arachidonate 5-lipoxygenase
ALOX5
NM_000698






(204446_s_at)


Hs.8986
713
complement component 1, q subcomponent,
C1QB
NM_000491




beta polypeptide

(202953_at)


Hs.9098
26266
solute carrier family 13 (sodium/sulfate
SLC13A4
NM_012450




symporters), member 4

(219824_at)


Hs.9641
712
complement component 1, q subcomponent,
C1QA
NM_015991




alpha polypeptide

(218232_at)


Hs.9963
7305
TYRO protein tyrosine kinase
TYROBP
NM_003332




binding protein

(204122_at)
















TABLE 19










DLPFC - RIBOSOME















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.108957
51065
ribosomal
RPS27L
NM_015920




protein

(218007_s_at)




S27-like


Hs.274417
28973
mitochondrial
MRPS18B
AL050361




ribosomal

(217408_at)




protein S18B


Hs.275865
6222
ribosomal
RPS18
NM_022551




protein S18

(201049_s_at)


Hs.298262
6223
ribosomal
RPS19
BE259729




protein S19

(213414_s_at)


Hs.302588
6181
ribosomal
RPLP2
NM_001004




protein,

(200909_s_at)




large P2


Hs.334807
6156
ribosomal
RPL30
L05095




protein L30

(200062_s_at)


Hs.337766
6142
ribosomal
RPL18A
NM_000980




protein L18a

(200869_at)


Hs.354176
6188
ribosomal
RPS3
U14990




protein S3

(208692_at)


Hs.355957
6231
ribosomal
RPS26
NM_001029




protein S26

(217753_s_at)


Hs.397609
6217
ribosomal
RPS16
AI200589




protein S16

(213890_x_at)


Hs.399720
6202
ribosomal
RPS8
NM_001012




protein S8

(200858_s_at)


Hs.406341
6187
ribosomal
RPS2
AA630314




protein S2

(212433_x_at)


Hs.406478
6170
ribosomal
RPL39
BC001019




protein L39

(208695_s_at)


Hs.424299
6176
ribosomal protein,
RPLP1
NM_001003




large, P1

(200763_s_at)


Hs.430207
6159
ribosomal
RPL29
NM_000992




protein L29

(200823_x_at)


Hs.431392
6137
ribosomal
RPL13
BC004954




protein L13

(208929_x_at)


Hs.433406
6210
ribosomal
RPS15A
NM_001019




protein S15a

(200781_s_at)


Hs.434029
6206
ribosomal
RPS12
AI799007




protein S12

(213377_x_at)


Hs.458148
6134
ribosomal
RPL10
NM_006013




protein L10

(200725_x_at)


Hs.76064
6157
ribosomal
RPL27A
NM_000990




protein L27a

(203034_s_at)


Hs.76698
27230
stress-asso-
SERP1
BG107676




ciated endo-

(200969_at)




plasmic reticulum




protein 1
















TABLE 20










ANCg - PROTEIN TARGETING















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.10842
5901
RAN, member RAS
RAN
AF054183




oncogene family

(200750_s_at)


Hs.111126
754
pituitary tumor-transforming 1
PTTG1IP
NM_004339




interacting protein

(200677_at)


Hs.113503
3843
karyopherin
KPNB3
AU148466




(importin) beta 3

(211953_s_at)


Hs.159557
3838
karyopherin alpha 2 (RAG cohort
KPNA2
NM_002266




1, importin alpha 1)

(201088_at)


Hs.199179
5903
RAN binding protein 2
RANBP2
D42063






(201713_s_at)


Hs.220689
10146
Ras-GTPase-activating protein
G3BP
BG500067




SH3-domain-binding protein

(201503_at)


Hs.3886
3839
karyopherin alpha 3
KPNA3
AF034756




(importin alpha 4)

(221503_s_at)


Hs.433496
9908
Ras-GTPase activating protein SH3
G3BP2
AB014560




domain-binding protein 2

(208841_s_at)


Hs.49346
6729
signal recognition
SRP54
NM_003136




particle 54 kDa

(203605_at)


Hs.72916
2737
GLI-Kruppel family member GLI3
GLI3
NM_000168




(Greig cephalopolysyndactyly

(205201_at)




syndrome)


Hs.75187
9804
translocase of outer mitochondrial
TOMM20-
NM_014765




membrane 20 (yeast) homolog
PENDING
(200662_s_at)


Hs.79037
3329
heat shock 60 kDa protein 1
HSPD1
BE256479




(chaperonin)

(200806_s_at)


Hs.79090
7514
exportin 1 (CRM1 homolog, yeast)
XPO1
D89729






(208775_at)


Hs.8180
6386
syndecan binding protein
SDCBP
NM_005625




(syntenin)

(200958_s_at)


Hs.90073
1434
CSE1 chromosome segregation 1-
CSE1L
AF053641




like (yeast)

(201111_at)


Hs.9950
23480
Sec61 gamma
SEC61G
NM_014302






(203484_at)
















TABLE 21










AnCg-ER















ACCESSION


UniGene
LocusID
Description
Symbol
(Probe ID)














Hs.11125
28972
signal peptidase 12 kDa
SPC12
NM_014041






(217927_at)


Hs.11899
3156
3-hydroxy-3-methylglutaryl-
HMGCR
AL518627




Coenzyme A reductase

(202539_s_at)


Hs.154654
1545
cytochrome P450, family 1,
CYP1B1
NM_000104




subfamily B, polypeptide 1

(202437_s_at)


Hs.185973
8560
degenerative spermatocyte homolog,
DEGS
BC000961




lipid desaturase (Drosophila)

(209250_at)


Hs.227327
5861
RAB1A, member RAS oncogene family
RAB1A
BC000905






(208724_s_at)


Hs.237825
6731
signal recognition particle 72 kDa
SRP72
AI493872






(208802_at)


Hs.239926
6307
sterol-C4-methyl oxidase-like
SC4MOL
AV704962






(209146_at)


Hs.24752
10006
spectrin SH3 domain binding
SSH3BP1
AF006516




protein 1

(209028_s_at)


Hs.251531
5685
proteasome (prosome, macropain)
PSMA4
NM_002789




subunit, alpha type, 4

(203396_at)


Hs.25253
4121
mannosidase, alpha, class 1A,
MAN1A1
BG287153




member 1

(221760_at)


Hs.252831
10313
reticulon 3
RTN3
NM_006054






(219549_s_at)


Hs.272927
10484
Sec23 homolog A (S. cerevisiae)
SEC23A
AI753659






(212887_at)


Hs.283664
444
aspartate beta-hydroxylase
ASPH
AF289489






(209135_at)


Hs.296244
10652
SNARE protein Ykt6
YKT6
NM_006555






(217785_s_at)


Hs.346918
5684
proteasome (prosome, macropain)
PSMA3
NM_002788




subunit, alpha type, 3

(201532_at)


Hs.353170
811
calreticulin
CALR
AI348935






(214315_x_at)


Hs.3887
5707
proteasome (prosome, macropain)
PSMD1
AI860431




26S subunit, non-ATPase, 1

(201198_s_at)


Hs.406532
6185
ribophorin II
RPN2
AI560720






(213399_x_at)


Hs.407981
5689
proteasome (prosome, macropain)
PSMB1
W86293




subunit, beta type, 1

(214288_s_at)


Hs.410276
5687
proteasome (prosome, macropain)
PSMA6
BC002979




subunit, alpha type, 6

(208805_at)


Hs.41270
5352
procollagen-lysine, 2-oxoglutarate
PLOD2
NM_000935




5-dioxygenase (lysine hydroxylase) 2

(202620_s_at)


Hs.426142
5281
phosphatidylinositol glycan,
PIGF
NM_002643




class F

(205078_at)


Hs.432605
7357
UDP-glucose ceramide
UGCG
NM_003358




glucosyltransferase

(204881_s_at)


Hs.48876
2222
farnesyl-diphosphate
FDFT1
AA872727




farnesyltransferase 1

(208647_at)


Hs.49346
6729
signal recognition particle 54 kDa
SRP54
NM_003136






(203605_at)


Hs.5085
8813
dolichyl-phosphate mannosyltransferase
DPMI
NM_003859




polypeptide 1, catalytic subunit

(202673_at)


Hs.585
338
apolipoprotein B (including Ag(x)
APOB
NM_000384




antigen)

(205108_s_at)


Hs.7239
10427
SEC24 related gene family, member B
SEC24B
NM_006323




(S. cerevisiae)

(202798_at)


Hs.76698
27230
stress-associated endoplasmic
SERP1
AL136807




reticulum protein 1

(200970_s_at)


Hs.78305
5862
RAB2, member RAS oncogene family
RAB2
AU158062






(208731_at)


Hs.78466
5714
proteasome (prosome, macropain)
PSMD8
NM_002812




26S subunit, non-ATPase, 8

(200820_at)


Hs.79137
5110
protein-L-isoaspartate (D-aspartate)
PCMT1
D25547




O-methyltransferase

(210156_s_at)


Hs.8180
6386
syndecan binding protein (syntenin)
SDCBP
NM_005625






(200958_s_at)


Hs.82159
5682
proteasome (prosome, macropain)
PSMA1
BC005932




subunit, alpha type, 1

(211746_x_at)


Hs.89545
5692
proteasome (prosome, macropain)
PSMB4
NM_002796




subunit, beta type, 4

(202243_s_at)


Hs.9950
23480
Sec61 gamma
SEC61G
NM_014302






(203484_at)
















TABLE 22










ALL REGIONS - 1.2 FOLD












Gene



LOCUSLINK
Gene Name
Symbol
GO Category













6347
chemokine (C—C motif) ligand 2
CCL2
cation homeostasis


54997
hypothetical protein FLJ20607
TSC
cation homeostasis


11147
HERV-H LTR-associating 3
HHLA3
cation homeostasis


9900
synaptic vesicle glycoprotein 2A
SV2A
cation homeostasis


475
ATX1 antioxidant protein 1 homolog (yeast)
ATOX1
cation homeostasis


9843
hephaestin
HEPH
cation homeostasis


10479
solute carrier family 9 (sodium/hydrogen
SLC9A6
cation homeostasis



exchanger), isoform 6


4495
metallothionein 1G
MT1G
cation homeostasis


1356
ceruloplasmin (ferroxidase)
CP
cation homeostasis


6348
chemokine (C—C motif) ligand 3
CCL3
cation homeostasis


4306
nuclear receptor subfamily 3, group C, member 2
NR3C2
cation homeostasis


6358
chemokine (C—C motif) ligand 14
CCL14
cation homeostasis


794
calbindin 2, 29 kDa (calretinin)
CALB2
cation homeostasis


793
calbindin 1, 28 kDa
CALB1
cation homeostasis


4504
metallothionein 3 (growth inhibitory factor
MT3
cation homeostasis



(neurotrophic))


4496
metallothionein 1H
MT1H
cation homeostasis


4501
metallothionein 1X
MT1X
cation homeostasis


7037
transferrin receptor (p90, CD71)
TFRC
cation homeostasis


6717
sorcin
SRI
cation homeostasis


6387
chemokine (C—X—C motif) ligand 12 (stromal cell-
CXCL12
cation homeostasis



derived factor 1)


27032
ATPase, Ca++ transporting, type 2C, member 1
ATP2C1
cation homeostasis


6356
chemokine (C—C motif) ligand 11
CCL11
cation homeostasis


8671
solute carrier family 4, sodium bicarbonate
SLC4A4
cation homeostasis



cotransporter, member 4


846
calcium-sensing receptor (hypocalciuric
CASR
cation homeostasis



hypercalcemia 1, severe neonatal



hyperparathyroidism)


23333
KIAA0877 protein
KIAA0877
cation homeostasis


2512
ferritin, light polypeptide
FTL
cation homeostasis


7439
ferritin, heavy polypeptide 1
FTH1
cation homeostasis


351
amyloid beta (A4) precursor protein (protease
APP
cation homeostasis



nexin-II, Alzheimer disease)


4502
metallothionein 2A
MT2A
Copper ion homeostasis


3337
DnaJ (Hsp40) homolog, subfmaily B, member 1
DNAJB1
Heat shock protein


3313
heat shock 70 kDa protein 9B (mortalin-2)
HSPA9B
Heat shock protein


3329
heat shock 60 kDa protein 1 (chaperonin)
HSPD1
Heat shock protein


3301
DnaJ (Hsp40) homolog, subfamily A, member 1
DNAJA1
Heat shock protein


3300
DnaJ (Hsp40) homolog, subfamily B, member 2
DNAJB2
Heat shock protein


11080
DnaJ (Hsp40) homolog, subfamily B, member 4
DNAJB4
Heat shock protein


3336
heat shock 10 kDa protein 1 (chaperonin 10)
HSPE1
Heat shock protein


10808
heat shock 105 kDa/110 kDa protein 1
HSPH1
Heat shock protein


3298
heat shock transcription factor 2
HSF2
Heat shock protein


3320
heat shock 90 kDa protein 1, alpha
HSPCA
Heat shock protein


3312
heat shock 70 kDa protein 8
HSPA8
Heat shock protein


3308
heat shock 70 kDa protein 4
HSPA4
Heat shock protein


25822
DnaJ (Hsp40) homolog, subfamily B, member 5
DNAJB5
Heat shock protein


3326
heat shock 90 kDa protein 1, beta
HSPCB
Heat shock protein


26353
protein kinase H11
H11
Heat shock protein


56034
platelet derived growth factor C
PDGFC
Neurogenesis


474
atonal homolog 1 (Drosophila)
ATOH1
Neurogenesis


6647
superoxide dismutase 1, soluble (amyotrophic
SOD1
Neurogenesis



lateral sclerosis 1 (adult))


65108
MARCKS-like protein
MLP
Neurogenesis


1639
dynactin 1 (p150, glued homolog, Drosophila)
DCTN1
Neurogenesis


8507
ectodermal-neural cortex (with BTB-like domain)
ENC1
Neurogenesis


26227
phosphoglycerate dehydrogenase
PHGDH
Neurogenesis


1809
dihydropyrimidinase-like 3
DPYSL3
Neurogenesis


10523
calcium homeostasis endoplasmic reticulum protein
CHERP
Neurogenesis


648
B lymphoma Mo-MLV insertion region (mouse)
BMI1
Neurogenesis


6695
sparc/osteonectin, cwcv and kazal-like domains
SPOCK
Neurogenesis



proteoglycan (testican)


1400
collapsin response mediator protein 1
CRMP1
Neurogenesis


51232
cysteine-rich motor neuron 1
CRIM1
Neurogenesis


7466
Wolfram syndrome 1 (wolframin)
WFS1
Neurogenesis


7869
sema domain, immunoglobulin domain (Ig), short
SEMA3B
Neurogenesis



basic domain, secreted, (semaphorin) 3B


3720
jumonji homolog (mouse)
JMJ
Neurogenesis


3280
hairy and enhancer of split 1, (Drosophila)
HES1
Neurogenesis


5634
phosphoribosyl pyrophosphate synthetase 2
PRPS2
Neurogenesis


10231
Down syndrome critical region gene 1-like 1
DSCR1L1
Neurogenesis


10507
sema domain, immunoglobulin domain (Ig),
SEMA4D
Neurogenesis



transmembrane domain (TM) and short cytoplasmic



domain, (semaphorin) 4D


9638
fasciculation and elongation protein zeta 1 (zygin I)
FEZ1
Neurogenesis


9839
zinc finger homeobox 1b
ZFHX1B
Neurogenesis


10512
sema domain, immunoglobulin domain (Ig), short
SEMA3C
Neurogenesis



basic domain, secreted, (semaphorin) 3C


104
adenosine deaminase, RNA-specific, B1 (RED1
ADARB1
Neurogenesis



homolog rat)


4900
neurogranin (protein kinase C substrate, RC3)
NRGN
Neurogenesis


27333
golgi phosphoprotein 4
GOLPH4
Neurogenesis


2247
fibroblast growth factor 2 (basic)
FGF2
Neurogenesis


5803
protein tyrosine phosphatase, receptor-type, Z
PTPRZ1
Neurogenesis



polypeptide 1


4929
nuclear receptor subfamily 4, group A, member 2
NR4A2
Neurogenesis


2775
guanine nucleotide binding protein (G protein),
GNAO1
Neurogenesis



alpha activating activity polypeptide O


1641
doublecortex; lissencephaly, X-linked (doublecortin)
DCX
Neurogenesis


2705
gap junction protein, beta 1, 32 kDa (connexin 32,
GJB1
Neurogenesis



Charcot-Marie-Tooth neuropathy, X-linked)


2173
fatty acid binding protein 7, brain
FABP7
Neurogenesis


3730
Kallmann syndrome 1 sequence
KAL1
Neurogenesis


10458
BAI1-associated protein 2
BAIAP2
Neurogenesis


5274
serine (or cysteine) proteinase inhibitor, clade I
SERPINI1
Neurogenesis



(neuroserpin), member 1


9201
doublecortin and CaM kinase-like 1
DCAMKL1
Neurogenesis


11341
scrapie responsive protein 1
SCRG1
Neurogenesis


10178
odz, odd Oz/ten-m homolog 1(Drosophila)
ODZ1
Neurogenesis


6456
SH3-domain GRB2-like 2
SH3GL2
Neurogenesis


4693
Norrie disease (pseudoglioma)
NDP
Neurogenesis


4745
NEL-like 1 (chicken)
NELL1
Neurogenesis


4081
mab-21-like 1 (C. elegans)
MAB21L1
Neurogenesis


4760
neurogenic differentiation 1
NEUROD1
Neurogenesis


9211
leucine-rich, glioma inactivated 1
LGI1
Neurogenesis


7545
Zic family member 1 (odd-paired homolog,
ZIC1
Neurogenesis




Drosophila)



6496
sine oculis homeobox homolog 3 (Drosophila)
SIX3
Neurogenesis


320
amyloid beta (A4) precursor protein-binding, family
APBA1
Neurogenesis



A, member 1 (X11)


1910
endothelin receptor type B
EDNRB
Neurogenesis


22865
KIAA0848 protein
KIAA0848
Neurogenesis


4062
lymphocyte antigen 6 complex, locus H
LY6H
Neurogenesis


1415
crystallin, beta B2
CRYBB2
Neurogenesis


4821
NK2 transcription factor related, locus 2
NKX2-2
Neurogenesis



(Drosophila)


27255
contactin 6
CNTN6
Neurogenesis


7101
nuclear receptor subfamily 2, group E, member 1
NR2E1
Neurogenesis


1821
dystrophin related protein 2
DRP2
Neurogenesis


4336
myelin-associated oligodendrocyte basic protein
MOBP
Neurogenesis


10787
NCK-associated protein 1
NCKAP1
Neurogenesis


6622
synuclein, alpha (non A4 component of amyloid
SNCA
Neurogenesis



precursor)


2821
glucose phosphate isomerase
GPI
Neurogenesis


4762
neurogenin 1
NEUROG1
Neurogenesis


1859
dual-specificity tyrosine-(Y)-phosphorylation
DYRK1A
Neurogenesis



regulated kinase 1A


2824
glycoprotein M6B
GPM6B
Neurogenesis


4208
MADS box transcription enhancer factor 2,
MEF2C
Neurogenesis



polypeptide C (myocyte enhancer factor 2C)


333
amyloid beta (A4) precursor-like protein 1
APLP1
Neurogenesis


5764
pleiotrophin (heparin binding growth factor 8,
PTN
Neurogenesis



neurite growth-promoting factor 1)


2823
glycoprotein M6A
GPM6A
Neurogenesis


2048
EphB2
EPHB2
Neurogenesis


9353
slit homolog 2 (Drosophila)
SLIT2
Neurogenesis


9048
artemin
ARTN
Neurogenesis


3785
potassium voltage-gated channel, KQT-like
KCNQ2
Neurogenesis



subfamily, member 2


1742
discs, large (Drosophila) homolog 4
DLG4
Neurogenesis


195
AHNAK nucleoprotein (desmoyokin)
AHNAK
Neurogenesis


7155
topoisomerase (DNA) II beta 180 kDa
TOP2B
Neurogenesis


8829
neuropilin 1
NRP1
Neurogenesis


3241
hippocalcin-like 1
HPCAL1
Neurogenesis


9444
quaking homolog, KH domain RNA binding (mouse)
QKI
Neurogenesis


10376
tubulin, alpha 3
TUBA3
Neurogenesis


23180
KIAA0084 protein
KIAA0084
Neurogenesis


10439
olfactomedin 1
OLFM1
Neurogenesis


429
achaete-scute complex-like 1 (Drosophila)
ASCL1
Neurogenesis


1200
ceroid-lipofuscinosis, neuronal 2, late infantile
CLN2
Neurogenesis



(Jansky-Bielschowsky disease)


2257
fibroblast growth factor 12
FGF12
Neurogenesis


4915
neurotrophic tyrosine kinase, receptor, type 2
NTRK2
Neurogenesis


5361
plexin A1
PLXNA1
Neurogenesis


26050
KIAA0918 protein
KIAA0918
Neurogenesis


773
calcium channel, voltage-dependent, P/Q type,
CACNA1A
Neurogenesis



alpha 1A subunit


2752
glutamate-ammonia ligase (glutamine synthase)
GLUL
Neurogenesis


51399
PTD009 protein
PTD009
Neurogenesis


26585
cysteine knot superfamily 1, BMP antagonist 1
CKTSF1B1
Neurogenesis


64218
hypothetical protein FLJ12287 similar to
FLJ12287
Neurogenesis



semaphorins


10313
reticulon 3
RTN3
Neurogenesis


4815
ninjurin 2
NINJ2
Neurogenesis


51440
hippocalcin like 4
HPCAL4
Neurogenesis


10842
chromosome 7 open reading frame 16
C7orf16
Neurogenesis


55727
function unknown protein 1
FLJ10648
Neurogenesis


64388
hypothetical protein FLJ21195 similar to protein
FLJ21195
Neurogenesis



related to DAC and cerberus


56934
carbonic anhydrase X
CA10
Neurogenesis


55607
protein phosphatase 1, regulatory (inhibitor) subunit
PPP1R9A
Neurogenesis



9A


2259
fibroblast growth factor 14
FGF14
Neurogenesis


58158
neurogenic differentiation 4
NEUROD4
Neurogenesis


23462
hairy/enhancer-of-split related with YRPW motif 1
HEY1
Neurogenesis


23493
hairy/enhancer-of-split related with YRPW motif 2
HEY2
Neurogenesis


6477
seven in absentia homolog 1 (Drosophila)
SIAH1
Neurogenesis


9637
fasciculation and elongation protein zeta 2 (zygin II)
FEZ2
Neurogenesis


11189
trinucleotide repeat containing 4
TNRC4
Neurogenesis


2596
growth associated protein 43
GAP43
Neurogenesis


10858
cytochrome P450, family 46, subfamily A,
CYP46A1
Neurogenesis



polypeptide 1


6134
ribosomal protein L10
RPL10
Ribosome


6158
ribosomal protein L28
RPL28
Ribosome


4736
ribosomal protein L10a
RPL10A
Ribosome


9045
ribosomal protein L14
RPL14
Ribosome


6176
ribosomal protein, large, P1
RPLP1
Ribosome


6210
ribosomal protein S15a
RPS15A
Ribosome


6159
ribosomal protein L29
RPL29
Ribosome


6202
ribosomal protein S8
RPS8
Ribosome


6142
ribosomal protein L18a
RPL18A
Ribosome


6181
ribosomal protein, large P2
RPLP2
Ribosome


6132
ribosomal protein L8
RPL8
Ribosome


6160
ribosomal protein L31
RPL31
Ribosome


6169
ribosomal protein L38
RPL38
Ribosome


6157
ribosomal protein L27a
RPL27A
Ribosome


6188
ribosomal protein S3
RPS3
Ribosome


6170
ribosomal protein L39
RPL39
Ribosome


6137
ribosomal protein L13
RPL13
Ribosome


6187
ribosomal protein S2
RPS2
Ribosome


6218
ribosomal protein S17
RPS17
Ribosome



ribosomal protein L35a
RPL35A
Ribosome


716
ribosomal protein S12
RPS12
Ribosome


6223
ribosomal protein S19
RPS19
Ribosome


6217
ribosomal protein S16
RPS16
Ribosome


6168
ribosomal protein L37a
RPL37A
Ribosome


6175
ribosomal protein, large, P0
RPLP0
Ribosome


6130
ribosomal protein L7a
RPL7A
Ribosome


6203
ribosomal protein S9
RPS9
Ribosome


6125
ribosomal protein L5
RPL5
Ribosome


6231
ribosomal protein S26
RPS26
Ribosome


27115
phosphodiesterase 7B
PDE7B
Synaptic transmission


6866
tachykinin 3 (neuromedin K, neurokinin beta)
TAC3
Synaptic transmission


2558
gamma-aminobutyric acid (GABA) A receptor,
GABRA5
Synaptic transmission



alpha 5


4684
neural cell adhesion molecule 1
NCAM1
Synaptic transmission


8938
BAI1-associated protein 3
BAIAP3
Synaptic transmission


6386
syndecan binding protein (syntenin)
SDCBP
Synaptic transmission


6856
synaptophysin-like protein
SYPL
Synaptic transmission


6535
solute carrier family 6 (neurotransmitter transporter,
SLC6A8
Synaptic transmission



creatine), member 8


22839
KIAA0964 protein
KIAA0964
Synaptic transmission


5864
RAB3A, member RAS oncogene family
RAB3A
Synaptic transmission


6529
solute carrier family 6 (neurotransmitter transporter,
SLC6A1
Synaptic transmission



GABA), member 1


6712
spectrin, beta, non-erythrocytic 2
SPTBN2
Synaptic transmission


273
amphiphysin (Stiff-Man syndrome with breast
AMPH
Synaptic transmission



cancer 128 kDa autoantigen)


2743
glycine receptor, beta
GLRB
Synaptic transmission


43
acetylcholinesterase (YT blood group)
ACHE
Synaptic transmission


590
butyrylcholinesterase
BCHE
Synaptic transmission


6324
sodium channel, voltage-gated, type I, beta
SCN1B
Synaptic transmission


1392
corticotropin releasing hormone
CRH
Synaptic transmission


869
cerebellin 1 precursor
CBLN1
Synaptic transmission


2913
glutamate receptor, metabotropic 3
GRM3
Synaptic transmission


6861
synaptotagmin V
SYT5
Synaptic transmission


9229
discs, large (Drosophila) homolog-associated
DLGAP1
Synaptic transmission



protein 1


1134
cholinergic receptor, nicotinic, alpha polypeptide 1
CHRNA1
Synaptic transmission



(muscle)


2571
glutamate decarboxylase 1 (brain, 67 kDa)
GAD1
Synaptic transmission


2554
gamma-aminobutyric acid (GABA) A receptor,
GABRA1
Synaptic transmission



alpha 1


5173
prodynorphin
PDYN
Synaptic transmission


2566
gamma-aminobutyric acid (GABA) A receptor,
GABRG2
Synaptic transmission



gamma 2


6511
solute carrier family 1 (high affinity
SLC1A6
Synaptic transmission



aspartate/glutamate transporter), member 6


6014
Ras-like without CAAX 2
RIT2
Synaptic transmission


2560
gamma-aminobutyric acid (GABA) A receptor, beta 1
GABRB1
Synaptic transmission


2555
gamma-aminobutyric acid (GABA) A receptor,
GABRA2
Synaptic transmission



alpha 2


5297
phosphatidylinositol 4-kinase, catalytic, alpha
PIK4CA
Synaptic transmission



polypeptide


3356
5-hydroxytryptamine (serotonin) receptor 2A
HTR2A
Synaptic transmission


2559
gamma-aminobutyric acid (GABA) A receptor,
GABRA6
Synaptic transmission



alpha 6


2911
glutamate receptor, metabotropic 1
GRM1
Synaptic transmission


3352
5-hydroxytryptamine (serotonin) receptor 1D
HTR1D
Synaptic transmission


1175
adaptor-related protein complex 2, sigma 1 subunit
AP2S1
Synaptic transmission


2563
gamma-aminobutyric acid (GABA) A receptor, delta
GABRD
Synaptic transmission


1312
catechol-O-methyltransferase
COMT
Synaptic transmission


1267
2′,3′-cyclic nucleotide 3′ phosphodiesterase
CNP
Synaptic transmission


2890
glutamate receptor, ionotropic, AMPA 1
GRIA1
Synaptic transmission


9568
G protein-coupled receptor 51
GPR51
Synaptic transmission


1325
cortistatin
CORT
Synaptic transmission


1136
cholinergic receptor, nicotinic, alpha polypeptide 3
CHRNA3
Synaptic transmission


6854
synapsin II
SYN2
Synaptic transmission


9362
copine VI (neuronal)
CPNE6
Synaptic transmission


1728
NAD(P)H dehydrogenase, quinone 1
NQO1
Synaptic transmission


3351
5-hydroxytryptamine (serotonin) receptor 1B
HTR1B
Synaptic transmission


2902
glutamate receptor, ionotropic, N-methyl D-
GRIN1
Synaptic transmission



aspartate 1


51552
RAB14, member RAS oncogene family
RAB14
Synaptic transmission


5594
mitogen-activated protein kinase 1
MAPK1
Synaptic transmission


4128
monoamine oxidase A
MAOA
Synaptic transmission


8867
synaptojanin 1
SYNJ1
Synaptic transmission


23467
neuronal pentraxin receptor
NPTXR
Synaptic transmission


27065
DNA segment on chromosome 4 (unique) 234
D4S234E
Synaptic transmission



expressed sequence


27445
piccolo (presynaptic cytomatrix protein)
PCLO
Synaptic transmission


6505
solute carrier family 1 (neuronal/epithelial high
SLC1A1
Synaptic transmission



affinity glutamate transporter, system Xag), member 1


9456
homer homolog 1 (Drosophila)
HOMER1
Synaptic transmission


274
bridging integrator 1
BIN1
Synaptic transmission


1759
dynamin 1
DNM1
Synaptic transmission


10142
A kinase (PRKA) anchor protein (yotiao) 9
AKAP9
Synaptic transmission


25873
ribosomal protein L36
RPL36
Synaptic transmission


50632
calcyon; D1 dopamine receptor-interacting protein
CALCYON
Synaptic transmission





















TABLE 22













Repre-
DLPFC
AnCg
Amy





















UniGene
sentative

Chromosomal

Probe set ID

Gene
Brain region
p
Fold
p
Fold
p
Fold


ID
Public ID
LocusLink
Location
OMIM
UG-1
Gene Title
Symbol
affected
value
change
value
change
value
change
























Hs.259768
AL120173
107
chr7p13-p12
103072
Hs.259768_at
adenylate cyclase 1 (brain)
ADCY1
DLPFC,
0.044
1.213
0.005
1.238
0.005
1.520










AnCg, Amy


Hs.272891
AL136591
51440
chr1p34.2

Hs.272891_at
hippocalcin like 4
HPCAL4
DLPFC,
0.046
1.243
0.010
1.326
0.007
1.458










AnCg, Amy


Hs.283110
NM_020178
56934
chr17q21
604642
Hs.283110_at
carbonic anhydrase X
CA10
DLPFC,
0.019
1.309
0.025
1.236
0.010
1.344










AnCg, Amy


Hs.284394
NM_000064
718
chr19p13.3-p13.2
120700
Hs.284394_at
complement component 3
C3
DLPFC,
0.039
0.613
0.026
0.637
0.006
0.419










AnCg, Amy


Hs.356523
NM_012324
23542
chr22q13.33
607755
Hs.356523_at
mitogen-activated protein
MAPK8IP2
DLPFC,
0.018
1.270
0.002
1.239
0.032
1.328








kinase 8 interacting protein 2

AnCg, Amy


Hs.379386
AA928255
115286
chr3p14.1

Hs.379386_at
solute carrier family 25
SLC25A26
DLPFC,
0.030
1.243
0.002
1.595
0.019
1.675








(mitochondrial carrier,

AnCg, Amy








phosphate carrier), member 26


Hs.429761
NM_022159
64123
chr1p33-p32

Hs.429761_at
EGF, latrophilin and seven
ELTD1
DLPFC,
0.016
0.822
0.016
0.733
0.045
0.668








transmembrane domain

AnCg, Amy








containing 1


Hs.74561
BF056828
2
chr12p13.3-p12.3
103950
Hs.74561_at
alpha-2-macroglobulin
A2M
DLPFC,
0.033
0.645
0.009
0.728
0.000
0.570










AnCg, Amy


Hs.151032
BC001072
79033
chr1p32

Hs.151032_at
prion protein interacting protein
PRNPIP
DLPFC,
0.022
1.339
0.035
1.280
0.091
1.473










AnCg


Hs.201920
X95425
2044
chr4q13.1
600004
Hs.201920_at
EphA5
EPHA5
DLPFC,
0.023
1.377
0.027
1.411
0.059
1.543










AnCg


Hs.274404
NM_000930
5327
chr8p12
173370
Hs.274404_at
plasminogen activator, tissue
PLAT
DLPFC,
0.016
0.639
0.019
0.697
0.164
0.763










AnCg


Hs.288654
BC001777
3208
chr1p35-p34.2
142622
Hs.288654_at
hippocalcin
HPCA
DLPFC,
0.025
1.300
0.049
1.233
0.056
1.366










AnCg


Hs.418083
NM_006744
5950
chr10q23-q24
180250
Hs.418083_at
retinol binding protein 4, plasma
RBP4
DLPFC,
0.041
1.362
0.046
1.312
0.699
1.095










AnCg


Hs.4221
AL359592
55530
chr12q24.11

Hs.4221_at
hypothetical protein
DKFZp761H039
DLPFC,
0.016
1.288
0.029
1.257
0.118
1.302








DKFZp761H039

AnCg


Hs.437224
NM_002894
5932
chr18q11.2
604124
Hs.437224_at
retinoblastoma binding protein 8
RBBP8
DLPFC,
0.020
0.830
0.005
0.774
0.666
0.921










AnCg


Hs.527093
NM_000740
1131
chr1q41-q44
118494
Hs.527093_at
cholinergic receptor, muscarinic 3
CHRM3
DLPFC,
0.024
1.369
0.031
1.312
0.240
1.094










AnCg


Hs.155090
BC011671
10681
chr15q21.2
604447
Hs.155090_at
guanine nucleotide binding
GNB5
DLPFC, Amy
0.026
1.584
0.160
1.239
0.041
1.467








protein (G protein), beta 5


Hs.343586
NM_003407
7538
chr19q13.1
190700
Hs.343586_at
zinc finger protein 36, C3H type,
ZFP36
DLPFC, Amy
0.031
0.711
0.289
0.704
0.045
0.575








homolog (mouse)


Hs.369441
NM_014030
28964
chr17p11.2
608434
Hs.369441_at
G protein-coupled receptor
GIT1
DLPFC, Amy
0.040
1.323
0.155
1.206
0.027
1.307








kinase-interactor 1


Hs.105352
Y11339
55808
chr17q25.1

Hs.105352_at
sialyltransferase 7 ((alpha-N-
SIAT7A
AnCg, Amy
0.258
1.076
0.033
0.783
0.036
0.702








acetylneuraminyl-2,3-beta-








galactosyl-1,3)-N-acetyl








galactosaminide alpha-2,6-








sialyltransferase) A


Hs.105468
NM_024711
79765
chr7q36.1

Hs.105468_at
human Immune associated
hIAN2
AnCg, Amy
0.064
0.912
0.048
0.810
0.001
0.631








nucleotide 2


Hs.106674
AB002534
8314
chr3p21.31-p21.2
603089
Hs.106674_at
BRCA1 associated protein-1
BAP1
AnCg, Amy
0.484
1.150
0.003
1.308
0.008
1.478








(ubiquitin carboxy-terminal








hydrolase)


Hs.108222
NM_020248
56998
chr1p36.22
607758
Hs.108222_at
catenin, beta interacting protein 1
CTNNBIP1
AnCg, Amy
0.366
1.130
0.000
1.217
0.004
1.239


Hs.118554
NM_016027
51110
chr8p22-q22.3

Hs.118554_at
lactamase, beta 2
CGI-83
AnCg, Amy
0.862
1.015
0.039
0.739
0.012
0.684


Hs.120228
AA731713
23109
chr12q13.12

Hs.120228_at
dendrin
DDN
AnCg, Amy
0.508
1.085
0.024
1.276
0.014
1.348


Hs.124675
AA858297
168537
chr7q36.1

Hs.124675_at
immune associated nucleotide
hIAN7
AnCg, Amy
0.493
0.902
0.029
0.737
0.013
0.528


Hs.15099
AB018283
9886
chr10q21.2
607351
Hs.15099_at
Rho-related BTB domain
RHOBTB1
AnCg, Amy
0.747
1.049
0.033
0.814
0.001
0.607








containing 1


Hs.169182
NM_017596
23046
chr1pter-q31.3
608322
Hs.169182_at
kinesin family member 21B
KIF21B
AnCg, Amy
0.427
1.094
0.010
1.246
0.009
1.327


Hs.17109
AL021786
9452
chrxq13.3-xq21.2
300222
Hs.17109_at
integral membrane protein 2A
ITM2A
AnCg, Amy
0.116
0.772
0.008
0.743
0.000
0.503


Hs.182536
AB006622
283638
chr14q32.33

Hs.182536_at
KIAA0284
KIAA0284
AnCg, Amy
0.063
1.156
0.025
1.236
0.008
1.322


Hs.194720
AF098951
9429
chr4q22
603756
Hs.194720_at
ATP-binding cassette, sub-
ABCG2
AnCg, Amy
0.063
0.640
0.019
0.604
0.001
0.429








family G (WHITE), member 2


Hs.21330
AF016535
5243
chr7q21.1
171050
Hs.21330_at
ATP-binding cassette, sub-
ABCB1
AnCg, Amy
0.052
0.810
0.013
0.745
0.001
0.528








family B (MDR/TAP), member 1


Hs.21611
AF035621
3797
chr2p23
602845
Hs.21611_at
kinesin family member 3C
KIF3C
AnCg, Amy
0.176
1.279
0.042
1.248
0.034
1.448


Hs.22026
AI721164
116441
chr3q25.1

Hs.22026_at
hypothetical protein BC014339
LOC116441
AnCg, Amy
0.074
0.921
0.045
0.771
0.005
0.637


Hs.235750
AF152354
26519
chr11q12.1-q12.3
602251
Hs.235750_at
translocase of inner
TIMM10
AnCg, Amy
0.192
1.139
0.008
1.233
0.025
1.298








mitochondrial membrane 10








homolog (yeast)


Hs.274256
AW138767
79993
chr5q12.1

Hs.274256_at
hypothetical protein FLJ23563
FLJ23563
AnCg, Amy
0.449
0.886
0.049
0.594
0.021
0.451


Hs.279909
AW166283
5522
chr4p16.1
605997
Hs.279909_at
protein phosphatase 2 (formerly
PPP2R2C
AnCg, Amy
0.019
1.188
0.012
1.214
0.008
1.373








2A), regulatory subunit B (PR








52), gamma isoform


Hs.29169
NM_024610
79663
chr3q21.1
608263
Hs.29169_at
HSPB (heat shock 27 kDa)
HSPBAP1
AnCg, Amy
0.048
0.863
0.007
0.660
0.011
0.737








associated protein 1


Hs.303172
AL120332
220164
chr18q22.2

Hs.303172_at
hypothetical protein MGC20785
MGC20785
AnCg, Amy
0.101
1.279
0.023
1.330
0.046
1.415


Hs.30822
NM_018326
55303
chr7q36.1
608087
Hs.30822_at
immunity associated protein 4
HIMAP4
AnCg, Amy
0.078
0.857
0.010
0.817
0.003
0.484


Hs.311553
NM_001270
1105
chr5q15-q21
602118
Hs.311553_at
chromodomain helicase DNA
CHD1
AnCg, Amy
0.066
0.907
0.001
0.798
0.004
0.754








binding protein 1


Hs.346203
AK090879
55084
chr6q21

Hs.346203_at
hypothetical protein FLJ10159
FLJ10159
AnCg, Amy
0.022
1.135
0.016
1.206
0.002
1.324


Hs.348478
NM_021105
5359
chr3q23
604170
Hs.348478_at
phospholipid scramblase 1
PLSCR1
AnCg, Amy
0.044
0.841
0.011
0.781
0.001
0.625


Hs.374638
NM_000801
2280
chr20p13
186945
Hs.374638_at
FK506 binding protein 1A,
FKBP1A
AnCg, Amy
0.482
1.042
0.030
1.301
0.032
1.218








12 kDa


Hs.37706
NM_017612
55596
chr12q24.31

Hs.37706_at
hypothetical protein
DKFZp434E2220
AnCg, Amy
0.453
0.965
0.003
0.788
0.001
0.701








DKFZp434E2220


Hs.381008
NM_005516
3133
chr6p21.3
143010
Hs.381008_at
major histocompatibility
HLA-E
AnCg, Amy
0.219
0.843
0.005
0.806
0.000
0.725








complex, class I, E


Hs.381214
AL136871
84221
chr21q22.3

Hs.381214_at
chromosome 21 open reading
C21orf56
AnCg, Amy
0.217
1.383
0.048
1.440
0.011
1.382








frame 56


Hs.388014
NM_013352
29940
chr6q22
605942
Hs.388014_at
squamous cell carcinoma
SART2
AnCg, Amy
0.511
0.961
0.031
0.811
0.011
0.787








antigen recognized by T cells 2


Hs.408302
AL522296
92703
chr1q32.1

Hs.408302_at
chromosome 1 open reading
C1orf37
AnCg, Amy
0.461
1.122
0.036
1.410
0.035
1.495








frame 37


Hs.428112
BC038383
10522
chr11p15.5
602635
Hs.428112_at
deformed epidermal
DEAF1
AnCg, Amy
0.623
1.161
0.001
1.317
0.005
1.357








autoregulatory factor 1








(Drosophila)


Hs.428446
AB018195
770
chr19q13.3
604644
Hs.428446_at
carbonic anhydrase XI
CA11
AnCg, Amy
0.823
1.094
0.002
1.290
0.019
1.428


Hs.433303
NM_000873
3384
chr17q23-q25
146630
Hs.433303_at
Intercellular adhesion molecule 2
ICAM2
AnCg, Amy
0.259
0.958
0.030
0.812
0.024
0.816


Hs.436200
AI589086
7805
chr1p34
601476
Hs.436200_at
Lysosomal-associated
LAPTM5
AnCg, Amy
0.146
0.787
0.031
0.656
0.006
0.379








multispanning membrane








protein-5


Hs.445552
AI539370
221424
chr6p21.1

Hs.445552_at
chromosome 6 open reading
C6orf154
AnCg, Amy
0.294
1.291
0.030
1.377
0.033
1.621








frame 154


Hs.6434
NM_020215
56967
chr14q32.2

Hs.6434_at
chromosome 14 open reading
C14orf132
AnCg, Amy
0.935
1.022
0.015
1.219
0.003
1.370








frame 132


Hs.71791
NM_013313
29799
chr22q11.2
608082
Hs.71791_at
yippee-like 1 (Drosophila)
YPEL1
AnCg, Amy
0.020
1.139
0.006
1.266
0.017
1.468


Hs.74624
NM_002847
5799
chr7q36
601698
Hs.74624_at
protein tyrosine phosphatase,
PTPRN2
AnCg, Amy
0.164
1.184
0.011
1.269
0.036
1.262








receptor type, N polypeptide 2


Hs.75262
AV729484
1519
chr4q31-q32
600550
Hs.75262_at
cathepsin O
CTSO
AnCg, Amy
0.069
0.865
0.034
0.696
0.027
0.687


Hs.80658
U82819
7351
chr11q13
601693
Hs.80658_at
uncoupling protein 2
UCP2
AnCg, Amy
0.356
0.915
0.000
0.745
0.003
0.786








(mitochondrial, proton carrier)


Hs.94953
AI184968
714
chr1p36.11
120575
Hs.94953_at
complement component 1, q
C1QG
AnCg, Amy
0.199
0.869
0.026
0.558
0.003
0.339








subcomponent, gamma








polypeptide


Hs.9963
NM_003332
7305
chr19q13.1
604142
Hs.9963_at
TYRO protein tyrosine kinase
TYROBP
AnCg, Amy
0.784
1.027
0.033
0.796
0.031
0.563








binding protein


Hs.100914
NM_018069
55125
chr18p11.21

Hs.100914_at
hypothetical protein FLJ10352
FLJ10352
DLPFC
0.034
1.284
0.702
1.057
0.542
0.911


Hs.10119
AB051536
84952
chr15q21.3
607856
Hs.10119_at
hypothetical protein FLJ14957
FLJ14957
DLPFC
0.030
0.671
0.744
0.955
0.480
0.876


Hs.106552
AC005378
26047
chr7q35-q36
604569
Hs.106552_at
contactin associated protein-like 2
CNTNAP2
DLPFC
0.014
1.247
0.303
1.121
0.083
1.273


Hs.109760
NM_002491
4709
chr2q31.3
603839
Hs.109760_at
NADH dehydrogenase
NDUFB3
DLPFC
0.032
1.210
0.327
1.111
0.283
1.165








(ubiquinone) 1 beta








subcomplex, 3, 12 kDa


Hs.11614
BG054922
29070
chr16q21

Hs.11614_at
HSPC065 protein
HSPC065
DLPFC
0.036
1.216
0.061
1.158
0.594
1.078


Hs.117865
NM_012434
26503
chr6q14-q15
604322
Hs.117865_at
solute carrier family 17
SLC17A5
DLPFC
0.007
0.714
0.937
1.014
0.955
0.995








(anion/sugar transporter),








member 5


Hs.118684
NM_006923
6388
chr17q11.2
602934
Hs.118684_at
stromal cell-derived factor 2
SDF2
DLPFC
0.042
1.239
0.198
1.550
0.472
1.177


Hs.12313
BE856822
84892
chr3p22.1

Hs.12313_at
hypothetical protein FLJ14566
FLJ14566
DLPFC
0.045
1.214
0.165
1.140
0.149
1.156


Hs.12887
BC015207
57180
chr7q32-q36

Hs.12887_at
actin-related protein 3-beta
ARP3BETA
DLPFC
0.046
1.272
0.069
1.272
0.158
1.330


Hs.13423
AI634532
138046
chr8q21.2

Hs.13423_at
hypothetical protein LOC138046
LOC138046
DLPFC
0.032
1.291
0.249
1.104
0.058
1.372


Hs.134640
AI082251
3888
chr12q13
601078
Hs.134640_at
keratin, hair, basic, 2
KRTHB2
DLPFC
0.023
0.738
0.098
0.790
0.119
0.829


Hs.13885
BC003353
84246
chr5p15.31

Hs.13885_at
hypothetical protein MGC5309
MGC5309
DLPFC
0.017
1.259
0.162
1.198
0.782
1.045


Hs.139226
M87338
5982
chr7q11.23
600404
Hs.139226_at
replication factor C (activator 1)
RFC2
DLPFC
0.026
1.273
0.150
1.198
0.499
1.098








2, 40 kDa


Hs.151408
AL535113
5332
chr20p12
600810
Hs.151408_at
phospholipase C, beta 4
PLCB4
DLPFC
0.039
1.351
0.367
1.188
0.933
1.013


Hs.157236
BC001913
10493
chr17q21
604631
Hs.157236_at
vesicle amine transport protein
VAT1
DLPFC
0.033
0.823
0.379
0.924
0.224
0.857








1 homolog (T. californica)


Hs.158748
BF968270
148641
chr1q42.2

Hs.158748_at
solute carrier family 35, member
SLC35F3
DLPFC
0.032
1.303
0.779
1.036
0.130
1.386








F3


Hs.159161
D13989
396
chr17q25.3
601925
Hs.159161_at
Rho GDP dissociation inhibitor
ARHGDIA
DLPFC
0.003
1.243
0.069
1.132
0.424
1.092








(GDI) alpha


Hs.166351
NM_014906
22843
chr17q23.2

Hs.166351_at
protein phosphatase 1E (PP2C
PPM1E
DLPFC
0.016
1.273
0.396
1.118
0.549
1.118








domain containing)


Hs.170673
AI440266
195814
chr8q12.1

Hs.170673_at
retinal short chain
RDH-E2
DLPFC
0.025
1.291
0.183
1.249
0.582
1.126








dehydrogenase reductase


Hs.171835
NM_018180
55760
chr10q26.2
607960
Hs.171835_at
DEAD/H (Asp-Glu-Ala-Asp/His)
DDX32
DLPFC
0.000
0.752
0.157
0.929
0.669
1.036








box polypeptide 32


Hs.172589
BE796924
11137
chr12q23.3

Hs.172589_at
nuclear phosphoprotein similar
PWP1
DLPFC
0.013
1.275
0.562
1.058
0.343
1.089








to S. cerevisiae PWP1


Hs.182626
NM_012264
25829
chr22q12

Hs.182626_at
chromosome 22 open reading
C22orf5
DLPFC
0.029
1.212
0.940
1.007
0.257
1.121








frame 5


Hs.198288
NM_002849
5801
chr12q15
602853
Hs.198288_at
protein tyrosine phosphatase,
PTPRR
DLPFC
0.043
1.396
0.395
1.179
0.382
1.280








receptor type, R


Hs.200666
AL548363
9270
chr2p25.2
607153
Hs.200666_at
integrin beta 1 binding protein 1
ITGB1BP1
DLPFC
0.028
1.410
0.094
1.333
0.276
1.281


Hs.209983
NM_005563
3925
chr1p36.1-p35
151442
Hs.209983_at
stathmin 1/oncoprotein 18
STMN1
DLPFC
0.010
1.271
0.651
1.038
0.344
1.200


Hs.21577
NM_005701
10073
chr15q23
607902
Hs.21577_at
RNA, U transporter 1
RNUT1
DLPFC
0.023
1.205
0.120
1.213
0.185
1.232


Hs.21943
NM_021824
60491
chr2q33
605778
Hs.21943_at
NIF3 NGG1 interacting factor 3-
NIF3L1
DLPFC
0.011
1.564
0.876
1.014
0.853
1.024








like 1 (S. pombe)


Hs.223296
NM_017861
54965
chr3q29

Hs.223296_at
hypothetical protein FLJ20522
FLJ20522
DLPFC
0.003
1.231
0.375
1.085
0.261
1.154


Hs.22791
AB017269
23671
chr2q32.3
605734
Hs.22791_at
transmembrane protein with
TMEFF2
DLPFC
0.032
1.394
0.894
1.017
0.874
0.967








EGF-like and two follistatin-like








domains 2


Hs.2281
NM_001819
1114
chr20pter-p12
118920
Hs.2281_at
chromogranin B (secretogranin
CHGB
DLPFC
0.046
1.389
0.350
1.172
0.520
1.195








1)


Hs.237517
AV703769
25791
chr2q37
605991
Hs.237517_at
neuronal guanine nucleotide
NGEF
DLPFC
0.007
1.361
0.107
1.086
0.115
1.224








exchange factor


Hs.239758
NM_023928
65985
chr12q24.31

Hs.239758_at
acetoacetyl-CoA synthetase
AACS
DLPFC
0.034
1.207
0.511
1.064
0.146
1.295


Hs.241523
NM_018008
55079
chr3p14.2
607414
Hs.241523_at
likely ortholog of mouse and
FEZL
DLPFC
0.004
1.238
0.680
1.049
0.164
1.291








zebrafish forebrain embryonic








zinc finger-like


Hs.24970
AV724323
116442
chrxq28

Hs.24970_at
RAB39B, member RAS
RAB39B
DLPFC
0.026
1.287
0.239
1.140
0.381
1.144








oncogene family


Hs.24979
NM_018423
55359
chr12p13.2

Hs.24979_at
hypothetical protein
DKFZp761P1010
DLPFC
0.028
1.284
0.184
1.313
0.194
1.322








DKFZp761P1010


Hs.255149
NM_005907
4121
chr6q22
604344
Hs.255149_at
mannosidase, alpha, class 1A,
MAN1A1
DLPFC
0.032
1.203
0.434
1.099
0.813
1.042








member 1


Hs.27160
R75637
113444
chr1p34.3

Hs.27160_at
hypothetical protein BC011880
LOC113444
DLPFC
0.020
1.261
0.384
1.105
0.399
1.140


Hs.27524
BF673779
132332
chr4q27

Hs.27524−_at
hypothetical protein FLJ30834
FLJ30834
DLPFC
0.040
1.274
0.935
1.011
0.555
1.314


Hs.279939
AF189289
23787
chr6pter-p24.1

Hs.279939_at
mitochondrial carrier homolog 1
MTCH1
DLPFC
0.037
1.303
0.054
1.137
0.269
1.158








(C. elegans)


Hs.283393
AL575735
1290
chr2q14-q32
120190
Hs.283393_at
collagen, type V, alpha 2
COL5A2
DLPFC
0.018
1.255
0.677
1.039
0.814
1.014


Hs.285280
AA534210
122830
chr14q22.3

Hs.285280+_at
chromosome 14 open reading
C14orf35
DLPFC
0.021
1.239
0.258
1.136
0.076
1.272








frame 35


Hs.286173
AB046815
57696
chr12q24.31

Hs.286173_at
DEAD (Asp-Glu-Ala-Asp) box
DDX55
DLPFC
0.005
1.258
0.360
1.057
0.888
0.988








polypeptide 55


Hs.291070
NM_138687
8396
chr17q12
603261
Hs.291070_at
phosphatidylinositol-4-
PIP5K2B
DLPFC
0.013
1.254
0.118
1.207
0.092
1.169








phosphate 5-kinase, type II,








beta


Hs.29222
NM_003427
7629
chr6p21.3-p21.2
194549
Hs.29222_at
zinc finger protein 76
ZNF76
DLPFC
0.034
1.216
0.507
1.080
0.967
1.003








(expressed in testis)


Hs.29344
AF070530
148022
chr19p13.3
607601
Hs.29344_at
TIR domain containing adaptor
TRIF
DLPFC
0.023
1.297
0.324
1.132
0.394
1.095








inducing interferon-beta


Hs.300670
AB033030
57514
chr3q13.32-q13.33

Hs.300670_at
KIAA1204 protein
CDGAP
DLPFC
0.042
0.808
0.556
0.952
0.653
0.945


Hs.302460
NM_021930
60561
chr7q22.3

Hs.302460_at
Rad50-interacting protein 1
FLJ11785
DLPFC
0.017
1.303
0.881
0.988
0.676
0.937


Hs.30991
BE677131
22881
chr6q14.2-q16.1

Hs.30991_at
ankyrin repeat domain 6
ANKRD6
DLPFC
0.041
1.257
0.058
1.328
0.282
1.174


Hs.317335
NM_006012
8192
chr19p13.3
601119
Hs.317335_at
ClpP caseinolytic protease,
CLPP
DLPFC
0.047
1.294
0.106
1.144
0.462
1.101








ATP-dependent, proteolytic








subunit homolog (E. coli)


Hs.321501
NM_025238
53339
chr15q24
608530
Hs.321501_at
BTB (POZ) domain containing 1
BTBD1
DLPFC
0.018
1.331
0.179
1.130
0.436
1.101


Hs.323537
AK023015
84058
chr2p13.1

Hs.323537_at
hypothetical protein FLJ12953
FLJ12953
DLPFC
0.046
1.220
0.588
1.070
0.592
1.119








similar to Mus musculus








D3Mm3e


Hs.32539
AB040812
57144
chr20p12
608038
Hs.32539_at
p21(CDKN1A)-activated kinase 7
PAK7
DLPFC
0.009
1.223
0.679
1.039
0.069
1.348


Hs.333118
AL136879
84222
chr22q11.21

Hs.333118_at
hypothetical protein
DKFZp434N035
DLPFC
0.038
1.698
0.502
1.214
0.254
1.331








DKFZp434N035


Hs.335433
AF397394
118427
chr1p22
607567
Hs.335433_at
olfactomedin 3
OLFM3
DLPFC
0.022
1.340
0.760
1.031
0.108
1.369


Hs.348446
W37431
5601
chr5q35
602896
Hs.348446_at
mitogen-activated protein
MAPK9
DLPFC
0.047
1.280
0.196
1.108
0.320
1.222








kinase 9


Hs.349111
AL022237
27349
chr22q13.31

Hs.349111_at
malonyl-CoA: acyl carrier protein
MT
DLPFC
0.041
1.375
0.309
1.205
0.157
1.303








transacylase








(malonyltransferase)


Hs.349695




Hs.349695_at
tubulin, alpha 2
TUBA2
DLPFC
0.009
1.346
0.086
1.136
0.245
1.146


Hs.350065




Hs.350065_at
hypothetical protein FLJ30634
FLJ30634
DLPFC
0.031
0.801
0.516
0.933
0.229
1.180


Hs.355141
NM_006058
10318
chr5q32-q33.1
607714
Hs.355141_at
TNFAIP3 interacting protein 1
TNIP1
DLPFC
0.043
1.358
0.832
1.012
0.281
1.055


Hs.355281
NM_003586
8448
chr16p11.2
604567
Hs.355281_at
double C2-like domains, alpha
DOC2A
DLPFC
0.015
1.400
0.493
1.102
0.090
1.515


Hs.356358
BC014311
115548
chr5q13.2

Hs.356358_at
hypothetical protein BC014311
LOC115548
DLPFC
0.007
0.833
0.995
1.000
0.076
0.832


Hs.362806
BF941499
221395
chr6p12.3

Hs.362806_at
G protein-coupled receptor 116
GPR116
DLPFC
0.039
0.792
0.061
0.883
0.308
0.887


Hs.36761
NM_020386
57110
chr3q29
606487
Hs.36761_at
HRAS-like suppressor
HRASLS
DLPFC
0.031
1.241
0.227
1.185
0.268
1.169


Hs.380887
NM_018141
55173
chr6p21.1-p12.1

Hs.380887_at
mitochondrial ribosomal protein
MRPS10
DLPFC
0.033
1.243
0.545
1.081
0.278
1.133








S10


Hs.386392
BC000009
55651
chr5q35.3
606470
Hs.386392_at
nucleolar protein family A,
NOLA2
DLPFC
0.014
1.291
0.134
1.220
0.218
1.230








member 2 (H/ACA small








nucleolar RNPs)


Hs.40510
NM_004277
9481
chr6p11.2-q12

Hs.40510_at
solute carrier family 25, member
SLC25A27
DLPFC
0.005
1.408
0.148
1.191
0.192
1.269








27


Hs.4082
AI659005
3964
chr1q42-q43
606099
Hs.4082+_at
lectin, galactoside-binding,
LGALS8
DLPFC
0.032
1.201
0.990
0.999
0.776
1.038








soluble, 8 (galectin 8)


Hs.410618
BC034626
9675
chr20q12

Hs.410618_at
KIAA0406 gene product
KIAA0406
DLPFC
0.030
1.221
0.551
1.055
0.618
1.058


Hs.410745
AB014486
8935
chr7p21-p15
605215
Hs.410745_at
src family associated
SCAP2
DLPFC
0.036
1.288
0.343
1.100
0.723
1.060








phosphoprotein 2


Hs.410748
NM_022003
53826
chr11q23.3
606683
Hs.410748_at
FXYD domain containing ion
FXYD6
DLPFC
0.016
1.349
0.119
1.188
0.387
1.157








transport regulator 6


Hs.416061
BQ894022
5136
chr2q32.1
171890
Hs.416061_at
phosphodiesterase 1A,
PDE1A
DLPFC
0.038
1.598
0.274
1.253
0.324
1.405








calmodulin-dependent


Hs.416216
NM_007240
11266
chr1q21-q22
604835
Hs.416216_at
dual specificity phosphatase 12
DUSP12
DLPFC
0.025
1.284
0.303
1.138
0.843
0.966


Hs.419151
NM_017917
55012
chr14q13.2

Hs.419151_at
chromosome 14 open reading
C14orf10
DLPFC
0.046
1.338
0.098
1.401
0.347
1.180








frame 10


Hs.419240
AI631159
6515
chr12p13.3
138170
Hs.419240_at
solute carrier family 2 (facilitated
SLC2A3
DLPFC
0.009
1.352
0.505
1.066
0.820
1.048








glucose transporter), member 3


Hs.421202
AF327657
20
chr9q34
600047
Hs.421202_at
ATP-binding cassette, sub-
ABCA2
DLPFC
0.048
1.229
0.720
1.065
0.215
0.771








family A (ABC1), member 2


Hs.422662
NM_003384
7443
chr14q32
602168
Hs.422662_at
vaccinia related kinase 1
VRK1
DLPFC
0.019
1.466
0.867
1.013
0.446
1.153


Hs.422688
AI733027
116362
chr1p36.22
608604
Hs.422688_at
retinoid binding protein 7
CRBPIV
DLPFC
0.045
1.241
0.916
1.036
0.122
0.639


Hs.423348
NM_000244
4221
chr11q13
131100
Hs.423348_at
multiple endocrine neoplasia I
MEN1
DLPFC
0.008
0.795
0.925
1.006
0.545
1.072


Hs.424551
BC000027
23423
chr15q24-q25

Hs.424551_at
integral type I protein
P24B
DLPFC
0.050
1.262
0.203
1.146
0.404
1.109


Hs.426324
AU158251
7991
chr8p22
601385
Hs.426324_at
Putative prostate cancer tumor
N33
DLPFC
0.008
1.320
0.162
1.169
0.530
1.084








suppressor


Hs.43112
NM_173517
154807
chr7q11.21
608838
Hs.43112_at
hypothetical protein LOC154807
LOC154807
DLPFC
0.044
1.254
0.020
1.118
0.145
1.124


Hs.433326
NM_000597
3485
chr2q33-q34
146731
Hs.433326_at
insulin-like growth factor binding
IGFBP2
DLPFC
0.044
1.451
0.867
0.968
0.359
1.147








protein 2, 36 kDa


Hs.435342
NM_006425
10569
chr5q33.3
605974
Hs.435342_at
step II splicing factor SLU7
SLU7
DLPFC
0.034
1.223
0.294
1.097
0.316
1.113


Hs.440950
AK021433
25844
chr6p21.1

Hs.440950_at
chromosome 6 open reading
C6orf109
DLPFC
0.006
1.235
0.046
1.124
0.417
1.107








frame 109


Hs.443683
NM_003970
9172
chr8p23.3
603509
Hs.443683_at
myomesin (M-protein) 2,
MYOM2
DLPFC
0.020
0.742
0.487
0.914
0.539
1.078








165 kDa


Hs.444846
AU147317
55831
chr3p25.3

Hs.444846_at
30 kDa protein
LOC55831
DLPFC
0.021
1.284
0.233
1.114
0.242
1.140


Hs.445132
NM_145257
126731
chr1q42.13

Hs.445132_at
LOC126731
LOC126731
DLPFC
0.007
1.229
0.028
1.099
0.185
1.065


Hs.458268




Hs.458268_at
potassium inwardly-rectifying
KCNJ6
DLPFC
0.043
1.241
0.105
1.190
0.098
1.217








channel, subfamily J, member 6


Hs.4742
NM_003801
8733
chr8q24.3
603048
Hs.4742_at
GPAA1P anchor attachment
GPAA1
DLPFC
0.009
1.454
0.107
1.222
0.262
1.222








protein 1 homolog (yeast)


Hs.4817
NM_002545
4978
chr11q25
600632
Hs.4817_at
oploid binding protein/cell
OPCML
DLPFC
0.013
1.293
0.493
1.052
0.155
1.253








adhesion molecule-like


Hs.500495
W68731
374819
chr17q24.2

Hs.500495_at
FLJ34306 protein
FLJ34306
DLPFC
0.038
1.610
0.234
1.149
0.614
1.121


Hs.5019
BC004344
91782
chr8p21.3

Hs.5019_at
hypothetical protein MGC29816
MGC29816
DLPFC
0.045
1.271
0.299
1.053
0.819
1.015


Hs.511768
NM_007234
11258
chr9p13
607387
Hs.511768_at
dynactin 3 (p22)
DCTN3
DLPFC
0.034
1.277
0.180
1.158
0.332
1.175


Hs.511974
CA411757
255403
chr4p16.3

Hs.511974_at
hypothetical protein FLJ90036
FLJ90036
DLPFC
0.035
0.789
0.382
0.927
0.186
0.882


Hs.512644
AF249278
56479
chr6q14
607357
Hs.512644_at
potassium voltage-gated
KCNQ5
DLPFC
0.041
1.560
0.300
1.266
0.219
1.042








channel, KQT-like subfamily,








member 5


Hs.54886
AL117515
23228
chr3p24.3

Hs.54886_at
phospholipase C-like 2
PLCL2
DLPFC
0.019
1.228
0.103
1.119
0.245
1.122


Hs.7117
AL567302
2890
chr5q31.1
138248
Hs.7117_at
glutamate receptor, ionotropic,
GRIA1
DLPFC
0.043
1.328
0.266
1.112
0.673
1.062








AMPA 1


Hs.76206
NM_001795
1003
chr16q22.1
601120
Hs.76206_at
cadherin 5, type 2, VE-cadherin
CDH5
DLPFC
0.042
0.779
0.229
0.874
0.054
0.777








(vascular epithelium)


Hs.77917
NM_006002
7347
chr13q22.2
603090
Hs.77917_at
ubiquitin carboxyl-terminal
UCHL3
DLPFC
0.003
1.408
0.634
1.047
0.472
0.887








esterase L3 (ubiquitin








thiolesterase)


Hs.80296
NM_006198
5121
chr21q22.2
601629
Hs.80296_at
Purkinje cell protein 4
PCP4
DLPFC
0.028
1.397
0.129
1.196
0.909
0.970


Hs.8040
AF105378
9951
chr16p11.2
604059
Hs.8040_at
heparan sulfate (glucosamine)
HS3ST4
DLPFC
0.048
1.269
0.072
1.221
0.200
1.512








3-O-sulfotransferase 4


Hs.83753
J04564
6628
chr20p13
182282
Hs.83753_at
small nuclear ribonucleoprotein
SNRPB
DLPFC
0.043
1.258
0.173
1.192
0.251
1.255








polypeptides B and B1


Hs.84120
BC006123
84303
chr3q21.2

Hs.84120_at
hypothetical protein MGC13016
MGC13016
DLPFC
0.010
1.234
0.135
1.239
0.092
1.441


Hs.85539
NM_007100
521
chr4p16.3
601519
Hs.85539_at
ATP synthase, H+ transporting,
ATP5I
DLPFC
0.004
1.209
0.184
1.132
0.869
0.984








mitochondrial F0 complex,








subunit e


Hs.9003
NM_022744
64755
chr16p11.2

Hs.9003_at
hypothetical protein FLJ13868
FLJ13868
DLPFC
0.020
1.218
0.211
1.185
0.607
1.025


Hs.91390
NM_003631
8505
chr10q11.23
603501
Hs.91390_at
poly (ADP-ribose)
PARG
DLPFC
0.040
1.257
0.325
1.127
0.887
1.022








glycohydrolase


Hs.93872
NM_019061
54545
chr5p13.3
606501
Hs.93872_at
phosphatidylinositol-3-
PIP3AP
DLPFC
0.012
1.240
0.017
1.131
0.286
1.085








phosphate associated protein


Hs.98493
NM_006297
7515
chr19q13.2
194360
Hs.98493_at
X-ray repair complementing
XRCC1
DLPFC
0.033
1.355
0.393
1.117
0.903
0.989








defective repair in Chinese








hamster cells 1


Hs.102456
NM_003616
8487
chr14q13
602595
Hs.102456_at
survival of motor neuron protein
SIP1
AnCg
0.042
1.193
0.003
1.246
0.998
1.000








interacting protein 1


Hs.104576
NM_003654
8534
chr11p11.2-p11.1
603797
Hs.104576_at
carbohydrate (keratan sulfate
CHST1
AnCg
0.313
1.345
0.011
1.259
0.257
1.215








Gal-6) sulfotransferase 1


Hs.110488
NM_014918
22856
chr15q26.3
608183
Hs.110488_at
carbohydrate (chondroitin)
CHSY1
AnCg
0.848
0.975
0.017
0.723
0.224
0.839








synthase 1


Hs.115721
NM_013247
27429
chr2p12
606441
Hs.115721_at
protease, serine, 25
PRSS25
AnCg
0.785
1.014
0.013
1.206
0.284
1.097


Hs.1176
NM_005070
6508
chr2q36
106195
Hs.1176_at
solute carrier family 4, anion
SLC4A3
AnCg
0.949
1.008
0.022
1.227
0.282
1.168








exchanger, member 3


Hs.119302
AF329838
114900
chr11q11

Hs.119302_at
C1q and tumor necrosis factor
C1QTNF4
AnCg
0.425
1.158
0.042
1.313
0.092
1.258








related protein 4


Hs.119598
NM_000967
6122
chr22q13
604163
Hs.119598_at
ribosomal protein L3
RPL3
AnCg
0.626
1.321
0.008
1.261
0.863
1.015


Hs.12751
R46128
2849
chr10q26.2
604847
Hs.12751_at
G protein-coupled receptor 26
GPR26
AnCg
0.900
1.020
0.025
1.286
0.191
1.155


Hs.130979
NM_173528
161502
chr15q25.1

Hs.130979_at
hypothetical protein FLJ38615
FLJ38615
AnCg
0.174
0.864
0.043
1.201
0.188
0.915


Hs.13308
AI744123
134548
chr5q23.3

Hs.13308_at
hypothetical protein LOC134548
LOC134548
AnCg
0.169
1.158
0.016
1.410
0.058
1.255


Hs.140720
AB045118
23401
chr10q24.1
605006
Hs.140720_at
frequently rearranged in
FRAT2
AnCg
0.174
1.077
0.027
1.282
0.864
1.020








advanced T-cell lymphomas 2


Hs.14511
AF183424
6341
chr17p12-p13
603644
Hs.14511_at
SCO cytochrome oxidase
SCO1
AnCg
0.324
1.019
0.033
1.411
0.453
1.110








deficient homolog 1 (yeast)


Hs.145156
NM_024046
79012
chr3p21.31

Hs.145156_at
hypothetical protein MGC8407
MGC8407
AnCg
0.100
1.219
0.029
1.306
0.090
1.322


Hs.158798
H17349
254778
chr8q13.1

Hs.158798_at
hypothetical protein MGC33510
MGC33510
AnCg
0.054
1.588
0.036
1.378
0.524
1.138


Hs.1608
BC005264
6119
chr7p22
179837
Hs.1608_at
replication protein A3, 14 kDa
RPA3
AnCg
0.067
1.248
0.025
1.311
0.564
1.153


Hs.173902
NM_014225
5518
chr19q13.41
605983
Hs.173902_at
protein phosphatase 2 (formerly
PPP2R1A
AnCg
0.680
1.168
0.036
1.230
0.131
1.214








2A), regulatory subunit A (PR








65), alpha isoform


Hs.179770
NM_002842
5794
chr19q13.4
602510
Hs.179770_at
protein tyrosine phosphatase,
PTPRH
AnCg
0.560
1.056
0.041
1.229
0.836
0.984








receptor type, H


Hs.183646
NM_016011
51102
chr1pter-p22.3
608205
Hs.183646_at
nuclear receptor binding factor 1
CGI-63
AnCg
0.638
1.087
0.033
1.208
0.121
1.459


Hs.185202
BC035082
286032
chr8p22

Hs.185202_at
hypothetical protein FLJ36980
FLJ36980
AnCg
0.881
1.002
0.011
1.224
0.617
1.010


Hs.190559
AI828026
255426
chr5q35.3

Hs.190559_at
hypothetical protein LOC255426
LOC255426
AnCg
0.525
0.981
0.000
1.282
0.005
1.124


Hs.192822
N32557
81706
chr6q24.3-q25.3

Hs.192822_at
protein phosphatase 1,
PPP1R14C
AnCg
0.159
1.105
0.035
1.357
0.219
1.366








regulatory (inhibitor) subunit








14C


Hs.194673
BC002426
8682
chr1q21.1
603434
Hs.194673_at
phosphoprotein enriched in
PEA15
AnCg
0.607
1.150
0.006
1.228
0.044
1.173








astrocytes 15


Hs.197922
NM_018584
55450
chr1p36.12

Hs.197922_at
calcium/calmodulin-dependent
CaMKIINalpha
AnCg
0.430
1.278
0.013
1.356
0.071
1.372








protein kinase II


Hs.198998
AF080157
1147
chr10q24-q25
600664
Hs.198998_at
conserved helix-loop-helix
CHUK
AnCg
0.998
0.999
0.020
0.798
0.022
0.852








ubiquitous kinase


Hs.201058
NM_030795
81551
chr8p21.2

Hs.201058_at
stathmin-like 4
STMN4
AnCg
0.102
1.105
0.037
1.230
0.635
1.107


Hs.20191
U76248
6478
chr3q25
602213
Hs.20191_at
seven in absentia homolog 2
SIAH2
AnCg
0.658
1.064
0.030
1.482
0.307
1.140








(Drosophila)


Hs.21415




Hs.21415_at
hypothetical protein MGC39820
MGC39820
AnCg
0.076
1.282
0.034
1.226
0.099
1.336


Hs.22181
AL031658
81572
chr20q11.21

Hs.22181_at
chromosome 20 open reading
C20orf126
AnCg
0.603
0.967
0.007
1.256
0.322
1.160








frame 126


Hs.235195
NM_018019
55090
chr17p11.2

Hs.235195_at
hypothetical protein FLJ10193
FLJ10193
AnCg
0.716
0.974
0.030
1.262
0.345
1.130


Hs.23735
AF029780
3754
chr2p25
603787
Hs.23735_at
potassium voltage-gated
KCNF1
AnCg
0.081
1.170
0.024
1.222
0.025
1.187








channel, subfamily F, member 1


Hs.241564
AB014559
747
chr11q12.2

Hs.241564_at
chromosome 11 open reading
C11orf11
AnCg
0.844
1.004
0.015
1.263
0.071
1.170








frame 11


Hs.24969
NM_000810
2558
chr15q11.2-q12
137142
Hs.24969_at
gamma-aminobutyric acid
GABRA5
AnCg
0.381
1.686
0.027
1.475
0.306
1.524








(GABA) A receptor, alpha 5


Hs.250692
AI810712
3131
chr17q22
142385
Hs.250692_at
hepatic leukemia factor
HLF
AnCg
0.070
1.334
0.049
1.221
0.086
1.366


Hs.254406
NM_013375
29777
chr6p22.1

Hs.254406_at
activator of basal transcription 1
ABT1
AnCg
0.669
0.990
0.014
1.440
0.591
1.053


Hs.254414
NM_080743
135295
chr6q15

Hs.254414_at
serine-arginine repressor
SRrp35
AnCg
0.660
0.988
0.050
1.211
0.329
1.065








protein (35 kDa)


Hs.2624
X58987
1812
chr5q35.1
126449
Hs.2624_at
dopamine receptor D1
DRD1
AnCg
0.163
1.093
0.044
1.227
0.538
1.060


Hs.271272
BF510581
121551
chr12q23.3

Hs.271272_at
BTB (POZ) domain containing
BTBD11
AnCg
0.798
0.984
0.020
1.241
0.118
1.283








11


Hs.273307
BG398597
6730
chr17q25.1
604858
Hs.273307_at
signal recognition particle
SRP68
AnCg
0.877
1.032
0.041
1.204
0.168
1.153








68 kDa


Hs.277517
NM_013265
738
chr11q13

Hs.277517_at
chromosome 11 open reading
C11orf2
AnCg
0.229
1.181
0.040
1.217
0.124
1.232








frame2


Hs.288520
AK024467
90011
chr19q13.42

Hs.288520_at
hypothetical gene FLJ00060
FLJ00060
AnCg
0.665
0.894
0.017
0.547
0.444
0.898


Hs.288932
NM_025146
80218
chr3q13.2

Hs.288932_at
likely ortholog of mouse Mak3p
MAK3P
AnCg
0.244
1.251
0.024
1.210
0.548
1.074








homolog (S. cerevisiae)


Hs.2890
NM_002739
5582
chr19q13.4
176980
Hs.2890_at
protein kinase C, gamma
PRKCG
AnCg
0.168
1.179
0.043
1.214
0.102
1.292


Hs.28980
AI674647
84888
chr15q21.2
608238
Hs.28980_at
putative intramembrane
SPPL2A
AnCg
0.695
1.048
0.018
0.774
0.128
0.726








cleaving protease


Hs.293336
NM_018264
55253
chr7q11.21

Hs.293336_at
hypothetical protein FLJ10900
FLJ10900
AnCg
0.206
0.834
0.026
0.749
0.813
0.977


Hs.293660
AW249467
91107
chr17q24-q25

Hs.293660_at
tripartite motif-containing 47
TRIM47
AnCg
0.196
0.917
0.037
0.828
0.064
0.809


Hs.295137
NM_001144
267
chr16q21
603243
Hs.295137_at
autocrine motility factor receptor
AMFR
AnCg
0.806
0.958
0.023
0.482
0.095
0.562


Hs.298351
NM_024083
79058
chr17q25
606236
Hs.298351_at
alveolar soft part sarcoma
ASPSCR1
AnCg
0.215
0.982
0.014
1.323
0.470
0.955








chromosome region, candidate 1


Hs.300906
BC010136
55197
chr18q12.2

Hs.300906_at
hypothetical protein FLJ10656
P15RS
AnCg
0.399
1.242
0.015
1.245
0.306
1.148


Hs.312129
NM_015925
51599
chr19q13.12

Hs.312129_at
liver-specific bHLH-Zip
LISCH7
AnCg
0.765
1.018
0.027
0.800
0.397
0.893








transcription factor


Hs.325321
BC001648
57418
chr19p13.3

Hs.325321_at
WD repeat domain 18
WDR18
AnCg
0.717
0.996
0.016
1.278
0.685
1.037


Hs.348380
NM_005748
10138
chr12q12
607534
Hs.348380_at
YY1 associated factor 2
YAF2
AnCg
0.035
1.093
0.029
1.256
0.226
1.158


Hs.350194
AA205643
153527
chr5q31.3

Hs.350194_at
hypothetical protein FLJ31121
FLJ31121
AnCg
0.172
1.258
0.044
1.346
0.111
1.349


Hs.365690
NM_021161
54207
chr14q31
605873
Hs.365690_at
potassium channel, subfamily K,
KCNK10
AnCg
0.786
1.005
0.044
0.733
0.005
0.852








member 10


Hs.367669
BG285881
166336
chr3p14.1
608501
Hs.367669_at
prickle-like 2 (Drosophila)
PRICKLE2
AnCg
0.095
1.192
0.023
1.259
0.075
1.297


Hs.368866
BC017771
60492
chr11q14.1

Hs.368866_at
hypothetical protein MDS025
MDS025
AnCg
0.324
0.926
0.014
0.808
0.064
0.803


Hs.369579
BC015963
830
chr7q31.2-q31.3
601571
Hs.369579_at
capping protein (actin filament)
CAPZA2
AnCg
0.059
1.237
0.029
1.227
0.943
1.010








muscle Z-line, alpha 2


Hs.374285
AA307731
339344
chr19q13.32

Hs.374285_at
hypothetical protein LOC339344
LOC339344
AnCg
0.190
0.951
0.011
1.222
0.901
1.013


Hs.375641
NM_019042
54517
chr7q22.3

Hs.375641_at
hypothetical protein FLJ20485
FLJ20485
AnCg
0.525
1.142
0.036
0.779
0.925
0.973


Hs.379010
AK092432
8000
chr8q24.2
602470
Hs.379010+_at
prostate stem cell antigen
PSCA
AnCg
0.864
1.021
0.018
1.314
0.874
0.981


Hs.381050
NM_018644
27087
chr11q25
606375
Hs.381050_at
beta-1,3-glucuronyltransferase
B3GAT1
AnCg
0.355
1.209
0.031
1.243
0.053
1.200








1 (glucuronosyltransferase P)


Hs.381264
U37028
3681
chr16p11.2
602453
Hs.381264_at
integrin, alpha D
ITGAD
AnCg
0.648
0.968
0.009
0.829
0.903
0.992


Hs.388645
BF203664
84987
chr12q13.12

Hs.388645_at
hypothetical protein MGC14288
MGC14288
AnCg
0.270
1.126
0.045
1.224
0.203
1.226


Hs.38961
AL121756
149954
chr20q11.21

Hs.38961_at
chromosome 20 open reading
C20orf186
AnCg
0.206
0.923
0.024
0.762
0.902
1.011








frame 186


Hs.410953
AK094809
5924
chr5q13
606614
Hs.410953_at
Ras protein-specific guanine
RASGRF2
AnCg
0.085
1.199
0.026
1.377
0.114
1.372








nucleotide-releasing factor 2


Hs.411358
NM_012286
9643
chrxq22
300409
Hs.411358_at
mortality factor 4 like 2
MORF4L2
AnCg
0.727
1.033
0.008
0.733
0.091
0.745


Hs.412587
NM_002876
5889
chr17q22-q23
602774
Hs.412587_at
RAD51 homolog C (S. cerevisiae)
RAD51C
AnCg
0.124
1.158
0.037
1.252
0.150
1.226


Hs.418367
NM_006681
10874
chr4q12
605103
Hs.418367_at
neuromedin U
NMU
AnCg
0.143
1.086
0.024
1.213
0.134
1.225


Hs.422986
BC000182
307
chr2p13
106491
Hs.422986_at
annexin A4
ANXA4
AnCg
0.953
1.005
0.024
0.791
0.480
0.887


Hs.426142
NM_002643
5281
chr2p21-p16
600153
Hs.426142_at
phosphatidylinositol glycan,
PIGF
AnCg
0.321
1.182
0.029
1.353
0.910
0.985








class F


Hs.429904
BC000975
283755
chr15q11.2

Hs.429904_at
hypothetical protein LOC283755
LOC283755
AnCg
0.062
0.709
0.049
0.792
0.114
0.730


Hs.434124
AK057562
149086
chr1p35.2

Hs.434124+_at
hypothetical protein LOC149086
LOC149086
AnCg
0.195
0.795
0.042
0.640
0.562
1.079


Hs.435051
U20498
1032
chr19p13
600927
Hs.435051_at
cyclin-dependent kinase
CDKN2D
AnCg
0.147
1.261
0.027
1.234
0.173
1.206








inhibitor 2D (p19, inhibits CDK4)


Hs.437186
NM_016310
51728
chr16p13.3
606007
Hs.437186_at
polymerase (RNA) III (DNA
POLR3K
AnCg
0.187
1.305
0.043
1.241
0.397
1.135








directed) polypeptide K, 12.3 kDa


Hs.438830
NM_013238
29103
chr13q14.1

Hs.438830_at
DnaJ (Hsp40) homolog,
DNAJD1
AnCg
0.598
1.087
0.028
1.375
0.154
1.285








subfamily D, member 1


Hs.439909
NM_020689
57419
chr20p13

Hs.439909_at
solute carrier family 24
SLC24A3
AnCg
0.260
1.086
0.031
1.214
0.881
0.974








(sodium/potassium/calcium








exchanger), member 3


Hs.440310
AF151034
51239
chr2q11.2

Hs.440310_at
hypothetical protein MGC41816
MGC41816
AnCg
0.067
1.116
0.009
1.288
0.788
1.045


Hs.444749
NM_001001
6166
chr14q21
180469
Hs.444749_at
ribosomal protein L36a-like
RPL36AL
AnCg
0.230
1.274
0.040
1.222
0.748
0.959


Hs.447902
AF094508
1834
chr4q21.3
125485
Hs.447902_at
dentin sialophosphoprotein
DSPP
AnCg
0.779
0.968
0.021
1.234
0.344
0.900


Hs.448353
R24798
58512
chr1p35.3-p34.1

Hs.448353_at
SAP90/PSD-95-associated
SAPAP3
AnCg
0.112
1.045
0.003
1.318
0.062
1.407








protein 3


Hs.451604
NM_003803
8736
chr18p11.32-p11.31
603508
Hs.451604_at
myomesin 1 (skelemin) 185 kDa
MYOM1
AnCg
0.488
0.912
0.014
0.762
0.346
0.927


Hs.458308




Hs.458308_at
chromosome 21 open reading
C21orf55
AnCg
0.440
1.064
0.043
0.794
0.888
0.986








frame 55


Hs.467587




Hs.467587_at
hypothetical protein AE2
AE2
AnCg
0.994
0.999
0.007
1.433
0.664
1.036


Hs.46794
AA872588
148979
chr1p32.3

Hs.46794_at
likely ortholog of mouse Gli-
FLJ36155
AnCg
0.244
0.930
0.019
0.787
0.260
1.105








similar 1 Kruppel-like zinc finger








(Glis1)


Hs.473788
AL523776
55611
chr11q13.1
608337
Hs.473788_at
OTU domain, ubiquitin aldehyde
OTUB1
AnCg
0.073
1.255
0.043
1.207
0.111
1.291








binding 1


Hs.49230
R38624
140767
chr6p22.2

Hs.49230_at
vesicular membrane protein p24
VMP
AnCg
0.460
1.192
0.018
1.234
0.051
1.479


Hs.4992
NM_003310
7260
chr2p25.2

Hs.4992_at
tumor suppressing
TSSC1
AnCg
0.307
1.073
0.005
1.303
0.388
1.189








subtransferable candidate 1


Hs.500165
AL528911
84313
chr17q21.2

Hs.500165_at
hypothetical protein MGC10540
MGC10540
AnCg
0.351
1.063
0.041
1.214
0.468
1.088


Hs.50282
NM_016656
10325
chrxp11.22

Hs.50282_at
Ras-related GTP binding B
RRAGB
AnCg
0.664
1.004
0.042
1.217
0.330
1.120


Hs.511807




Hs.511807_at
hypothetical protein FLJ90005
FLJ90005
AnCg
0.624
1.017
0.036
1.293
0.233
1.136


Hs.511950
AF083108
23410
chr11p15.5
604481
Hs.511950_at
sirtuin (silent mating type
SIRT3
AnCg
0.786
1.021
0.028
1.224
0.079
1.185








information regulation 2








homolog) 3 (S. cerevisiae)


Hs.512579




Hs.512579_at
keratin, hair, acidic, 3A
KRTHA3A
AnCg
0.036
1.108
0.010
1.291
0.483
1.032


Hs.512607
NM_016641
51573
chr16p12-p11.2
605943
Hs.512607_at
membrane interacting protein of
MIR16
AnCg
0.464
1.197
0.028
1.241
0.537
1.074








RGS16


Hs.512743
NM_024920
79982
chr4q23

Hs.512743_at
hypothetical protein FLJ14281
FLJ14281
AnCg
0.613
1.147
0.032
0.822
0.791
1.022


Hs.515246




Hs.515246_at
UDP-GlcNAc:betaGal beta-1,3-
B3GNT3
AnCg
0.463
0.910
0.023
0.744
0.229
1.154








N-








acetylglucosaminyltransferase 3


Hs.518164
AK025047
80193
chr3p21.1-q13.13

Hs.518164_at
hypothetical protein FLJ21394
FLJ21394
AnCg
0.461
0.893
0.023
0.826
0.490
1.060


Hs.58488
NM_003798
8727
chr9q31.2
604785
Hs.58488_at
catenin (cadherin-associated
CTNNAL1
AnCg
0.299
0.877
0.025
0.775
0.243
0.825








protein), alpha-like 1


Hs.59729
NM_020163
56920
chr3p21.1

Hs.59729_at
semaphorin sem2
LOC56920
AnCg
0.105
0.834
0.015
0.770
0.062
0.759


Hs.6140
AL566367
84966
chr1p36.13

Hs.6140_at
hypothetical protein MGC15730
MGC15730
AnCg
0.893
1.010
0.004
1.400
0.574
1.100


Hs.6877
NM_018108
55148
chr14q32.13

Hs.6877_at
chromosome 14 open reading
C14orf130
AnCg
0.270
1.174
0.032
1.205
0.407
1.094








frame 130


Hs.75137
NM_014766
9805
chr7p14.3-p14.1

Hs.75137_at
secemin 1
SES1
AnCg
0.633
1.196
0.020
1.204
0.049
1.200


Hs.79058
BC002802
6827
chr17q21-q23
603555
Hs.79058_at
suppressor of Ty 4 homolog 1
SUPT4H1
AnCg
0.784
1.029
0.034
1.201
0.271
1.211








(S. cerevisiae)


Hs.7935
NM_014962
22903
chr20p12.2

Hs.7935_at
BTB (POZ) domain containing 3
BTBD3
AnCg
0.165
1.365
0.019
1.203
0.420
1.153


Hs.7991
AA206763
128434
chr20q11.23

Hs.7991_at
chromosome 20 open reading
C20orf102
AnCg
0.216
1.190
0.030
1.203
0.060
1.425








frame 102


Hs.82023
BC000850
54461
chr9q34.3

Hs.82023_at
F-box and WD-40 domain
FBXW5
AnCg
0.389
1.156
0.006
1.206
0.094
1.216








protein 5


Hs.82120
AI935096
4929
chr2q22-q23
601828
Hs.82120_at
nuclear receptor subfamily 4,
NR4A2
AnCg
0.351
0.875
0.016
0.655
0.765
0.847








group A, member 2


Hs.88367
NM_017714
55617
chr20p12.1
608270
Hs.88367_at
chromosome 20 open reading
C20orf13
AnCg
0.584
1.090
0.028
1.273
0.427
1.096








frame 13


Hs.90063
AF251061
83988
chr8q22-q23
606722
Hs.90063_at
neurocalcin delta
NCALD
AnCg
0.406
1.314
0.017
1.236
0.173
1.566


Hs.9629
BC004913
5546
chr1q21.1
179755
Hs.9629_at
papillary renal cell carcinoma
PRCC
AnCg
0.237
1.278
0.003
1.202
0.868
1.020








(translocation-associated)


Hs.100194
NM_001629
241
chr13q12
603700
Hs.100194_at
arachidonate 5-lipoxygenase-
ALOX5AP
Amy
0.847
1.015
0.445
0.920
0.025
0.340








activating protein


Hs.100343
NM_152704
219287
chr13q12.13

Hs.100343_at
hypothetical protein FLJ25477
FLJ25477
Amy
0.862
1.033
0.412
0.868
0.015
0.714


Hs.10043
NM_022062
63876
chr11q24

Hs.10043_at
PBX/knotted 1 homeobox 2
PKNOX2
Amy
0.525
1.038
0.933
0.996
0.001
1.521


Hs.101672
AW157571
152789
chr4p16.1

Hs.101672_at
hypothetical protein FLJ31564
FLJ31564
Amy
0.169
1.098
0.071
1.137
0.023
1.264


Hs.103291
NM_016588
51299
chr6p25.1
607409
Hs.103291_at
neuritin 1
NRN1
Amy
0.432
1.214
0.040
1.140
0.019
1.360


Hs.103378
AL136885
83641
chr10p13

Hs.103378_at
chromosome 10 open reading
C10orf45
Amy
0.612
1.213
0.764
0.881
0.025
0.613








frame 45


Hs.103395
NM_024709
79762
chr1q41

Hs.103395_at
hypothetical protein FLJ14146
FLJ14146
Amy
0.286
1.105
0.106
1.116
0.006
1.438


Hs.10526
NM_001321
1466
chr12q1.1
601871
Hs.10526_at
cysteine and glycine-rich protein 2
CSRP2
Amy
0.580
0.921
0.313
0.863
0.047
0.698


Hs.106688
NM_004709
9142
chrxq27.3

Hs.106688_at
chromosome X open reading
CXorf1
Amy
0.575
1.062
0.282
1.245
0.011
1.463








frame 1


Hs.107056
AF200715
51454
chr2q32.3-q33
608165
Hs.107056_at
GULP, engulfment adaptor PTB
GULP1
Amy
0.570
1.075
0.267
1.069
0.044
1.310








domain containing 1


Hs.107393
BC013610
56650
chr3p11-q11

Hs.107393_at
chromosome 3 open reading
C3orf4
Amy
0.611
1.160
0.791
0.945
0.024
0.666








frame 4


Hs.108689
BE513151
6721
chr22q13
600481
Hs.108689_at
sterol regulatory element
SREBF2
Amy
0.532
1.073
0.239
1.057
0.043
1.208








binding transcription factor 2


Hs.109299
BE501428
8541
chr19q13.33
603144
Hs.109299_at
protein tyrosine phosphatase,
PPFIA3
Amy
0.690
0.944
0.382
1.071
0.001
1.515








receptor type, f polypeptide








(PTPRF), interacting protein








(liprin), alpha 3


Hs.109309
NM_017631
55601
chr4q32.3

Hs.109309_at
hypothetical protein FLJ20035
FLJ20035
Amy
0.033
0.868
0.188
0.911
0.019
0.759


Hs.109358
AW006935
23120
chr5q34

Hs.109358_at
ATPase, Class V, type 10B
ATP10B
Amy
0.998
1.000
0.658
0.975
0.021
0.773


Hs.109438
AA551075
115207
chr13q22.3

Hs.109438_at
potassium channel
KCTD12
Amy
0.449
0.935
0.153
0.880
0.009
0.746








tetramerisation domain








containing 12


Hs.11065
BF515889
85313
chr6q24-q25
607609
Hs.11065_at
peptidylprolyl isomerase
PPIL4
Amy
0.916
1.016
0.381
0.880
0.014
0.709








(cyclophilin)-like 4


Hs.110736
NM_001046
6558
chr5q23.3
600840
Hs.110736_at
solute carrier family 12
SLC12A2
Amy
0.883
0.979
0.129
0.779
0.016
0.637








(sodium/potassium/chloride








transporters), member 2


Hs.111676
AF133207
26353
chr12q24.23
608014
Hs.111676_at
protein kinase H11
H11
Amy
0.790
0.910
0.827
1.017
0.005
0.732


Hs.111779
NM_003118
6678
chr5q31.3-q32
182120
Hs.111779_at
secreted protein, acidic,
SPARC
Amy
0.917
0.987
0.783
1.038
0.047
0.658








cysteine-rich (osteonectin)


Hs.112356
NM_015929
51601
chr2q11.2

Hs.112356_at
lipoyltransferase
LIPT1
Amy
0.446
0.958
0.302
0.861
0.024
0.677


Hs.112499
NM_004758
9256
chr17q22-q23

Hs.112499_at
benzodiazapine receptor
BZRAP1
Amy
0.820
0.977
0.620
1.034
0.007
1.445








(peripheral) associated protein 1


Hs.112928
AF493870
54331
chr14q21
606981
Hs.112928_at
guanine nucleotide binding
GNG2
Amy
0.071
1.104
0.080
1.156
0.020
1.277








protein (G protein), gamma 2


Hs.112933
NM_016948
50855
chr16q22.1
607484
Hs.112933_at
par-6 partitioning defective 6
PARD6A
Amy
0.953
0.995
0.135
1.191
0.001
1.407








homolog alpha (C. elegans)


Hs.1162
NM_002118
3109
chr6p21.3
142856
Hs.1162_at
major histocompatibility
HLA-DMB
Amy
0.339
0.911
0.106
0.914
0.027
0.750








complex, class II, DM beta


Hs.117060
AI473096
1842
chr9q22.3
603479
Hs.117060_at
extracellular matrix protein 2,
ECM2
Amy
0.511
0.987
0.694
0.959
0.046
0.760








female organ and adipocyte








specific


Hs.117339
AF285447
10870
chr19q13.1
604089
Hs.117339_at
hematopoietic cell signal
HCST
Amy
0.756
0.972
0.449
0.947
0.033
0.738








transducer


Hs.117780
NM_002251
3787
chr20q12
602905
Hs.117780_at
potassium voltage-gated
KCNS1
Amy
0.773
0.986
0.460
0.940
0.015
1.329








channel, delayed-rectifier,








subfamily S, member 1


Hs.117956
NM_006914
6096
chr9q22
601972
Hs.117956_at
RAR-related orphan receptor B
RORB
Amy
0.108
1.156
0.577
0.922
0.009
1.507


Hs.118110
NM_004335
684
chr19p13.2
600534
Hs.118110_at
bone marrow stromal cell
BST2
Amy
0.108
0.938
0.439
0.923
0.001
0.741








antigen 2


Hs.118281
AA868898
10781
chr19p13.2
604751
Hs.118281_at
zinc finger protein 266
ZNF266
Amy
0.584
1.105
0.336
0.909
0.044
0.776


Hs.118483
AA877789
4646
chr6q13
600970
Hs.118483_at
myosin VI
MYO6
Amy
0.858
0.978
0.447
0.898
0.044
0.798


Hs.118843
AB049127
57787
chr19q13.3
606495
Hs.118843_at
MAP/microtubule affinity-
MARK4
Amy
0.562
1.084
0.320
1.053
0.006
1.280








regulating kinase 4


Hs.119062
AW612149
285800
chr6q27

Hs.119062_at
hypothetical protein MGC35308
MGC35308
Amy
0.721
1.104
0.534
0.778
0.028
0.550


Hs.120963
BC016343
55421
chr17p13.3

Hs.120963_at
ELG protein
HSA277841
Amy
0.073
0.975
0.933
1.006
0.034
0.802


Hs.122440
AL050376
130872
chr2p16.1-p15

Hs.122440_at
AHA1, activator of heat shock
AHSA2
Amy
0.679
1.019
0.500
0.953
0.004
0.726








90 kDa protein ATPase homolog








2 (yeast)


Hs.12264
AA001423
57463
chr1p13.3

Hs.12264_at
amphoterin-induced gene
KIAA1163
Amy
0.271
1.046
0.727
1.016
0.044
1.308


Hs.123119




Hs.123119_at
MAD, mothers against
MADH9
Amy
0.751
1.075
0.472
0.905
0.018
0.647








decapentaplegic homolog 9








(Drosophila)


Hs.12332
AA758861
144100
chr11p15.1

Hs.12332_at
hypothetical protein LOC144100
LOC144100
Amy
0.844
1.008
0.308
0.953
0.006
0.809


Hs.123464
BC039373
10161
chr13q14

Hs.123464_at
purinergic receptor P2Y, G-
P2RY5
Amy
0.378
0.882
0.194
0.795
0.003
0.374








protein coupled, 5


Hs.12381
AI041543
144423
chr12q24.32

Hs.12381_at
hypothetical protein FLJ31978
FLJ31978
Amy
0.468
1.096
0.358
1.065
0.025
1.302


Hs.12409
NM_001048
6750
chr3q28
182450
Hs.12409_at
somatostatin
SST
Amy
0.585
1.129
0.430
1.137
0.045
0.547


Hs.124177
NM_016090
10179
chr11q23.1-q23.2

Hs.124177_at
RNA binding motif protein 7
RBM7
Amy
0.556
0.886
0.901
1.021
0.010
0.698


Hs.12449
N63401
93377
chr10q23-q24

Hs.12449_at
transmembrane protein 10
TMEM10
Amy
0.298
1.472
0.774
0.907
0.020
0.567


Hs.124951
AL039862
157638
chr8q24.21

Hs.124951_at
breast cancer membrane
NSE2
Amy
0.785
1.014
0.761
0.980
0.001
0.781








protein 101


Hs.125221
NM_030755
81542
chr14q22.1

Hs.125221_at
thioredoxin domain containing
TXNDC
Amy
0.646
1.050
0.340
0.910
0.006
0.748


Hs.125293
BF446578
221002
chr10q11.21

Hs.125293_at
CG4853 gene product
LOC221002
Amy
0.840
1.009
0.224
1.081
0.004
1.235


Hs.126357
NM_000276
4952
chrxq25-q26.1
309000
Hs.126357_at
oculocerebrorenal syndrome of
OCRL
Amy
0.775
1.060
0.019
1.178
0.035
1.410








Lowe


Hs.126372
NM_016056
51643
chr12q14.1-q15

Hs.126372_at
CGI-119 protein
CGI-119
Amy
0.631
1.072
0.468
0.938
0.028
0.789


Hs.126825
BE672097
348487
chr1p36.13

Hs.126825_at
hypothetical protein FLJ36766
FLJ36766
Amy
0.774
0.974
0.485
1.167
0.047
1.482


Hs.12696
AF131790
22941
chr11q13.3-q13.4
603290
Hs.12696_at
SH3 and multiple ankyrin repeat
SHANK2
Amy
0.571
1.027
0.290
1.070
0.001
1.341








domains 2


Hs.127196
AI970061
151556
chr2q31.1

Hs.127196_at
G protein-coupled receptor 155
GPR155
Amy
0.054
1.195
0.381
1.082
0.036
1.245


Hs.12813
BC033324
25976
chr3q25.31

Hs.12813_at
TCDD-inducible poly(ADP-
TIPARP
Amy
0.316
0.933
0.121
0.796
0.036
0.709








ribose) polymerase


Hs.128690
AW172584
255783
chr19q13.33

Hs.128690_at
hypothetical protein LOC255783
LOC255783
Amy
0.783
1.018
0.417
1.056
0.046
1.258


Hs.129051
BE550452
9456
chr5q14.2
604798
Hs.129051_at
homer homolog 1 (Drosophila)
HOMER1
Amy
0.137
1.191
0.544
1.067
0.047
1.314


Hs.12953
AI692180
8495
chr11p15.4
603142
Hs.12953_at
PTPRF interacting protein,
PPFIBP2
Amy
0.770
1.013
0.179
0.839
0.003
0.589








binding protein 2 (liprin beta 2)


Hs.129783
AF107028
6327
chr11q23
601327
Hs.129783_at
sodium channel, voltage-gated,
SCN2B
Amy
0.374
1.184
0.139
1.196
0.037
1.275








type II, beta


Hs.130065
NM_020397
57118
chr10p13
607957
Hs.130065_at
calcium/calmodulin-dependent
CAMK1D
Amy
0.929
1.009
0.647
0.976
0.022
1.269








protein kinase ID


Hs.13014
BC005122
26286
chr22q13.2-q13.3

Hs.13014_at
ADP-ribosylation factor GTPase
ARFGAP3
Amy
0.717
1.017
0.849
1.016
0.041
0.802








activating protein 3


Hs.13040
NM_023914
53829
chr3q24
606380
Hs.13040_at
G protein-coupled receptor 86
GPR86
Amy
0.472
0.990
0.460
0.981
0.030
0.573


Hs.131055
AI016313
10361
chr8p21.3
608073
Hs.131055_at
nucleophosmin/nucleoplasmin, 2
NPM2
Amy
0.171
1.128
0.216
1.079
0.011
1.328


Hs.131315
AF307338
83666
chr3q13-q21

Hs.131315_at
B aggressive lymphoma gene
BAL
Amy
0.220
0.975
0.079
0.926
0.000
0.717


Hs.132275
AI458003
116159
chr21q21.2

Hs.132275_at
cysteine and tyrosine-rich 1
CYYR1
Amy
0.244
0.948
0.124
0.931
0.013
0.806


Hs.132380
NM_024306
79152
chr16q23

Hs.132380_at
fatty acid 2-hydroxylase
FA2H
Amy
0.608
1.085
0.643
0.886
0.023
0.594


Hs.132554
R15072
151473
chr2q36.3

Hs.132554_at
hypothetical protein FLJ30794
FLJ30794
Amy
0.082
1.251
0.140
1.142
0.025
1.359


Hs.13340
NM_003642
8520
chr2q31.2-q33.1
603053
Hs.13340_at
histone acetyltransferase 1
HAT1
Amy
0.362
0.881
0.730
1.039
0.020
0.786


Hs.134065
NM_138339
171582
chr10q26.13

Hs.134065_at
hypothetical protein
DKFZp761H2121
Amy
0.078
1.331
0.102
1.278
0.043
1.260








DKFZp761H2121


Hs.134292
BC006362
84814
chr9q34.13

Hs.134292_at
chromosome 9 open reading
C9orf67
Amy
0.657
1.048
0.342
1.105
0.027
1.399








frame 67


Hs.135056
AL121758
140809
chr20p13

Hs.135056_at
chromosome 20 open reading
C20orf139
Amy
0.862
1.019
0.271
1.067
0.002
1.277








frame 139


Hs.135183
NM_006869
11033
chr7p22.3
608114
Hs.135183_at
centaurin, alpha 1
CENTA1
Amy
0.976
1.004
0.492
1.050
0.038
1.212


Hs.141308
U18840
4340
chr6p22-p21.3
159465
Hs.141308_at
myelin oligodendrocyte
MOG
Amy
0.501
1.355
0.801
0.894
0.017
0.455








glycoprotein


Hs.144287
NM_012259
23493
chr6q22.2-q22.33
604674
Hs.144287_at
hairy/enhancer-of-split related
HEY2
Amy
0.087
0.914
0.514
0.935
0.015
0.754








with YRPW motif 2


Hs.144502
NM_024779
79837
chr12q13.3

Hs.144502_at
phosphatidylinositol-4-
PIP5K2C
Amy
0.007
1.171
0.110
1.137
0.036
1.225








phosphate 5-kinase, type II,








gamma


Hs.14453




Hs.14453_at
interferon consensus sequence
ICSBP1
Amy
0.287
0.871
0.186
0.862
0.027
0.760








binding protein 1


Hs.145741
NM_001154
308
chr4q28-q32
131230
Hs.145741_at
annexin A5
ANXA5
Amy
0.631
0.832
0.354
0.878
0.005
0.651


Hs.14601
NM_005335
3059
chr3q13
601306
Hs.14601_at
hematopoletic cell-specific Lyn
HCLS1
Amy
0.117
0.936
0.062
0.830
0.006
0.543








substrate 1


Hs.146393
AF217990
9709
chr16q12.2-q13
608070
Hs.146393_at
homocysteine-inducible,
HERPUD1
Amy
0.729
1.034
0.418
0.971
0.010
0.796








endoplasmic reticulum stress-








inducible, ubiquitin-like domain








member 1


Hs.14845
N25732
2309
chr6q21
602681
Hs.14845_at
forkhead box O3A
FOXO3A
Amy
0.432
1.130
0.075
1.091
0.027
1.249


Hs.149156
NM_000170
2731
chr9p22
238300
Hs.149156_at
glycine dehydrogenase
GLDC
Amy
0.542
1.022
0.120
1.134
0.026
1.280








(decarboxylating; glycine








decarboxylase, glycine








cleavage system protein P)


Hs.150101
J03263
3916
chr13q34
153330
Hs.150101_at
lysosomal-associated
LAMP1
Amy
0.207
1.077
0.866
1.015
0.045
0.807








membrane protein 1


Hs.150956
NM_004455
2134
chr1p36.1
601738
Hs.150956_at
exostoses (multiple)-like 1
EXTL1
Amy
0.843
1.011
0.130
1.133
0.003
1.322


Hs.151414
AW409611
91404
chr2q31.2

Hs.151414_at
hypothetical protein
DKFZp434O
Amy
0.917
1.024
0.567
0.949
0.017
0.781








DKFZp434O0515
0515


Hs.15159
NM_016951
51192
chr16q22.1

Hs.15159_at
chemokine-like factor
CKLF
Amy
0.468
0.970
0.841
1.008
0.019
0.803


Hs.152149
AL137589
54620
chr16p11.2

Hs.152149_at
hypothetical protein
DKFZP434K0410
Amy
0.849
1.020
0.876
1.012
0.031
1.288








DKFZp434K0410


Hs.153355
AF142421
9444
chr6q26-27

Hs.153355_at
quaking homolog, KH domain
QKI
Amy
0.784
0.969
0.585
0.926
0.020
0.789








RNA binding (mouse)


Hs.153563
NM_002349
4065
chr2q24
604524
Hs.153563_at
lymphocyte antigen 75
LY75
Amy
0.689
0.976
0.082
0.789
0.037
0.669


Hs.153647
NM_002380
4147
chr8q22
602108
Hs.153647_at
matrilin 2
MATN2
Amy
0.813
0.984
0.262
0.835
0.042
0.635


Hs.153716
AI377497
259230
chr10q11.2

Hs.153716_at
mob protein
MOB
Amy
0.940
1.034
0.317
0.844
0.050
0.781


Hs.153792
N29717
4552
chr5p15.3-p15.2
602568
Hs.153792_at
5-methyltetrahydrofolate-
MTRR
Amy
0.351
0.957
0.143
0.863
0.007
0.765








homocysteine








methyltransferase reductase


Hs.153837
NM_002432
4332
chr1q22
159553
Hs.153837_at
myeloid cell nuclear
MNDA
Amy
0.216
0.889
0.805
0.964
0.018
0.597








differentiation antigen


Hs.154437
NM_002599
5138
chr11q13.4
602658
Hs.154437_at
phosphodiesterase 2A, cGMP-
PDE2A
Amy
0.057
1.191
0.072
1.152
0.014
1.343








stimulated


Hs.154658
NM_002779
5662
chr10q24
602327
Hs.154658_at
pleckstrin and Sec7 domain
PSD
Amy
0.791
0.982
0.123
1.182
0.044
1.248








protein


Hs.154729
NM_002613
5170
chr16p13.3
605213
Hs.154729_at
3-phosphoinositide dependent
PDPK1
Amy
0.999
1.000
0.725
1.013
0.000
1.213








protein kinase-1


Hs.155718
NM_018434
55819
chr5q35.3

Hs.155718_at
ring finger protein 130
RNF130
Amy
0.426
1.116
0.867
0.975
0.007
0.706


Hs.155935
U62027
719
chr12p13.31
605246
Hs.155935_at
complemet component 3a
C3AR1
Amy
0.261
0.935
0.011
0.856
0.017
0.751








receptor 1


Hs.15711
NM_015254
23303
chr8p12
607350
Hs.15711_at
kinesin family member 13B
KIF13B
Amy
0.214
1.108
0.903
0.982
0.013
0.677


Hs.157427




Hs.157427_at
ret finger protein-like 2
RFPL2
Amy
0.512
0.863
0.779
0.954
0.040
1.355


Hs.15783
AW664953
85362
chr20q13.33

Hs.15783_at
chromosome 20 open reading
C20orf158
Amy
0.271
1.093
0.146
0.916
0.018
0.815








frame 158


Hs.158867
AU145019
23150
chr3p14.2

Hs.158867_at
GRP1-binding protein GRSP1
GRSP1
Amy
0.629
0.966
0.862
0.977
0.012
0.679


Hs.1588
NM_000663
18
chr16p13.2
137150
Hs.1588_at
4-aminobutyrate
ABAT
Amy
0.595
1.119
0.041
1.080
0.007
1.222








aminotransferase


Hs.159425
AB056866
50859
chr4q32.3
607989
Hs.159425_at
sparc/osteonectin, cwcv and
SPOCK3
Amy
0.164
1.148
0.690
1.040
0.009
0.655








kazal-like domains proteoglycan








(testican) 3


Hs.161999
NM_003244
7050
chr18p11.3
602630
Hs.161999_at
TGFB-induced factor (TALE
TGIF
Amy
0.447
0.938
0.297
1.079
0.017
0.691








family homeobox)


Hs.1619
BE797438
429
chr12q22-q23
100790
Hs.1619_at
achaete-scute complex-like 1
ASCL1
Amy
0.066
0.777
0.140
0.788
0.012
0.779








(Drosophila)


Hs.163113
NM_024510
79415
chr17q25.3

Hs.163113_at
hypothetical protein MGC4368
MGC4368
Amy
0.957
0.995
0.437
0.966
0.048
0.813


Hs.16512
NM_024576
79627
chr6q13

Hs.16512_at
oploid growth factor receptor-
OGFRL1
Amy
0.128
0.959
0.078
0.866
0.012
0.824








like 1


Hs.165563
AL118506
80331
chr20q13.33

Hs.165563_at
DnaJ (Hsp40) homolog,
DNAJC5
Amy
0.063
1.135
0.073
1.126
0.030
1.266








subfamily C, member 5


Hs.166017
BC012503
4286
chr3p14.2-p14.1
156845
Hs.166017_at
microphthalmia-associated
MITF
Amy
0.880
1.011
0.679
0.960
0.033
0.781








transcription factor


Hs.166244
NM_023933
65990
chr16p13.3

Hs.166244_at
hypothetical protein MGC2494
MGC2494
Amy
0.964
0.993
0.421
1.082
0.018
1.201


Hs.166684
NM_006281
6788
chr8q22.2
605030
Hs.166684_at
serine/threonine kinase 3
STK3
Amy
0.718
0.958
0.176
0.820
0.026
0.677








(STE20 homolog, yeast)


Hs.166705
AF062006
8549
chr12q22-q23
606667
Hs.166705_at
G protein-coupled receptor 49
GPR49
Amy
0.265
1.041
0.649
1.049
0.039
0.829


Hs.167746
NM_013314
29760
chr10q23.2-q23.33
604515
Hs.167746_at
B-cell linker
BLNK
Amy
0.284
0.961
0.348
0.858
0.003
0.467


Hs.167
U89330
4133
chr2q34-q35
157130
Hs.167_at
microtubule-associated protein 2
MAP2
Amy
0.239
1.254
0.043
1.090
0.030
1.272


Hs.169600
BC021803
23045
chr4p12

Hs.169600_at
KIAA0826 protein
KIAA0826
Amy
0.641
1.023
0.908
0.990
0.032
0.796


Hs.170087
NM_001621
196
chr7p15
600253
Hs.170087_at
aryl hydrocarbon receptor
AHR
Amy
0.757
1.055
0.273
0.875
0.032
0.591


Hs.170198
BF214329
9650
chr8q13.1

Hs.170198_at
likely ortholog of chicken
CHPPR
Amy
0.222
0.972
0.991
1.000
0.017
0.805








chondrocyte protein with a polyproline








region


Hs.170328
NM_002444
4478
chrxq11.2-q12
309845
Hs.170328_at
moesin
MSN
Amy
0.125
0.764
0.208
0.867
0.029
0.800


Hs.1706




Hs.1706_at
interferon-stimulated
ISGF3G
Amy
0.121
0.780
0.168
0.866
0.001
0.764








transcription factor 3, gamma








48 kDa


Hs.171834
NM_006201
5127
chrxp11.3-p11.23
311550
Hs.171834_at
PCTAIRE protein kinase 1
PCTK1
Amy
0.474
1.038
0.005
1.162
0.027
1.264





p11.23


Hs.172089
BG538627
114908
chr11q22.1
606356
Hs.172089_at
pro-oncosis receptor inducing
PORIMIN
Amy
0.630
0.828
0.137
0.735
0.006
0.637








membrane injury gene


Hs.172550
NM_002819
5725
chr19p13.3
600693
Hs.172550_at
polypyrimidine tract binding
PTBP1
Amy
0.101
0.921
0.147
0.877
0.033
0.789








protein 1


Hs.172631
NM_000632
3684
chr16p11.2
120980
Hs.172631_at
integrin, alpha M (complement
ITGAM
Amy
0.180
0.952
0.217
0.843
0.010
0.534








component receptor 3, alpha;








also known as CD11b (p170),








macrophage antigen alpha








polypeptide)


Hs.173392
BG177562
57458
chr12q22

Hs.173392_at
KIAA1145 protein
KIAA1145
Amy
0.588
1.068
0.527
0.873
0.011
0.595


Hs.173438
NM_018147
55179
chr3q22.3

Hs.173438_at
Fas apoptotic inhibitory
FAIM
Amy
0.403
1.135
0.848
0.978
0.049
0.833








molecule


Hs.173560
AB032953
57451
chr5q34

Hs.173560_at
odd Oz/ten-m homolog 2
ODZ2
Amy
0.293
1.216
0.147
1.142
0.009
1.338


Hs.173864
AB011133
23031
chr19p13.12-p13.11

Hs.173864_at
KIAA0561 protein
KIAA0561
Amy
0.605
1.170
0.094
1.203
0.027
1.346


Hs.174142
NM_005211
1436
chr5q33-q35
164770
Hs.174142_at
colony stimulating factor 1
CSF1R
Amy
0.538
0.907
0.054
0.628
0.004
0.472








receptor, formerly McDonough








feline sarcoma viral (v-fms)








oncogene homolog


Hs.174195
NM_006435
10581
chr11p15.5
605578
Hs.174195_at
interferon induced
IFITM2
Amy
0.794
1.106
0.370
0.892
0.021
0.700








transmembrane protein 2 (1-8D)


Hs.1742
NM_003870
8826
chr15q26.1
603379
Hs.1742_at
IQ motif containing GTPase
IQGAP1
Amy
0.321
0.964
0.072
0.924
0.014
0.820








activating protein 1


Hs.174312
NM_138557
7099
chr9q32-q33
603030
Hs.174312_at
toll-like receptor 4
TLR4
Amy
0.049
0.945
0.958
0.997
0.043
0.803


Hs.17466
NM_004585
5920
chr11q23
605092
Hs.17466_at
retinoic acid receptor responder
RARRES3
Amy
0.599
0.968
0.936
1.012
0.030
0.728








(tazarotene induced) 3


Hs.176227
BC035811
55314
chr4q32.1

Hs.176227_at
hypothetical protein FLJ11155
FLJ11155
Amy
0.710
1.064
0.638
0.871
0.012
0.541


Hs.177534
AK022513
11221
chr1q41
608867
Hs.177534_at
dual specificity phosphatase 10
DUSP10
Amy
0.812
0.989
0.530
1.041
0.026
0.831


Hs.1780
X98405
4099
chr19q13.1
159460
Hs.1780_at
myelin associated glycoprotein
MAG
Amy
0.256
1.331
0.850
0.937
0.028
0.533


Hs.178137
AA675892
10140
chr17q21
605523
Hs.178137_at
transducer of ERBB2, 1
TOB1
Amy
0.541
0.836
0.064
0.788
0.027
0.662


Hs.1787
BC002665
5354
chrxq22
300401
Hs.1787_at
proteolipid protein 1 (Pelizaeus-
PLP1
Amy
0.625
1.246
0.739
0.927
0.009
0.741








Merzbacher disease, spastic








paraplegia 2, uncomplicated)


Hs.180141
AF134802
1073
chr14q12
601443
Hs.180141_at
cofilin2 (muscle)
CFL2
Amy
0.693
1.093
0.893
0.982
0.020
0.719


Hs.180403
NM_016271
51444
chr18q12.1

Hs.180403_at
ring finger protein 138
RNF138
Amy
0.415
1.127
0.244
0.875
0.037
0.800


Hs.180545
AJ245600
91614
chr11p13

Hs.180545_at
novel 58.3 KDA protein
LOC91614
Amy
0.774
0.989
0.737
0.967
0.014
0.646


Hs.180866
NM_000416
3459
chr6q23-q24
107470
Hs.180866_at
interferon gamma receptor 1
IFNGR1
Amy
0.703
0.927
0.185
0.854
0.009
0.687


Hs.180877
BC001124
3021
chr17q25
601058
Hs.180877_at
H3 histone, family 3B (H3.3B)
H3F3B
Amy
1.000
1.000
0.816
1.021
0.017
0.794


Hs.181046
AL048503
1845
chr17q21
600183
Hs.181046_at
dual specificity phosphatase 3
DUSP3
Amy
0.077
1.252
0.296
1.095
0.020
1.245








(vaccinia virus phosphatase








VH1-related)


Hs.181244
AA573862
3105
chr6p21.3
142800
Hs.181244_at
major histocompatibility
HLA-A
Amy
0.464
0.921
0.208
0.916
0.030
0.769








complex, class I, A


Hs.181301
BC002642
1520
chr1q21
116845
Hs.181301_at
cathepsin S
CTSS
Amy
0.167
0.943
0.370
0.956
0.004
0.770


Hs.182579
NM_015907
51056
chr4p15.32
170250
Hs.182579_at
leucine aminopeptidase 3
LAP3
Amy
0.263
1.098
0.319
1.079
0.002
0.789


Hs.1832
NM_000905
4852
chr7p15.1
162640
Hs.1832_at
neuropeptide Y
NPY
Amy
0.403
1.128
0.751
0.942
0.002
0.491


Hs.183506
BC008922
79899
chr11p13-p12

Hs.183506_at
hypothetical protein FLJ14213
FLJ14213
Amy
0.807
1.010
0.932
1.004
0.011
0.739


Hs.183702
AK021814
92344
chr1q24.2
607983
Hs.183702_at
hypothetical protein FLJ11752
FLJ11752
Amy
0.260
1.077
0.765
0.964
0.024
0.811


Hs.184018
NM_004271
9450
chr6p25.1
605241
Hs.184018_at
lymphocyte antigen 86
LY86
Amy
0.938
0.993
0.052
0.810
0.043
0.603


Hs.187377
NM_024847
79905
chr16p12.3

Hs.187377_at
transmembrane channel-like 7
TMC7
Amy
0.393
1.051
0.147
0.867
0.016
0.795


Hs.188011
AI301935
58475
chr11q12
606502
Hs.188011_at
membrane-spanning 4-
MS4A7
Amy
0.040
0.943
0.052
0.884
0.047
0.621








domains, subfamily A, member 7


Hs.188
NM_002600
5142
chr1p31
600127
Hs.188_at
phosphodiesterase 4B, cAMP-
PDE4B
Amy
0.483
1.076
0.922
0.994
0.024
0.792








specific (phosphodiesterase E4








dunce homolog, Drosophila)


Hs.190043
AW469184
158747
chrxp22.2

Hs.190043_at
hypothetical protein MGC26706
MGC26706
Amy
0.818
1.033
0.618
0.918
0.003
0.605


Hs.1908
BC022313
5552
chr10q22.1
177040
Hs.1908_at
proteoglycan 1, secretory
PRG1
Amy
0.091
0.952
0.258
0.810
0.001
0.524








granule


Hs.1915
NM_004476
2346
chr11p11.2
600934
Hs.1915_at
folate hydrolase (prostate-
FOLH1
Amy
0.465
1.109
0.620
0.799
0.011
0.402








specific membrane antigen) 1


Hs.19210
BF690150
84975
chr12q13.13

Hs.19210_at
hypothetical protein MGC11308
MGC11308
Amy
0.305
1.045
0.102
1.104
0.006
1.252


Hs.192491
NM_012113
23632
chr1q21
604832
Hs.192491_at
carbonic anhydrase XIV
CA14
Amy
0.544
0.971
0.541
0.943
0.029
0.786


Hs.193115
T52285
85444
chr8q21.2

Hs.193115_at
KIAA1764 protein
KIAA1764
Amy
0.024
0.842
0.246
0.807
0.022
0.577


Hs.194684
NM_003458
8927
chr3p21.31
604020
Hs.194684_at
bassoon (presynaptic cytomatrix
BSN
Amy
0.955
0.987
0.999
1.000
0.025
1.529








protein)


Hs.195471
NM_004566
5209
chr10p14-p15
605319
Hs.195471_at
6-phosphofructo-2-
PFKFB3
Amy
0.922
0.988
0.060
0.865
0.013
0.762








kinase/fructose-2,6-








biphosphatase 3


Hs.196083
AL137653
1487
chr4p16
602618
Hs.196083_at
C-terminal binding protein 1
CTBP1
Amy
0.230
1.215
0.109
1.166
0.035
1.247


Hs.197045
BF435286
25938
chr14q12

Hs.197045_at
chromosome 14 open reading
C14orf125
Amy
0.196
0.841
0.314
0.817
0.027
0.739








frame 125


Hs.197298
AF205218
10625
chr1q25.1-q31.1

Hs.197298_at
influenza virus NS1A binding
IVNS1ABP
Amy
0.337
1.150
0.907
0.986
0.049
0.794








protein


Hs.197335
NM_006102
10404
chr8q22.2

Hs.197335_at
plasma glutamate
PGCP
Amy
0.127
0.955
0.507
0.927
0.023
0.807








carboxypeptidase


Hs.199068
AW016039
57172
chr1q32-q41

Hs.199068_at
calcium/calmodulin-dependent
CAMK1G
Amy
0.208
1.179
0.087
1.164
0.037
1.410








protein kinase IG


Hs.199364
NM_018103
55144
chr1p22.2

Hs.199364_at
leucine rich repeat containing 5
LRRC5
Amy
0.130
1.129
0.669
0.963
0.039
0.750


Hs.200481
NM_018340
55313
chr16p13.12

Hs.200481_at
hypothetical protein FLJ11151
FLJ11151
Amy
0.155
1.035
0.964
1.001
0.013
0.825


Hs.200586
NM_001703
576
chr1p35
602683
Hs.200586_at
brain-specific angiogenesis
BAI2
Amy
0.714
1.150
0.191
1.095
0.046
1.267








inhibitor 2


Hs.201369
NM_015559
26040
chr18q21.1

Hs.201369_at
SET binding protein 1
SETBP1
Amy
0.996
1.000
0.103
1.093
0.047
1.236


Hs.20137
AW504018
55589
chr4q21.23

Hs.20137_at
BMP2 inducible kinase
BMP2K
Amy
0.945
0.994
0.827
0.980
0.002
0.781


Hs.201702
AI868167
286097
chr8p22

Hs.201702_at
hypothetical protein LOC286097
LOC286097
Amy
0.316
1.218
0.763
1.031
0.027
1.267


Hs.202308
BC003686
8773
chr15q15.1
602534
Hs.202308_at
synaptosomal-associated
SNAP23
Amy
0.376
0.969
0.563
0.963
0.000
0.781








protein, 23 kDa


Hs.20252
AL096776
58480
chr1q42.11-q42.3
606366
Hs.20252_at
ras homolog gene family,
ARHU
Amy
0.841
1.023
0.678
0.914
0.006
0.604








member U


Hs.202687
NM_012281
3751
chr7q31
605410
Hs.202687_at
potassium voltage-gated
KCND2
Amy
0.384
1.332
0.149
1.178
0.010
1.346








channel, Shal-related subfamily,








member 2


Hs.203213
NM_000461
7068
chr3p24.3
190160
Hs.203213_at
thyroid hormone receptor, beta
THRB
Amy
0.352
1.080
0.367
1.053
0.012
1.473








(erythroblastic leukemia viral (verb-








a) oncogene homolog 2,








avian)


Hs.20369
BE466825
147929
chr19q13.12

Hs.20369_at
hypothetical protein FLJ36991
FLJ36991
Amy
0.102
0.838
0.132
0.870
0.027
0.740


Hs.204539
BC002461
663
chr15q22.2
603292
Hs.204539_at
BCL2/adenovirus E1B 19 kDa
BNIP2
Amy
0.483
0.979
0.638
0.960
0.011
0.812








interacting protein 2


Hs.205088
AK002207
23111
chr13q13.3
607111
Hs.205088_at
spastic paraplegia 20, spartin
SPG20
Amy
0.816
0.975
0.759
0.972
0.012
0.781








(Troyer syndrome)


Hs.205865
AW043782
143458
chr11p13

Hs.205865_at
hypothetical protein LOC143458
LOC143458
Amy
0.025
0.849
0.062
0.753
0.037
0.698


Hs.206770
AL523144
9278
chr6p21.3

Hs.206770_at
zinc finger protein 297
ZNF297
Amy
0.271
1.080
0.208
1.113
0.029
1.247


Hs.207428
BF213279
10160
chr13q32.2
602654
Hs.207428_at
FERM, RhoGEF (ARHGEF) and
FARP1
Amy
0.402
1.069
0.294
1.102
0.004
1.305








pleckstrin domain protein 1








(chondrocyte-derived)


Hs.207776




Hs.207776_at
aspartylglucosaminidase
AGA
Amy
0.824
1.015
0.326
0.861
0.008
0.648


Hs.21104
NM_173602
57609
chr12q13.13

Hs.21104_at
KIAA1463 protein
KIAA1463
Amy
0.667
1.024
0.490
0.945
0.031
0.772


Hs.21126
AB014594
55619
chr2q36.3

Hs.21126_at
dedicator of cytokinesis 10
DOCK10
Amy
0.579
1.025
0.399
1.090
0.023
0.744


Hs.211569
AI338653
2869
chr10q24-qter
600870
Hs.211569_at
G protein-coupled receptor
GPRK5
Amy
0.046
1.050
0.561
1.041
0.045
1.237








kinase 5


Hs.211751
NM_020836
57596
chr14q32.2

Hs.211751_at
brain-enriched guanylate
KIAA1446
Amy
0.421
0.969
0.330
1.078
0.010
1.232








kinase-associated protein


Hs.212296
NM_000210
3655
chr2q31.1
147556
Hs.212296_at
integrin, alpha 6
ITGA6
Amy
0.386
0.901
0.042
0.875
0.017
0.671


Hs.212957
BC034803
286827
chr3q26.1

Hs.212957_at
tumor suppressor TSBF1
TSBF1
Amy
0.963
1.003
0.550
0.873
0.030
0.551


Hs.21420
BC035596
56924
chr15q14
608110
Hs.21420_at
p21(CDKN1A)-activated kinase 6
PAK6
Amy
0.988
1.001
0.035
1.198
0.041
1.336


Hs.217112
BC004271
84735
chr18q22.3

Hs.217112_at
camosinase 1
CN1
Amy
0.416
0.768
0.207
0.545
0.001
0.340


Hs.217409
AA908763
118812
chr10q24.2

Hs.217409_at
44050 protein
LOC118812
Amy
0.820
1.007
0.004
1.164
0.001
1.225


Hs.21938
NM_024586
114883
chr1p32.3
606737
Hs.21938_at
oxysterol binding protein-like 9
OSBPL9
Amy
0.749
0.914
0.656
0.976
0.025
0.820


Hs.22140
NM_016564
51286
chr11p15.5
608213
Hs.22140_at
BM88 antigen
BM88
Amy
0.394
1.109
0.185
1.092
0.029
1.211


Hs.22270
AI879661
120196
chr11p13

Hs.22270_at
hypothetical protein MGC34830
MGC34830
Amy
0.309
1.222
0.141
1.145
0.010
1.700


Hs.2236
Z25434
4752
chr13q14.13
604044
Hs.2236_at
NIMA (never in mitosis gene a)-
NEK3
Amy
0.843
0.995
0.921
1.012
0.020
0.685








related kinase 3


Hs.224505
AV710838
83875
chr11q22.3-q23.1

Hs.224505_at
beta-carotene dioxygenase 2
BCDO2
Amy
0.397
1.056
0.158
0.890
0.004
0.802


Hs.227059
NM_012128
22802
chr1p31-p22

Hs.227059_at
chloride channel, calcium
CLCA4
Amy
0.725
0.962
0.879
0.954
0.003
0.328








activated, family member 4


Hs.23106
AI023317
9862
chr17q21.1
607000
Hs.23106_at
thyraid hormone receptor-
TRAP100
Amy
0.337
1.109
0.168
1.102
0.011
1.527








associated protein (100 kDa)


Hs.23158
AA906578
150726
chr2p13.2

Hs.23158_at
KIAA1940 protein
KIAA1940
Amy
0.419
1.107
0.047
1.123
0.012
1.297


Hs.232004
NM_006176
4900
chr11q24
602350
Hs.232004_at
neurogranin (protein kinase C
NRGN
Amy
0.482
1.165
0.048
1.136
0.003
1.641








substrate, RC3)


Hs.232400
NM_002137
3181
chr7p15
600124
Hs.232400_at
heterogeneous nuclear
HNRPA2B1
Amy
0.832
1.027
0.969
1.002
0.039
0.828








ribonucleoprotein A2/B1


Hs.232432
NM_013995
3920
chrxq24
309060
Hs.232432_at
lysosomal-associated
LAMP2
Amy
0.626
1.102
0.410
0.853
0.008
0.595








membrane protein 2


Hs.23567
NM_003787
8715
chr18q12
603577
Hs.23567_at
nucleolar protein 4
NOL4
Amy
0.499
1.056
0.195
1.093
0.002
1.289


Hs.237536
AL526783
115024
chr17q21.2

Hs.237536_at
hypothetical protein MGC20781
MGC20781
Amy
0.964
1.005
0.064
1.118
0.017
1.229


Hs.23765
AL359575
127281
chr1p36.32

Hs.23765_at
hypothetical protein MGC26818
MGC26818
Amy
0.827
1.016
0.374
1.054
0.029
1.261


Hs.2391
NM_001649
357
chrxp22.3
300103
Hs.2391_at
apical protein-like (Xenopus
APXL
Amy
0.456
1.128
0.242
1.163
0.005
1.522








laevis)


Hs.239500
BC007207
84326
chr16p13.3

Hs.239500_at
hypothetical protein MGC13114
MGC13114
Amy
0.718
1.059
0.052
1.244
0.029
1.294


Hs.23954
AA654142
51148
chr9q34.11

Hs.23954_at
cerebral endothelial cell
CEECAM1
Amy
0.940
1.018
0.450
0.809
0.013
0.527








adhesion molecule 1


Hs.24030
NM_001860
1318
chr9q31-q32
603088
Hs.24030_at
solute carrier family 31 (copper
SLC31A2
Amy
0.922
0.968
0.446
0.762
0.009
0.392








transporters), member 2


Hs.241471
NM_016337
51466
chr14q32.2

Hs.241471_at
Enah/Vasp-like
EVL
Amy
0.355
1.093
0.043
1.097
0.031
1.209


Hs.242947
NM_004717
9162
chr7q32.3-q33
604072
Hs.242947_at
diacylglycerol kinase, lota
DGKI
Amy
0.082
1.357
0.491
1.122
0.027
1.355


Hs.24341
AA081084
25937
chr3q23-q24
607392
Hs.24341_at
transcriptional co-activator with
TAZ
Amy
0.413
0.957
0.183
0.900
0.002
0.771








PDZ-binding motif (TAZ)


Hs.245537
AI474054
128338
chr1p13.3

Hs.245537_at
hypothetical protein MGC54289
MGC54289
Amy
0.467
0.968
0.580
0.942
0.006
0.708


Hs.24587
NM_005864
10278
chr14q11.2-q12

Hs.24587_at
embryonal Fyn-associated
EFS
Amy
0.755
0.979
0.506
0.880
0.007
0.720








substrate


Hs.246381
NM_001251
968
chr17p13
153634
Hs.246381_at
CD68 antigen
CD68
Amy
0.697
0.943
0.681
0.972
0.001
0.595


Hs.246970
AW298170
11183
chr14q11.2-q21
604923
Hs.246970_at
mitogen-activated protein
MAP4K5
Amy
0.449
1.198
0.377
0.903
0.030
0.694








kinase kinase kinase kinase 5


Hs.24725
AI251283
246330
chr11q13.2

Hs.24725_at
pellino 3 alpha
MGC35521
Amy
0.487
1.074
0.974
0.997
0.007
1.281


Hs.248112
NM_000809
2557
chr4p12
137141
Hs.248112_at
gamma-aminobutyric acid
GABRA4
Amy
0.656
0.951
0.757
1.029
0.002
1.278








(GABA) A receptor, alpha 4


Hs.24879
AF047760
8612
chr19p13
607126
Hs.24879_at
phosphatidic acid phosphatase
PPAP2C
Amy
0.416
1.158
0.623
0.872
0.011
0.615








type 2C


Hs.25035
AF109196
25932
chr1p36.11
606536
Hs.25035_at
chloride intracellular channel 4
CLIC4
Amy
0.944
1.014
0.162
0.809
0.005
0.534


Hs.250712
U07139
784
chr12q13
601958
Hs.250712_at
calcium channel, voltage-
CACNB3
Amy
0.197
1.136
0.243
1.124
0.014
1.417








dependent, beta 3 subunit


Hs.25155
AW263232
10276
chr10p15
606450
Hs.25155_at
neuroepithelial cell transforming
NET1
Amy
0.960
1.014
0.467
0.907
0.024
0.721








gene 1


Hs.254122
BC035848
55580


Hs.254122_at
hypothetical protein LOC55580
LOC55580
Amy
0.967
1.007
0.104
0.723
0.037
0.560


Hs.2551




Hs.2551_at
adrenergic, beta-2-, receptor,
ADRB2
Amy
0.286
1.034
0.676
1.027
0.010
0.745








surface


Hs.255230
NM_000181
2990
chr7q21.11
253220
Hs.255230_at
glucuronidase, beta
GUSB
Amy
0.689
0.979
0.297
0.937
0.026
0.807


Hs.25597
NM_016031
64834
chr1p34.2

Hs.25597_at
elongation of very long chain
ELOVL1
Amy
0.343
1.245
0.912
0.967
0.041
0.578








fatty acids (FEN1/Elo2,








SUR4/Elo3, yeast)-like 1


Hs.25601
BE379542
1107
chr17p13.1
602120
Hs.25601_at
chromodomain helicase DNA
CHD3
Amy
0.684
1.033
0.251
1.108
0.014
1.330








binding protein 3


Hs.25647
BC004490
2353
chr14q24.3
164810
Hs.25647_at
v-fos FBJ murine osteosarcoma
FOS
Amy
0.142
0.491
0.174
0.357
0.015
0.164








viral oncogene homolog


Hs.25748
AV722990
56121
chr5q31
606341
Hs.25748_at
protocadherin beta 15
PCDHB15
Amy
0.129
0.959
0.568
1.018
0.043
0.733


Hs.258326
NM_016524
51760
chr16p12.3

Hs.258326_at
B/K protein
LOC51760
Amy
0.313
1.189
0.476
1.073
0.029
1.315


Hs.25999
NM_024294
64771
chr6p21.31

Hs.25999_at
chromosome 6 open reading
C6orf106
Amy
0.694
1.034
0.270
1.070
0.043
1.209








frame 106


Hs.263671
NM_002906
5962
chr11q23
179410
Hs.263671_at
radixin
RDX
Amy
0.527
1.149
0.457
0.907
0.007
0.688


Hs.263928
AI817976
126259
chr19p13.3

Hs.263928_at
hypothetical protein MGC23244
MGC23244
Amy
0.281
0.915
0.411
0.937
0.032
0.828


Hs.26458
BC040270
4482
chr8p23.1
601250
Hs.26458_at
methionine sulfoxide reductase A
MSRA
Amy
0.049
1.198
0.160
1.110
0.040
1.276


Hs.266175
AI860212
55824
chr8q21.13
605767
Hs.266175_at
phosphoprotein associated with
PAG
Amy
0.456
0.957
0.768
0.974
0.037
0.827








glycosphingolipid-enriched








microdomains


Hs.26663
NM_016323
51191
chr4q22.1-q23
608242
Hs.26663_at
cyclin-E binding protein 1
CEB1
Amy
0.008
0.952
0.280
0.949
0.001
0.713


Hs.26704
BC005097
23191
chr15q11
606322
Hs.26704_at
cytoplasmic FMR1 interacting
CYFIP1
Amy
0.087
0.889
0.067
0.873
0.020
0.725








protein 1


Hs.26812
BC004870
84886
chr1q42.13-q43

Hs.26812_at
hypothetical protein FLJ14525
FLJ14525
Amy
0.523
0.911
0.519
0.911
0.019
0.802


Hs.268545
NM_006078
10369
chr22q13.1
602911
Hs.268545_at
calcium channel, voltage-
CACNG2
Amy
0.154
1.051
0.117
1.148
0.002
1.365








dependent, gamma subunit 2


Hs.272254
AB037738
57528
chr5q31.3

Hs.272254_at
KIAA1317 protein
KIAA1317
Amy
0.130
1.181
0.209
1.143
0.010
1.328


Hs.2722
NM_002220
3706
chr15q14-q21
147521
Hs.2722_at
inositol 1,4,5-trisphosphate 3-
ITPKA
Amy
0.352
1.281
0.207
1.190
0.039
1.778








kinase A


Hs.272458
NM_000944
5530
chr4q21-q24
114105
Hs.272458_at
protein phosphatase 3 (formerly
PPP3CA
Amy
0.472
1.144
0.428
1.037
0.014
1.361








2B), catalytic subunit, alpha








isoform (calcineurin A alpha)


Hs.274122
NM_001978
2039
chr8p21.1
125305
Hs.274122_at
erythrocyte membrane protein
EPB49
Amy
0.450
1.168
0.082
1.149
0.028
1.396








band 4.9 (dematin)


Hs.274293
NM_003360
7368
chr4q26
601291
Hs.274293_at
UDP glycosyltransferase 8
UGT8
Amy
0.624
1.230
0.479
0.705
0.005
0.385








(UDP-galactose ceramide








galactosyltransferase)


Hs.274317
NM_016222
51428
chr5q35.3
608170
Hs.274317_at
DEAD (Asp-Glu-Ala-Asp) box
DDX41
Amy
0.089
1.240
0.054
1.149
0.026
1.281








polypeptide 41


Hs.274351
BC003128
51114
chr9

Hs.274351_at
zinc finger, DHHC domain
ZDHHC9
Amy
0.339
1.084
0.518
0.898
0.032
0.683








containing 9


Hs.274363
NM_021257
58157
chr14q24
605304
Hs.274363_at
neuroglobin
NGB
Amy
0.706
1.041
0.727
1.021
0.006
1.230


Hs.275675
NM_005886
10300
chr16q13
602703
Hs.275675_at
katanin p80 (WD repeat
KATNB1
Amy
0.306
1.047
0.051
1.121
0.011
1.251








containing) subunit B 1


Hs.275775
NM_005410
6414
chrsq31
601484
Hs.275775_at
selenoprotein P, plasma, 1
SEPP1
Amy
0.972
1.004
0.288
0.863
0.008
0.727


Hs.276210
BC037315
286002
chr7q22.3

Hs.276210_at
hypothetical protein LOC286002
LOC286002
Amy
0.493
1.085
0.899
1.013
0.048
1.617


Hs.278613
NM_005532
3429
chr14q32
600009
Hs.278613_at
interferon, alpha-inducible
IFI27
Amy
0.882
0.969
0.203
0.861
0.002
0.576








protein 27


Hs.278954
NM_033136
2246
chr5q31
131220
Hs.278954_at
fibroblast growth factor 1
FGF1
Amy
0.974
1.010
0.951
1.012
0.049
0.746








(acidic)


Hs.279008
NM_017696
54844
chr6q22.31

Hs.279008_at
chromosome 6 open reading
C6orf61
Amy
0.391
0.970
0.398
0.933
0.036
0.790








frame 61


Hs.27935
BC004233
94015
chr17q24
608855
Hs.27935_at
tweety homolog 2 (Drosophila)
TTYH2
Amy
0.431
1.142
0.492
0.853
0.014
0.597


Hs.279669
NM_016437
27175
chr17q21
605785
Hs.279669_at
tubulin, gamma 2
TUBG2
Amy
0.309
1.101
0.445
1.059
0.013
1.295


Hs.279912
BC030223
9738
chr16p12.3

Hs.279912_at
CP110 protein
CP110
Amy
0.471
1.038
0.717
0.967
0.028
0.769


Hs.280311
AK026977
4628
chr17p13
160776
Hs.280311_at
myosin, heavy polypeptide 10,
MYH10
Amy
0.105
1.149
0.583
1.036
0.046
1.240








non-muscle


Hs.280354
NM_172193
122773
chr14q21.3

Hs.280354_at
kelch domain containing 1
KLHDC1
Amy
0.465
0.943
0.766
0.983
0.012
0.771


Hs.282177
AB011161
23396
chr19p13.3
606102
Hs.282177_at
phosphatidylinositol-4-
PIP5K1C
Amy
0.349
1.082
0.260
1.087
0.018
1.300








phosphate 5-kinase, type I,








gamma


Hs.282233
BC007859
4302
chr17q21
600328
Hs.282233_at
myeloid/lymphoid or mixed-
MLLT6
Amy
0.820
0.992
0.441
1.037
0.013
1.251








lineage leukemia (trithorax








homolog, Drosophila);








translocated to, 6


Hs.283063
NM_005574
4005
chr11p13
180385
Hs.283063_at
LIM domain only 2 (rhombotin-
LMO2
Amy
0.183
0.869
0.100
0.817
0.005
0.611








like 1)


Hs.283091
NM_020415
56729
chr19p13.2
605565
Hs.283091_at
resistin
RETN
Amy
0.627
1.105
0.361
1.089
0.032
1.238


Hs.283661
NM_018938
56131
chr5q31
606330
Hs.283661_at
protocadherin beta 4
PCDHB4
Amy
0.719
1.010
0.371
0.932
0.018
0.781


Hs.283902
AC007743
114800
chr2p16.1

Hs.283902_at
KIAA1912 protein
KIAA1912
Amy
0.083
1.086
0.241
1.039
0.042
1.201


Hs.28423
NM_014517
7342
chr3p23

Hs.28423_at
upstream binding protein 1
UBP1
Amy
0.024
1.191
0.048
1.173
0.042
1.220








(LBP-1a)


Hs.285976
AK001105
29956
chr1q21.2
606920
Hs.285976_at
LAG1 longevity assurance
LASS2
Amy
0.991
0.999
0.548
0.894
0.012
0.688








homolog 2 (S. cerevisiae)


Hs.28607
BE963444
57149
chr16p11.2

Hs.28607_at
hypothetical protein A-211C6.1
LOC57149
Amy
0.375
1.082
0.110
1.119
0.031
1.230


Hs.286849
NM_021822
60489
chr22q13.1-q13.2
607113
Hs.286849_at
apolipoprotein B mRNA editing
APOBEC3G
Amy
0.656
0.967
0.760
0.979
0.008
0.716








enzyme, catalytic polypeptide-








like 3G


Hs.2868
NM_002677
5375
chr8q21.3-q22.1
170715
Hs.2868_at
peripheral myelin protein 2
PMP2
Amy
0.395
0.800
0.102
0.736
0.024
0.754


Hs.287521
NM_024988
80054
chr19q13.11

Hs.287521_at
hypothetical protein FLJ12355
FLJ12355
Amy
0.832
0.984
0.842
1.011
0.000
1.241


Hs.287921
AF029674
10488
chr9pter-p22.1
606443
Hs.287921_at
cAMP responsive element
CREB3
Amy
0.824
1.058
0.130
1.102
0.031
1.235








binding protein 3


Hs.288010
AW662189
128346
chr1p13.2

Hs.288010_at
hypothetical protein MGC24133
MGC24133
Amy
0.118
0.935
0.136
0.908
0.019
0.802


Hs.288284
NM_025078
80148
chr18q23

Hs.288284_at
PQ loop repeat containing 1
PQLC1
Amy
0.808
0.986
0.143
1.083
0.001
1.283


Hs.290270
NM_004746
9229
chr18p11.3
605445
Hs.290270_at
discs, large (Drosophila)
DLGAP1
Amy
0.202
1.114
0.293
1.067
0.036
1.283








homolog-associated protein 1


Hs.29052
NM_017704
54851
chr11q21

Hs.29052_at
fetal globin-inducing factor
FGIF
Amy
0.062
0.851
0.180
0.886
0.020
0.757


Hs.29190
AI732488
149563
chr1p36.13

Hs.29190_at
hypothetical protein MGC24047
MGC24047
Amy
0.119
0.877
0.535
0.935
0.048
0.826


Hs.29202
AF039686
2857
chrxp11.4-p11.3
300241
Hs.29202_at
G protein-coupled receptor 34
GPR34
Amy
0.217
0.952
0.076
0.774
0.014
0.324


Hs.292738
AF498927
397
chr12p12.3
602843
Hs.292738_at
Rho GDP dissociation inhibitor
ARHGDIB
Amy
0.042
0.836
0.020
0.849
0.002
0.548








(GDI) beta


Hs.293907
NM_022068
63895
chr18p11.22

Hs.293907_at
hypothetical protein FLJ23403
FLJ23403
Amy
0.584
1.036
0.912
0.990
0.019
0.764


Hs.294027
AA057445
283225
chr11q14.1

Hs.294027_at
hypothetical protein FLJ37266
FLJ37266
Amy
0.259
1.172
0.058
1.157
0.001
1.315


Hs.294145
AL577758
133957
chr5p15.33

Hs.294145_at
similar to RIKEN cDNA
LOC133957
Amy
0.109
1.145
0.105
1.118
0.013
1.252








0610011N22


Hs.297343
NM_006549
10645
chr12q24.2

Hs.297343_at
calcium/calmodulin-dependent
CAMKK2
Amy
0.382
1.162
0.060
1.245
0.008
1.460








protein kinase kinase 2, beta


Hs.298275
NM_018573
54407
chr12q
605180
Hs.298275_at
solute carrier family 38, member 2
SLC38A2
Amy
0.971
1.010
0.677
0.960
0.009
0.706


Hs.2998
NM_005076
6900
chr1q32.1
190197
Hs.2998_at
contactin 2 (axonal)
CNTN2
Amy
0.132
1.303
0.848
0.935
0.050
0.553


Hs.300642
N32526
10000
chr1q43-q44

Hs.300642_at
v-akt murine thymoma viral
AKT3
Amy
0.062
1.169
0.150
1.081
0.005
1.244








oncogene homolog 3 (protein








kinase B, gamma)


Hs.301206
NM_004798
9371
chr20q11.21
603754
Hs.301206_at
kinesin family member 3B
KIF3B
Amy
0.177
1.195
0.022
1.197
0.009
1.243


Hs.301394
AK022644
79007
chr16q24.3

Hs.301394_at
hypothetical protein MGC3101
MGC3101
Amy
0.139
1.120
0.017
1.174
0.038
1.345


Hs.301760
NM_014286
23413
chr9q34
603315
Hs.301760_at
frequenin homolog (Drosophila)
FREQ
Amy
0.783
1.031
0.663
1.026
0.024
1.285


Hs.301920
AI799702
80863
chr6p21.32

Hs.301920_at
chromosome 6 open reading
C6orf31
Amy
0.069
1.062
0.008
1.166
0.034
1.203








frame 31


Hs.30213
AI911687
1203
chr13q21.1-q32
608102
Hs.30213_at
ceroid-lipofuscinosis, neuronal 5
CLN5
Amy
0.801
1.008
0.665
0.970
0.010
0.779


Hs.303649
S69738
6347
chr17q11.2-q21.1
158105
Hs.303649_at
chemokine (C—C motif) ligand 2
CCL2
Amy
0.252
0.883
0.345
0.820
0.006
0.695


Hs.306221
AI057121
284695
chr1p22.2

Hs.306221_at
hypothetical protein FLJ20403
FLJ20403
Amy
0.830
1.006
0.345
0.953
0.008
0.813


Hs.30818
AK023743
91351
chr4q32.3

Hs.30818_at
hypothetical protein FLJ31033
FLJ31033
Amy
0.104
0.822
0.068
0.836
0.001
0.708


Hs.311559
NM_017617
4851
chr9q34.3
190198
Hs.311559_at
Notch homolog 1, translocation-
NOTCH1
Amy
0.103
0.953
0.853
0.990
0.026
0.833








associated (Drosophila)


Hs.312503
NM_018315
55294
chr4q31.3
606278
Hs.312503_at
F-box and WD-40 domain
FBXW7
Amy
0.449
1.143
0.852
1.012
0.021
1.333








protein 7 (archipelago homolog,









Drosophila)



Hs.313247
BC002331
54949
chr11q12.2

Hs.313247_at
hypothetical protein FLJ20487
FLJ20487
Amy
0.922
1.001
0.098
1.084
0.012
1.311


Hs.313
AB019562
6696
chr4q21-q25
166490
Hs.313_at
secreted phosphoprotein 1
SPP1
Amy
0.740
1.121
0.201
0.630
0.002
0.360








(osteopontin, bone sialoprotein








I, early T-lymphocyte activation








1)


Hs.315379
N24643
26118
chr17q11.1

Hs.315379_at
SOCS box-containing WD
WSB1
Amy
0.834
1.040
0.066
0.873
0.017
0.701








protein SWIP-1


Hs.31595
NM_005602
5010
chr3q26.2-q26.3
601326
Hs.31595_at
claudin 11 (oligodendrocyte
CLDN11
Amy
0.419
1.168
0.532
0.860
0.026
0.568








transmembrane protein)


Hs.317614
BQ022804
143903
chr11q23.2

Hs.317614+_at
layilin
L0C143903
Amy
0.482
1.059
0.292
0.747
0.026
0.496


Hs.318501
AA083478
10346
chr11p15
606559
Hs.318501_at
tripartite motif-containing 22
TRIM22
Amy
0.276
0.855
0.151
0.774
0.002
0.500


Hs.318529
BG258131
339983
chr4p16.3

Hs.318529_at
hypothetical protein FLJ37478
FLJ37478
Amy
0.762
1.044
0.526
1.042
0.011
1.257


Hs.32017
NM_020645
56675
chr11p15.3

Hs.32017_at
nuclear receptor interacting
NRIP3
Amy
0.085
1.169
0.271
1.098
0.004
1.242








protein 3


Hs.320834
AL136903
84937
chr16q22.3

Hs.320834_at
zinc and ring finger protein 1
ZNRF1
Amy
0.258
1.022
0.087
1.099
0.021
1.229


Hs.321164
NM_002518
4862
chr2q11.2
603347
Hs.321164_at
neuronal PAS domain protein 2
NPAS2
Amy
0.405
1.030
0.013
1.114
0.000
1.330


Hs.321653
AK022832
84134
chr1q23.3

Hs.321653_at
hypothetical protein FLJ12770
FLJ12770
Amy
0.695
1.022
0.127
1.166
0.016
1.361


Hs.323562
AL136636
84061
chrxq21.1

Hs.323562_at
implantation-associated protein
DKFZp564K142
Amy
0.731
0.927
0.308
0.778
0.046
0.704


Hs.323949




Hs.323949_at
kangai 1 (suppression of
KAI1
Amy
0.327
1.017
0.798
0.956
0.043
0.812








tumorigenicity 6, prostate; CD82








antigen (R2 leukocyte antigen,








antigen detected by monoclonal








and antibody IA4))


Hs.324051
NM_006663
10848
chr19q13.32
607463
Hs.324051_at
ReIA-associated inhibitor
RAI
Amy
0.425
0.872
0.206
0.852
0.024
0.733


Hs.333303
NM_000166
2705
chrxq13.1
304040
Hs.333303_at
gap junction protein, beta 1,
GJB1
Amy
0.782
0.964
0.872
1.031
0.045
0.800








32 kDa (connexin 32, Charcot-








Marie-Tooth neuropathy, X-








linked)


Hs.33461




Hs.33461_at
formin-like 2
FMNL2
Amy
0.791
1.036
0.193
0.816
0.021
0.763


Hs.334688
NM_014759
9796
chr8p21.3
608511
Hs.334688_at
phytanoyl-CoA hydroxylase
PHYHIP
Amy
0.645
1.140
0.237
1.097
0.028
1.328








interacting protein


Hs.334873
NM_001874
1368
chr12q14.3
114860
Hs.334873_at
carboxypeptidase M
CPM
Amy
0.099
0.917
0.530
0.957
0.001
0.831


Hs.33922
AL035369
92342
chr1q24.2

Hs.33922_at
hypothetical protein MGC9084
MGC9084
Amy
0.817
0.988
0.963
1.008
0.030
0.774


Hs.342307
NM_018061
55119
chr1p13.3

Hs.342307_at
hypothetical protein FLJ10330
FLJ10330
Amy
0.542
0.944
0.097
0.851
0.013
0.748


Hs.3459
NM_019116
56061
chr16p12

Hs.3459_at
similar to ubiquitin binding
UBPH
Amy
0.502
1.098
0.799
1.018
0.029
1.213








protein


Hs.347534
BE044440
57476
chr11q24.1

Hs.347534_at
KIAA1201 protein
KIAA1201
Amy
0.667
1.057
0.192
1.099
0.026
1.266


Hs.34780
NM_000555
1641
chrxq22.3-q23
300121
Hs.34780_at
doublecortex; lissencephaly, X-
DCX
Amy
0.427
1.058
0.280
1.116
0.022
1.286








linked (doublecortin)


Hs.348037
AA156998
94274
chr19q13.1
608153
Hs.348037_at
protein phosphatase 1,
PPP1R14A
Amy
0.423
1.157
0.623
0.876
0.043
0.618








regulatory (inhibitor) subunit








14A


Hs.348260
NM_014770
116986
chr12q14.1
605476
Hs.348260_at
centaurin, gamma 1
CENTG1
Amy
0.554
0.928
0.114
1.379
0.006
1.675


Hs.348415
NM_030786
81493
chr1p34.3-p33

Hs.348415_at
intermediate filament protein
SYNCOILIN
Amy
0.908
1.047
0.278
1.134
0.021
0.787








syncoilin


Hs.349227
NM_012219
22808
chr3q22.3
608435
Hs.349227_at
muscle RAS oncogene homolog
MRAS
Amy
0.596
0.915
0.250
1.072
0.014
1.247


Hs.349262
BF515750
128061
chr1q42.2

Hs.349262_at
hypothetical protein
DKFZp547B1713
Amy
0.349
0.975
0.864
0.981
0.013
0.774








DKFZp547B1713


Hs.349955
AV730849
122060
chr13q22.3

Hs.349955_at
hypothetical protein FLJ30046
FLJ30046
Amy
0.657
1.141
0.500
0.844
0.020
0.601


Hs.35086
AW499935
7398
chr1p32.1-p31.3
603478
Hs.35086_at
ubiquitin specific protease 1
USP1
Amy
0.424
1.173
0.858
1.017
0.048
0.813


Hs.351279
X76775
3108
chr6p21.3
142855
Hs.351279_at
major histocompatibility
HLA-DMA
Amy
0.779
1.024
0.087
0.683
0.020
0.519








complex, class II, DM alpha


Hs.351623
AK022955
55536
chr7p15.3

Hs.351623_at
transcription factor RAM2
RAM2
Amy
0.536
1.036
0.672
1.074
0.007
0.640


Hs.352153
NM_138818
158471
chr9q21.2

Hs.352153_at
chromosome 9 open reading
C9orf65
Amy
0.581
1.076
0.167
0.662
0.004
0.395








frame 65


Hs.352388
AI218954
157310
chr8p21.3

Hs.352388_at
hypothetical protein MGC22776
MGC22776
Amy
0.367
1.025
0.306
0.927
0.047
0.821


Hs.353087
N74056
57465
chr16p13.3

Hs.353087_at
KIAA1171 protein
KIAA1171
Amy
0.194
1.089
0.787
0.978
0.044
1.292


Hs.35380
BU689085
56987
chr3q13.1

Hs.35380_at
bobby sox homolog
BBX
Amy
0.654
0.978
0.540
0.917
0.029
0.819








(Drosophila)


Hs.355933
AI679968
84327
chr5q13.3

Hs.355933_at
zinc finger, BED domain
ZBED3
Amy
0.498
1.028
0.265
0.878
0.011
0.745








containing 3


Hs.356130




Hs.356130_at
proline rich membrane anchor 1
PRIMA1
Amy
0.816
0.962
0.264
0.743
0.012
0.520


Hs.356359
BF338045
126282
chr19p13.3

Hs.356359_at
hypothetical protein MGC17791
MGC17791
Amy
0.957
0.995
0.464
1.081
0.018
1.413


Hs.356416
AV648364
23492
chr22q13.1
608457
Hs.356416_at
chromobox homolog 7
CBX7
Amy
0.366
1.130
0.073
1.137
0.034
1.295


Hs.368109
AF285109
55964
chr22q13.2
608314
Hs.368109_at
septin 3
SEPT3
Amy
0.579
1.124
0.065
1.115
0.008
1.235


Hs.368861
NM_005163
207
chr14q32.32
164730
Hs.368861_at
v-akt murine thymoma viral
AKT1
Amy
0.893
0.995
0.523
0.963
0.023
1.231








oncogene homolog 1


Hs.369026
NM_004339
754
chr21q22.3
603784
Hs.369026_at
pituitary tumor-transforming 1
PTTG1IP
Amy
0.187
0.799
0.353
0.880
0.037
0.778








interacting protein


Hs.369288
NM_017797
55643
chr19p13.3
608531
Hs.369288_at
BTB (POZ) domain containing 2
BTBD2
Amy
0.723
1.079
0.005
1.176
0.044
1.366


Hs.369994
NM_004775
9331
chr18q11
604017
Hs.369994_at
UDP-Gal: betaGIcNAc beta 1,4-
B4GALT6
Amy
0.147
1.329
0.318
1.120
0.012
1.313








galactosyltransferase,








polypeptide 6


Hs.37054
AW189015
1944
chr1q21-q22
601381
Hs.37054_at
ephrin-A3
EFNA3
Amy
0.694
1.032
0.814
1.014
0.032
1.272


Hs.370873
NM_005531
3428
chr1q22
147586
Hs.370873_at
interferon, gamma-inducible
IFI16
Amy
0.173
0.950
0.091
0.830
0.000
0.611








protein 16


Hs.371416
AA551784
10498
chr19p13.2
603934
Hs.371416_at
coactivator-associated arginine
CARM1
Amy
0.381
1.112
0.347
1.056
0.003
1.307








methyltransferase 1


Hs.371468
BC000076
595
chr11q13
168461
Hs.371468_at
cyclin D1 (PRAD1: parathyroid
CCND1
Amy
0.203
0.926
0.286
0.918
0.037
0.773








adenomatosis 1)


Hs.371612
NM_022349
64231
chr11q12.1
606548
Hs.371612_at
membrane-spanning 4-
MS4A6A
Amy
0.302
0.974
0.286
0.981
0.049
0.830








domains, subfamily A, member








6A


Hs.372031
L03203
5376
chr17p12-p11.2
601097
Hs.372031_at
peripheral myelin protein 22
PMP22
Amy
0.825
1.060
0.659
0.882
0.017
0.622


Hs.374350
NM_016575
51559
chr12q22-q23.1

Hs.374350_at
TU12B1-TY protein
TU12B1-TY
Amy
0.978
1.003
0.169
1.136
0.013
1.279


Hs.374649
AB037854
55917
chr1p13.2

Hs.374649_at
hypothetical protein
DKFZp547A023
Amy
0.107
0.963
0.043
0.929
0.005
0.816








DKFZp547A023


Hs.376984
AI367319
6663
chr22q13.1
602229
Hs.376984_at
SRY (sex determining region
SOX10
Amy
0.736
1.030
0.668
0.919
0.045
0.747








Y)-box 10


Hs.377593
AA196034
79041
chr19p13.11

Hs.377593_at
hypothetical protein MGC3169
MGC3169
Amy
0.281
1.092
0.349
1.158
0.021
1.257


Hs.378949
NM_000328
6103
chrxp11.4
312610
Hs.378949_at
retinitis pigmentosa GTPase
RPGR
Amy
0.428
0.951
0.435
0.927
0.037
0.747








regulator


Hs.380089




Hs.380089_at
EphB6
EPHB6
Amy
0.809
1.072
0.530
1.044
0.041
1.335


Hs.380976
NM_016533
4815
chr12p13
607297
Hs.380976_at
ninjurin 2
NINJ2
Amy
0.959
1.009
0.769
0.885
0.028
0.466


Hs.381099
J02923
3936
chr13q14.3
153430
Hs.381099_at
lymphocyte cytosolic protein 1
LCP1
Amy
0.306
0.958
0.104
0.869
0.011
0.694








(L-plastin)


Hs.381256
NM_016433
51228
chr12q24.11

Hs.381256_at
glycolipid transfer protein
GLTP
Amy
0.709
0.973
0.156
0.796
0.012
0.674


Hs.382202
M80927
1116
chr1q32.1
601525
Hs.382202_at
chitinase 3-like 1 (cartilage
CHI3L1
Amy
0.066
0.797
0.065
0.601
0.021
0.555








glycoprotein-39)


Hs.38516
AI130705
375061
chr1q42.2

Hs.38516_at
hypothetical gene supported by
MGC15887
Amy
0.228
0.911
0.215
0.880
0.018
0.792








BC009447


Hs.387400
BG289001
253782
chr2q24.3

Hs.387400_at
hypothetical protein LOC253782
LOC253782
Amy
0.061
1.272
0.190
1.120
0.026
1.255


Hs.387579
NM_001769
928
chr12p13.3
143030
Hs.387579_at
CD9 antigen (p24)
CD9
Amy
0.533
1.251
0.871
0.955
0.008
0.525


Hs.387871
U57059
8743
chr3q26
603598
Hs.387871_at
tumor necrosis factor (ligand)
TNFSF10
Amy
0.141
0.896
0.160
0.747
0.010
0.542








superfamily, member 10


Hs.388126
AL035406
26038
chr1p36.31

Hs.388126_at
chromodomain helicase DNA
CHD5
Amy
0.104
1.068
0.323
1.065
0.003
1.337








binding protein 5


Hs.389057
NM_004647
8193
chr19q13.13-q13.2
601670
Hs.389057_at
D4, zinc and double PHD
DPF1
Amy
0.099
1.098
0.170
1.097
0.021
1.251








fingers family 1


Hs.389724
NM_006820
10964
chr1p31.1

Hs.389724_at
chromosome 1 open reading
C1orf29
Amy
0.148
0.642
0.084
0.602
0.001
0.437








frame 29


Hs.391858
BC015944
7072
chr2p13
603518
Hs.391858_at
TIA1 cytotoxic granule-
TIA1
Amy
0.688
1.027
0.713
0.984
0.034
0.814








associated RNA binding protein


Hs.392004
AI967971
87178
chr2p15

Hs.392004_at
polyribonucleotide
PNPT1
Amy
0.948
1.009
0.953
0.993
0.003
0.677








nucleotidyltransferase 1


Hs.39252
NM_007166
8301
chr11q14
603025
Hs.39252_at
phosphatidylinositol binding
PICALM
Amy
0.530
1.108
0.230
0.926
0.032
0.776








clathrin assembly protein


Hs.394609
BE622952
6272
chr1p21.3-p13.1
602458
Hs.394609_at
sortilin 1
SORT1
Amy
0.435
1.139
0.631
1.034
0.037
0.780


Hs.400383
BE963437
145567
chr14q32.12

Hs.400383_at
tetratricopeptide repeat domain
TTC7L1
Amy
0.427
1.061
0.020
1.172
0.008
1.245








7 like 1


Hs.400556
NM_003657
8537
chr20q13.2-q13.3
602968
Hs.400556_at
breast carcinoma amplified
BCAS1
Amy
0.943
0.993
0.810
0.970
0.017
0.774








sequence 1


Hs.40098
AF154054
26585
chr15q13-q15
603054
Hs.40098_at
cysteine knot superfamily 1,
CKTSF1B1
Amy
0.392
1.303
0.734
0.899
0.018
0.329








BMP antagonist 1


Hs.404930
NM_000271
4864
chr18q11-q12
607623
Hs.404930_at
Niemann-Pick disease, type C1
NPC1
Amy
0.368
1.140
0.446
0.878
0.004
0.602


Hs.406094
U87460
2861
chr7q31
602583
Hs.406094_at
G protein-coupled receptor 37
GPR37
Amy
0.654
1.185
0.475
0.724
0.007
0.381








(endothelin receptor type B-like)


Hs.406266
AI761561
3099
chr2p13
601125
Hs.406266_at
hexokinase 2
HK2
Amy
0.812
1.009
0.877
0.987
0.024
0.664


Hs.40637
NM_000950
5638
chrxp21.1
604428
Hs.40637_at
proline-rich Gla (G-
PRRG1
Amy
0.517
1.112
0.641
0.871
0.030
0.588








carboxyglutamic acid)








polypeptide 1


Hs.406397
NM_002055
2670
chr17q21
137780
Hs.406397_at
glial fibrillary acidic protein
GFAP
Amy
0.582
0.805
0.308
0.891
0.001
0695


Hs.406612
AL021707
25777
chr22q13.1

Hs.406612_at
unc-84 homolog B (C. elegans)
UNC84B
Amy
0.534
1.106
0.916
1.015
0.039
0.812


Hs.407474
BC035157
26033
chr10q26

Hs.407474_at
KIAA0534 protein
KIAA0534
Amy
0.117
1.219
0.250
1.144
0.023
1.518


Hs.408658
NM_004702
9134
chr8q22.1
603775
Hs.408658_at
cyclin E2
CCNE2
Amy
0.865
1.009
0.859
1.032
0.046
0.668


Hs.408767
AF007162
1410
chr11q22.3-q23.1
123590
Hs.408767_at
crystallin, alpha B
CRYAB
Amy
0.688
1.176
0.896
0.968
0.010
0.673


Hs.40919
BE967331
85365
chr9q22.33
607905
Hs.40919_at
asparagine-linked glycosylation
ALG2
Amy
0.195
1.099
0.679
0.957
0.043
0.821








2 homolog (yeast, alpha-1,3-








mannosyltransferase)


Hs.409826
BC006230
11343
chr3q21.3

Hs.409826_at
monoglyceride lipase
MGLL
Amy
0.844
0.963
0.219
1.117
0.036
1.369


Hs.410629
NM_144633
131096
chr3p24.3

Hs.410629_at
potassium voltage-gated
KCNH8
Amy
0.451
1.152
0.809
0.925
0.028
0.377








channel, subfamily H (eag-








related), member 8


Hs.411308
BF055343
117248
chr3p25.1

Hs.411308_at
UDP-N-acetyl-alpha-D-
GALNT7
Amy
0.473
0.933
0.528
0.912
0.000
0.592








galactosamine: polypeptide N-








acetylgalactosaminyltransferase 7


Hs.41135
NM_016242
51705
chr4q24
608350
Hs.41135_at
endomucin
EMCN
Amy
0.191
0.918
0.352
0.923
0.003
0.806


Hs.41154
U79264
7545
chr3q24
600470
Hs.41154_at
Zic family member 1 (odd-
ZIC1
Amy
0.625
0.905
0.345
0.831
0.038
0.648








paired homolog, Drosophila)


Hs.411865
NM_024658
79711
chr14q11.2

Hs.411865_at
importin 4
IPO4
Amy
0.974
0.998
0.405
0.950
0.015
0.814


Hs.411958
NM_018950
3134
chr6p21.3
143110
Hs.411958_at
major histocompatibility
HLA-F
Amy
0.679
1.015
0.345
0.953
0.027
0.795








complex, class I, F


Hs.412286
BG036668
84909
chr9q22.32

Hs.412286_at
hypothetical protein FLJ14675
FLJ14675
Amy
0.822
0.969
0.944
1.003
0.022
0.805


Hs.412468
BC001793
116138
chr6p21.1

Hs.412468_at
kelch domain containing 3
KLHDC3
Amy
0.173
1.297
0.078
1.130
0.022
1.306


Hs.412836
BC036122
84230
chr1p22.2

Hs.412836_at
hypothetical protein AD158
AD158
Amy
0.045
0.872
0.526
0.960
0.045
0.824


Hs.41296
NM_013281
23767
chr20p11
604808
Hs.41296_at
fibronectin leucine rich
FLRT3
Amy
0.025
1.104
0.777
0.976
0.005
1.267








transmembrane protein 3


Hs.414151
BQ024796
23500
chr6p21.1
606627
Hs.414151_at
dishevelled associated activator
DAAM2
Amy
0.776
1.143
0.997
0.999
0.024
0.753








of morphogenesis 2


Hs.414164
AB037845
57584
chr10p12.1

Hs.414164_at
Rho GTPase activating protein
ARHGAP21
Amy
0.468
0.913
0.231
0.888
0.045
0.755








21


Hs.414362
NM_016229
51700
chr11p15.4
608342
Hs.414362_at
cytochrome b5 reductase b5R.2
CYB5R2
Amy
0.257
1.222
0.610
0.831
0.021
0.479


Hs.414390
NM_005861
10273
chr16p13.3
607207
Hs.414390_at
STIP1 homology and U-Box
STUB1
Amy
0.706
1.113
0.078
1.118
0.045
1.220








containing protein 1


Hs.414455
AU146275
7716
chr17q23.2
606747
Hs.414455_at
zinc finger protein 161
ZNF161
Amy
0.950
1.012
0.320
0.847
0.004
0.698


Hs.414728
AK022549
23446
chr9q31.2
606105
Hs.414728_at
choline transporter-like protein 1
CTL1
Amy
0.462
1.115
0.797
0.937
0.013
0.580


Hs.4147
BC000687
23471
chr8q13.3
605190
Hs.4147_at
translocation associated
TRAM1
Amy
0.900
1.017
0.168
0.887
0.044
0.789








membrane protein 1


Hs.41502
NM_024633
79686
chr14q32.13

Hs.41502_at
chromosome 14 open reading
C14orf139
Amy
0.742
0.954
0.869
0.964
0.025
0.693








frame 139


Hs.415240
AL512757
81844
chr7q22.1

Hs.415240_at
tripartite motif-containing 56
TRIM56
Amy
0.492
0.959
0.582
0.945
0.004
0.770


Hs.416026
NM_002971
6304
chr3p23
602075
Hs.416026_at
special AT-rich sequence
SATB1
Amy
0.554
1.049
0.552
0.959
0.045
1.276








binding protein 1 (binds to








nuclear matrix/scaffold-








associating DNA's


Hs.417004
NM_005620
6282
chr1q21
603114
Hs.417004_at
S100 calcium binding protein
S100A11
Amy
0.160
0.931
0.316
0.838
0.008
0.687








A11 (calgizzarin)


Hs.418542
AF418285
25953
chr2q35

Hs.418542_at
myofibrillogenesis regulator 1
MR-1
Amy
0.701
1.059
0.330
1.090
0.005
1.254


Hs.418692
AF135266
26471
chr16p11.2

Hs.418692_at
p8 protein (candidate of
P8
Amy
0.830
1.014
0.963
0.994
0.023
0.756








metastasis 1)


Hs.421457
NM_003164
6811
chr11q12.3
603189
Hs.421457_at
syntaxin 5A
STX5A
Amy
0.453
1.038
0.016
1.164
0.026
1.234


Hs.42771
BC015877
28513
chr18q22-q23
603016
Hs.42771_at
cadherin 19, type 2
CDH19
Amy
0.821
0.986
0.356
0.887
0.029
0.673


Hs.429643
AY004175
23236
chr20p12
607120
Hs.429643_at
phospholipase C, beta 1
PLCB1
Amy
0.309
1.173
0.479
0.946
0.002
1.283








(phosphoinositide-specific)


Hs.429961
NM_018475
55858
chr4q12

Hs.429961_at
TPA regulated locus
TPARL
Amy
0.463
1.124
0.908
1.018
0.042
0.676


Hs.430156
NM_015993
51090
chr16q13
600340
Hs.430156_at
transmembrane 4 superfamily
TM4SF11
Amy
0.794
0.945
0.563
0.840
0.036
0.564








member 11 (plasmolipin)


Hs.430606
BC000105
1431
chr12q13.2-q13.3
118950
Hs.430606_at
citrate synthase
CS
Amy
0.753
1.117
0.513
1.076
0.039
1.461


Hs.432574
U37689
5437
chr3q28
606023
Hs.432574_at
polymerase (RNA) II (DNA
POLR2H
Amy
0.915
1.007
0.075
1.114
0.021
1.281








directed) polypeptide H


Hs.432648




Hs.432648_at
heat shock 70 kDa protein 2
HSPA2
Amy
0.622
1.177
0.741
0.888
0.010
0.571


Hs.432726
AI953478
134359
chr5q13.3

Hs.432726_at
hypothetical protein FLJ35779
FLJ35779
Amy
0.068
0.939
0.027
0.862
0.027
0.832


Hs.432945
AW194999
122416
chr14q32.32

Hs.432945_at
ankyrin repeat domain 9
ANKRD9
Amy
0.865
1.013
0.229
1.093
0.039
1.236


Hs.433159
NM_000803
2350
chr11q13.3-q13.5
136425
Hs.433159_at
folate receptor 2 (fetal)
FOLR2
Amy
0.959
0.993
0.108
0.915
0.034
0.781


Hs.433300
BC020763
2207
chr1q23
147139
Hs.433300_at
Fc fragment of IgE, high affinity
FCER1G
Amy
0.030
0.906
0.064
0.715
0.006
0.421








I, receptor for, gamma








polypeptide


Hs.433328
NM_019056
54539
chrxp11.3
300403
Hs.433328_at
neuronal protein 17.3
P17.3
Amy
0.410
1.081
0.332
1.091
0.041
1.286


Hs.433452
AA121502
57493
chr3q21.2

Hs.433452_at
HEG homolog
HEG
Amy
0.022
0.863
0.041
0.848
0.030
0.800


Hs.433573
AF073483
83638
chr11q13.1

Hs.433573_at
hypothetical protein p5326
P5326
Amy
0.341
1.040
0.597
1.038
0.029
1.213


Hs.433574
N95026
23543
chr22q13.1

Hs.433574_at
RNA binding motif protein 9
RBM9
Amy
0.401
1.146
0.491
1.043
0.016
1.321


Hs.433732
AI251890
1195
chr2q33
601951
Hs.433732_at
CDO-like kinase 1
CLK1
Amy
0.783
0.949
0.106
0.837
0.004
0.612


Hs.433753
NM_004710
9144
chr17q25.3
603926
Hs.433753_at
synaptogyrin 2
SYNGR2
Amy
0.122
1.103
0.635
0.944
0.003
0.727


Hs.433839
NM_001958
1917
chr20q13.3
602959
Hs.433839_at
eukaryotic translation elongation
EEF1A2
Amy
0.468
1.373
0.039
1.168
0.030
1.371








factor 1 alpha 2


Hs.434004
AL527773
29
chr17p13.3
600365
Hs.434004_at
active BCR-related gene
ABR
Amy
0.228
1.230
0.022
1.147
0.014
1.297


Hs.434418
AF036943
23040
chr2p25.3

Hs.434418_at
myelin transcription factor 1-like
MYT1L
Amy
0.331
1.121
0.061
1.031
0.049
1.228


Hs.434488
BF590263
1462
chr5q14.3
118661
Hs.434488_at
chondroitin sulfate proteoglycan
CSPG2
Amy
0.311
0.875
0.288
0.845
0.022
0.693








2 (versican)


Hs.434502
AW242125
159195
chr10q22.2

Hs.434502_at
chromosome 10 open reading
C10orf29
Amy
0.974
0.997
0.437
0.881
0.015
0.696








frame 29


Hs.435166
NM_002296
3930
chr1q42.1
600024
Hs.435166_at
lamin B receptor
LBR
Amy
0.914
1.016
0.617
0.931
0.015
0.653


Hs.435295
NM_018965
54209
chr6p21.1
605086
Hs.435295_at
triggering receptor expressed
TREM2
Amy
0.330
0.984
0.323
0.979
0.018
0.727








on myeloid cells 2


Hs.435326
NM_004301
86
chr3q26.33
604958
Hs.435326_at
BAF53
BAF53A
Amy
0.510
0.917
0.378
0.783
0.007
0.602


Hs.435670
NM_002067
2767
chr19p13.3
139313
Hs.435670_at
guanine nucleotide binding
GNA11
Amy
0.586
1.047
0.121
1.077
0.003
1.233








protein (G protein), alpha 11








(Gq class)


Hs.435786
AF465485
783
chr10p12
600003
Hs.435786_at
calcium channel, voltage-
CACNB2
Amy
0.055
1.297
0.080
1.244
0.043
1.516








dependent, beta 2 subunit


Hs.435800
AI520969
7431
chr10p13
193060
Hs.435800_at
vimentin
VIM
Amy
0.130
0.871
0.925
0.983
0.007
0.784


Hs.435976
AW593887
56853
chr18q12

Hs.435976_at
bruno-like 4, RNA binding
BRUNOL4
Amy
0.263
1.050
0.697
1.027
0.013
1.212








protein (Drosophila)


Hs.436066
AF000425
7940
chr6p21.3
109170
Hs.436066_at
leukocyte specific transcript 1
LST1
Amy
0.429
0.948
0.463
0.940
0.025
0.751


Hs.436196
BC036809
9639
chr8p23
608136
Hs.436196_at
Rho guanine nucleotide
ARHGEF10
Amy
0.870
0.992
0.540
0.944
0.020
0.768








exchange factor (GEF) 10


Hs.436325
NM_004984
3798
chr12q13.13
602821
Hs.436325_at
kinesin family member 5A
KIF5A
Amy
0.608
1.109
0.172
1.152
0.044
1.611


Hs.436488
AA102574
11177
chr14q12-q13
605680
Hs.436488_at
bromodomain adjacent to zinc
BAZ1A
Amy
0.525
0.961
0.127
0.875
0.000
0.635








finger domain, 1A


Hs.436494
NM_021219
58494
chr21q21.2
606870
Hs.436494_at
junctional adhesion molecule 2
JAM2
Amy
0.428
0.916
0.101
0.807
0.017
0.761


Hs.436542
AF142573
83690
chr8q21.11

Hs.436542_at
CocoaCrisp
LOC83690
Amy
0.349
1.109
0.785
0.972
0.000
0.651


Hs.436596
AL583171
10193
chr12q13.2-q13.3

Hs.436596_at
ring finger protein 41
RNF41
Amy
0.221
1.158
0.077
1.187
0.033
1.212


Hs.436617
AV715391
115106
chr18q21.1
608775
Hs.436617_at
coiled-coil domain containing 5
CCDC5
Amy
0.320
0.838
0.133
0.860
0.016
0.833








(spindle associated)


Hs.436667
AI986390
139728
chrxq28

Hs.436667_at
Similar to calcium/calmodulin-
MGC45419
Amy
0.139
1.178
0.187
1.141
0.011
1.295








dependent protein kinase 1,








beta


Hs.436847
AI141670
131408
chr3q27.1

Hs.436847_at
hypothetical protein MGC21688
MGC21688
Amy
0.092
1.237
0.098
1.112
0.048
1.203


Hs.437257
BF308645
57580
chr20q13.13
606905
Hs.437257_at
phosphatidylinositol 3,4,5-
PREX1
Amy
0.931
0.985
0.769
0.945
0.019
0.766








trisphosphate-dependent RAC








exchanger 1


Hs.437277
NM_014275
11282
chr5q35
604561
Hs.437277_at
mannosyl (alpha-1,3-)-
MGAT4B
Amy
0.903
1.021
0.289
1.086
0.021
1.220








glycoprotein beta-1,4-N-








acetylglucosaminyltransferase,








isoenzyme B


Hs.437362
AB051515
85461
chr2q24.2

Hs.437362_at
KIAA1728 protein
KIAA1728
Amy
0.719
1.015
0.165
0.804
0.012
0.709


Hs.437632
AY029176
80333
chr4p15.31
608182
Hs.437632_at
Kv channel interacting protein 4
KCNIP4
Amy
0.054
1.268
0.116
1.232
0.021
1.541


Hs.437819
BF058311
146059
chr15q14
607465
Hs.437819_at
congenital dyserythropoietic
CDAN1
Amy
0.196
0.877
0.642
0.962
0.026
0.828








anemia, type I


Hs.438691
NM_021971
29925
chr3p21.31

Hs.438691_at
GDP-mannose
GMPPB
Amy
0.746
1.048
0.133
1.097
0.021
1.220








pyrophosphorylase B


Hs.438720
D55716
4176
chr7q21.3-q22.1
600592
Hs.438720_at
MCM7 minichromosome
MCM7
Amy
0.364
0.972
0.591
0.987
0.026
0.830








maintenance deficient 7 (S. cerevisiae)


Hs.43910
NM_006016
8763
chr6q21
603356
Hs.43910_at
CD164 antigen, sialomucin
CD164
Amy
0.875
0.959
0.303
1.095
0.015
0.748


Hs.43913
NM_006346
10464
chr13q22.1
607532
Hs.43913_at
progesterone-induced blocking
PIBF1
Amy
0.112
0.889
0.994
0.999
0.004
0.720








factor 1


Hs.439188
AF479418
23063
chr10q23.2

Hs.439188_at
KIAA0261
KIAA0261
Amy
0.345
1.065
0.847
0.989
0.020
0.815


Hs.439190
N30138
122786
chr14q22.1

Hs.439190_at
chromosome 14 open reading
C14orf31
Amy
0.762
0.958
0.314
0.912
0.006
0.754








frame 31


Hs.439463
NM_001129
165
chr7p13
602981
Hs.439463_at
AE binding protein 1
AEBP1
Amy
0.488
0.940
0.288
0.855
0.006
0.718


Hs.439599
NM_002372
4124
chr5q21-q22
154582
Hs.439599_at
mannosidase, alpha, class 2A,
MAN2A1
Amy
0.340
1.238
0.886
0.971
0.045
0.595








member 1


Hs.439671
NM_005380
4681
chr1p36.13-p36.11
600613
Hs.439671_at
neuroblastoma, suppression of
NBL1
Amy
0.348
1.113
0.022
1.173
0.003
1.318








tumorigenicity 1


Hs.440379
NM_014715
9743
chr11q24-q25
608541
Hs.440379_at
Rho GTPase-activating protein
RICS
Amy
0.948
0.990
0.339
1.095
0.040
1.213


Hs.44038
NM_021255
57161
chr14q21

Hs.44038_at
pellino homolog 2 (Drosophila)
PELI2
Amy
0.183
0.916
0.152
0.798
0.046
0.786


Hs.440401
AK098125
54884
chr2p11.2

Hs.440401_at
hypothetical protein FLJ20296
FLJ20296
Amy
0.194
1.123
0.768
0.966
0.003
0.751


Hs.440497
AL520102
8514
chr1p36.3
601142
Hs.440497_at
potassium voltage-gated
KCNAB2
Amy
0.300
1.181
0.033
1.143
0.042
1.251








channel, shaker-related








subfamily, beta member 2


Hs.440808
AB011126
23048
chr9q34
606191
Hs.440808_at
formin binding protein 1
FNBP1
Amy
0.589
1.048
0.560
0.929
0.043
0.764


Hs.441281
AF242529
29993
chr6p21.3
606512
Hs.441281_at
protein kinase C and casein
PACSIN1
Amy
0.078
1.160
0.035
1.131
0.012
1.287








kinase substrate in neurons 1


Hs.442733
M63310
306
chr4q13-q22
106490
Hs.442733_at
annexin A3
ANXA3
Amy
0.321
0.803
0.050
0.667
0.013
0.617


Hs.44313
NM—002908
5966
chr2p13-p12
164910
Hs.44313_at
v-rel reticuloendotheliosis viral
REL
Amy
0.113
0.910
0.067
0.789
0.001
0.726








oncogene homolog (avian)


Hs.443435
NM_001797
1009
chr16q22.1
600023
Hs.443435_at
cadherin 11, type 2, OB-
CDH11
Amy
0.517
1.057
0.539
0.952
0.037
0.818








cadherin (osteoblast)


Hs.443468
AL133031
254251
chr4p15.32

Hs.443468_at
chromosome condensation
HCAP-G
Amy
0.515
0.964
0.957
0.993
0.021
0.797








protein G


Hs.443495
AW235051
80777
chr16q22.1

Hs.443495_at
cytochrome b5 outer
CYB5-M
Amy
0.081
1.113
0.172
1.072
0.035
1.224








mitochondrial membrane








precursor


Hs.443836
AK098048
1267
chr17q21
123830
Hs.443836_at
2′,3′-cyclic nucleotide 3′
CNP
Amy
0.408
1.207
0.702
0.907
0.018
0.634








phosphodiesterase


Hs.444327
NM_004251
9367
chrxp22.2
300284
Hs.444327_at
RAB9A, member RAS
RAB9A
Amy
0.630
1.067
0.208
1.225
0.008
0.766








oncogene family


Hs.44439
NM_016387
9306
chr18q22.2
605118
Hs.44439_at
suppressor of cytokine signaling 4
SOCS4
Amy
0.769
0.925
0.444
0.888
0.020
0.720


Hs.444445
NM_003078
6604
chr7q35-q36
601737
Hs.444445_at
SWI/SNF related, matrix
SMARCD3
Amy
0.422
1.135
0.119
1.166
0.007
1.243








associated, actin dependent








regulator of chromatin,








subfamily d, member 3


Hs.444510
NM_030984
6916
chr7q34-q35
274180
Hs.444510_at
thromboxane A synthase 1
TBXAS1
Amy
0.346
1.038
0.537
1.029
0.004
0.829








(platelet, cytochrome P450,








family 5, subfamily A)


Hs.444983




Hs.444983_at
purinergic receptor P2Y, G-
P2RY12
Amy
0.340
0.795
0.106
0.783
0.019
0.344








protein coupled, 12


Hs.445489
AF081583
58473
chr11q13.5-q14.1
607651
Hs.445489_at
pleckstrin homology domain
PLEKHB1
Amy
0.965
0.975
0.771
0.955
0.018
0.788








containing, family B (evectins)








member 1


Hs.446325
AL353746
158038
chr9p21.2-p21.1

Hs.446325_at
hypothetical protein FLJ31810
FLJ31810
Amy
0.674
1.061
0.082
1.139
0.018
1.406


Hs.446471
M28590
972
chr5q32
142790
Hs.446471_at
CD74 antigen (invariant
CD74
Amy
0.746
0.994
0.113
0.781
0.006
0.434








polypeptide of major








histocompatibility complex,








class II antigen-associated)


Hs.446677




Hs.446677_at
zinc finger protein 238
ZNF238
Amy
0.252
1.260
0.137
1.161
0.034
1.432


Hs.448805
AF202640
51704
chr16p12
605948
Hs.448805_at
G protein-coupled receptor,
GPRC5B
Amy
0.771
0.915
0.795
0.937
0.021
0.680








family C, group 5, member B


Hs.449718
AL521682
338773
chr12q23.3

Hs.449718_at
hypothetical protein LOC338773
LOC338773
Amy
0.117
0.953
0.366
0.982
0.017
0.794


Hs.45056
NM_052904
114792
chr6q16.1

Hs.45056_at
KIAA1900
KIAA1900
Amy
0.500
1.163
0.430
0.825
0.014
0.567


Hs.456
NM_000897
4056
chr5q35
246530
Hs.456_at
leukotriene C4 synthase
LTC4S
Amy
0.398
1.038
0.087
0.842
0.035
0.774


Hs.458291
NM_000297
5311
chr4q21-q23
173910
Hs.458291_at
polycystic kidney disease 2
PKD2
Amy
0.621
0.869
0.225
0.894
0.012
0.726








(autosomal dominant)


Hs.458320
AI937543
56941
chr3q21.3

Hs.458320_at
DC12 protein
DC12
Amy
0.327
1.053
0.275
1.075
0.042
1.241


Hs.458335




Hs.458335_at
chromosome 21 open reading
C21orf97
Amy
0.891
1.019
0.142
1.078
0.021
1.228








frame 97


Hs.458354
NM_003247
7058
chr6q27
188061
Hs.458354_at
thrombospondin 2
THBS2
Amy
0.825
0.934
0.201
0.729
0.033
0.537


Hs.458482
NM_004276
9478
chr12q24.31
605563
Hs.458482_at
calcium binding protein 1
CABP1
Amy
0.916
1.038
0.778
1.033
0.010
1.551








(calbrain)


Hs.459470
NM_018639
55884
chr12q24.23

Hs.459470_at
WD repeat and SOCS box
WSB2
Amy
0.248
1.124
0.131
1.085
0.029
1.281








containing protein 2


Hs.459987
AV712577
10541
chr9q22.32

Hs.459987_at
acidic (leucine-rich) nuclear
ANP32B
Amy
0.564
1.085
0.513
0.929
0.032
0.762








phosphoprotein 32 family,








member B


Hs.461300
AK054714
126661
chr1p34.1

Hs.461300−_at
hypothetical protein LOC126661
LOC126661
Amy
0.782
0.976
0.530
0.980
0.022
0.765


Hs.46440
NM_021094
6579
chr12p12
602883
Hs.46440_at
solute carrier organic anion
SLCO1A2
Amy
0.805
1.012
0.576
1.046
0.001
0.586








transporter family, member 1A2


Hs.47061
AB018265
8408
chr12q24.3
603168
Hs.47061_at
unc-51-like kinase 1 (C.
ULK1
Amy
0.734
1.099
0.146
1.091
0.013
1.386









elegans)



Hs.47357
NM_003956
9023
chr10q23
604551
Hs.47357_at
cholesterol 25-hydroxylase
CH25H
Amy
0.158
0.903
0.137
0.675
0.035
0.700


Hs.47517
NM_005619
6253
chr19q13.32
603183
Hs.47517_at
reticulon 2
RTN2
Amy
0.076
1.208
0.059
1.161
0.022
1.336


Hs.475848
NM_017512
55556
chr18p11.32
607427
Hs.475848_at
rTS beta protein
HSRTSBETA
Amy
0.476
1.093
0.656
1.089
0.028
0.614


Hs.4766
NM_014077
26017
chr19pter-p13.3

Hs.4766_at
DKFZP586O0120 protein
DKFZP586O
Amy
0.246
1.261
0.201
1.111
0.038
1.205









0120


Hs.479888
NM_173808
257194
chr1p31.1

Hs.479888_at
neuronal growth regulator 1
NEGR1
Amy
0.067
1.473
0.382
1.094
0.013
1.374


Hs.484950




Hs.484950_at
histone 1, H2ac
HIST1H2AC
Amy
0.624
1.114
0.585
0.757
0.002
0.427


Hs.48516
NM_004048
567
chr15q21-q22.2
109700
Hs.48516_at
beta-2-microglobulin
B2M
Amy
0.798
0.950
0.303
0.929
0.001
0.760


Hs.4859
AF367476
57018
chr3q25.31

Hs.4859_at
cyclin L1
CCNL1
Amy
0.013
0.948
0.808
0.987
0.006
0.828


Hs.48998
AF169676
23768
chr14q24-q32
604807
Hs.48998_at
fibronectin leucine rich
FLRT2
Amy
0.970
0.997
0.946
1.004
0.008
1.213








transmembrane protein 2


Hs.4980
NM_001290
9079
chr4p16
603450
Hs.4980_at
LIM domain binding 2
LDB2
Amy
0.083
1.231
0.180
1.119
0.029
1.622


Hs.498494




Hs.498494_at
paired basic amino acid
PACE4
Amy
0.233
1.199
0.609
0.866
0.020
0.526








cleaving system 4


Hs.4993
AB037734
57526
chrXq13.3
300460
Hs.4993_at
protocadherin 19
PCDH19
Amy
0.988
1.001
0.117
1.084
0.014
1.293


Hs.499659
AK000478
23108
chr17p13.3

Hs.499659_at
KIAA1039 protein
KIAA1039
Amy
0.054
1.098
0.114
1.127
0.004
1.495


Hs.500197
NM_006695
10900
chr17q21.31
605448
Hs.500197_at
RaP2 interacting protein 8
RPIP8
Amy
0.595
1.105
0.040
1.157
0.006
1.402


Hs.508459
NM_153456
266722
chr13q32.1

Hs.508459_at
heparan sulfate 6-O-
HS6ST3
Amy
0.349
1.039
0.245
1.096
0.039
1.242








sulfotransferase 3


Hs.509841
NM_014989
22999
chr6q12-q13
606629
Hs.509841_at
regulating synaptic membrane
RIMS1
Amy
0.209
1.081
0.062
1.089
0.022
1.217








exocytosis 1


Hs.511745
NM_006317
10409
chr5p15.1-p14
605940
Hs.511745_at
brain abundant, membrane
BASP1
Amy
0.150
1.152
0.084
1.094
0.040
1.294








attached signal protein 1


Hs.511922
AF261715
219595
chr11q14.3

Hs.511922_at
prostate-specific membrane
PSMAL/GCP
Amy
0.652
1.046
0.714
0.912
0.036
0.575








antigen-like protein
III


Hs.511936




Hs.511936_at
ring finger protein 44
RNF44
Amy
0.113
1.166
0.007
1.162
0.008
1.270


Hs.511952
AI458128
23466
chr22q13.1

Hs.511952_at
chromobox homolog 6
CBX6
Amy
0.443
1.154
0.026
1.137
0.009
1.242


Hs.512000
NM_000407
2812
chr22q11.21
138720
Hs.512000_at
glycoprotein lb (platelet), beta
GP1BB
Amy
0.318
1.100
0.209
1.137
0.047
1.236








polypeptide


Hs.512319
BC018336
374875
chr19p13.3

Hs.512319_at
short-chain
SCDR10
Amy
0.562
1.068
0.089
1.106
0.015
1.233








dehydrogenase/reductase 10


Hs.512651
AL390158
56970
chr17q21.31

Hs.512651_at
hypothetical protein
DKFZp761G
Amy
0.716
1.034
0.052
1.096
0.022
1.241








DKFZp761G2113
2113


Hs.523532
BC034024
758
chr22q13.31
602112
Hs.523532_at
chromosome 22 open reading
C22orf1
Amy
0.663
0.965
0.400
0.876
0.003
0.635








frame 1


Hs.528148
AA736604
57471
chr2q24.2

Hs.528148_at
KIAA1189 protein
KIAA1189
Amy
0.417
1.412
0.846
0.934
0.022
0.599


Hs.53066
NM_012267
23640
chr19q13.42

Hs.53066_at
hsp70-interacting protein
HSPBP1
Amy
0.210
1.086
0.318
1.073
0.027
1.321


Hs.54483
NM_004688
9111
chr2p24.3-q21.3
603525
Hs.54483_at
N-myc (and STAT) interactor
NMI
Amy
0.427
0.985
0.811
0.976
0.000
0.523


Hs.5452
NM_006676
10868
chr9q34.11

Hs.5452_at
ubiquitin specific protease 20
USP20
Amy
0.160
1.086
0.037
1.060
0.004
1.211


Hs.54697
AI625739
23229
chrxq11.2
300429
Hs.54697_at
Cdc42 guanine nucleotide
ARHGEF9
Amy
0.421
1.220
0.050
1.165
0.021
1.342








exchange factor (GEF) 9


Hs.5509
BC005926
2124
chr17q11.2
158381
Hs.5509_at
ecotropic viral integration site
EVI2B
Amy
0.336
0.928
0.099
0.802
0.006
0.495








2B


Hs.55209
BC030654
91833
chr14q32.32

Hs.55209_at
WD repeat domain 20
WDR20
Amy
0.654
1.018
0.470
0.949
0.023
0.786


Hs.552
NM_001047
6715
chr5p15
184753
Hs.552_at
steroid-5-alpha-reductase,
SRD5A1
Amy
0.468
1.035
0.121
1.183
0.018
1.297








alpha polypeptide 1 (3-oxo-5








alpha-steroid delta 4-








dehydrogenase alpha 1)


Hs.56607
BC006080
7462
chr7q11.23
605719
Hs.56607_at
Williams-Beuren syndrome
WBSCR5
Amy
0.489
0.967
0.228
0.901
0.005
0.712








chromosome region 5


Hs.5737
BF115776
9917
chr1p36.13-q41

Hs.5737_at
family with sequence similarity
FAM20B
Amy
0.345
1.229
0.076
1.135
0.003
1.231








20, member B


Hs.57856
NM_012395
5218
chr7q21-q22

Hs.57856_at
PFTAIRE protein kinase 1
PFTK1
Amy
0.062
1.213
0.987
1.001
0.004
1.273


Hs.57937
NM_145892
54715
chr16p13.3
605104
Hs.57937_at
ataxin 2-binding protein 1
A2BP1
Amy
0.191
1.222
0.133
1.145
0.019
1.461


Hs.58351
AK090894
10351
chr17q24

Hs.58351_at
ATP-binding cassette, sub-
ABCA8
Amy
0.521
1.364
0.414
0.693
0.011
0.370








family A (ABC1), member 8


Hs.58617
AL049383
9475
chr2p24
604002
Hs.58617_at
Rho-associated, coiled-coil
ROCK2
Amy
0.721
1.122
0.796
0.978
0.035
1.244








containing protein kinase 2


Hs.60177
AL568422
22873
chr13q32.1
608671
Hs.60177_at
DAZ interacting protein 1
DZIP1
Amy
0.407
1.158
0.031
1.143
0.015
1.273


Hs.62180
NM_018685
54443
chr7p15-p14

Hs.62180_at
anillin, actin binding protein
ANLN
Amy
0.458
1.293
0.739
0.864
0.011
0.514








(scraps homolog, Drosophila)


Hs.62661
BC002666
2633
chr1p22.2
600411
Hs.62661_at
guanylate binding protein 1,
GBP1
Amy
0.943
1.004
0.384
0.927
0.004
0.555








interferon-inducible, 67 kDa


Hs.6479
BC006299
84315
chr3p21.31

Hs.6479_at
hypothetical protein MGC13272
MGC13272
Amy
0.263
1.074
0.393
1.076
0.018
1.220


Hs.65239
AW026241
6330
chr11q23.3
608256
Hs.65239_at
sodium channel, voltage-gated,
SCN4B
Amy
0.836
0.957
0.702
1.051
0.028
1.428








type IV, beta


Hs.65848
AL136594
84258
chr19q13.33
600327
Hs.65848_at
synaptotagmin III
SYT3
Amy
0.635
1.050
0.176
1.120
0.038
1.299


Hs.66159
AB037820
57574
chr2q35
608208
Hs.66159_at
KIAA1399 protein
KIAA1399
Amy
0.402
1.034
0.108
1.130
0.034
1.231


Hs.66309
BC004875
84272
chr2p22.3

Hs.66309_at
hypothetical protein MGC11061
MGC11061
Amy
0.688
1.030
0.657
0.938
0.028
0.770


Hs.6658
BE221674
152404
chr3q13.32
608351
Hs.6658_at
immunoglobulin superfamily,
IGSF11
Amy
0.391
0.892
0.785
0.928
0.050
0.701








member 11


Hs.66708
BC003570
9341
chr1p36.23
603657
Hs.66708_at
vesicle-associated membrane
VAMP3
Amy
0.926
0.981
0.936
1.014
0.038
0.762








protein 3 (cellubrevin)


Hs.6820
AF413522
219771
chr10p11.21

Hs.6820_at
chromosome 10 open reading
C10orf9
Amy
0.226
1.173
0.013
1.143
0.022
1.214








frame 9


Hs.6900
AF070558
11342
chr3q25.1

Hs.6900_at
ring finger protein 13
RNF13
Amy
0.914
1.022
0.956
0.994
0.015
0.707


Hs.70327
U36190
1397
chr14q32.3
601183
Hs.70327_at
cysteine-rich protein 2
CRIP2
Amy
0.448
1.228
0.080
1.328
0.042
1.417


Hs.70499
NM_014210
2123
chr17q11.2
158380
Hs.70499_at
ecotropic viral integration site
EVI2A
Amy
0.213
1.640
0.533
0.756
0.005
0.428








2A


Hs.72325
BF694956
135114
chr6q22.32

Hs.72325_at
histidine triad nucleotide binding
HINT3
Amy
0.364
1.137
0.077
1.424
0.021
1.219








protein 3


Hs.72782
AK023183
55783
chr16q22.2

Hs.72782_at
hypothetical protein FLJ11171
FLJ11171
Amy
0.329
0.893
0.350
0.855
0.020
0.635


Hs.74376
NM_006334
10439
chr9q34.3
605366
Hs.74376_at
olfactomedin 1
OLFM1
Amy
0.347
1.196
0.343
1.062
0.013
1.436


Hs.74569
AB020649
23207
chr1p36.13

Hs.74569_at
KIAA0842 protein
KIAA0842
Amy
0.513
0.937
0.303
1.052
0.036
1.297


Hs.75082
NM_001665
391
chr11p15.5-p15.4
179505
Hs.75082_at
ras homolog gene family,
ARHG
Amy
0.058
0.839
0.191
0.828
0.010
0.747








member G (rho G)


Hs.75236
NM_021952
1996
chr1p34
168360
Hs.75236_at
ELAV (embryonic lethal,
ELAVL4
Amy
0.220
1.198
0.791
1.022
0.049
1.374








abnormal vision, Drosophila)-








like 4 (Hu antigen D)


Hs.75256
NM_002922
5996
chr1q31
600323
Hs.75256_at
regulator of G-protein signalling 1
RGS1
Amy
0.181
0.870
0.320
0.554
0.042
0.280


Hs.75438
BC000576
5860
chr4p15.31
261630
Hs.75438_at
quinoid dihydropteridine
QDPR
Amy
0.551
1.083
0.527
0.940
0.038
0.747








reductase


Hs.75452
NM_005345
3303
chr6p21.3
140550
Hs.75452_at
heat shock 70 kDa protein 1A
HSPA1A
Amy
0.191
1.355
0.520
0.870
0.017
0.645


Hs.75462
BG339064
7832
chr1q32
601597
Hs.75462_at
BTG family, member 2
BTG2
Amy
0.084
0.801
0.158
0.764
0.031
0.721


Hs.75671
NM_004603
6804
chr7q11.23
186590
Hs.75671_at
syntaxin 1A (brain)
STX1A
Amy
0.061
1.140
0.090
1.097
0.034
1.297


Hs.75794
AW269335
1902
chr9q31.3
602282
Hs.75794_at
endothelial differentiation,
EDG2
Amy
0.982
0.996
0.941
0.984
0.029
0.687








lysophosphatidic acid G-protein-








coupled receptor, 2


Hs.76057
AK096127
2582
chr1p36-p35
606953
Hs.76057_at
galactose-4-epimerase, UDP-
GALE
Amy
0.157
1.223
0.799
1.023
0.028
1.338


Hs.76224
AI826799
2202
chr2p16
601548
Hs.76224_at
EGF-containing fibulin-like
EFEMP1
Amy
0.142
0.496
0.089
0.520
0.027
0.502








extracellular matrix protein 1


Hs.76289
NM_000713
645
chr19q13.1-q13.2
600941
Hs.76289_at
biliverdin reductase B (flavin
BLVRB
Amy
0.913
0.992
0.183
1.090
0.013
1.247








reductase (NADPH))


Hs.76364
NM_004847
199
chr6p21.3
601833
Hs.76364_at
allograft inflammatory factor 1
AIF1
Amy
0.302
0.930
0.118
0.883
0.042
0.805


Hs.76507
AF010312
9516
chr16p13.3-p12
603795
Hs.76507_at
lipopolysaccharide-induced TNF
LITAF
Amy
0.830
1.017
0.921
1.017
0.018
0.717








factor


Hs.76894
AI656493
1635
chr4q35.1
607638
Hs.76894_at
dCMP deaminase
DCTD
Amy
0.259
1.107
0.030
1.137
0.010
1.227


Hs.76917
BC040456
26269
chr4q34.1
605649
Hs.76917_at
F-box only protein 8
FBXO8
Amy
0.566
0.923
0.409
0.894
0.041
0.782


Hs.77422
NM_002668
5355
chrxp11.23
300112
Hs.77422_at
proteolipid protein 2 (colonic
PLP2
Amy
0.426
0.961
0.480
0.917
0.046
0.807








epithelium-enriched)


Hs.77646
BC014479
54899
chr3p14.3

Hs.77646_at
PX domain containing
PXK
Amy
0.293
1.328
0.980
1.007
0.034
0.542








serine/threonine kinase


Hs.7778
NM_018205
55222
chr10q22.1

Hs.7778_at
hypothetical protein FLJ10751
FLJ10751
Amy
0.686
1.026
0.069
1.095
0.036
1.209


Hs.77961
D83043
3106
chr6p21.3
142830
Hs.77961_at
major histocompatibility
HLA-B
Amy
0.843
0.915
0.275
0.927
0.008
0.724








complex, class I, B


Hs.78224
NM_002933
6035
chr14q11.2
180440
Hs.78224_at
ribonuclease, RNase A family, 1
RNASE1
Amy
0.942
0.983
0.197
0.762
0.006
0.515








(pancreatic)


Hs.7845
NM_023939
65996
chr19q13.43

Hs.7845_at
hypothetical protein MGC2752
MGC2752
Amy
0.681
1.010
0.384
1.064
0.012
1.202


Hs.78746
NM_002605
5151
chr15q25.3
602972
Hs.78746_at
phosphodiesterase 8A
PDE8A
Amy
0.816
0.962
0.369
0.881
0.025
0.622


Hs.78748
NM_014747
9783
chr1pter-p22.2

Hs.78748_at
regulating synaptic membrane
RIMS3
Amy
0.121
1.216
0.035
1.120
0.023
1.394








exocytosis 3


Hs.78769
NM_003249
7064
chr19q13.3
601117
Hs.78769_at
thimet oligopeptidase 1
THOP1
Amy
0.887
0.987
0.336
1.067
0.019
1.489


Hs.7886
NM_020651
57162
chr2p13.3

Hs.7886_at
pellino homolog 1 (Drosophila)
PELI1
Amy
0.545
0.963
0.224
0.869
0.024
0.705


Hs.78913
AI033393
1524
chr3p21.3
601470
Hs.78913_at
chemokine (C-X3-C motif)
CX3CR1
Amy
0.571
0.931
0.083
0.772
0.009
0.475








receptor 1


Hs.78
D13318
2551
chr21q21.3
600609
Hs.78_at
GA binding protein transcription
GABPA
Amy
0.295
0.913
0.407
0.940
0.009
0.828








factor, alpha subunit 60 kDa


Hs.79000
NM_002045
2596
chr3q13.1-q13.2
162060
Hs.79000_at
growth associated protein 43
GAP43
Amy
0.213
1.176
0.393
1.045
0.041
1.404


Hs.79226
NM_005103
9638
chr11q24.2
604825
Hs.79226_at
fasciculation and elongation
FEZ1
Amy
0.736
1.058
0.494
1.049
0.008
0.811








protein zeta 1 (zygin I)


Hs.79299
N66633
10184
chr5q14.1

Hs.79299_at
lipoma HMGIC fusion partner-
LHFPL2
Amy
0.567
1.038
0.291
0.890
0.036
0.814








like 2


Hs.7934
BE222801
192683
chr15q23

Hs.7934_at
secretory carrier membrane
SCAMP5
Amy
0.642
1.036
0.165
1.079
0.035
1.203








protein 5


Hs.7946
AI695017
57509
chr8p22

Hs.7946_at
mitochondrial tumor suppressor
MTSG1
Amy
0.993
1.003
0.878
0.963
0.035
0.724








gene 1


Hs.7989
AB028968
23349
chr9p13.2

Hs.7989_at
KIAA1045
KIAA1045
Amy
0.205
1.173
0.076
1.179
0.004
1.559


Hs.80680
NM_017458
9961
chr16p13.1-P11.2
605088
Hs.80680_at
major vault protein
MVP
Amy
0.354
0.990
0.838
0.976
0.015
0.808


Hs.80720
AK074381
2649
chr4q31.21
604439
Hs.80720+_at
GRB2-associated binding
GAB1
Amy
0.999
1.000
0.464
0.893
0.002
0.620








protein 1


Hs.808
AI591354
3185
chr10q11.21-q11.22
601037
Hs.808_at
heterogeneous nuclear
HNRPF
Amy
0.386
0.942
0.984
1.002
0.008
0.725








ribonucleoprotein F


Hs.80919
AI768845
6856
chr7q22.3

Hs.80919_at
synaptophysin-like protein
SYPL
Amy
0.964
0.990
0.700
0.944
0.001
0.655


Hs.8117
NM_018695
55914
chr5q12.3
606944
Hs.8117_at
erbb2 interacting protein
ERBB2IP
Amy
0.766
0.922
0.290
0.860
0.003
0.706


Hs.81424
U67122
7341
chr2q33
601912
Hs.81424_at
ubiquitin-like 1 (sentrin)
UBL1
Amy
0.093
1.337
0.113
1.158
0.033
1.230


Hs.82128
NM_006670
7162
chr6q14-q15
190920
Hs.82128_at
trophoblast glycoprotein
TPBG
Amy
0.725
1.065
0.606
0.913
0.022
1.267


Hs.82163
NM_000898
4129
chrxp11.23
309860
Hs.82163_at
monoamine oxidase B
MAOB
Amy
0.685
0.938
0.311
1.080
0.047
0.775


Hs.8217
NM_006603
10735
chrxq25
604359
Hs.8217_at
stromal antigen 2
STAG2
Amy
0.882
1.020
0.308
0.900
0.010
0.817


Hs.82222
NM_004636
7869
chr3p21.3
601281
Hs.82222_at
sema domain, immunoglobulin
SEMA3B
Amy
0.702
0.966
0.642
0.941
0.017
0.745








domain (Ig), short basic domain,








secreted, (semaphorin) 3B


Hs.82280
W19676
6001
chr10q25
602856
Hs.82280_at
regulator of G-protein signalling
RGS10
Amy
0.522
0.940
0.207
0.865
0.019
0.592








10


Hs.82318
AB020707
10810
chr13q12
605068
Hs.82318_at
WAS protein family, member 3
WASF3
Amy
0.767
1.049
0.018
1.138
0.032
1.203


Hs.82353
NM_006404
10544
chr20q11.2
600646
Hs.82353_at
protein C receptor, endothelial
PROCR
Amy
0.370
0.913
0.591
0.974
0.031
0.743








(EPCR)


Hs.82407




Hs.82407_at
chemokine (C-X-C motif) ligand
CXCL16
Amy
0.556
1.029
0.173
0.844
0.004
0.636








16


Hs.82568
NM_000784
1593
chr2q33-qter
606530
Hs.82568_at
cytochrome P450, family 27,
CYP27A1
Amy
0.156
1.090
0.366
0.900
0.001
0.748








subfamily A, polypeptide 1


Hs.82646
BG537255
3337
chr19p13.2
604572
Hs.82646_at
DnaJ (Hsp40) homolog,
DNAJB1
Amy
0.539
1.100
0.834
1.020
0.034
0.825








subfamily B, member 1


Hs.82771
NM_006296
7444
chr2p16-p15
602169
Hs.82771_at
vaccinia related kinase 2
VRK2
Amy
0.190
1.091
0.855
0.966
0.015
0.635


Hs.82927
AI916249
271
chr1p13.3
102771
Hs.82927_at
adenosine monophosphate
AMPD2
Amy
0.360
1.048
0.146
1.104
0.004
1.247








deaminase 2 (isoform L)


Hs.83077
NM_001562
3606
chr11q22.2-q22.3
600953
Hs.83077_at
interleukin 18 (interferon-
IL18
Amy
0.620
0.923
0.460
0.904
0.045
0.768








gamma-inducing factor)


Hs.83381
NM_004126
2791
chr7q31-q32
604390
Hs.83381_at
guanine nucleotide binding
GNG11
Amy
0.043
0.838
0.074
0.803
0.027
0.797








protein (G protein), gamma 11


Hs.84665
NM_006790
9499
chr5q31
604103
Hs.84665_at
titin immunoglobulin domain
TTID
Amy
0.447
1.027
0.453
0.848
0.009
0.479








protein (myotilin)


Hs.85155
BE620915
677
chr14q22-q24
601064
Hs.85155_at
zinc finger protein 36, C3H type-
ZFP36L1
Amy
0.118
0.868
0.488
0.911
0.028
0.771








like 1


Hs.85226
BC040833
3988
chr10q23.2-q23.3
278000
Hs.85226_at
lipase A, lysosomal acid,
LIPA
Amy
0.793
1.024
0.644
0.964
0.011
0.708








cholesterol esterase (Wolman








disease)


Hs.85618
AW963951
256435
chr1p31.1

Hs.85618_at
sialyltransferase 7 ((alpha-N-
SIAT7C
Amy
0.946
0.988
0.529
0.913
0.044
0.759








acetylneuraminyl-2,3-beta-








galactosyl-1,3)-N-acetyl








galactosaminide alpha-2,6-








sialyltransferase) C


Hs.8594
BC006316
57179
chr5q35.2

Hs.8594_at
KIAA1191 protein
KIAA1191
Amy
0.472
1.330
0.042
1.106
0.008
1.253


Hs.87729
NM_022783
64798
chr8q24.12

Hs.87729_at
hypothetical protein FLJ12428
FLJ12428
Amy
0.893
0.981
0.270
0.808
0.036
0.628


Hs.878
NM_003104
6652
chr15q158.3
182500
Hs.878_at
sorbitol dehydrogenase
SORD
Amy
0.847
1.010
0.217
1.168
0.025
0.791


Hs.8813
BC028028
6814
chr1p13.3
608339
Hs.8813_at
syntaxin binding protein 3
STXBP3
Amy
0.649
0.962
0.300
0.898
0.013
0.747


Hs.88778
BC002511
873
chr21q22.13
114830
Hs.88778_at
carbonyl reductase 1
CBR1
Amy
0.790
0.959
0.967
0.992
0.025
0.724


Hs.8904
NM_007268
11326
chrxq12-q13.3
300353
Hs.8904_at
Ig superfamily protein
Z39IG
Amy
0.289
0.860
0.159
0.884
0.007
0.605


Hs.89512
R52647
491
chr3p25.3
108733
Hs.89512_at
ATPase, Ca++ transporting,
ATP2B2
Amy
0.327
1.142
0.096
1.166
0.032
1.275








plasma membrane 2


Hs.8986
NM_000491
713
chr1p36.3-p34.1
120570
Hs.8986_at
complement component 1, q
C1QB
Amy
0.242
0.948
0.112
0.772
0.009
0.459








subcomponent, beta








polypeptide


Hs.90436
NM_004890
9552
chr17p13.2

Hs.90436_at
sperm associated antigen 7
SPAG7
Amy
0.773
0.981
0.186
1.083
0.011
1.273


Hs.9082
AU146949
53371
chr4q21.1
607607
Hs.9082_at
nucleoporin 54 kDa
NUP54
Amy
0.475
1.040
0.319
0.951
0.003
0.827


Hs.91448
NM_007026
11072
chr17q12
606618
Hs.91448_at
dual specificity phosphatase 14
DUSP14
Amy
0.508
1.097
0.485
1.072
0.014
1.233


Hs.914
M27487
3113
chr6p21.3
142880
Hs.914_at
major histocompatibility
HLA-DPA1
Amy
0.146
0.888
0.131
0.668
0.004
0.381








complex, class II, DP alpha 1


Hs.92732
BC002606
57595
chrxq28

Hs.92732_at
LU1 protein
KIAA1444
Amy
0.996
1.000
0.099
1.187
0.013
1.393


Hs.9315
NM_020190
56944
chr1p13.2

Hs.9315_at
HNOEL-iso protein
HNOEL-iso
Amy
0.695
1.007
0.289
0.805
0.029
0.621


Hs.9599
NM_014251
10165
chr7q21.3
603859
Hs.9599_at
solute carrier family 25, member
SLC25A13
Amy
0.451
0.928
0.904
1.013
0.017
0.734








13 (citrin)


Hs.9622
NM_018135
55168
chr6p21.3

Hs.9622_at
mitochondrial ribosomal protein
MRPS18A
Amy
0.398
1.026
0.228
1.082
0.019
1.252








S18A


Hs.9641
NM_015991
712
chr1p36.3-p34.1
120550
Hs.9641_at
complement component 1, q
C1QA
Amy
0.766
0.963
0.200
0.692
0.003
0.373








subcomponent, alpha








polypeptide


Hs.96
AI857639
5366
chr18q21.32
604959
Hs.96_at
phorbol-12-myristate-13-
PMAIP1
Amy
0.892
0.995
0.320
0.942
0.019
0.833








acetate-induced protein 1


Hs.9741
AK024269
93643
chr6p21.1

Hs.9741_at
tight junction protein 4
TJP4
Amy
0.756
0.967
0.884
1.017
0.013
0.736








(peripheral)


Hs.97616
NM_003025
6455
chr19p13.3
601768
Hs.97616_at
SH3-domain GRB2-like 1
SH3GL1
Amy
0.266
1.090
0.085
1.155
0.013
1.229


Hs.99272
AI147740
116173
chr14q11.2
607888
Hs.99272_at
chemokine-like factor super
CKLFSF5
Amy
0.085
1.256
0.661
0.895
0.032
0.687








family 5


Hs.9927
AI969112
55023
chr6q14

Hs.9927-_at
pleckstrin homology domain
PHIP
Amy
0.328
0.885
0.928
1.009
0.020
0.828








interacting protein


























TABLE 23









Repre-

Chromo-









UniGene
sentative
Locus
somal

Probe set

Gene
Platform,

fold


ID
Public ID
Link
Location
OMIM
ID UG-1
Gene Title
Symbol
Region
t-test
change

























Hs.284137
NM_024945
80010
chr9q21.32

Hs.284137_at
chromosome
C9orf76
AnCg
0.020725
0.816708








9 open








reading








frame 76


Hs.407155
NM_025097
80167
chr4q28.2

Hs.407155_at
hypothetical
FLJ21106
AnCg
0.026331
0.808572








protein








FLJ21106


Hs.170081
NM_173675
285780
chr6p25.1

Hs.170081_at
hypothetical
FLJ33708
AnCg
0.047521
1.24261








protein








FLJ33708


Hs.114218
NM_003506
8323
chr8q22.3-
603409
Hs.114218_at
frizzled
FZD6
AnCg
0.03536
0.762731





q23.1


homolog 6








(Drosophila)


Hs.26312
NM_006338
10446
chr1q32.1
605492
Hs.26312_at
leucine rich
LRRN5
AnCg
0.039771
1.201087








repeat








neuronal 5


Hs.408161
AW007241
57611
chr15q24.1

Hs.408161_at
KIAA1465
KIAA1465
AnCg
0.020208
1.261026








protein


Hs.30581
H05918
84623
chr11q24
607761
Hs.30581_at
kin of
KIRREL3
AnCg
0.02756
1.242475








IRRE like 3








(Drosophila)


Hs.285782
NM_024993
80059
chr2p12

Hs.285782_at
leucine
LRRTM4
AnCg
0.049497
1.358254








rich repeat








transmembrane








neuronal 4


Hs.148932
NM_020241
10501
chr19p13.3

Hs.148932_at
sema domain,
SEMA6B
AnCg
0.023939
1.261144








transmembrane








domain








(TM), and








cytoplasmic








domain,








(semaphorin)








6B


Hs.247302
NM_020648
57045
chr18p11.3
605049
Hs.247302_at
twisted
TWSG1
AnCg
0.028339
0.75457








gastrulation








homolog 1








(Drosophila)


Hs.128705




Hs.128705_at


AnCg
0.003369
0.629083


Hs.134441




Hs.134441_at


AnCg
0.006414
0.74478


Hs.143134
AW207243



Hs.143134_at
CDNA FLJ38181

AnCg
0.038675
1.25541








fis, clone








FCBBF1000125


Hs.146268
AW001557



Hs.146268_at
Clone DNA59613

AnCg
0.030621
1.325909








phospholipase








inhibitor








(UNQ511) mRNA,








complete cds


Hs.162203




Hs.162203_at


AnCg
0.023928
0.814199


Hs.170973




Hs.170973_at


AnCg
0.035994
1.320933


Hs.170999
AK025747
55137
chr2q24.3
605295
Hs.170999_at
fidgetin
FIGN
AnCg
0.017672
0.771728


Hs.191346




Hs.191346_at


AnCg
0.002449
0.734099


Hs.213501




Hs.213501_at


AnCg
0.016879
1.363411


Hs.250879
BF982289
404217
chr19p13.2

Hs.250879_at
cortexin 1
CTXN1
AnCg
0.011148
1.357262


Hs.306834




Hs.306834_at


AnCg
0.041437
1.275879


Hs.307559




Hs.307559_at


AnCg
0.015434
0.552768


Hs.369984




Hs.369984_at


AnCg
0.037255
0.768352


Hs.379010
AK092432
8000
chr8q24.2
602470
Hs.379010_at
prostate stem
PSCA
AnCg
0.024803
1.310589








cell antigen


Hs.4204
AA700440



Hs.4204_at
CDNA FLJ30779

AnCg
0.043015
1.289724








fis, clone








FEBRA2000815


Hs.42294




Hs.42294_at


AnCg
0.005224
0.797537


Hs.434124
AK057562
149086
chr1p35.2

Hs.434124_at
hypothetical
LOC149086
AnCg
0.004279
0.577431








protein








LOC149086


Hs.435222




Hs.435222_at


AnCg
0.022825
1.722226


Hs.437332




Hs.437332_at


AnCg
0.020915
1.200778


Hs.438801




Hs.438801_at


AnCg
0.007572
1.279146


Hs.446394
NM_004327
613
chr22q11.23
151410
Hs.446394_at
breakpoint
BCR
AnCg
0.013515
1.291847








duster








region


Hs.446593
BC029534



Hs.446593_at
CDNA clone

AnCg
0.018501
1.294104








IMAGE: 6101590,








partial cds


Hs.448624




Hs.448624_at


AnCg
0.049625
1.259765


Hs.452203
AI939400
400999
chr2q14.1

Hs.452203_at
Hypothetical

AnCg
0.009538
1.410325








gene supported








by AK124342


Hs.458379




Hs.458379_at


AnCg
0.00181
1.290973


Hs.493302
AK021913



Hs.493302_at
CDNA FLJ11851

AnCg
0.004343
1.404944








fis, clone








HEMBA1006744


Hs.514146




Hs.514146_at


AnCg
0.017236
1.2257


Hs.515369




Hs.515369_at


AnCg
0.04564
0.461191


Hs.516311
BF056746



Hs.516311_at
MRNA; cDNA

AnCg
0.017839
0.676076








DKFZp686E10196








(from clone








DKFZp686E10196);








complete cds


Hs.517410




Hs.517410_at


AnCg
0.001473
1.382544


Hs.519758




Hs.519758_at


AnCg
0.019567
1.392608


Hs.521215




Hs.521215_at


AnCg
0.000387
0.708137


Hs.531424
BF111846
399563


Hs.531424_at
hypothetical
FLJ43806
AnCg
0.01124
1.265719








protein








FLJ43806


Hs.531897




Hs.531897_at


AnCg
0.013124
0.606227


Hs.66095




Hs.66095_at


AnCg
0.00517
0.61691


Hs.74832




Hs.74832_at


AnCg
0.021275
0.775137


Hs.88558




Hs.88558_at


AnCg
0.036854
0.791453







_at







_at


Hs.4863
NM_030797
81553
chr2p24.3-

Hs.4863_at
family with
FAM49A
DLPFC
0.022942
1.382579





p24.2


sequence








similarity 49,








member A///








family with








sequence








similarity








49, member A


Hs.127286
BF109660
346887
chr8q23.1

Hs.127286_at
Similar to solute

DLPFC
0.001526
1.35149








carrier family








16 (monocar-








boxylic acid








transporters),








member 14


Hs.134228
NM_020794
57554
chr1p31.1

Hs.134228_at
densin-180
KIAA1365
DLPFC
0.049737
1.243024


Hs.170357
BC036602



Hs.170357_at
Clone IMAGE:

DLPFC
0.010211
1.725662








5274542,








mRNA


Hs.21374




Hs.21374_at


DLPFC
0.039593
1.316786


Hs.235795
AW043859



Hs.235795_at
Clone IMAGE:

DLPFC
0.037066
0.756002








5263020,








mRNA


Hs.307559




Hs.307559_at


DLPFC
0.011602
0.574393


Hs.390616
AF070581
5063
chrXq22.3-
300142
Hs.390616_at
p21 (CDKN1A)-
PAK3
DLPFC
0.025615
1.449205





q23


activated








kinase 3


Hs.446340




Hs.446340_at


DLPFC
0.011087
1.544746


Hs.46550




Hs.46550_at


DLPFC
0.02093
1.432785


Hs.512343




Hs.512343_at


DLPFC
0.006425
1.268103


Hs.519673




Hs.519673_at


DLPFC
0.04574
0.627049


Hs.521800




Hs.521800_at


DLPFC
0.048286
1.279609


Hs.7413




Hs.7413_at


DLPFC
0.032118
1.575143


Hs.334854
NM_024551
79602
chr12p13.31
607946
Hs.334854_at
adiponectin
ADIPOR2
Amygdala
0.003159
0.665698








receptor 2


Hs.442808
BC002431
8704
chr1p34-
604013
Hs.442808_at
UDP-Gal:
B4GALT2
Amygdala
0.023737
1.270982





p33


betaGlcNAc








beta 1,4-








galactosyl-








transferase,








polypeptide 2


Hs.380389
NM_016014
51104
chr9q21.13

Hs.380389_at
chromosome
C9orf77
Amygdala
0.008226
0.66








9 open








reading








frame 77


Hs.301478
NM_024734
79789
chr14q32.13

Hs.301478_at
calmin
CLMN
Amygdala
0.015269
0.75244








(calponin-








like, trans-








membrane)


Hs.268764
AW006648
342035
chr15q21.2
608603
Hs.268764_at
coliomin
COLM
Amygdala
0.011039
0.648707


Hs.511884
AA501453
163786
chr1p21.3

Hs.511884_at
hypothetical
DKFZp761-
Amygdala
0.049152
0.778291








protein
A078








DKFZp761A078


Hs.441044
AA297258
10085
chr5q14
606018
Hs.441044_at
EGF-like
EDIL3
Amygdala
0.024605
0.744337








repeats and








discoidin








I-like








domains 3


Hs.30318
NM_018252
55248
chr1q32.3

Hs.30318_at
hypothetical
FLJ 10874
Amygdala
0.029049
0.750136








protein








FLJ10874


Hs.310422
NM_022771
64786
chr12q21.1

Hs.310422_at
TBC1 domain
TBC1D15
Amygdala
0.019059
0.738469








family,








member 15


Hs.135146
BC025250
79828
chr2q31.1

Hs.135146_at
hypothetical
FLJ13984
Amygdala
0.028425
0.790096








protein








FLJ13984


Hs.523544
NM_025032
80100
chr1q21.2

Hs.523544_at
hypothetical
FLJ21272
Amygdala
0.02064
0.56112








protein








FLJ21272


Hs.47122
NM_003838
8790
chr1p31.1
603609
Hs.47122_at
fucose-1-
FPGT
Amygdala
0.010068
0.753436








phosphate








guanylyl-








transferase


Hs.287721
NM_022873
2537
chr1p35
147572
Hs.287721_at
interferon,
G1P3
Amygdala
0.023733
0.786625








alpha-








inducible








protein








(clone








IFI-6-16)


Hs.239155




Hs.239155_at


Amygdala
0.032254
0.787257


Hs.438303
NM_015340
23395
chr3p21.3
604544
Hs.438303_at
leucyl-tRNA
LARS2
Amygdala
0.036951
1.21561








synthetase








2, mito-








chondrial


Hs.129694
NM_025168
55227
chr6p12.1
608195
Hs.129694_at
leucine
LRRC1
Amygdala
0.040074
0.721154








rich repeat








containing 1


Hs.116459
NM_006122
4122
chr15q26.1
600988
Hs.116459_at
mannosidase,
MAN2A2
Amygdala
0.047118
0.828848








alpha, class








2A, member 2


Hs.93121
AB052917
23155
chr1p13.3

Hs.93121_at
Mid-1-related
MCLC
Amygdala
0.03374
0.818216








chloride








channel 1


Hs.63236
BG497783
128308
chr1q42.13

Hs.63236_at
mitochondrial
MRPL55
Amygdala
0.026502
1.240988








ribosomal








protein L55


Hs.436836
NM_002462
4599
chr21q22.3
147150
Hs.436836_at
myxovirus
MX1
Amygdala
0.027157
0.797802








(influenza








virus)








resistance 1,








interferon-








inducible








protein p78








(mouse)


Hs.164682
NM_000466
5189
chr7q21-
602136
Hs.164682_at
peroxisome
PEX1
Amygdala
0.027517
0.739133





q22


biogenesis








factor 1


Hs.282702
NM_006212
5208
chr1q31
171835
Hs.282702_at
6-phospho-
PFKFB2
Amygdala
0.014018
0.791098








fructo-2-








kinase/








fructose-








2,6-biphos-








phatase 2


Hs.343329
NM_002646
5287
chr1q32
602838
Hs.343329_at
phospho-
PIK3C2B
Amygdala
0.049244
0.682849








inositide-3-








kinase,








class 2,








beta








polypeptide


Hs.286073
NM_003620
8493
chr17q23.2
605100
Hs.286073_at
protein phos-
PPM1D
Amygdala
0.004151
0.827801








phatase 1D








magnesium-








dependent,








delta isoform


Hs.152337
AL551971
10196
chr11p15.1
603190
Hs.152337_at
HMT1 hnRNP
HRMT1L3
Amygdala
0.021309
0.775057








methyl-








transferase-








like 3








(S. cerevisiae)


Hs.442356
BF439330
85358
chr22q13.3
606230
Hs.442356_at
SH3 and
SHANK3
Amygdala
0.026712
1.250287








multiple








ankyrin








repeat








domains 3


Hs.343603
NM_003673
8557
chr17q12
604488
Hs.343603_at
titin-cap
TCAP
Amygdala
0.03464
1.277915








(telethonin)


Hs.48499
NM_016516
51542
chr2p13-

Hs.48499_at
vacuolar
VPS54
Amygdala
0.019562
0.795823





p14


protein








sorting








54 (yeast)


Hs.10359




Hs.10359_at


Amygdala
0.036402
0.615377


Hs.105769




Hs.105769_at


Amygdala
0.025621
0.748727


Hs.106148
AL133577



Hs.106148_at
MRNA; cDNA

Amygdala
0.030866
0.823174








DKFZp434G0972








(from clone








DKFZp434G0972)


Hs.112592




Hs.112592_at


Amygdala
0.033801
0.649288


Hs.117864




Hs.117864_at


Amygdala
0.006598
0.782827


Hs.121806
AU146685



Hs.121806_at
CDNA FLJ11971

Amygdala
0.009175
0.663875








fis, clone








HEMBB1001208


Hs.124944




Hs.124944_at


Amygdala
0.001677
0.79208


Hs.12867




Hs.12867_at


Amygdala
0.008073
0.711258


Hs.135229
AI674243
339162
chr17q25.3

Hs.135229_at
Similar to

Amygdala
0.001917
1.371978








ataxin 2








binding








protein 1








isoform gamma;








hexaribo-








nucleotide








binding








protein 1


Hs.143821




Hs.143821_at


Amygdala
0.020925
0.588934


Hs.145421
AI939363



Hs.145421_at
CDNA FLJ43322

Amygdala
0.003488
1.461045








fis, clone








NT2RI2027975


Hs.146268
AW001557



Hs.146268_at
Clone DNA59613

Amygdala
0.017818
1.314676








phospholipase








inhibitor








(UNQ511) mRNA,








complete cds


Hs.155113




Hs.155113_at


Amygdala
0.00243
0.611274


Hs.156672
BE858593
344148
chr2q21.2
608789
Hs.156672_at
Nck-associated
NAP5
Amygdala
0.002186
0.586409








protein 5


Hs.161359




Hs.161359_at


Amygdala
0.023195
0.58472


Hs.163893




Hs.163893_at


Amygdala
0.007779
0.639002


Hs.164502
BE783668
23025
chr19p13.12

Hs.164502_at
unc-13
UNC13A
Amygdala
0.003794
1.302452








homolog A








(C. elegans)


Hs.170953




Hs.170953_at


Amygdala
0.001139
0.560582


Hs.171939
AI693178



Hs.171939_at
MRNA; cDNA

Amygdala
0.016426
1.337931








DKFZp761L1121








(from clone








DKFZp761L1121)


Hs.177502




Hs.177502_at


Amygdala
0.027013
0.71576


Hs.178393




Hs.178393_at


Amygdala
0.004451
1.543364


Hs.182606
AI471969



Hs.182606_at
Clone IMAGE:

Amygdala
0.012741
1.483865








5301129,








mRNA


Hs.184454




Hs.184454_at


Amygdala
0.013842
1.347984


Hs.187328




Hs.187328_at


Amygdala
0.004842
0.453853


Hs.190334




Hs.190334_at


Amygdala
0.008215
0.726692


Hs.191463




Hs.191463_at


Amygdala
0.026121
0.684305


Hs.202121




Hs.202121_at


Amygdala
0.017193
1.466848


Hs.205647




Hs.205647_at


Amygdala
0.007703
0.757727


Hs.21349




Hs.21349_at


Amygdala
0.026684
1.583208


Hs.221612




Hs.221612_at


Amygdala
0.013255
0.67585


Hs.224794
BQ002274



Hs.224794_at
CDNA FLJ33375

Amygdala
0.002619
0.757862








fis, clone








BRACE2006137


Hs.22511




Hs.22511_at


Amygdala
0.010206
0.524585


Hs.225161




Hs.225161_at


Amygdala
0.013364
0.569931


Hs.23079
H05023
401190
chr5q12.3

Hs.23079_at
hypothetical
DKFZp686-
Amygdala
0.002046
1.921977








protein
I0554








DKFZp686l0554


Hs.23100
NM_152530
27031
chr3q22.1
604387
Hs.23100_at
nephronoph-
NPHP3
Amygdala
0.025067
0.741499








thisis 3








(adolescent)


Hs.235795
AW043859



Hs.235795_at
Clone IMAGE:

Amygdala
2.72E-05
0.35862








5263020,








mRNA


Hs.240443
AU134977



Hs.240443_at
Trophoblast-

Amygdala
0.004325
0.636113








derived








noncoding








RNA


Hs.255049




Hs.255049_at


Amygdala
0.001256
0.794556


Hs.266457




Hs.266457_at


Amygdala
0.001958
0.723099


Hs.266619




Hs.266619_at


Amygdala
0.023573
0.659342


Hs.269099




Hs.269099_at


Amygdala
0.007654
0.588292


Hs.270244




Hs.270244_at


Amygdala
0.021368
0.677287


Hs.271609
H21394



Hs.271609_at
Full length

Amygdala
0.034287
0.562163








insert cDNA








YN68A11


Hs.276976
AW003140
401597
chrXq13.1-

Hs.276976_at
Hypothetical

Amygdala
0.035991
0.759303





q13.2


gene supported








by AK125301


Hs.278648
AW836210



Hs.278648_at
CDNA FLJ14085

Amygdala
0.002245
0.658288








fis, clone








HEMBB1002534


Hs.28170




Hs.28170_at


Amygdala
0.000576
0.595206


Hs.284707
BC033052



Hs.284707_at
CDNA clone

Amygdala
0.017452
0.824605








IMAGE: 4770316,








partial cds


Hs.290550
AI800515



Hs.290550_at
Clone IMAGE:

Amygdala
0.004158
0.646001








5288238, mRNA


Hs.290830
AW952920



Hs.290830_at
Full length

Amygdala
0.002352
0.715007








insert cDNA








clone YU27F12


Hs.291967




Hs.291967_at


Amygdala
0.018922
0.703836


Hs.292679




Hs.292679_at


Amygdala
0.009456
0.729281


Hs.293334




Hs.293334_at


Amygdala
0.019492
0.730359


Hs.293748
BF447954



Hs.293748_at
CDNA FLJ26063

Amygdala
0.006689
0.445111








fis, clone








PRS04788


Hs.293748
BF447954



Hs.293748_at
CDNA FLJ26063

Amygdala
0.005118
0.503619








fis, clone








PRS04788


Hs.293912
AL137510



Hs.293912_at
MRNA; cDNA

Amygdala
0.001303
0.610613








DKFZp761F052








(from clone








DKFZp761F052)


Hs.296276




Hs.296276_at


Amygdala
0.001696
0.33197


Hs.298014
AU148154



Hs.298014_at
CDNA FLJ14136

Amygdala
0.0023
0.625751








fis, clone








MAMMA1002744


Hs.298250




Hs.298250_at


Amygdala
0.017026
0.799761


Hs.301237
AU147177



Hs.301237_at
CDNA FLJ12095

Amygdala
0.003289
0.627277








fis, clone








HEMBB1002610


Hs.304253




Hs.304253_at


Amygdala
0.004511
0.456269


Hs.306329
AL109684



Hs.306329_at
MRNA full

Amygdala
0.01041
0.741482








length insert








cDNA clone








EUROIMAGE








27080


Hs.306458
AL137424



Hs.306458_at
MRNA; cDNA

Amygdala
0.015341
0.744289








DKFZp761G2123








(from clone








DKFZp761G2123)


Hs.312469
BF529886



Hs.312469_at
CDNA FLJ45559

Amygdala
0.001127
1.675411








fis, clone








BRTHA3003225


Hs.317614
BQ022804
143903
chr11q23.2

Hs.317614_at
layilin
LOC143903
Amygdala
0.001917
0.390905


Hs.31841
AI521765



Hs.31841_at
CDNA FLJ33489

Amygdala
0.004573
0.691038








fis, clone








BRAMY2003585


Hs.332620
BG545582



Hs.332620_at
Clone IMAGE:

Amygdala
0.011093
0.714316








4418644,








mRNA


Hs.337506
AW611486



Hs.337506_at
MRNA; cDNA

Amygdala
0.002515
0.700655








DKFZp566D053








(from clone








DKFZp566D053)


Hs.348325
BF692592



Hs.348325_at
Clone IMAGE:

Amygdala
0.022077
0.611878








4043849,








mRNA


Hs.349656
AA885297
950
chr4q21.1
602257
Hs.349656_at
scavenger
SCARB2
Amygdala
0.049096
0.708297








receptor








class B,








member 2


Hs.352604
AK054833



Hs.352604_at
CDNA FLJ30271

Amygdala
0.006646
0.759894








fis, clone








BRACE2002676


Hs.356721
NM_002136
3178
chr12q13.1
164017
Hs.356721_at
heterogeneous
HNRPA1
Amygdala
0.013735
0.77917








nuclear ribo-








nucleoprotein








A1///








heterogeneous








nuclear








ribonucleo-








protein A1


Hs.36190




Hs.36190_at


Amygdala
0.002178
0.73084


Hs.368747




Hs.368747_at


Amygdala
0.0235
0.690354


Hs.370868




Hs.370868_at


Amygdala
0.003122
0.592345


Hs.372914




Hs.372914_at


Amygdala
0.002545
0.722778


Hs.375064
BC030757



Hs.375064_at
Clone IMAGE:

Amygdala
0.020267
0.513317








4797534,








mRNA,








partial cds


Hs.378706
AU147038



Hs.378706_at
CDNA FLJ12064

Amygdala
0.00199
0.740046








fis, clone








HEMBB1002232


Hs.380331
BC015390



Hs.380331_at
CDNA FLJ41173

Amygdala
0.030727
2.243787








fis, clone








BRACE2042394


Hs.381882
AL512701



Hs.381882_at
CDNA FLJ39866

Amygdala
0.010168
0.73564








fis, clone








SPLEN2015276


Hs.383007




Hs.383007_at


Amygdala
0.014769
0.709824


Hs.384620
AF086073



Hs.384620_at
Full length

Amygdala
0.013717
0.562816








insert cDNA








clone YZ55H04


Hs.384626
AF086037



Hs.384626_at
Full length

Amygdala
0.004341
0.655612








insert cDNA








clone YW28D08


Hs.386147




Hs.386147_at


Amygdala
0.02646
0.681543


Hs.390616
AF070581
5063
chrXq22.3-
300142
Hs.390616_at
p21 (CDKN1A)-
PAK3
Amygdala
0.023157
1.472364





q23


activated








kinase 3


Hs.397085
BC033548



Hs.397085_at
Clone IMAGE:

Amygdala
0.04571
0.743093








4825215,








mRNA


Hs.397369
AU147851



Hs.397369_at
CDNA FLJ11958

Amygdala
0.013779
0.697461








fis, clone








HEMBB1000996


Hs.400590
AI819043



Hs.400590_at
CDNA FLJ32589

Amygdala
0.005598
0.43








fis, clone








SPLEN2000443


Hs.40794
AI368415
388135
chr15q22.33

Hs.40794_at
Similar to

Amygdala
0.011758
1.26403








RIKEN cDNA








6030419C18








gene


Hs.408264
BU620691
283417///
chr12q14.2///

Hs.408264_at
hypothetical
FLJ32949///
Amygdala
0.017538
1.537381




349152
chr7q22.1


protein
FLJ36166








FLJ32949///








hypothetical








protein








FLJ36166


Hs.41688
AI864441



Hs.41688_at
CDNA FLJ42958

Amygdala
0.027645
1.30913








fis, clone








BRSTN2010750


Hs.4241




Hs.4241_at


Amygdala
0.005819
1.345413


Hs.429581




Hs.429581_at


Amygdala
0.017093
0.606702


Hs.429591




Hs.429591_at


Amygdala
0.008943
0.50843


Hs.432924
AW014647



Hs.432924_at
Full length

Amygdala
0.003946
1.420431








insert cDNA








YI37C01


Hs.433053




Hs.433053_at


Amygdala
0.012291
0.65199


Hs.433923
NM_001063
7018
chr3q22.1
190000
Hs.433923_at
transferrin
TF
Amygdala
0.009177
0.416645


Hs.436623




Hs.436623_at


Amygdala
0.01242
0.523161


Hs.443287




Hs.443287_at


Amygdala
0.02899
0.755498


Hs.443487




Hs.443487_at


Amygdala
0.004501
0.575491


Hs.444181




Hs.444181_at


Amygdala
0.033273
0.705257


Hs.444335




Hs.444335_at


Amygdala
0.000938
0.650602


Hs.444555




Hs.444555_at


Amygdala
0.004951
1.288085


Hs.444665
AA430151



Hs.444665_at
MRNA; cDNA

Amygdala
0.021285
1.655944








DKFZp686E1944








(from clone








DKFZp686E1944)


Hs.461300
AK054714
126661
chr1p34.1

Hs.461300_at
hypothetical
LOC126661
Amygdala
0.009085
0.822552








protein








LOC126661


Hs.466301




Hs.466301_at


Amygdala
0.003635
0.642776


Hs.472323




Hs.472323_at


Amygdala
0.008676
0.644228


Hs.501272




Hs.501272_at


Amygdala
0.008857
1.268105


Hs.502810




Hs.502810_at


Amygdala
0.007839
0.546665


Hs.504709




Hs.504709_at


Amygdala
0.008043
1.291178


Hs.50495




Hs.50495_at


Amygdala
0.010546
0.720397


Hs.508763
BM353142



Hs.508763_at
CDNA FLJ39845

Amygdala
0.002216
0.672116








fis, clone








SPLEN2014452


Hs.512151




Hs.512151_at


Amygdala
0.017229
0.367527


Hs.513796




Hs.513796_at


Amygdala
0.004
1.441776


Hs.514559




Hs.514559_at


Amygdala
0.040767
1.262803


Hs.514909




Hs.514909_at


Amygdala
0.025037
0.714495


Hs.514934




Hs.514934_at


Amygdala
0.02093
0.657218


Hs.515369




Hs.515369_at


Amygdala
0.011008
0.360543


Hs.515610




Hs.515610_at


Amygdala
6.24E−05
1.481497


Hs.517410




Hs.517410_at


Amygdala
0.027833
1.464479


Hs.517622




Hs.517622_at


Amygdala
0.003107
0.558423


Hs.519673




Hs.519673_at


Amygdala
0.004901
0.430537


Hs.519758




Hs.519758_at


Amygdala
0.004805
1.235818


Hs.520047




Hs.520047_at


Amygdala
0.006288
0.256084


Hs.522373




Hs.522373_at


Amygdala
0.002654
0.631341


Hs.522551




Hs.522551_at


Amygdala
0.004278
1.593644


Hs.524138




Hs.524138_at


Amygdala
0.026311
1.284691


Hs.524947




Hs.524947_at


Amygdala
0.004034
0.658967


Hs.525410




Hs.525410_at


Amygdala
0.002438
0.390568


Hs.525566




Hs.525566_at


Amygdala
0.01019
0.573626


Hs.526756
CA776505



Hs.526756_at
Full length

Amygdala
0.003311
0.591593








insert cDNA








clone YF43G08


Hs.528308
BC001387
11145
chr11q12.3-

Hs.528308_at
HRAS-like
HRASLS3
Amygdala
0.00474
0.684806





q13.1


suppressor 3


Hs.528702
AB000888
8611
chr5q11
607124
Hs.528702_at
phosphatidic
PPAP2A
Amygdala
0.022873
0.783506








acid phospha-








tase type 2A


Hs.529221




Hs.529221_at


Amygdala
0.00261
0.725799


Hs.530015




Hs.530015_at


Amygdala
0.017647
0.649954


Hs.530304




Hs.530304_at


Amygdala
0.035698
0.613183


Hs.530540




Hs.530540_at


Amygdala
0.006211
0.675555


Hs.530633
BG112359



Hs.530633_at
CDNA clone

Amygdala
0.005983
0.59179








MGC: 24463








IMAGE:








4082362,








complete cds


Hs.530863
NM_020764
57524
chr16p13.3

Hs.530863_at
CASK
CASKIN1
Amygdala
0.009288
1.271367








interacting








protein 1


Hs.530988
NM_016384



Hs.530988_at
MRNA; cDNA

Amygdala
0.014742
0.786987








DKFZp779H233








(from clone








DKFZp779H233)


Hs.6655
AL355688



Hs.6655_at
EST from clone

Amygdala
0.044777
0.775312








208499, full








insert


Hs.71913




Hs.71913_at


Amygdala
0.036543
0.501381


Hs.80720
AK074381
2549
chr4q31.21
604439
Hs.80720_at
GRB2-
GAB1
Amygdala
0.001894
0.579585








associated








binding








protein 1

























TABLE 24
















code











link
FC










normalized,
Code-



Repre-

Chromo-




p-value
link


UniGene
sentative
Locus
somal

Probe

Gene
(Diag-
Raw


ID
Public ID
Link
Location
OMIM
Name
Gene Title
Symbol
nostics)
log2
























Hs.194720
AF098951
9429
chr4q22
603756
GE81445
ATP-binding cassette,
ABCG2
0.001313
0.562347








subfamily G (WHITE),








member 2


Hs.234898
NM_001093
32
chr12q24.1
601557
GE554953
acetyl-Coenzyme A
ACACB
0.000557
0.560812








carboxylase beta


Hs.287558
NM_000700
301
chr9q12-q21.2
151690
GE59671
annexin A1
ANXA1
0.009335
2.078546


Hs.268571
NM_001645
341
chr19q13.2
107710
GE505140
apolipoprotein C-I
APOC1
0.001325
2.509905


Hs.40888
AF193421
23237
chr8q24.3

GE57416
activity-regulated
ARC
0.012693
1.949471








cytoskeleton-








associated protein


Hs.512643
D90427
563
chr7q22.1
194460
GE59850
alpha-2-glycoprotein
AZGP1
0.012211
0.437674








1, zinc


Hs.171825
BG326045
8553
chr3p26
604256
GE85322
basic helix-loop-
BHLHB2
0.006207
1.836491








helix domain con-








taining, class B, 2


Hs.77311
BC028229
10950
chr21q21.1-
605674
GE81683
BTG family, member 3
BTG3
0.00466
2.027951





q21.2


Hs.283683
NM_020130
56892
chr8p11.2
607702
GE87019
chromosome 8 open
C8orf4
0.001216
2.588593








reading frame 4


Hs.192491
NM_012113
23632
chr1q21
604832
GE86437
carbonic anhydrase
CA14
0.000934
0.710337








XIV


Hs.446471
M28590
972
chr5q32
142790
GE79594
CD74 antigen (invariant
CD74
0.033704
2.330845








polypeptide of major








histocompatibility








complex, class II








antigen-associated)


Hs.380627
BC006171
54918
chr3p22.3
607889
GE85308
chemokine-like factor
CKLFSF6
0.040862
1.424176








super family 6


Hs.274127
NM_016438
51751
chr17q21.31

GE80242
CLST 11240 protein
CLST11240
0.000593
0.568223


Hs.79187
AY072911
1525
chr21q21.1
602621
GE81683
coxsackie virus and
CXADR
0.00466
2.027951








adenovirus receptor


Hs.26704
BC005097
23191
chr15q11
606322
GE59548
cytoplasmic FMR1
CYFIP1
0.027249
2.226976








interacting protein 1


Hs.165636
NM_017594
54769
chr9q22.2
607863
GE846112
DIRAS family, GTP-
DIRAS2
0.002726
3.180369








binding RAS-like 2


Hs.356742
NM_006442
10589
chr11q13.3
602289
GE81638
DR1-associated pro-
DRAP1
0.005496
1.728007








tein 1 (negative








cofactor 2 alpha)


Hs.420569
NM_004089
1831
chrxq22.3
602960
GE56426
delta sleep inducing
DSIPI
0.000619
0.525127








peptide, immunoreactor


Hs.2128
U16996
1847
chr10q25
603069
GE58962
dual specificity
DUSP5
0.008311
2.29312








phosphatase 5


Hs.23853
BE386445
253461
chr3q23

GE79184
hypothetical protein
FLJ35036
0.004127
1.472645








FLJ35036


Hs.110571
NM_015675
4616
chr19p13.3
604948
GE82030
growth arrest and
GADD45B
0.000325
3.730464








DNA-damage-inducible,








beta


Hs.62661
BC002666
2633
chr1p22.2
600411
GE81108
guanylate binding
GBP1
0.007744
1.951445








protein 1, interferon-








inducible, 67 kDa


Hs.46453
NM_005291
2840
chr2q21
603071
GE60447
G protein-coupled
GPR17
0.019726
0.314979








receptor 17


Hs.75652
NM_000851
2949
chr1p13.3
138385
GE57545
glutathione S-trans-
GSTM5
0.008865
0.545885








ferase M5


Hs.8821
NM_021175
57817
chr19q13.1
606464
GE82598
hepcidin antimicro-
HAMP
0.003586
3.9895








bial peptide


Hs.352109
NM_003518.3
8339
6p21.3
602798
GE85033
histone 1, H2bg
HIST1H2BG
0.030363
1.766648


Hs.70937
NM_003536
8357
chr6p22-p21.3
602818
GE572087
histone 1, H3h
HIST1H3H
0.004033
2.255584


Hs.3268
X51757
3310
chr1q23
140555
GE59761
heat shock 70 kDa
HSPA6
0.012769
2.047918








protein 6 (HSP70B′)


Hs.370873
NM_005531
3428
chr1q22
147586
GE58028
interferon, gamma-
IFI16
0.003499
2.056085








inducible protein 16


Hs.14623
NM_006332
10437
chr19p13.1
604664
GE81622
interferon, gamma-
IFI30
0.004441
2.296817








inducible protein 30


Hs.512234
NM_000600.1
3569
7p21
147620
GE59660
interleukin 6 (inter-
IL6
0.00397
2.048871








feron, beta 2)


Hs.416385
BE300521
3638
chr7q36
602055
GE85346
insulin induced
INSIG1
0.034064
2.350952








gene 1


Hs.80645
NM_002198
3659
chr5q31.1
147575
GE59715
interferon regu-
IRF1
0.002739
2.737088








latory factor 1


Hs.78465
BG491844
3725
chr1p32-p31
165160
GE57500
v-jun sarcoma virus
JUN
0.031737
2.110769








17 oncogene homolog








(avian)


Hs.283063
NM_005574
4005
chr11p13
180385
GE79375
LIM domain only 2
LMO2
0.029926
1.606316








(rhombotin-like 1)


Hs.365706
NM_000900
4256
chr12p13.1-
154870
GE80964
matrix Gla protein
MGP
0.007283
2.151154





p12.3


Hs.105547
NM_015392
56654
chr9q34.3
605798
GE56276
neural proliferation,
NPDC1
0.00336
1.65195








differentiation and








control, 1


Hs.94070
AI765819
4958
chr9q22.31

GE53008
osteomodulin
OMD
0.020759
0.643537


Hs.293464
BC020691
10135
chr7q22.3
608764
GE86807
pre-B-cell colony
PBEF1
0.00851
2.697207








enhancing








factor 1


Hs.51
NM_002641
5277
chrxp22.1
311770
GE57051
phosphatidylinositol
PIGA
0.001235
2.017032








glycan, class A








(paroxysmal nocturnal








hemoglobinuria)


Hs.371003
NM_016619
51316
chr4q21.3
607515
GE55372
placenta-specific 8
PLAC8
0.041597
2.088607


Hs.307033
AI983043
55041
chr2q21.2

GE544254
pleckstrin homology
PLEKHB2
0.017474
1.277814








domain containing,








family B (evectins)








member 2


Hs.348478
NM_021105
5359
chr3q23
604170
GE62320
phospholipid
PLSCR1
0.015981
2.015066








scramblase 1


Hs.76556
NM_014330
23645
chr19q13.2

GE81913
protein phosphatase 1,
PPP1R15A
0.010526
3.266182








regulatory (inhibitor)








subunit 15A


Hs.381081
NM_002800
5698
chr6p21.3
177045
GE60353
proteasome (prosome,
PSMB9
0.00082
1.846565








macropain) subunit,








beta type, 9 (large








multifunctional








protease 2)


Hs.436577
NM_003469
7857
chr2q35-q36
118930
GE57887
secretogranin II
SCG2
0.007024
3.218546








(chromogranin C)


Hs.89546
NM_000450
6401
chr1q22-q25
131210
GE56057
selectin E (endothelial
SELE
0.006493
3.21028








adhesion molecule 1)


Hs.109051
NM_031286
83442
chr1p35-p34.3

GE79881
SH3 domain binding
SH3BGRL3
0.00726
1.712547








glutamic acid-rich








protein like 3///SH3








domain binding gluta-








mic acid-rich protein








like 3


Hs.435735
NM_021095
8884
chr2p23
604024
GE56379
solute carrier family
SLC5A6
0.001515
0.678555








5 (sodium-dependent








vitamin transporter),








member 6


Hs.380991
NM_030751
150094
chr21q22.3
605705
GE62158
SNF1-like kinase///
SNF1LK
0.019364
2.386375








SNF1-like kinase


Hs.398157
NM_006622
10769
chr5q12.1-q13.2
607023
GE54551
polo-like kinase 2
PLK2
0.014722
1.853032








(Drosophila)


Hs.352018
NM_000593
6890
chr6p21.3
170260
GE79181
transporter 1, ATP-
TAP1
0.000286
2.297921








binding cassette, sub-








family B (MDR/TAP)


Hs.78824
AL833389
7075
chr1p34-p33
600222
GE59865
tyrosine kinase with
TIE
0.000246
0.467508








immunoglobulin and








epidermal growth factor








homology domains


Hs.211600
AI738896
7128
chr6q23
191163
GE61999
tumor necrosis factor,
TNFAIP3
0.019227
2.354308








alpha-induced protein 3


Hs.114412
NM_004786
9352
chr18q21.2
603049
GE539832
thioredoxin-like 1
TXNL1
0.000351
1.632106


Hs.17917
AL574194
10894
chr11p15
605702
GE58413
extracellular link
XLKD1
0.049184
2.328181








domain containing 1


Hs.268571
NM_001645
341
chr19q13.2
107710
GE505140
apolipoprotein C-1
APOC1
p < 0.05,
2.509905










3 batches


Hs.47546
AW968493
55780
chr6q27

GE87817
chromosome 6 open
C6orf70
p < 0.05,
0.682264








reading frame 70

3 batches


Hs.140944
NM_012135
26240
chr6p25-pter

GE60346
DNA segment on chromo-
D6S2654E
p < 0.05,
0.848706








some 6(unique) 2654

3 batches








expressed sequence


Hs.18788
NM_016246
51171
chr19q13.33

GE58712
dehydrogenase/reductase
DHRS10
p < 0.05,
1.344068








(SDR family) member 10

3 batches


Hs.494204
AW299245
91298
chr12q21.33

GE56729
hypothetical protein
DKFZp434
p < 0.05,
0.544692








DKFZp434N2030
N2030
3 batches


Hs.76591
BF116183
23197
chr5q35.2

GE53562
expressed in T-cells
ETEA
p < 0.05,
0.851599








and eosinophils in

3 batches








atopic dermatitis


Hs.287629
NM_025027
80095
chr19q13.4

GE479292
zinc finger protein
ZNF606
p < 0.05,
0.765441








606

3 batches


Hs.135569
AL831857
84913
chr2p11.2

GE83540
atonal homolog 8
ATOH8
p < 0.05,
0.684805








(Drosophila)

3 batches


Hs.89519
T85841.1
54726
4q31.21

GE53713
HIV-1 induced protein
HSHIN1
p < 0.05,
0.763166








HIN-1

3 batches


Hs.26745
AF151078
51259
chr11q13.1

GE82136
HSPC244
MGC: 13379
p < 0.05,
0.716451










3 batches


Hs.315167
L11372
79075
chr8q24.12

GE63328
defective in sister
DCC1
p < 0.05,
0.606126








chromatid cohesion

3 batches








homolog 1








(S. cerevisiae)


Hs.404
BC030550
4300
chr9p22
159558
GE81406
myeloid/lymphoid or
MLLT3
p < 0.05,
0.727899








mixed-lineage leukemia

3 batches








(trithorax homolog,









Drosophila); trans-









located to, 3


Hs.196585
NM_015485
25950
chr1p21.3

GE88260
RWD domain containing 3
RWDD3
p < 0.05,
0.784195










3 batches


Hs.78824
AL833389
7075
chr1p34-p33
600222
GE59865
tyrosine kinase with
TIE
p < 0.05,
0.467508








immunoglobulin and

3 batches








epidermal growth








factor homology








domains


Hs.179526
NM_006472.1
10628
1q21.2
606599
GE58805
thioredoxin interacting
TXNIP
p < 0.05,
0.433622








protein

3 batches


Hs.76561
AA084273
342908
chr19q13.32

GE85622
zinc finger protein 404
ZNF404
p < 0.05,
0.557599










3 batches


Hs.355957
NM_001029
6231
chr12q13
603701
GE80976
ribosomal protein S26
RPS26
p < 0.05,
1.749582










3 batches


NULL
AP003480.1



GE86003


p < 0.05.
1.648659










3 batches


Hs.299123
BF593518.1



GE607429


p < 0.05,
1.529494










3 batches


Hs.334931
BC008122.1



GE748859


p < 0.05,
1.441456










3 batches


Hs.475880
BE072907.1



GE573233


p < 0.05,
1.323119










3 batches


Hs.48797
N94759.1



GE557728


p < 0.05,
0.901628










3 batches


Hs.49658
BC013872
57212
chr1p36.32

GE53221
KIAA0495
KIAA0495
p < 0.05,
0.750704










3 batches


Hs.518925
BM699227.1



GE88534


p < 0.05,
0.737717










3 batches


Hs.273099
AK023774.1



GE572395


p < 0.05,
0.672578










3 batches


Hs.433156
NM_005162
91445
chr22

GE61190
hypothetical protein
FLJ38628
p < 0.05,
0.662088








FLJ38628

3 batches


Hs.433156
NM_005162
91445
chr22

GE61190
hypothetical protein
FLJ38628
p < 0.05,
0.662088








FLJ38628

3 batches


Hs.314413
AI289609.1



GE754401


p < 0.05,
0.644233










3 batches


NULL
NM_199050.1



GE56267


p < 0.05,
0.60657










3 batches


Hs.133536
AI379149.1



GE633524


p < 0.05,
0.592899










3 batches


Hs.377159
BM713079.1



GE826874


p < 0.05,
0.576892










3 batches


NULL
INCYTE



GE87335


p < 0.05,
0.571783



UNIQUE






3 batches


Hs.278081
AV718725.1



GE500797


p < 0.05,
0.382559










3 batches
















TABLE 25










Schizophrenia Cohort 2: AnCg, DLPFC, Amygdala.









number of


Pathway
probe sets











Apoptosis
55


Blood group glycolipid biosynthesis-neolactoseries
3


Cell_cycle1-5 TGF_Beta_Signaling_Pathway
27


Electron_Transport_Chain
1


G_Protein_Signaling MAPK_Cascade
5


G13_Signaling_Pathway Integrin-
4


mediated_cell_adhesion Wnt_signaling


Glycerolipid metabolism
3


GPCRs_Class_A_Rhodopsin-like Peptide_GPCRs
6


GPCRs_Class_B_Secretin-like
8


GPCRs_Other
3


Hypertrophy_model
2


Integrin-mediated_cell_adhesion
7


Nuclear_Receptors
4


Ovarian_Infertility_Genes
3


Phosphatidylinositol signaling system
16


Prostaglandin and leukotriene metabolism
1








Claims
  • 1. A method for determining whether a subject has or is predisposed for a mental disorder, the method comprising the steps of: (i) obtaining a biological sample from a subject; (ii) contacting the sample with a reagent that selectively associates with a polynucleotide or polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleotide sequence of Tables 1 and 22-24; and (iii) detecting the level of reagent that selectively associates with the sample, thereby determining whether the subject has or is predisposed for a mental disorder.
  • 2. The method of claim 1, wherein the reagent is an antibody.
  • 3. The method of claim 1, wherein the reagent is a nucleic acid.
  • 4. The method of claim 1, wherein the reagent associates with a polynucleotide.
  • 5. The method of claim 1, wherein the regent associates with a polypeptide.
  • 6. The method of claim 1, wherein the level of reagent that associates with the sample is different from a level associated with humans without a mental disorder.
  • 7. The method of claim 1, wherein the biological sample is obtained from amniotic fluid.
  • 8. The method of claim 1, wherein the mental disorder is a psychotic disorder.
  • 9. The method of claim 6, wherein the level of reagent that associates with the sample is higher than a level associated with humans without a mental disorder.
  • 10. The method of claim 8, wherein the psychotic disorder is schizophrenia.
  • 11. A method of identifying a compound for treatment of a mental disorder, the method comprising the steps of: (i) contacting the compound with a polypeptide, the polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a nucleic acid sequence comprising a nucleotide sequence of Tables 1 and 22-24; and (ii) determining the functional effect of the compound upon the polypeptide, thereby identifying a compound for treatment of a mental disorder.
  • 12. The method of claim 11, wherein the contacting step is performed in vitro.
  • 13. The method of claim 11, wherein the polypeptide is expressed in a cell and the cell is contacted with the compound.
  • 14. The method of claim 11, wherein the mental disorder is a psychotic disorder.
  • 15. The method of claim 14, wherein the psychotic disorder is schizophrenia.
  • 16. The method of claim 14, further comprising administering the compound to an animal and determining the effect on the animal.
  • 17. The method of claim 16, wherein the determining step comprises testing the animal's mental function.
  • 18. A method of identifying a compound for treatment of a mental disorder in a subject, the method comprising the steps of: (i) contacting the compound to a cell, the cell comprising a polynucleotide that hybridizes under stringent conditions to a nucleotide sequence of Tables 1 and 22-24; and (ii) selecting a compound that modulates expression of the polynucleotide, thereby identifying a compound for treatment of a mental disorder.
  • 19. The method of claim 18, wherein the expression of the polynucleotide is enhanced.
  • 20. The method of claim 18, wherein the expression of the polynucleotide is decreased.
  • 21. The method of claim 18, further comprising administering the compound to an animal and determining the effect on the animal.
  • 22. The method of claim 21, wherein the determining step comprises testing the animal's mental function.
  • 23. The method of claim 18, wherein the mental disorder is a psychotic disorder.
  • 24. The method of claim 23, wherein the psychotic disorder is schizophrenia
  • 25. A method of treating a mental disorder in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified using the method of claim 11 or claim 18.
  • 26. The method of claim 25, wherein the mental disorder is a psychotic disorder.
  • 27. The method of claim 25, wherein the compound is a small organic molecule.
  • 28. The method of claim 26, wherein the psychotic disorder is schizophrenia.
  • 29. A method of treating mental disorder in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a polypeptide, the polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a nucleotide sequence of Tables 1 and 22-24.
  • 30. The method of claim 29, wherein the mental disorder is schizophrenia.
  • 31. A method of treating mental disorder in a subject, the method comprising the stepof administering to the subject a therapeutically effective amount of a nucleic acid, wherein the nucleic acid hybridizes under stringent conditions to a nucleotide sequence of Tables 1 and 22-24.
  • 32. The method of claim 31, wherein the mental disorder is schizophrenia.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application claims priority to U.S. Ser. No. 60/517,751, filed Nov. 5, 2003, herein incorporated by reference in it entirety.

Provisional Applications (1)
Number Date Country
60517751 Nov 2003 US